WO2014018423A2 - Inducible dna binding proteins and genome perturbation tools and applications thereof - Google Patents

Inducible dna binding proteins and genome perturbation tools and applications thereof Download PDF

Info

Publication number
WO2014018423A2
WO2014018423A2 PCT/US2013/051418 US2013051418W WO2014018423A2 WO 2014018423 A2 WO2014018423 A2 WO 2014018423A2 US 2013051418 W US2013051418 W US 2013051418W WO 2014018423 A2 WO2014018423 A2 WO 2014018423A2
Authority
WO
WIPO (PCT)
Prior art keywords
domain
tale
histone
dna
crispr
Prior art date
Application number
PCT/US2013/051418
Other languages
French (fr)
Other versions
WO2014018423A8 (en
WO2014018423A3 (en
Inventor
Feng Zhang
Mark BRIGHAM
Le Cong
Silvana KONERMANN
Neville Espi SANJAN
Original Assignee
The Broad Institute, Inc.
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48914461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014018423(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2879997A priority Critical patent/CA2879997A1/en
Priority to CN201380049665.5A priority patent/CN105188767A/en
Priority to EP13744916.1A priority patent/EP2877213B1/en
Priority to AU2013293270A priority patent/AU2013293270B2/en
Priority to EP20195578.8A priority patent/EP3808844A1/en
Priority to CN202310274470.6A priority patent/CN116622704A/en
Priority to KR1020157004939A priority patent/KR102530118B1/en
Priority to PL18200462T priority patent/PL3494997T3/en
Priority to KR1020237014846A priority patent/KR20230065381A/en
Application filed by The Broad Institute, Inc., Massachusetts Institute Of Technology filed Critical The Broad Institute, Inc.
Priority to EP18200462.2A priority patent/EP3494997B1/en
Priority to JP2015524358A priority patent/JP2015527889A/en
Publication of WO2014018423A2 publication Critical patent/WO2014018423A2/en
Publication of WO2014018423A3 publication Critical patent/WO2014018423A3/en
Publication of WO2014018423A8 publication Critical patent/WO2014018423A8/en
Priority to US14/604,641 priority patent/US20150291966A1/en
Priority to HK15111902.7A priority patent/HK1210965A1/en
Priority to US15/388,248 priority patent/US20170166903A1/en
Priority to AU2018211340A priority patent/AU2018211340A1/en
Priority to AU2018247306A priority patent/AU2018247306B2/en
Priority to US16/297,560 priority patent/US20190203212A1/en
Priority to US16/535,042 priority patent/US20190390204A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention generally relates to methods and compositions used for the spatial and temporal control of gene expression, such as genome perturbation, that may use inducible transcriptional effectors.
  • Inducible gene expression systems have typically been designed to allow for chemically induced activation of an inserted open reading frame or shRNA sequence, resulting in gene overexpression or repression, respectively.
  • Disadvantages of using open reading frames for overexpression include loss of splice variation and limitation of gene size.
  • Gene repression via RNA interference despite its transformative power in human biology, can be hindered by complicated off-target effects.
  • Certain inducible systems including estrogen, ecdysone, and FKBP12/FRAP based systems are known to activate off-target endogenous genes. The potentially deleterious effects of long-term antibiotic treatment can complicate the use of tetracycline transactivator (TET) based systems.
  • TET tetracycline transactivator
  • US Patent Publication No. 20030049799 relates to engineered stimulus-responsive switches to cause a detectable output in response to a preselected stimulus.
  • the invention provides a non-naturally occurring or engineered TALE or CRISPR-Cas system which may comprise at least one switch wherein the activity of said TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch.
  • the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system may be activated, enhanced, terminated or repressed.
  • the contact with the at least one inducer energy source may result in a first effect and a second effect.
  • the first effect may be one or more of nuclear import, nuclear export, recruitment of a secondary component (such as an effector molecule), conformational change (of protein, DNA or RNA), cleavage, release of cargo (such as a caged molecule or a co-factor), association or dissociation.
  • the second effect may be one or more of activation, enhancement, termination or repression of the control as to the at least one switch or the activity of said TALE or CRISPR- Cas system.
  • the first effect and the second effect may occur in a cascade.
  • the TALE or CRISPR-Cas system may further comprise at least one nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation.
  • the one or more of the NLS, the NES or the functional domain may be conditionally activated or inactivated.
  • the mutation may be one or more of a mutation in a transcription factor homology region, a mutation in a DNA binding domain (such as mutating basic residues of a basic helix loop helix), a mutation in an endogenous NLS or a mutation in an endogenous NES.
  • the inducer energy source may be heat, ultrasound, electromagnetic energy or chemical.
  • the inducer energy source may be an antibiotic, a small molecule, a hormone, a hormone derivative, a steroid or a steroid derivative.
  • the inducer energy source maybe abscisic acid (ABA), doxycycline (DOX), cumate, rapamycin, 4-hydroxytamoxifen (40HT), estrogen or ecdysone.
  • ABA abscisic acid
  • DOX doxycycline
  • 40HT 4-hydroxytamoxifen
  • the at least one switch may be selected from the group consisting of antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems.
  • the at least one switch may be selected from the group consisting of tetracycline (Tet)/DOX inducible systems, light inducible systems, ABA inducible systems, cumate repressor/operator systems, 40HT/estrogen inducible systems, ecdysone-based inducible systems and FKBP12/FRAP (FKBP12-rapamycin complex) inducible systems.
  • Tet tetracycline
  • DOX light inducible systems
  • ABA inducible systems cumate repressor/operator systems
  • 40HT/estrogen inducible systems ecdysone-based inducible systems
  • FKBP12/FRAP FKBP12-rapamycin complex
  • the inducer energy source is electromagnetic energy.
  • the electromagnetic energy may be a component of visible light having a wavelength in the range of 450nm-700nm.
  • the component of visible light may have a wavelength in the range of 450nm-500nm and may be blue light.
  • the blue light may have an intensity of at least 0.2m W/cm 2 , or more preferably at least 4mW/cm 2 .
  • the component of visible light may have a wavelength in the range of 620-700nm and is red light.
  • the invention comprehends systems wherein the at least one functional domain may be selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, histone deribosylase, histone derib
  • the invention also provides for use of the system for perturbing a genomic or epigenomic locus of interest. Also provided are uses of the system for the preparation of a pharmaceutical compound.
  • the invention provides a method of controlling a non-naturally occurring or engineered TALE or CRISPR-Cas system, comprising providing said TALE or CRISPR-Cas system comprising at least one switch wherein the activity of said TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch.
  • the invention provides methods wherein the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system may be activated, enhanced, terminated or repressed.
  • the contact with the at least one inducer energy source may result in a first effect and a second effect.
  • the first effect may be one or more of nuclear import, nuclear export, recruitment of a secondary component (such as an effector molecule), conformational change (of protein, DNA or RNA), cleavage, release of cargo (such as a caged molecule or a co-factor), association or dissociation.
  • the second effect may be one or more of activation, enhancement, termination or repression of the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system.
  • the first effect and the second effect may occur in a cascade.
  • the TALE or CRISPR-Cas system may further comprise at least one nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation.
  • the one or more of the NLS, the NES or the functional domain may be conditionally activated or inactivated.
  • the mutation may be one or more of a mutation in a transcription factor homology region, a mutation in a DNA binding domain (such as mutating basic residues of a basic helix loop helix), a mutation in an endogenous NLS or a mutation in an endogenous NES.
  • the inducer energy source may be heat, ultrasound, electromagnetic energy or chemical.
  • the inducer energy source may be an antibiotic, a small molecule, a hormone, a hormone derivative, a steroid or a steroid derivative.
  • the inducer energy source maybe abscisic acid (ABA), doxycycline (DOX), cumate, rapamycin, 4-hydroxytamoxifen (40HT), estrogen or ecdysone.
  • ABA abscisic acid
  • DOX doxycycline
  • 40HT 4-hydroxytamoxifen
  • the at least one switch may be selected from the group consisting of antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems.
  • the at least one switch may be selected from the group consisting of tetracycline (Tet)/DOX inducible systems, light inducible systems, ABA inducible systems, cumate repressor/operator systems, 40HT/estrogen inducible systems, ecdysone-based inducible systems and FKBP12/FRAP (FKBP12-rapamycin complex) inducible systems.
  • Tet tetracycline
  • DOX light inducible systems
  • ABA inducible systems cumate repressor/operator systems
  • 40HT/estrogen inducible systems ecdysone-based inducible systems
  • FKBP12/FRAP FKBP12-rapamycin complex
  • the inducer energy source is electromagnetic energy.
  • the electromagnetic energy may be a component of visible light having a wavelength in the range of 450nm-700nm.
  • the component of visible light may have a wavelength in the range of 450nm-500nm and may be blue light.
  • the blue light may have an intensity of at least 0.2mW/cm 2 , or more preferably at least 4mW/cm 2 .
  • the component of visible light may have a wavelength in the range of 620-700nm and is red light.
  • the invention comprehends methods wherein the at least one functional domain may be selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, histone deribosylase, histone derib
  • TALE Transcription activator-like effector
  • a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the locus of interest or
  • the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the inducer energy source.
  • the system or method of the invention provides the N- terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region.
  • the at least one RVD may be selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS, NN, SN, KN for recognition of guanine (G); (b) NI, KI, RI, HI, SI for recognition of adenine (A); (c) NG, HG, KG, RG for recognition of thymine (T); (d) RD, SD, HD, ND, KD, YG for recognition of cytosine (C); (e) NV, HN for recognition of A or G; and (f) H*, HA, KA, N*, NA, NC, NS, RA, S*for recognition of A or T or G or C, wherein (*) means that the amino acid at X13 is absent.
  • the at least one RVD may be selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS for recognition of guanine (G); (b) SI for recognition of adenine (A); (c) HG, KG, RG for recognition of thymine (T); (d) RD, SD for recognition of cytosine (C); (e) NV, HN for recognition of A or G and (f) H*, HA, KA, N*, NA, NC, NS, RA, S*for recognition of A or T or G or C, wherein (*) means that the amino acid at XI 3 is absent.
  • the RVD for the recognition of G is RN, NH, RH or KH; or the RVD for the recognition of A is SI; or the RVD for the recognition of T is KG or RG; and the RVD for the recognition of C is SD or RD.
  • at least one of the following is present [LTLD] or [LTLA] or [LTQV] at XI -4, or [EQHG] or [RDHG] at positions X30-33 or X31-34 or X32-35.
  • the TALE system is packaged into a AAV or a lentivirus vector.
  • the CRISPR system may comprise a vector system comprising: a) a first regulatory element operably linked to a CRISPR-Cas system guide RNA that targets a locus of interest, b) a second regulatory inducible element operably linked to a Cas protein, wherein components (a) and (b) may be located on same or different vectors of the system, wherein the guide RNA targets DNA of the locus of interest, wherein the Cas protein and the guide RNA do not naturally occur together.
  • the Cas protein is a Cas9 enzyme.
  • the invention also provides for the vector being a AAV or a lentivirus.
  • the invention particularly relates to inducible methods of altering expression of a genomic locus of interest and to compositions that inducibly alter expression of a genomic locus of interest wherein the genomic locus may be contacted with a non-naturally occurring or engineered composition comprising a deoxyribonucleic acid (DNA) binding polypeptide.
  • This polypeptide may include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half- monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to an energy sensitive protein or fragment thereof.
  • TALE Transcription activator-like effector
  • the energy sensitive protein or fragment thereof may undergo a conformational change upon induction by an energy source allowing it to bind an interacting partner.
  • the polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the energy source.
  • the method may also include applying the energy source and determining that the expression of the genomic locus is altered.
  • the genomic locus may be in a cell.
  • the invention also relates to inducible methods of repressing expression of a genomic locus of interest and to compositions that inducibly repress expression of a genomic locus of interest wherein the genomic locus may be contacted with a non-naturally occurring or engineered composition comprising a DNA binding polypeptide.
  • the polypeptide may include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or at least one or more repressor domains linked to an energy sensitive protein or fragment thereof.
  • TALE Transcription activator-like effector
  • the energy sensitive protein or fragment thereof may undergo a conformational change upon induction by an energy source allowing it to bind an interacting partner.
  • the polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the energy source.
  • the method may also include applying the energy source and determining that the expression of the genomic locus is repressed.
  • the genomic locus may be in a cell.
  • the invention also relates to inducible methods of activating expression of a genomic locus of interest and to compositions that inducibly activate expression of a genomic locus of interest wherein the genomic locus may be contacted with a non-naturally occurring or engineered composition comprising a DNA binding polypeptide.
  • the polypeptide may include a DNA binding domain comprising at least five or more TALE monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or at least one or more activator domains linked to an energy sensitive protein or fragment thereof.
  • the energy sensitive protein or fragment thereof may undergo a conformational change upon induction by an energy source allowing it to bind an interacting partner.
  • the polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the energy source.
  • the method may also include applying the energy source and determining that the expression of the genomic locus is activated.
  • the genomic locus may be in a cell.
  • the inducible effector may be a
  • LITE Light Inducible Transcriptional Effector
  • the inducible effector may be a chemical.
  • the present invention also contemplates an inducible multiplex genome engineering using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas systems.
  • the present invention also encompasses nucleic acid encoding the polypeptides of the present invention.
  • the nucleic acid may comprise a promoter, advantageously human Synapsin I promoter (hSyn).
  • the nucleic acid may be packaged into an adeno associated viral vector (AAV).
  • AAV adeno associated viral vector
  • the invention further also relates to methods of treatment or therapy that encompass the methods and compositions described herein.
  • FIG. 1 shows a schematic indicating the need for spatial and temporal precision.
  • FIG. 2 shows transcription activator like effectors (TALEs).
  • TALEs consist of 34 aa repeats at the core of their sequence. Each repeat corresponds to a base in the target DNA that is bound by the TALE. Repeats differ only by 2 variable amino acids at positions 12 and 13.
  • the code of this correspondence has been elucidated (Boch, J et al. , Science, 2009 and Moscou, M et al. , Science, 2009) and is shown in this figure.
  • Applicants have developed a method for the synthesis of designer TALEs incorporating this code and capable of binding a sequence of choice within the genome (Zhang, F et al. , Nature Biotechnology, 2011).
  • FIG. 3 shows a design of a LITE: TALE/Cryptochrome transcriptional activation.
  • Each LITE is a two-component system which may comprise a TALE fused to CRY2 and the cryptochrome binding partner CIB1 fused to VP64, a transcription activor.
  • the TALE localizes its fused CRY2 domain to the promoter region of the gene of interest.
  • CIB1 is unable to bind CRY2, leaving the CIB1-VP64 unbound in the nuclear space.
  • CRY2 Upon stimulation with 488 nm (blue) light, CRY2 undergoes a conformational change, revealing its ClBl binding site (Liu, H et al. , Science, 2008). Rapid binding of ClBl results in recruitment of the fused VP64 domain, which induces transcription of the target gene.
  • FIG. 4 shows effects of cryptochrome dimer truncations on LITE activity. Truncations known to alter the activity of CRY2 and ClBl (Kennedy M et al, Nature Methods 2010) were compared against the full length proteins. A LITE targeted to the promoter of Neurog2 was tested in Neuro-2a cells for each combination of domains. Following stimulation with 488 nm light, transcript levels of Neurog2 were quantified using qPCR for stimulated and unstimulated samples.
  • FIG. 5 shows a light-intensity dependent response of KLF4 LITE.
  • FIG. 6 shows activation kinetics of Neurog2 LITE and inactivation kinetics of
  • FIG. 7 A shows the base-preference of various RVDs as determined using the Applicants' RVD screening system.
  • FIG. 7B shows the base-preference of additional RVDs as determined using the Applicants' RVD screening system.
  • FIGS. 8A-D show in (a) Natural structure of TALEs derived from Xanthomonas sp.
  • the DNA-binding modules are flanked by nonrepetitive N and C termini, which carry the translocation, nuclear localization (NLS) and transcription activation (AD) domains.
  • a cryptic signal within the N terminus specifies a thymine as the first base of the target site
  • the TALE toolbox allows rapid and inexpensive construction of custom TALE-TFs and TALENs.
  • the kit consists of 12 plasmids in total: four monomer plasmids to be used as templates for PCR amplification, four TALE-TF and four TALEN cloning backbones corresponding to four different bases targeted by the 0.5 repeat.
  • CMV cytomegalovirus promoter
  • N term nonrepetitive N terminus from the Hax3 TALE
  • C term nonrepetitive C terminus from the Hax3 TALE
  • Bsal type lis restriction sites used for the insertion of custom TALE DNA-binding domains
  • ccdB + CmR negative selection cassette containing the ccdB negative selection gene and chloramphenicol resistance gene
  • NLS nuclear localization signal
  • VP64 synthetic transcriptional activator derived from VP 16 protein of herpes simplex virus
  • 2A 2A self-cleavage linker
  • EGFP enhanced green fluorescent protein
  • polyA signal polyadenylation signal
  • Fokl catalytic domain from the Fokl endonuclease.
  • TALEs may be used to generate custom TALE-TFs and modulate the transcription of endogenous genes from the genome.
  • the TALE DNA-binding domain is fused to the synthetic VP64 transcriptional activator, which recruits R A polymerase and other factors needed to initiate transcription
  • (d) TALENs may be used to generate site-specific double-strand breaks to facilitate genome editing through nonhomologous repair or homology directed repair. Two TALENs target a pair of binding sites flanking a 16-bp spacer. The left and right TALENs recognize the top and bottom strands of the target sites, respectively.
  • Each TALE DNA-binding domain is fused to the catalytic domain of Fokl endonuclease; when Fokl dimerizes, it cuts the DNA in the region between the left and right TALEN-binding sites.
  • FIG. 9A-F shows a table listing monomer sequences (excluding the RVDs at positions 12 and 13) and the frequency with which monomers having a particular sequence occur.
  • FIG. 10 shows the comparison of the effect of non-RVD amino acid on TALE activity.
  • FIG. 11 shows an activator screen comparing levels of activation between VP64, p65 and VP 16.
  • FIGS. 12A-D show the development of a TALE transcriptional repressor architecture, (a) Design of SOX2 TALE for TALE repressor screening. A TALE targeting a 14bp sequence within the SOX2 locus of the human genome was synthesized, (b) List of all repressors screened and their host origin (left).
  • FIGS. 13A-C shows the optimization of TALE transcriptional repressor architecture using SID and SID4X.
  • TALE targeting a 20bp sequence (pi I TALE binding site) within the pi I (slOOalO) locus of the mouse (Mus musculus) genome was synthesized, (b) Transcriptional repression of endogenous mouse pi I mR A.
  • TALEs targeting the mouse pi I locus harboring two different truncations of the wild type TALE architecture were fused to different repressor domains as indicated on the x-axis. The value in the bracket indicate the number of amino acids at the N- and C- termini of the TALE DNA binding domain flanking the DNA binding repeats, followed by the repressor domain used in the construct.
  • the endogenous pi 1 mRNA levels were measured using qRT-PCR and normalized to the level in the negative control cells transfected with a GFP-encoding construct, (c) Fold of transcriptional repression of endogenous mouse pi I.
  • the fold decrease of endogenous pi I mRNA is measured using qRT-PCR through dividing the pi I mRNA levels in cells transfected with a negative control GFP construct by pi I mRNA levels in cells transfected with each candidate TALE repressors.
  • the labeling of the constructs along the x-axis is the same as previous panel.
  • NLS nuclear localization signal
  • SID mSin interaction domain
  • FIG. 14 shows a comparison of two different types of TALE architecture.
  • FIGS. 15A-C show a chemically inducible TALE ABA inducible system.
  • ABI ABA insensitive 1
  • PYL PYL protein: pyrabactin resistance (PYR)/PYRl-like (PYL)
  • ABA Abscisic Acid
  • This plant hormone is a small molecule chemical that Applicants used in Applicants' inducible TALE system.
  • the TALE DNA-binding polypeptide is fused to the ABI domain, whereas the VP64 activation domain or SID repressor domain or any effector domains are linked to the PYL domain.
  • the two interacting domains, ABI and PYL will dimerize and allow the TALE to be linked to the effector domains to perform its activity in regulating target gene expression.
  • FIGS. 16A-B show a chemically inducible TALE 40HT inducible system.
  • FIG. 17 depicts an effect of cryptochrome2 heterodimer orientation on LITE functionality.
  • FIG. 18 depicts mGlur2 LITE activity in mouse cortical neuron culture.
  • FIG. 19 depicts transduction of primary mouse neurons with LITE AAV vectors.
  • FIG. 20 depicts expression of LITE component in vivo.
  • FIG. 21 depicts an improved design of the construct where the specific NES peptide sequence used is LDLASLIL.
  • FIG. 22 depicts Sox2 mRNA levels in the absence and presence of 40H tamoxifen.
  • FIGS. 23A-E depict a Type II CRISPR locus from Streptococcus pyogenes SF370 can be reconstituted in mammalian cells to facilitate targeted DSBs of DNA.
  • A Engineering of SpCas9 and SpRNase III with NLSs enables import into the mammalian nucleus.
  • B Mammalian expression of SpCas9 and SpRNase III are driven by the EFla promoter, whereas tracrRNA and pre-crRNA array (DR-Spacer-DR) are driven by the U6 promoter.
  • a protospacer (blue highlight) from the human EMX1 locus with PAM is used as template for the spacer in the pre-crRNA array.
  • C Schematic representation of base pairing between target locus and EMX1- targeting crRNA. Red arrow indicates putative cleavage site.
  • D SURVEYOR assay for SpCas9-mediated indels.
  • FIGS. 24A-C depict a SpCas9 can be reprogrammed to target multiple genomic loci in mammalian cells.
  • A Schematic of the human EMX1 locus showing the location of five protospacers, indicated by blue lines with corresponding PAM in magenta.
  • B Schematic of the pre-crRNA:tracrRNA complex (top) showing hybridization between the direct repeat (gray) region of the pre-crRNA and tracrRNA.
  • Schematic of a chimeric RNA design (M. Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012)) (bottom).
  • tracrRNA sequence is shown in red and the 20bp spacer sequence in blue.
  • C SURVEYOR assay comparing the efficacy of Cas9-mediated cleavage at five protospacers in the human EMX1 locus. Each protospacer is targeted using either processed pre-crRNA:tracrRNA complex (crRNA) or chimeric RNA (chiRNA).
  • crRNA pre-crRNA:tracrRNA complex
  • chiRNA chimeric RNA
  • FIGS. 25A-D depict an evaluation of the SpCas9 specificity and comparison of efficiency with TALENs.
  • A EMX1 -targeting chimeric crRNAs with single point mutations were generated to evaluate the effects of spacer-protospacer mismatches.
  • B SURVEYOR assay comparing the cleavage efficiency of different mutant chimeric RNAs.
  • C Schematic showing the design of TALENs targeting EMXl.
  • FIGS. 26A-G depict applications of Cas9 for homologous recombination and multiplex genome engineering.
  • A Mutation of the RuvC I domain converts Cas9 into a nicking enzyme (SpCas9n)
  • C Schematic representation of the recombination strategy. A repair template is designed to insert restriction sites into EMXl locus. Primers used to amplify the modified region are shown as red arrows.
  • D Restriction fragments length polymorphism gel analysis. Arrows indicate fragments generated by HmdIII digestion.
  • (F) SpCas9 can facilitate multiplex genome modification using a crRNA array containing two spacers targeting EMXl and PVALB. Schematic showing the design of the crRNA array (top). Both spacers mediate efficient protospacer cleavage (bottom).
  • (G) SpCas9 can be used to achieve precise genomic deletion. Two spacers targeting EMXl (top) mediated a 118bp genomic deletion (bottom).
  • FIG. 27 depicts a schematic of the type II CRISPR-mediated DNA double-strand break.
  • the type II CRISPR locus from Streptococcus pyogenes SF370 contains a cluster of four genes, Cas9, Casl, Cas2, and Csnl, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non- repetitive sequences (spacers, 30bp each) (15-18, 30, 31). Each spacer is typically derived from foreign genetic material (protospacer), and directs the specificity of CRISPR-mediated nucleic acid cleavage.
  • protospacer foreign genetic material
  • each protospacer is associated with a protospacer adjacent motif (PAM) whose recognition is specific to individual CRISPR systems (22, 23).
  • PAM protospacer adjacent motif
  • the Type II CRISPR system carries out targeted DNA double-strand break (DSB) in sequential steps (M. Jinek et al, Science 337, 816 (Aug 17, 2012); Gasiunas, R. et al. Proc Natl Acad Sci U S A 109, E2579 (Sep 25, 2012); J. E. Garneau et al, Nature 468, 67 (Nov 4, 2010); R. Sapranauskas et al, Nucleic Acids Res 39, 9275 (Nov, 2011); A. H. Magadan et al.
  • the pre-crRNA array and tracrRNA are transcribed from the CRISPR locus.
  • tracrRNA hybridizes to the direct repeats of pre-crRNA and associates with Cas9 as a duplex, which mediates the processing of the pre-crRNA into mature crRNAs containing individual,truncated spacer sequences.
  • the mature crRNA:tracrRNA duplex directs Cas9 to the DNA target consisting of the protospacer and the requisite PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA.
  • Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer.
  • FIGS. 28A-C depict a comparison of different tracrRNA transcripts for Cas9- mediated gene targeting.
  • A Schematic showing the design and sequences of two tracrRNA transcripts tested (short and long). Each transcript is driven by a U6 promoter. Transcription start site is marked as +1 and transcription terminator is as indicated. Blue line indicates the region whose reverse-complement sequence is used to generate northern blot probes for tracrRNA detection.
  • B SURVEYOR assay comparing the efficiency of hSpCas9-mediated cleavage of the EMXl locus. Two biological replicas are shown for each tracrRNA transcript.
  • FIG. 29 depicts a SURVEYOR assay for detection of double strand break-induced micro insertions and deletions (D. Y. Guschin et al. Methods Mol Biol 649, 247 (2010)).
  • genomic PCR gPCR
  • gPCR genomic PCR
  • the reannealed heteroduplexes are cleaved by SURVEYOR nuclease, whereas homoduplexes are left intact.
  • Cas9-mediated cleavage efficiency (% indel) is calculated based on the fraction of cleaved DNA.
  • FIG. 30A-B depict a Northern blot analysis of crRNA processing in mammalian cells.
  • A Schematic showing the expression vector for a single spacer flanked by two direct repeats (DR-EMX1 (l)-DR). The 30bp spacer targeting the human EMXl locus protospacer 1 (Table 1) is shown in blue and direct repeats are in shown in gray. Orange line indicates the region whose reversecomplement sequence is used to generate northern blot probes for EMXl (I) crRNA detection.
  • B Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying DR-E ⁇ 7(1)-DR.
  • DR-E ⁇ 7(1)-DR was processed into mature crRNAs only in the presence of SpCas9 and short tracrRNA, and was not dependent on the presence of SpRNase III.
  • the mature crRNA detected from transfected 293FT total RNA is ⁇ 33bp and is shorter than the 39-42bp mature crRNA from S. pyogenes (E. Deltcheva et al., Nature 471, 602 (Mar 31, 2011)), suggesting that the processed mature crRNA in human 293FT cells is likely different from the bacterial mature crRNA in S. pyogenes.
  • FIG. 31A-B depict a bicistronic expression vectors for pre-crRNA array or chimeric crRNA with Cas9.
  • A Schematic showing the design of an expression vector for the pre-crRNA array. Spacers can be inserted between two Bbsl sites using annealed oligonucleotides. Sequence design for the oligonucleotides are shown below with the appropriate ligation adapters indicated.
  • B Schematic of the expression vector for chimeric crRNA. The guide sequence can be inserted between two Bbsl sites using annealed oligonucleotides. The vector already contains the partial direct repeat (gray) and partial tracrRNA (red) sequences. WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element.
  • FIGS. 32A-B depict a selection of protospacers in the human PVALB and mouse Th loci. Schematic of the human PVALB (A) and mouse Th (B) loci and the location of the three protospacers within the last exon of the PVALB and Th genes, respectively.
  • the 30bp protospacers are indicated by black lines and the adjacent PAM sequences are indicated by the magenta bar. Protospacers on the sense and anti-sense strands are indicated above and below the DNA sequences respectively.
  • FIGS. 33A-C depict occurrences of PAM sequences in the human genome. Histograms of distances between adjacent Streptococcus pyogenes SF370 locus 1 PAM (NGG) (A) and Streptococcus thermophiles LMD9 locus 1 PAM (NNAGAAW) (B) in the human genome. (C) Distances for each PAM by chromosome. Chr, chromosome. Putative targets were identified using both the plus and minus strands of human chromosomal sequences. Given that there may be chromatin, DNA methylation-, RNA structure, and other factors that may limit the cleavage activity at some protospacer targets, it is important to note that the actual targeting ability might be less than the result of this computational analysis.
  • FIGS. 34A-D depict type II CRISPR from Streptococcus thermophilus LMD-9 can also function in eukaryotic cells.
  • A Schematic of CRISPR locus 2 from Streptococcus thermophilus LMD-9.
  • B Design of the expression system for the S. thermphilus CRISPR system. Human codon-optimized hStCas9 is expressed using a constitutive EFla promoter. Mature versions of tracrRNA and crRNA are expressed using the U6 promoter to ensure precise transcription initiation. Sequences for the mature crRNA and tracrRNA are shown.
  • RNA Pol III transcriptional terminator A single based indicated by the lower case "a" in the crRNA sequence was used to remove the polyU sequence, which serves as a RNA Pol III transcriptional terminator.
  • C Schematic showing protospacer and corresponding PAM sequences targets in the human EMX1 locus. Two protospacer sequences are highlighted and their corresponding PAM sequences satisfying the NNAGAAW motif are indicated by magenta lines. Both protospacers are targeting the anti-sense strand.
  • D SURVEYOR assay showing StCas9-mediated cleavage in the target locus. RNA guide spacers 1 and 2 induced 14% and 6.4% respectively. Statistical analysis of cleavage activity across biological replica at these two protospacer sites can be found in Table 1.
  • FIG. 36A-C depict design and optimization of the LITE system, (a) A TALE DNA- binding domain is fused to CRY2 and a transcriptional effector domain is fused to CIBl .
  • TALE-CRY2 In the inactive state, TALE-CRY2 binds the promoter region of the target gene while CIBl -effector remains unbound in the nucleus. The VP64 transcriptional activator is shown above.
  • TALE-CRY2 and CIBl -effector rapidly dimerize, recruiting CIB1- effector to the target promoter.
  • the effector in turn modulates transcription of the target gene, (b) Light-dependent upregulation of the endogenous target Neurog2 mRNA with LITEs containing functional truncations of its light-sensitive binding partners.
  • LITE -trans fected Neuro- 2a cells were stimulated for 24 h with 466 nm light at an intensity of 5mW/cm 2 and a duty cycle of 7%) (I s pulses at 0.066 Hz),
  • FIG. 37A-F depict in vitro and in vivo AAV-mediated TALE delivery targeting endogenous loci in neurons,
  • (a) General schematic of constitutive TALE transcriptional activator packaged into AAV. Effector domain VP64 highlighted.
  • hSyn human synapsin promoter
  • 2A foot-and-mouth disease-derived 2 A peptide
  • WPRE woodchuck hepatitis post-transcriptional response element
  • bGH pA bovine growth hormone poly-A signal
  • Representative images showing transduction with AAV-TALE-VP64 construct from (a) in primary cortical neurons. Cells were stained for GFP and neuronal marker NeuN. Scale bars 25 ⁇ .
  • AAV-TALE- VP64 constructs targeting a variety of endogenous loci were screened for transcriptional activation in primary cortical neurons (*, p ⁇ 0.05; **, p ⁇ 0.01 ; p ⁇ 0.001).
  • (d) Efficient delivery of TALE-VP64 by AAV into the ILC of mice. Scale bar 100 ⁇ .
  • e Higher magnification image of efficient transduction of neurons in ILC.
  • FIGS. 38A-I depict LITE-mediated optogenetic modulation of endogenous transcription in primary neurons and in vivo,
  • (b) Representative images showing co-transduction of AAV- delivered LITE constructs in primary neurons. Cells were stained for GFP, HA-tag, and DAPI. (Scale bars 25 ⁇ ).
  • NLS a _i mpor ti n and NLSsv4o nuclear localization signal from a-importin and simian virus 40 respectively;
  • GS Gly-Ser linker;
  • NLS* mutated NLS where the indicated residues have been substituted with Ala to prevent nuclear localization activity; ⁇ 318-334; deletion of a higher plant helix-loop-helix transcription factor homology region.
  • FIG. 39A-H depict TALE- and LITE-mediated epigenetic modifications
  • epiLITE LITE epigenetic modifiers
  • phiLOV2.1 330bp was used as a fluorescent marker rather than GFP (800bp) to ensure efficient AAV packaging
  • c epiLITE- mediated repression of endogenous Grm2 expression in primary cortical neurons with and without light stimulation.
  • FIG. 40 depicts an illustration of the absorption spectrum of CRY2 in vitro.
  • Cryptochrome 2 was optimally activated by 350-475 nm light 1 . A sharp drop in absorption and activation was seen for wavelengths greater than 480 nm. Spectrum was adapted from Banerjee, R. et al. The Signaling State of Arabidopsis Cryptochrome 2 Contains Flavin Semiquinone. Journal of ' Biological Chemistry 282, 14916-14922, doi: 10.1074/jbc.M700616200 (2007).
  • FIG. 43 depicts an impact of transcriptional activation domains on LITE-mediated gene expression.
  • Neurog2 up-regulation with and without light by LITEs using different transcriptional activation domains VP 16, VP64, and p65.
  • FIGS. 44A-C depict chemical induction of endogenous gene transcription
  • (c) Decrease of N ' eurogl mRNA levels after 24 h of ABA stimulation. All Neurogl mRNA levels were measured relative to expressing GFP control cells (mean ⁇ s.e.m.; n 3-4).
  • 293FT cells were transfected with an AAV vector carrying the gene of interest, the AAVl serotype packaging vector (pAAVl), and helper plasmid (pDF6) using PEL 48 h later, the supernatant was harvested and filtered through a 0.45 ⁇ PVDF membrane. Primary neurons were then transduced with supernatant and remaining aliquots were stored at -80°C. Stable levels of AAV construct expression were reached after 5-6 days. AAV supernatant production following this process can be used for production of up to 96 different viral constructs in 96-well format (employed for TALE screen in neurons shown in FIG. 37C).
  • FIG. 46 depicts selection of TALE target sites guided by DNasel-sensitive chromatin regions.
  • High DNasel sensitivity based on mouse cortical tissue data from ENCODE (http://genome.ucsc.edu) was used to identify open chromatin regions.
  • the peak with the highest amplitude within the region 2 kb upstream of the transcriptional start site was selected for targeting.
  • TALE binding targets were then picked within a 200 bp region at the center of the peak.
  • FIG. 47 depicts an impact of light duty cycle on primary neuron health.
  • the effect of light stimulation on primary cortical neuron health was compared for duty cycles of 7%, 0.8%, and no light conditions.
  • Calcein was used to evaluate neuron viability.
  • Bright-field images were captured to show morphology and cell integrity.
  • FIG. 48 depicts an image of a mouse during optogenetic stimulation.
  • An awake, freely behaving, LITE-injected mouse is pictured with a stereotactically implanted cannula and optical fiber.
  • FIG. 49 depicts co-transduction efficiency of LITE components by AAVl/2 in mouse infralimbic cortex.
  • Cells transduced by TALE(Grm2)-CIBl alone, CRY2PHR-VP64 alone, or co-transduced were calculated as a percentage of all transduced cells.
  • FIG. 50 depicts a contribution of individual LITE components to baseline transcription modulation.
  • Grm2 mRNA levels were determined in primary neurons transfected with individual LITE components.
  • Primary neurons expressing Grm2 TALE 1-CIB1 alone led to a similar increase in Grm2 mRNA levels as unstimulated cells expressing the complete LITE system, (mean ⁇ s.e.m.; n 3-4).
  • FIG. 51 depicts effects of LITE Component Engineering on Activation, Background Signal, and Fold Induction. Protein modifications were employed to find LITE components resulting in reduced background transcriptional activation while improving induction ratio by light. Protein alterations are discussed in detail below.
  • nuclear localization signals and mutations in an endogenous nuclear export signal were used to improve nuclear import of the CRY2PHR-VP64 component.
  • CIB1 intended to either reduce nuclear localization or CIB1 transcriptional activation were pursued in order to reduce the contribution of the TALE-CIBI component to background activity. The results of all combinations of CRY2PHR-VP64 and TALE-CIBI which were tested are shown above.
  • the table to the left of the bar graphs indicates the particular combination of domains/mutations used for each condition.
  • Each row of the table and bar graphs contains the component details, Light/No light activity, and induction ratio by light for the particular CRY2PHR/CIB1 combination. Combinations that resulted in both decreased background and increased fold induction compared to LITE 1.0 are highlighted in green in the table column marked "+" (t-test p ⁇ 0.05).
  • CRY2PHR- VP64 Constructs Three new constructs were designed with the goal of improving CRY2PHR- VP64 nuclear import.
  • the mutations L70A and L74A within a predicted endogenous nuclear export sequence of CRY2PHR were induced to limit nuclear export of the protein (referred to as '*' in the Effector column).
  • the a-importin nuclear localization sequence was fused to the N-terminus of CRY2PHR-VP64 (referred to as 'A' in the Effector column).
  • the SV40 nuclear localization sequence was fused to the C-terminus of CRY2PHR-VP64 (referred to as 'P' in the Effector column).
  • TALE-CIBI Linkers The SV40 NLS linker between TALE and CIB1 used in LITE 1.0 was replaced with one of several linkers designed to increase nuclear export of the TALE-CIBI protein (The symbols used in the CIB1 Linker column are shown in parentheses): a flexible glycine-serine linker (G), an adenovirus type 5 E1B nuclear export sequence (W), an HIV nuclear export sequence (M), a MAPK nuclear export sequence (K), and a PTK2 nuclear export sequence (P).
  • G flexible glycine-serine linker
  • W adenovirus type 5 E1B nuclear export sequence
  • M HIV nuclear export sequence
  • K MAPK nuclear export sequence
  • PTK2 nuclear export sequence PTK2 nuclear export sequence
  • NLS* constructs were designed in which regions of high homology to basic helix-loop-helix transcription factors in higher plants were removed. These deleted regions consisted of Aaa230-256, Aaa276-307, Aaa308-334 (referred to as ' 1 ' '2' and '3' in the ACIBl column). In each case, the deleted region was replaced with a 3 residue GGS link.
  • NES Insertions into CIB1 One strategy to facilitate light-dependent nuclear import of TALE- CIB1 was to insert an NES in CIB1 at its dimerization interface with CRY2PHR such that the signal would be concealed upon binding with CRY2PHR. To this end, an NES was inserted at different positions within the known CRY2 interaction domain CIBN (aa 1-170). The positions are as follows (The symbols used in the NES column are shown in parentheses): aa28 (1), aa52 (2), aa73 (3), aal20 (4), aal40 (5), aal60 (6).
  • *bHLH basic Helix-Loop-Helix Mutation To reduce direct CIB1-DNA interactions, several basic residues of the basic helix-loop-helix region in CIB 1 were mutated. The following mutations are present in all *bHLH constructs (referred to as 'B' in the *bHLH column of FIG. 51): R175A, G176A, R187A, and R189A.
  • FIG. 52 depicts an illustration of light mediated co-dependent nuclear import of TALE-CIBl
  • TALE-CIBl LITE component In the absence of light, the TALE-CIBl LITE component resides in the cytoplasm due to the absence of a nuclear localization signal, NLS (or the addition of a weak nuclear export signal, NES).
  • the CRY2PHR-VP64 component containing a NLS on the other hand is actively imported into the nucleus on its own.
  • TALE- CIBl binds to CRY2PHR.
  • the strong NLS present in CRY2PHR-VP64 now mediates nuclear import of the complex of both LITE components, enabling them to activate transcription at the targeted locus.
  • FIG. 53 depicts notable LITE 1.9 combinations.
  • CRY2PHR-VP64 :: TALE-CIBl combinations from the engineered LITE component screen were of particular note.
  • LITE 1.9.0 which combined the a-importin NLS effector construct with a mutated endogenous NLS and ⁇ 276-307 TALE-CIBl construct, exhibited an induction ratio greater than 9 and an absolute light activation of more than 180.
  • LITE 1.9.1 which combined the unmodified CRY2PHR-VP64 with a mutated NLS, ⁇ 318-334, AD5 NES TALE-CIBl construct, achieved an induction ratio of 4 with a background activation of 1.06.
  • a selection of other LITE 1.9 combinations with background activations lower than 2 and induction ratios ranging from 7 to 12 were also highlighted.
  • FIGS. 54A-D depict TALE SID4X repressor characterization and application in neurons
  • SID or SID4X was fused to a TALE designed to target the mouse pi I gene
  • Fold decrease in pi I mRNA was assayed using qRT-PCR.
  • hSyn human synapsin promoter
  • 2A foot-and-mouth disease- derived 2 A peptide
  • WPRE woodchuck hepatitis post-transcriptional response element
  • bGH pA bovine growth hormone poly-A signal.
  • phiLOV2.1 330bp was chosen as a shorter fluorescent marker to ensure efficient AAV packaging
  • FIGS. 55A-B depict a diverse set of epiTALEs mediate transcriptional repression in neurons and euro 2 a cells
  • FIGS. 56A-D depict epiTALEs mediating transcriptional repression along with histone modifications in Neuro 2A cells
  • FIGS. 57A-G depict RNA-guided DNA binding protein Cas9 can be used to target transcription effector domains to specific genomic loci
  • RNA-guided nuclease Cas9 from the type II Streptococcus pyogenes CRISPR/Cas system can be converted into a nucleolytically- inactive RNA-guided DNA binding protein (Cas9**) by introducing two alanine substitutions (D10A and H840A).
  • sgRNA synthetic guide RNA
  • the sgRNA contains a 20bp guide sequence at the 5' end which specifies the target sequence.
  • the 20bp target site needs to be followed by a 5'-NGG PAM motif
  • (b, c) Schematics showing the sgRNA target sites in the human KLF4 and SOX2 loci respectively. Each target site is indicated by the blue bar and the corresponding PAM sequence is indicated by the magenta bar.
  • (d, e) Schematics of the Cas9**-VP64 transcription activator and SID4X-Cas9** transcription repressor constructs,
  • (f, g) Cas9**-VP64 and SID4X-Cas9** mediated activation of KLF4 and repression of SOX2 respectively. All mRNA levels were measured relative to GFP mock transfected control cells (mean ⁇ s.e.m.; n 3).
  • FIG. 58 depicts 6 TALEs which were designed, with two TALEs targeting each of the endogenous mouse loci Grm5, Grin2a, and Grm2. TALEs were fused to the transcriptional activator domain VP64 or the repressor domain SID4X and virally transduced into primary neurons. Both the target gene upregulation via VP64 and downregulation via SID4X are shown for each TALE relative to levels in neurons expressing GFP only.
  • FIGS. 60A-B depict exchanging CRY2PHR and CIB1 components.
  • TALE- CIB1 ::CRY2PHR-VP64 was able to activate Ngn2 at higher levels than TALE- CRY2PHR::CIB1-VP64.
  • B Fold activation ratios (light versus no light) ratios of Ngn2 LITEs show similar efficiency for both designs. Stimulation parameters were the same as those used in FIG. 36B.
  • FIG. 61 depicts Tet Cas9 vector designs for inducible Cas9.
  • FIG. 62 depicts a vector and EGFP expression in 293FT cells after Doxycycline induction of Cas9 and EGFP.
  • nucleic acid refers to a deoxyribonucleic or ribonucleic oligonucleotide in either single- or double-stranded form.
  • the term encompasses nucleic acids, i.e., oligonucleotides, containing known analogues of natural nucleotides.
  • the term also encompasses nucleic-acid-like structures with synthetic backbones, see, e.g., Eckstein, 1991; Baserga et al, 1992; Milligan, 1993; WO 97/03211; WO 96/39154; Mata, 1997; Strauss- Soukup, 1997; and Straus, 1996.
  • recombinant refers to a polynucleotide synthesized or otherwise manipulated in vitro (e.g., “recombinant polynucleotide”), to methods of using recombinant polynucleotides to produce gene products in cells or other biological systems, or to a polypeptide ("recombinant protein") encoded by a recombinant polynucleotide.
  • “Recombinant means” encompasses the ligation of nucleic acids having various coding regions or domains or promoter sequences from different sources into an expression cassette or vector for expression of, e.g., inducible or constitutive expression of polypeptide coding sequences in the vectors of invention.
  • heterologous when used with reference to a nucleic acid, indicates that the nucleic acid is in a cell or a virus where it is not normally found in nature; or, comprises two or more subsequences that are not found in the same relationship to each other as normally found in nature, or is recombinantly engineered so that its level of expression, or physical relationship to other nucleic acids or other molecules in a cell, or structure, is not normally found in nature.
  • a similar term used in this context is "exogenous".
  • a heterologous nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged in a manner not found in nature; e.g., a human gene operably linked to a promoter sequence inserted into an adenovirus-based vector of the invention.
  • a heterologous nucleic acid of interest may encode an immunogenic gene product, wherein the adenovirus is administered therapeutically or prophylactically as a carrier or drug-vaccine composition.
  • Heterologous sequences may comprise various combinations of promoters and sequences, examples of which are described in detail herein.
  • a "therapeutic ligand” may be a substance which may bind to a receptor of a target cell with therapeutic effects.
  • a “therapeutic effect” may be a consequence of a medical treatment of any kind, the results of which are judged by one of skill in the field to be desirable and beneficial.
  • the “therapeutic effect” may be a behavioral or physiologic change which occurs as a response to the medical treatment. The result may be expected, unexpected, or even an unintended consequence of the medical treatment.
  • a “therapeutic effect” may include, for example, a reduction of symptoms in a subject suffering from infection by a pathogen.
  • a "target cell” may be a cell in which an alteration in its activity may induce a desired result or response.
  • a cell may be an in vitro cell.
  • the cell may be an isolated cell which may not be capable of developing into a complete organism.
  • a “ligand” may be any substance that binds to and forms a complex with a biomolecule to serve a biological purpose.
  • ligand may also refer to an "antigen” or “immunogen”.
  • antigen and “immunogen” are used interchangeably.
  • “Expression” of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context.
  • a "vector” is a tool that allows or facilitates the transfer of an entity from one environment to another.
  • some vectors used in recombinant DNA techniques allow entities, such as a segment of DNA (such as a heterologous DNA segment, such as a heterologous cDNA segment), to be transferred into a target cell.
  • the present invention comprehends recombinant vectors that may include viral vectors, bacterial vectors, protozoan vectors, DNA vectors, or recombinants thereof.
  • exogenous DNA for expression in a vector e.g., encoding an epitope of interest and/or an antigen and/or a therapeutic
  • documents providing such exogenous DNA as well as with respect to the expression of transcription and/or translation factors for enhancing expression of nucleic acid molecules, and as to terms such as "epitope of interest", “therapeutic”, “immune response”, “immunological response”, “protective immune response”, “immunological composition”, “immunogenic composition”, and “vaccine composition”, inter alia, reference is made to U.S. Patent No.
  • aspects of the invention comprehend the TALE and CRISPR-Cas systems of the invention being delivered into an organism or a cell or to a locus of interest via a delivery system.
  • a vector wherein the vector is a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-associated viral vectors, but other means of delivery are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided.
  • a viral vector such as a lenti- or baculo- or preferably adeno-viral/adeno-associated viral vectors, but other means of delivery are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided.
  • the viral or plasmid vectors may be delivered via nanoparticles, exosomes, microvesciles, or a gene-gun.
  • the terms “drug composition” and “drug”, “vaccinal composition”, “vaccine”, “vaccine composition”, “therapeutic composition” and “therapeutic-immunologic composition” cover any composition that induces protection against an antigen or pathogen.
  • the protection may be due to an inhibition or prevention of infection by a pathogen.
  • the protection may be induced by an immune response against the antigen(s) of interest, or which efficaciously protects against the antigen; for instance, after administration or injection into the subject, elicits a protective immune response against the targeted antigen or immunogen or provides efficacious protection against the antigen or immunogen expressed from the inventive adenovirus vectors of the invention.
  • pharmaceutical composition means any composition that is delivered to a subject. In some embodiments, the composition may be delivered to inhibit or prevent infection by a pathogen.
  • a “therapeutically effective amount” is an amount or concentration of the recombinant vector encoding the gene of interest, that, when administered to a subject, produces a therapeutic response or an immune response to the gene product of interest.
  • viral vector includes but is not limited to retroviruses, adenoviruses, adeno-associated viruses, alphaviruses, and herpes simplex virus.
  • the present invention comprehends spatiotemporal control of endogenous or exogenous gene expression using a form of energy.
  • the form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy.
  • the form of energy is electromagnetic radiation, preferably, light energy.
  • switch refers to a system or a set of components that act in a coordinated manner to affect a change, encompassing all aspects of biological function such as activation, repression, enhancement or termination of that function.
  • switch encompasses genetic switches which comprise the basic components of gene regulatory proteins and the specific DNA sequences that these proteins recognize.
  • switches relate to inducible and repressible systems used in gene regulation. In general, an inducible system may be off unless there is the presence of some molecule (called an inducer) that allows for gene expression. The molecule is said to "induce expression”.
  • a repressible system is on except in the presence of some molecule (called a corepressor) that suppresses gene expression.
  • the molecule is said to "repress expression”.
  • the manner by which this happens is dependent on the control mechanisms as well as differences in cell type.
  • the term "inducible” as used herein may encompass all aspects of a switch irrespective of the molecular mechanism involved. Accordingly a switch as comprehended by the invention may include but is not limited to antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems.
  • the switch may be a tetracycline (Tet)/DOX inducible system, a light inducible systems, a Abscisic acid (ABA) inducible system, a cumate repressor/operator system, a 40HT/estrogen inducible system, an ecdysone-based inducible systems or a FKBP12/FRAP (FKBP12-rapamycin complex) inducible system.
  • Tet tetracycline
  • ABA Abscisic acid
  • 40HT/estrogen inducible system an ecdysone-based inducible systems
  • FKBP12/FRAP FKBP12-rapamycin complex
  • At least one switch may be associated with a TALE or CRISPR-Cas system wherein the activity of the TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch.
  • the term "contact" as used herein for aspects of the invention refers to any associative relationship between the switch and the inducer energy source, which may be a physical interaction with a component (as in molecules or proteins which bind together) or being in the path or being struck by energy emitted by the energy source (as in the case of absorption or reflection of light, heat or sound).
  • the contact of the switch with the inducer energy source is brought about by application of the inducer energy source.
  • the invention also comprehends contact via passive feedback systems.
  • passive feedback systems This includes but is not limited to any passive regulation mechanism by which the TALE or CRISPR-Cas system activity is controlled by contact with an inducer energy source that is already present and hence does not need to be applied.
  • this energy source may be a molecule or protein already existent in the cell or in the cellular environment.
  • Interactions which bring about contact passively may include but are not limited to receptor/ligand binding, receptor/chemical ligand binding, receptor/protein binding, antibody/protein binding, protein dimerization, protein heterodimerization, protein multimerization, nuclear receptor/ligand binding, post-translational modifications such as phosphorylation, dephosphorylation, ubiquitination or deubiquitination.
  • TAL photoresponsive transcription activator-like
  • DNA binding specificity of engineered TAL effectors is utilized to localize the complex to a particular region in the genome.
  • light-induced protein dimerization is used to attract an activating or repressing domain to the region specified by the TAL effector, resulting in modulation of the downstream gene.
  • Inducible effectors are contemplated for in vitro or in vivo application in which temporally or spatially specific gene expression control is desired.
  • In vitro examples temporally precise induction/suppression of developmental genes to elucidate the timing of developmental cues, spatially controlled induction of cell fate reprogramming factors for the generation of cell- type patterned tissues.
  • In vivo examples combined temporal and spatial control of gene expression within specific brain regions.
  • the inducible effector is a Light Inducible Transcriptional Effector (LITE).
  • LITE Light Inducible Transcriptional Effector
  • TALE transcription activator like effector
  • VP64 the activation domain VP64 are utilized in the present invention.
  • LITEs are designed to modulate or alter expression of individual endogenous genes in a temporally and spatially precise manner.
  • Each LITE may comprise a two component system consisting of a customized DNA-binding transcription activator like effector (TALE) protein, a light-responsive cryptochrome heterodimer from Arabadopsis thaliana, and a transcriptional activation/repression domain.
  • TALE DNA-binding transcription activator like effector
  • the TALE is designed to bind to the promoter sequence of the gene of interest.
  • the TALE protein is fused to one half of the cryptochrome heterodimer (cryptochrome-2 or CIB1), while the remaining cryptochrome partner is fused to a transcriptional effector domain.
  • Effector domains may be either activators, such as VP 16, VP64, or p65, or repressors, such as KRAB, EnR, or SID.
  • activators such as VP 16, VP64, or p65
  • repressors such as KRAB, EnR, or SID.
  • the TALE- cryptochrome2 protein localizes to the promoter of the gene of interest, but is not bound to the CIB1 -effector protein.
  • cryptochrome-2 Upon stimulation of a LITE with blue spectrum light, cryptochrome-2 becomes activated, undergoes a conformational change, and reveals its binding domain.
  • CIB1 binds to cryptochrome-2 resulting in localization of the effector domain to the promoter region of the gene of interest and initiating gene overexpression or silencing.
  • Activator and repressor domains may selected on the basis of species, strength, mechanism, duration, size, or any number of other parameters.
  • Preferred effector domains include, but are not limited to, a transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-protein recruiting domain, cellular uptake activity associated domain, nucleic acid binding domain or antibody presentation domain.
  • Gene targeting in a LITE or in any other inducible effector may be achieved via the specificity of customized TALE DNA binding proteins.
  • a target sequence in the promoter region of the gene of interest is selected and a TALE customized to this sequence is designed.
  • the central portion of the TALE consists of tandem repeats 34 amino acids in length. Although the sequences of these repeats are nearly identical, the 12th and 13th amino acids (termed repeat variable diresidues) of each repeat vary, determining the nucleotide-binding specificity of each repeat.
  • a DNA binding protein specific to the target promoter sequence is created.
  • the methods provided herein use isolated, non-naturally occurring, recombinant or engineered DNA binding proteins that comprise TALE monomers or TALE monomers or half monomers as a part of their organizational structure that enable the targeting of nucleic acid sequences with improved efficiency and expanded specificity.
  • Naturally occurring TALEs or "wild type TALEs" are nucleic acid binding proteins secreted by numerous species of proteobacteria.
  • TALE polypeptides contain a nucleic acid binding domain composed of tandem repeats of highly conserved monomer polypeptides that are predominantly 33, 34 or 35 amino acids in length and that differ from each other mainly in amino acid positions 12 and 13.
  • the nucleic acid is DNA.
  • polypeptide monomers As used herein, the term "polypeptide monomers", “TALE monomers” or “monomers” will be used to refer to the highly conserved repetitive polypeptide sequences within the TALE nucleic acid binding domain and the term “repeat variable di-residues” or “RVD” will be used to refer to the highly variable amino acids at positions 12 and 13 of the polypeptide monomers.
  • a general representation of a TALE monomer which is comprised within the DNA binding domain is Xi_ n-(X 12 X 13 )-X 14-33 or 34 or 35, where the subscript indicates the amino acid position and X represents any amino acid.
  • X12X13 indicate the RVDs.
  • the variable amino acid at position 13 is missing or absent and in such monomers, the RVD consists of a single amino acid.
  • the RVD may be alternatively represented as X*, where X represents X12 and (*) indicates that X 13 is absent.
  • the DNA binding domain comprises several repeats of TALE monomers and this may be represented as (Xi_n-(Xi2Xi3)-Xi4-33 or 34 or 35 ) z , where in an advantageous embodiment, z is at least 5 to 40. In a further advantageous embodiment, z is at least 10 to 26.
  • the TALE monomers have a nucleotide binding affinity that is determined by the identity of the amino acids in its RVD.
  • polypeptide monomers with an RVD of NI preferentially bind to adenine (A)
  • monomers with an RVD of NG preferentially bind to thymine (T)
  • monomers with an RVD of HD preferentially bind to cytosine (C)
  • monomers with an RVD of NN preferentially bind to both adenine (A) and guanine (G).
  • monomers with an RVD of IG preferentially bind to T.
  • the number and order of the polypeptide monomer repeats in the nucleic acid binding domain of a TALE determines its nucleic acid target specificity.
  • monomers with an RVD of NS recognize all four base pairs and may bind to A, T, G or C.
  • the structure and function of TALEs is further described in, for example, Moscou et al, Science 326: 1501 (2009); Boch et al, Science 326:1509-1512 (2009); and Zhang et al, Nature Biotechnology 29: 149-153 (2011), each of which is incorporated by reference in its entirety.
  • polypeptides used in methods of the invention are isolated, non-naturally occurring, recombinant or engineered nucleic acid-binding proteins that have nucleic acid or DNA binding regions containing polypeptide monomer repeats that are designed to target specific nucleic acid sequences.
  • polypeptide monomers having an RVD of FIN or NH preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences.
  • polypeptide monomers having RVDs RN, N, NK, SN, NH, KN, HN, NQ, HH, RG, KH, RH and SS preferentially bind to guanine.
  • polypeptide monomers having RVDs RN, NK, NQ, HH, KH, RH, SS and SN preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences.
  • polypeptide monomers having RVDs HH, KH, NH, NK, NQ, RH, RN and SS preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences.
  • the RVDs that have high binding specificity for guanine are RN, NH RH and KH.
  • polypeptide monomers having an RVD of NV preferentially bind to adenine and guanine.
  • monomers having RVDs of H*, HA, KA, N*, NA, NC, NS, RA, and S* bind to adenine, guanine, cytosine and thymine with comparable affinity.
  • the RVDs that have a specificity for adenine are NI, RI, KI, HI, and SI.
  • the RVDs that have a specificity for adenine are HN, SI and RI, most preferably the RVD for adenine specificity is SI.
  • the RVDs that have a specificity for thymine are NG, HG, RG and KG.
  • the RVDs that have a specificity for thymine are KG, HG and RG, most preferably the RVD for thymine specificity is KG or RG.
  • the RVDs that have a specificity for cytosine are HD, ND, KD, RD, HH, YG and SD.
  • the RVDs that have a specificity for cytosine are SD and RD.
  • the variant TALE monomers may comprise any of the RVDs that exhibit specificity for a nucleotide as depicted in FIG. 7A.
  • the RVD NT may bind to G and A.
  • the RVD NP may bind to A, T and C.
  • At least one selected RVD may be NI, HD, NG, N, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, KI, HI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA or NC.
  • the predetermined N-terminal to C-terminal order of the one or more polypeptide monomers of the nucleic acid or DNA binding domain determines the corresponding predetermined target nucleic acid sequence to which the polypeptides of the invention will bind.
  • the monomers and at least one or more half monomers are "specifically ordered to target" the genomic locus or gene of interest.
  • the natural TALE-binding sites always begin with a thymine (T), which may be specified by a cryptic signal within the non- repetitive N-terminus of the TALE polypeptide; in some cases this region may be referred to as repeat 0.
  • TALE binding sites do not necessarily have to begin with a thymine (T) and polypeptides of the invention may target DNA sequences that begin with T, A, G or C.
  • T thymine
  • the tandem repeat of TALE monomers always ends with a half-length repeat or a stretch of sequence that may share identity with only the first 20 amino acids of a repetitive full length TALE monomer and this half repeat may be referred to as a half-monomer (FIG. 8). Therefore, it follows that the length of the nucleic acid or DNA being targeted is equal to the number of full monomers plus two.
  • nucleic acid binding domains may be engineered to contain 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more polypeptide monomers arranged in a N-terminal to C-terminal direction to bind to a predetermined 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotide length nucleic acid sequence.
  • nucleic acid binding domains may be engineered to contain 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or more full length polypeptide monomers that are specifically ordered or arranged to target nucleic acid sequences of length 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28 nucleotides, respectively.
  • the polypeptide monomers are contiguous.
  • half-monomers may be used in the place of one or more monomers, particularly if they are present at the C-terminus of the TALE polypeptide.
  • Polypeptide monomers are generally 33, 34 or 35 amino acids in length. With the exception of the RVD, the amino acid sequences of polypeptide monomers are highly conserved or as described herein, the amino acids in a polypeptide monomer, with the exception of the RVD, exhibit patterns that effect TALE activity, the identification of which may be used in preferred embodiments of the invention. Representative combinations of amino acids in the monomer sequence, excluding the RVD, are shown by the Applicants to have an effect on TALE activity (FIG. 10).
  • the DNA binding domain comprises (Xi_n-Xi 2 Xi3-Xi 4 -33 or 34 or 35 ) z , wherein X 1-n is a chain of 1 1 contiguous amino acids, wherein Xi 2 Xi 3 is a repeat variable diresidue (RVD), wherein Xi 4 _33 or 3 4 or 35 is a chain of 21 , 22 or 23 contiguous amino acids, wherein z is at least 5 to 26, then the preferred combinations of amino acids are [LTLD] or [LTLA] or [LTQV] at X 1-4 , or [EQHG] or [RDHG] at positions X30-33 or X 3 i_3 4 or X3 2 _3 5 .
  • amino acid combinations of interest in the monomers are [LTPD] at Xi_ 4 and [NQALE] at Xi 6 - 2 o and [DHG] at X3 2 _3 4 when the monomer is 34 amino acids in length.
  • the monomer is 33 or 35 amino acids long, then the corresponding shift occurs in the positions of the contiguous amino acids [NQALE] and [DHG]; preferably, embodiments of the invention may have [NQALE] at Xi 5 _i9 or Xi 7 _ 2 i and [DHG] at
  • amino acid combinations of interest in the monomers are [LTPD] at Xi_ 4 and [KRALE] at Xi 6 - 2 o and [AHG] at X3 2 _3 4 or [LTPE] at Xi_ 4 and [KRALE] at Xi 6 - 2 o and [DHG] at X3 2 _3 4 when the monomer is 34 amino acids in length.
  • the monomer is 33 or 35 amino acids long, then the corresponding shift occurs in the positions of the contiguous amino acids [KRALE], [AHG] and [DHG].
  • the positions of the contiguous amino acids may be ([LTPD] at Xi_ 4 and [KRALE] at Xi5_i9 and [AHG] at X31-33) or ([LTPE] at Xi_ 4 and [KRALE] at Xi 5 _i 9 and [DHG] at X31-33) or ([LTPD] at Xi_ 4 and [KRALE] at Xi 7 _ 2 i and [AHG] at X33-35) or ([LTPE] at Xi_ 4 and [KRALE] at Xi 7 _ 2 i and [DHG] at X33_3 5 ).
  • contiguous amino acids [NGKQALE] are present at positions Xi 4 - 2 o or X13-19 or X 15-21 . These representative positions put forward various embodiments of the invention and provide guidance to identify additional amino acids of interest or combinations of amino acids of interest in all the TALE monomers described herein (FIGs .9A-F and 10).
  • TALE monomers excluding the RVDs which may be denoted in a sequence (X 1-n -X 14-34 or ⁇ _ ⁇ - ⁇ 4 _ 35 ), wherein X is any amino acid and the subscript is the amino acid position is provided in FIG.9A-F. The frequency with which each monomer occurs is also indicated.
  • TALE polypeptide binding efficiency may be increased by including amino acid sequences from the "capping regions" that are directly N-terminal or C-terminal of the DNA binding region of naturally occurring TALEs into the engineered TALEs at positions N-terminal or C-terminal of the engineered TALE DNA binding region.
  • the TALE polypeptides described herein further comprise an N-terminal capping region and/or a C-terminal capping region.
  • N-terminal capping region An exemplary amino acid sequence of a N-terminal capping region is:
  • An exemplary amino acid sequence of a C-terminal capping region is:
  • the DNA binding domain comprising the repeat TALE monomers and the C-terminal capping region provide structural basis for the organization of different domains in the d-TALEs or polypeptides of the invention.
  • N-terminal and/or C-terminal capping regions are not necessary to enhance the binding activity of the DNA binding region. Therefore, in certain embodiments, fragments of the N-terminal and/or C-terminal capping regions are included in the TALE polypeptides described herein.
  • the TALE polypeptides described herein contain a N- terminal capping region fragment that included at least 10, 20, 30, 40, 50, 54, 60, 70, 80, 87, 90, 94, 100, 102, 110, 117, 120, 130, 140, 147, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260 or 270 amino acids of an N-terminal capping region.
  • the N- terminal capping region fragment amino acids are of the C-terminus (the DNA-binding region proximal end) of an N-terminal capping region.
  • N-terminal capping region fragments that include the C- terminal 240 amino acids enhance binding activity equal to the full length capping region, while fragments that include the C-terminal 147 amino acids retain greater than 80% of the efficacy of the full length capping region, and fragments that include the C-terminal 117 amino acids retain greater than 50% of the activity of the full-length capping region.
  • the TALE polypeptides described herein contain a C-terminal capping region fragment that included at least 6, 10, 20, 30, 37, 40, 50, 60, 68, 70, 80, 90, 100, 110, 120, 127, 130, 140, 150, 155, 160, 170, 180 amino acids of a C-terminal capping region.
  • the C-terminal capping region fragment amino acids are of the N-terminus (the DNA-binding region proximal end) of a C-terminal capping region.
  • C-terminal capping region fragments that include the C-terminal 68 amino acids enhance binding activity equal to the full length capping region, while fragments that include the C-terminal 20 amino acids retain greater than 50% of the efficacy of the full length capping region.
  • the capping regions of the TALE polypeptides described herein do not need to have identical sequences to the capping region sequences provided herein.
  • the capping region of the TALE polypeptides described herein have sequences that are at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%), 98%o or 99% identical or share identity to the capping region amino acid sequences provided herein. Sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs.
  • the capping region of the TALE polypeptides described herein have sequences that are at least 95% dentical or share identity to the capping region amino acid sequences provided herein.
  • Sequence homologies may be generated by any of a number of computer programs known in the art, which include but are not limited to BLAST or FASTA. Suitable computer program for carrying out alignments like the GCG Wisconsin Bestfit package may also be used. Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.
  • the TALE polypeptides of the invention include a nucleic acid binding domain linked to the one or more effector domains.
  • effector domain or “regulatory and functional domain” refer to a polypeptide sequence that has an activity other than binding to the nucleic acid sequence recognized by the nucleic acid binding domain.
  • the polypeptides of the invention may be used to target the one or more functions or activities mediated by the effector domain to a particular target DNA sequence to which the nucleic acid binding domain specifically binds.
  • effector domain and “functional domain” are used interchangeably throughout this application.
  • the activity mediated by the effector domain is a biological activity.
  • the effector domain is a transcriptional inhibitor (i.e., a repressor domain), such as an mSin interaction domain (SID). SID4X domain or a Kruppel-associated box (KRAB) or fragments of the KRAB domain.
  • the effector domain is an enhancer of transcription (i.e. an activation domain), such as the VP 16, VP64 or p65 activation domain.
  • VP 16 is a herpesvirus protein. It is a very strong transcriptional activator that specifically activates viral immediate early gene expression.
  • the VP 16 activation domain is rich in acidic residues and has been regarded as a classic acidic activation domain (AAD).
  • AAD acidic activation domain
  • VP64 activation doamin is a tetrameric repeat of VP16's minimal activation domain.
  • p65 is one of two proteins that the NF-kappa B transcription factor complex is composed of. The other protein is p50.
  • the p65 activation domain is a part of the p65 subunit is a potent transcriptional activator even in the absence of p50.
  • the effector domain is a mammalian protein or biologically active fragment thereof. Such effector domains are referred to as "mammalian effector domains.”
  • the nucleic acid binding is linked, for example, with an effector domain or functional domain that includes but is not limited to transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, his
  • the effector domain is a protein domain which exhibits activities which include but are not limited to transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity, nuclease activity, nuclear-localization signaling activity, transcriptional repressor activity, transcriptional activator activity, transcription factor recruiting activity, or cellular uptake signaling activity.
  • Other preferred embodiments of the invention may include any combination the activities described herein.
  • a TALE polypeptide having a nucleic acid binding domain and an effector domain may be used to target the effector domain's activity to a genomic position having a predetermined nucleic acid sequence recognized by the nucleic acid binding domain.
  • TALE polypeptides are designed and used for targeting gene regulatory activity, such as transcriptional or translational modifier activity, to a regulatory, coding, and/or intergenic region, such as enhancer and/or repressor activity, that may affect transcription upstream and downstream of coding regions, and may be used to enhance or repress gene expression.
  • TALEs polypeptide may comprise effector domains having DNA- binding domains from transcription factors, effector domains from transcription factors (activators, repressors, co-activators, co-repressors), silencers, nuclear hormone receptors, and/or chromatin associated proteins and their modifiers (e.g., methylases, kinases, phosphatases, acetylases and deacetylases).
  • the TALE polypeptide may comprise a nuclease domain.
  • the nuclease domain is a non-specific Fokl endonucleases catalytic domain.
  • useful domains for regulating gene expression may also be obtained from the gene products of oncogenes.
  • effector domains having integrase or transposase activity may be used to promote integration of exogenous nucleic acid sequence into specific nucleic acid sequence regions, eliminate (knock-out) specific endogenous nucleic acid sequence, and/or modify epigenetic signals and consequent gene regulation, such as by promoting DNA methyltransferase, DNA demethylase, histone acetylase and histone deacetylase activity.
  • effector domains having nuclease activity may be used to alter genome structure by nicking or digesting target sequences to which the polypeptides of the invention specifically bind, and may allow introduction of exogenous genes at those sites.
  • effector domains having invertase activity may be used to alter genome structure by swapping the orientation of a DNA fragment.
  • the polypeptides used in the methods of the invention may be used to target transcriptional activity.
  • transcription factor refers to a protein or polypeptide that binds specific DNA sequences associated with a genomic locus or gene of interest to control transcription. Transcription factors may promote (as an activator) or block (as a repressor) the recruitment of RNA polymerase to a gene of interest. Transcription factors may perform their function alone or as a part of a larger protein complex.
  • transcription factors include but are not limited to a) stabilization or destabilization of RNA polymerase binding, b) acetylation or deacetylation of histone proteins and c) recruitment of co-activator or co-repressor proteins.
  • transcription factors play roles in biological activities that include but are not limited to basal transcription, enhancement of transcription, development, response to intercellular signaling, response to environmental cues, cell-cycle control and pathogenesis.
  • basal transcription See Latchman and DS (1997) Int. J. Biochem. Cell Biol. 29 (12): 1305-12; Lee TI, Young RA (2000) Annu. Rev. Genet. 34: 77-137and Mitchell PJ, Tjian R (1989) Science 245 (4916): 371-8, herein incorporated by reference in their entirety.
  • Light responsiveness of a LITE is achieved via the activation and binding of cryptochrome-2 and CIB1.
  • blue light stimulation induces an activating conformational change in cryptochrome-2, resulting in recruitment of its binding partner CIB1.
  • This binding is fast and reversible, achieving saturation in ⁇ 15 sec following pulsed stimulation and returning to baseline ⁇ 15 min after the end of stimulation.
  • Crytochrome-2 activation is also highly sensitive, allowing for the use of low light intensity stimulation and mitigating the risks of phototoxicity.
  • variable light intensity may be used to control the size of a LITE stimulated region, allowing for greater precision than vector delivery alone may offer.
  • the modularity of the LITE system allows for any number of effector domains to be employed for transcriptional modulation.
  • activator and repressor domains may be selected on the basis of species, strength, mechanism, duration, size, or any number of other parameters.
  • the first example is a LITE designed to activate transcription of the mouse gene NEUROG2.
  • the sequence TGAATGATGATAATACGA, located in the upstream promoter region of mouse NEUROG2 was selected as the target and a TALE was designed and synthesized to match this sequence.
  • the TALE sequence was linked to the sequence for cryptochrome-2 via a nuclear localization signal (amino acids: SPKK R VEAS) to facilitate transport of the protein from the cytosol to the nuclear space.
  • a second vector was synthesized comprising the CIB1 domain linked to the transcriptional activator domain VP64 using the same nuclear localization signal.
  • This second vector also a GFP sequence, is separated from the CIB1-VP64 fusion sequence by a 2A translational skip signal.
  • Expression of each construct was driven by a ubiquitous, constitutive promoter (CMV or EFl-a).
  • CMV or EFl-a ubiquitous, constitutive promoter
  • Mouse neuroblastoma cells from the Neuro 2 A cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via qPCR.
  • the second prototypical example is a LITE designed to activate transcription of the human gene KLF4.
  • the TALE sequence was linked to the sequence for CRY2PHR via a nuclear localization signal (amino acids: SPKKKRKVEAS).
  • SPKKKRKVEAS amino acids
  • the identical CIB1-VP64 activator protein described above was also used in this manifestation of the LITE system.
  • Human embryonal kidney cells from the HEK293FT cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via q
  • the light-intensity response of the LITE system was tested by stimulating samples with increased light power (0-9 mW/cm 2 ). Upregulation of KLF4 mRNA levels was observed for stimulation as low as 0.2 mW/cm 2 . KLF4 upregulation became saturated at 5 mW/cm 2 (2.3 fold vs. YFP samples). Cell viability tests were also performed for powers up to 9 mW/cm 2 and showed >98% cell viability. Similarly, the KLF4 LITE response to varying duty cycles of stimulation was tested (1.6-100%). No difference in KLF4 activation was observed between different duty cycles indicating that a stimulation paradigm of as low as 0.25 sec every 15 sec should result in maximal activation.
  • the invention contemplates energy sources such as electromagnetic radiation, sound energy or thermal energy.
  • the electromagnetic radiation is a component of visible light.
  • the light is a blue light with a wavelength of about 450 to about 495 nm.
  • the wavelength is about 488 nm.
  • the light stimulation is via pulses.
  • the light power may range from about 0-9 mW/cm 2 .
  • a stimulation paradigm of as low as 0.25 sec every 15 sec should result in maximal activation.
  • the invention particularly relates to inducible methods of perturbing a genomic or epigenomic locus or altering expression of a genomic locus of interest in a cell wherein the genomic or epigenomic locus may be contacted with a non-naturally occurring or engineered composition comprising a deoxyribonucleic acid (DNA) binding polypeptide.
  • DNA deoxyribonucleic acid
  • the cells of the present invention may be a prokaryotic cell or a eukaryotic cell, advantageously an animal cell, more advantageously a mammalian cell.
  • This polypeptide may include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half- monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to a chemical sensitive protein or fragment thereof.
  • TALE Transcription activator-like effector
  • the chemical or energy sensitive protein or fragment thereof may undergo a conformational change upon induction by the binding of a chemical source allowing it to bind an interacting partner.
  • the polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the chemical or energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the chemical source.
  • the method may also include applying the chemical source and determining that the expression of the genomic locus is altered.
  • ABI-PYL based system inducible by Abscisic Acid (ABA) see, e.g., http://stke.sciencemag.org/cgi/content/abstract/sigtrans;4/164/rs2
  • FKBP-FRB based system inducible by rapamycin or related chemicals based on rapamycin
  • GID1-GAI based system inducible by Gibberellin (GA) see, e.g., http://www.nature.com/nchembio/joumal/v8/n5/full/nchembio.922.htm
  • Another system contemplated by the present invention is a chemical inducible system based on change in sub-cellular localization.
  • the polypeptide include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest linked to at least one or more effector domains are further linker to a chemical or energy sensitive protein.
  • TALE Transcription activator-like effector
  • This type of system could also be used to induce the cleavage of a genomic locus of interest in a cell when the effector domain is a nuclease.
  • ER estrogen receptor
  • 40HT 4-hydroxytamoxifen
  • ERT2 mutated ligand-binding domain of the estrogen receptor
  • Two tandem ERT2 domains were linked together with a flexible peptide linker and then fused to the TALE protein targeting a specific sequence in the mammalian genome and linked to one or more effector domains.
  • This polypeptide will be in the cytoplasm of cells in the absence of 40HT, which renders the TALE protein linked to the effector domains inactive.
  • 40HT the binding of 40HT to the tandem ERT2 domain will induce the transportation of the entire peptide into nucleus of cells, allowing the TALE protein linked to the effector domains become active.
  • the present invention may comprise a nuclear exporting signal (NES).
  • the NES may have the sequence of LDLASLIL.
  • any naturally occurring or engineered derivative of any nuclear receptor, thyroid hormone receptor, retinoic acid receptor, estrogren receptor, estrogen-related receptor, glucocorticoid receptor, progesterone receptor, androgen receptor may be used in inducible systems analogous to the ER based inducible system.
  • TRP Transient receptor potential
  • ion channel based system inducible by energy, heat or radio-wave
  • TRP family proteins respond to different stimuli, including light and heat.
  • the ion channel will open and allow the entering of ions such as calcium into the plasma membrane.
  • This inflex of ions will bind to intracellular ion interacting partners linked to a polypeptide include TALE protein and one or more effector domains, and the binding will induce the change of subcellular localization of the polypeptide, leading to the entire polypeptide entering the nucleus of cells. Once inside the nucleus, the TALE protein linked to the effector domains will be active and modulating target gene expression in cells.
  • This type of system could also be used to induce the cleavage of a genomic locus of interest in a cell when the effector domain is a nuclease.
  • the light could be generated with a laser or other forms of energy sources.
  • the heat could be generated by raise of temperature results from an energy source, or from nano-particles that release heat after absorbing energy from an energy source delivered in the form of radio-wave.
  • light activation may be an advantageous embodiment, sometimes it may be disadvantageous especially for in vivo applications in which the light may not penetrate the skin or other organs.
  • other methods of energy activation are contemplated, in particular, electric field energy and/or ultrasound which have a similar effect.
  • the proteins pairings of the LITE system may be altered and/or modified for maximal effect by another energy source.
  • Electric field energy is preferably administered substantially as described in the art, using one or more electric pulses of from about 1 Volt/cm to about 10 kVolts/cm under in vivo conditions.
  • the electric field may be delivered in a continuous manner.
  • the electric pulse may be applied for between 1 and 500 milliseconds, preferably between 1 and 100 milliseconds.
  • the electric field may be applied continuously or in a pulsed manner for 5 about minutes.
  • 'electric field energy' is the electrical energy to which a cell is exposed.
  • the electric field has a strength of from about 1 Volt/cm to about 10 kVolts/cm or more under in vivo conditions (see WO97/49450).
  • the term "electric field” includes one or more pulses at variable capacitance and voltage and including exponential and/or square wave and/or modulated wave and/or modulated square wave forms. References to electric fields and electricity should be taken to include reference the presence of an electric potential difference in the environment of a cell. Such an environment may be set up by way of static electricity, alternating current (AC), direct current (DC), etc, as known in the art.
  • the electric field may be uniform, non-uniform or otherwise, and may vary in strength and/or direction in a time dependent manner.
  • the ultrasound and/or the electric field may be delivered as single or multiple continuous applications, or as pulses (pulsatile delivery).
  • Electroporation has been used in both in vitro and in vivo procedures to introduce foreign material into living cells.
  • a sample of live cells is first mixed with the agent of interest and placed between electrodes such as parallel plates. Then, the electrodes apply an electrical field to the cell/implant mixture.
  • Examples of systems that perform in vitro electroporation include the Electro Cell Manipulator ECM600 product, and the Electro Square Porator T820, both made by the BTX Division of Genetronics, Inc (see U.S. Pat. No 5,869,326).
  • the known electroporation techniques function by applying a brief high voltage pulse to electrodes positioned around the treatment region.
  • the electric field generated between the electrodes causes the cell membranes to temporarily become porous, whereupon molecules of the agent of interest enter the cells.
  • this electric field comprises a single square wave pulse on the order of 1000 V/cm, of about 100 .mu.s duration.
  • Such a pulse may be generated, for example, in known applications of the Electro Square Porator T820.
  • the electric field has a strength of from about 1 V/cm to about 10 kV/cm under in vitro conditions.
  • the electric field may have a strength of 1 V/cm, 2 V/cm, 3 V/cm, 4 V/cm, 5 V/cm, 6 V/cm, 7 V/cm, 8 V/cm, 9 V/cm, 10 V/cm, 20 V/cm, 50 V/cm, 100 V/cm, 200 V/cm, 300 V/cm, 400 V/cm, 500 V/cm, 600 V/cm, 700 V/cm, 800 V/cm, 900 V/cm, 1 kV/cm, 2 kV/cm, 5 kV/cm, 10 kV/cm, 20 kV/cm, 50 kV/cm or more.
  • the electric field has a strength of from about 1 V/cm to about 10 kV/cm under in vivo conditions.
  • the electric field strengths may be lowered where the number of pulses delivered to the target site are increased.
  • pulsatile delivery of electric fields at lower field strengths is envisaged.
  • the application of the electric field is in the form of multiple pulses such as double pulses of the same strength and capacitance or sequential pulses of varying strength and/or capacitance.
  • pulse includes one or more electric pulses at variable capacitance and voltage and including exponential and/or square wave and/or modulated wave/square wave forms.
  • the electric pulse is delivered as a waveform selected from an exponential wave form, a square wave form, a modulated wave form and a modulated square wave form.
  • a preferred embodiment employs direct current at low voltage.
  • Applicants disclose the use of an electric field which is applied to the cell, tissue or tissue mass at a field strength of between lV/cm and 20V/cm, for a period of 100 milliseconds or more, preferably 15 minutes or more.
  • Ultrasound is advantageously administered at a power level of from about 0.05 W/cm 2 to about 100 W/cm 2 . Diagnostic or therapeutic ultrasound may be used, or combinations thereof.
  • the term "ultrasound” refers to a form of energy which consists of mechanical vibrations the frequencies of which are so high they are above the range of human hearing. Lower frequency limit of the ultrasonic spectrum may generally be taken as about 20 kHz. Most diagnostic applications of ultrasound employ frequencies in the range 1 and 15 MHz' (From Ultrasonics in Clinical Diagnosis, P. N. T. Wells, ed., 2nd. Edition, Publ. Churchill Livingstone [Edinburgh, London & NY, 1977]).
  • Ultrasound has been used in both diagnostic and therapeutic applications.
  • diagnostic ultrasound When used as a diagnostic tool (“diagnostic ultrasound"), ultrasound is typically used in an energy density range of up to about 100 mW/cm 2 (FDA recommendation), although energy densities of up to 750 mW/cm 2 have been used.
  • FDA recommendation energy densities of up to 750 mW/cm 2 have been used.
  • physiotherapy ultrasound is typically used as an energy source in a range up to about 3 to 4 W/cm 2 (WHO recommendation).
  • WHO recommendation W/cm 2
  • higher intensities of ultrasound may be employed, for example, HIFU at 100 W/cm up to 1 kW/cm 2 (or even higher) for short periods of time.
  • the term "ultrasound" as used in this specification is intended to encompass diagnostic, therapeutic and focused ultrasound.
  • Focused ultrasound allows thermal energy to be delivered without an invasive probe (see Morocz et al 1998 Journal of Magnetic Resonance Imaging Vol.8, No. 1, pp.136-142.
  • Another form of focused ultrasound is high intensity focused ultrasound (HIFU) which is reviewed by Moussatov et al in Ultrasonics (1998) Vol.36, No.8, pp.893-900 and TranHuuHue et al in Acustica (1997) Vol.83, No.6, pp.1103-1106.
  • a combination of diagnostic ultrasound and a therapeutic ultrasound is employed.
  • This combination is not intended to be limiting, however, and the skilled reader will appreciate that any variety of combinations of ultrasound may be used. Additionally, the energy density, frequency of ultrasound, and period of exposure may be varied.
  • the exposure to an ultrasound energy source is at a power density of from about 0.05 to about 100 Wcm "2 . Even more preferably, the exposure to an ultrasound energy source is at a power density of from about 1 to about 15 Wcm "2 .
  • the exposure to an ultrasound energy source is at a frequency of from about 0.015 to about 10.0 MHz. More preferably the exposure to an ultrasound energy source is at a frequency of from about 0.02 to about 5.0 MHz or about 6.0 MHz. Most preferably, the ultrasound is applied at a frequency of 3 MHz.
  • the exposure is for periods of from about 10 milliseconds to about 60 minutes. Preferably the exposure is for periods of from about 1 second to about 5 minutes. More preferably, the ultrasound is applied for about 2 minutes. Depending on the particular target cell to be disrupted, however, the exposure may be for a longer duration, for example, for 15 minutes.
  • the target tissue is exposed to an ultrasound energy source at an acoustic power density of from about 0.05 Wcm “2 to about 10 Wcm “2 with a frequency ranging from about 0.015 to about 10 MHz (see WO 98/52609).
  • an ultrasound energy source at an acoustic power density of above 100 Wcm "2 , but for reduced periods of time, for example, 1000 Wcm "2 for periods in the millisecond range or less.
  • the application of the ultrasound is in the form of multiple pulses; thus, both continuous wave and pulsed wave (pulsatile delivery of ultrasound) may be employed in any combination.
  • continuous wave ultrasound may be applied, followed by pulsed wave ultrasound, or vice versa. This may be repeated any number of times, in any order and combination.
  • the pulsed wave ultrasound may be applied against a background of continuous wave ultrasound, and any number of pulses may be used in any number of groups.
  • the ultrasound may comprise pulsed wave ultrasound.
  • the ultrasound is applied at a power density of 0.7 Wcm -2 or 1.25 Wcm -2 as a continuous wave. Higher power densities may be employed if pulsed wave ultrasound is used.
  • ultrasound is advantageous as, like light, it may be focused accurately on a target. Moreover, ultrasound is advantageous as it may be focused more deeply into tissues unlike light. It is therefore better suited to whole-tissue penetration (such as but not limited to a lobe of the liver) or whole organ (such as but not limited to the entire liver or an entire muscle, such as the heart) therapy. Another important advantage is that ultrasound is a non-invasive stimulus which is used in a wide variety of diagnostic and therapeutic applications. By way of example, ultrasound is well known in medical imaging techniques and, additionally, in orthopedic therapy. Furthermore, instruments suitable for the application of ultrasound to a subject vertebrate are widely available and their use is well known in the art.
  • LITEs may be used to study the dynamics of mRNA splice variant production upon induced expression of a target gene.
  • mRNA degradation studies are often performed in response to a strong extracellular stimulus, causing expression level changes in a plethora of genes.
  • LITEs may be utilized to reversibly induce transcription of an endogenous target, after which point stimulation may be stopped and the degradation kinetics of the unique target may be tracked.
  • LITEs may provide the power to time genetic regulation in concert with experimental interventions.
  • targets with suspected involvement in long-term potentiation may be modulated in organotypic or dissociated neuronal cultures, but only during stimulus to induce LTP, so as to avoid interfering with the normal development of the cells.
  • LTP long-term potentiation
  • targets suspected to be involved in the effectiveness of a particular therapy may be modulated only during treatment.
  • genetic targets may be modulated only during a pathological stimulus. Any number of experiments in which timing of genetic cues to external experimental stimuli is of relevance may potentially benefit from the utility of LITE modulation.
  • LITEs may be used in a transparent organism, such as an immobilized zebrafish, to allow for extremely precise laser induced local gene expression changes.
  • the present invention also contemplates a multiplex genome engineering using CRISPPv/Cas sytems. Functional elucidation of causal genetic variants and elements requires precise genome editing technologies.
  • the type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats) adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage.
  • Applicants engineered two different type II CRISPR systems and demonstrate that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells. Cas9 can also be converted into a nicking enzyme to facilitate homology-directed repair with minimal mutagenic activity.
  • multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several sites within the mammalian genome, demonstrating easy programmability and wide applicability of the CRISPR technology.
  • CRISPR system refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer” in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus.
  • a tracr trans-activating CRISPR
  • tracr-mate sequence encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system
  • guide sequence also referred to as a "spacer” in the context of an endogenous CRISPR system
  • one or more elements of a CRISPR system is derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system).
  • target sequence refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex.
  • a target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides.
  • a target sequence is located in the nucleus or cytoplasm of a cell.
  • a CRISPR complex comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins
  • formation of a CRISPR complex results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence.
  • all or a portion of the tracr sequence may also form part of a CRISPR complex, such as by hybridization to all or a portion of a tracr mate sequence that is operably linked to the guide sequence.
  • one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites.
  • a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors.
  • two or more of the elements expressed from the same or different regulatory elements may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector.
  • CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to ("upstream” of) or 3' with respect to ("downstream” of) a second element.
  • the coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction.
  • a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or all in a single intron).
  • the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.
  • a vector comprises one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site").
  • one or more insertion sites e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
  • a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that following insertion of a guide sequence into the insertion site and upon expression the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell.
  • a vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to allow insertion of a guide sequence at each site.
  • the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these.
  • a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell.
  • a single vector may comprise about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequence-containing vectors may be provided, and optionally delivered to a cell.
  • a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein.
  • Cas proteins include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, C
  • the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9.
  • the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence.
  • a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence.
  • an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand).
  • mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A.
  • two or more catalytic domains of Cas9 may be mutated to produce a mutated Cas9 substantially lacking all DNA cleavage activity.
  • a D10A mutation is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity.
  • a CRISPR enzyme is considered to substantially lack all DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%>, 1%>, 0.1 %>, 0.01%, or lower with respect to its non- mutated form.
  • an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells.
  • the eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate.
  • codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence.
  • Codon bias differs in codon usage between organisms
  • mRNA messenger RNA
  • tRNA transfer RNA
  • the predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database" available at www.kazusa.orjp/codon/ (visited Jul.
  • a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs.
  • the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy-terminus, or a combination of these (e.g. one or more NLS at the amino-terminus and one or more NLS at the carboxy terminus).
  • NLS When more than one NLS is present, each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies.
  • an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus.
  • NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV; the NLS from nucleoplasmin (e.g.
  • the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell.
  • strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors.
  • Detection of accumulation in the nucleus may be performed by any suitable technique.
  • a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be visualized, such as in combination with a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI).
  • Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR enzyme activity), as compared to a control no exposed to the CRISPR enzyme or complex, or exposed to a CRISPR enzyme lacking the one or more NLSs.
  • an assay for the effect of CRISPR complex formation e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR enzyme activity
  • the invention relates to an inducible CRISPR which may comprise an inducible Cas9.
  • the CRISPR system may be encoded within a vector system which may comprise one or more vectors which may comprise I. a first regulatory element operably linked to a CRISPR/Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence may comprise (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II.
  • chiRNA chimeric RNA
  • a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme which may comprise at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3 Orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex may comprise the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the enzyme coding sequence encoding the CRISPR enzyme further encodes a heterologous functional domain.
  • the inducible Cas9 may be prepared in a lentivirus.
  • FIG. 61 depicts Tet Cas9 vector designs and FIG. 62 depicts a vector and EGFP expression in 293FT cells.
  • an inducible tetracycline system is contemplated for an inducible CRISPR.
  • the vector may be designed as described in Markusic et al, Nucleic Acids Research, 2005, Vol. 33, No. 6 e63.
  • the tetracycline-dependent transcriptional regulatory system is based on the Escherichia coli TnlO Tetracycline resistance operator consisting of the tetracycline repressor protein (TetR) and a specific DNA-binding site, the tetracycline operator sequence (TetO). In the absence of tetracycline, TetR dimerizes and binds to the TetO. Tetracycline or doxycycline (a tetracycline derivative) can bind and induce a conformational change in the TetR leading to its disassociation from the TetO.
  • TetR tetracycline repressor protein
  • TetO tetracycline operator sequence
  • the vector may be a single Tet-On lentiviral vector with autoregulated rtTA expression for regulated expression of the CRISPR complex.
  • Tetracycline or doxycycline may be contemplated for activating the inducible CRISPR complex.
  • a cumate gene-switch system is contemplated for an inducible CRISPR.
  • the inducible cumate system involves regulatory mechanisms of bacterial operons (cmt and cym) to regulate gene expression in mammalian cells using three different strategies.
  • cmt and cym regulatory mechanisms of bacterial operons
  • regulation is mediated by the binding of the repressor (CymR) to the operator site (CuO), placed downstream of a strong constitutive promoter. Addition of cumate, a small molecule, relieves the repression.
  • a chimaeric transactivator (cTA) protein formed by the fusion of CymR with the activation domain of VP 16, is able to activate transcription when bound to multiple copies of CuO, placed upstream of the CMV minimal promoter. Cumate addition abrogates DNA binding and therefore transactivation by cTA.
  • the invention also contemplates a reverse cumate activator (rcTA), which activates transcription in the presence rather than the absence of cumate.
  • CymR may be used as a repressor that reversibly blocks expression from a strong promoter, such as CMV. Certain aspects of the Cumate repressor/operator system are further described in US patent No. 7745592.
  • the present invention also encompasses nucleic acid encoding the polypeptides of the present invention.
  • the nucleic acid may comprise a promoter, advantageously human Synapsin I promoter (hSyn).
  • the nucleic acid may be packaged into an adeno associated viral vector (AAV).
  • AAV adeno associated viral vector
  • adenovirus vectors may display an altered tropism for specific tissues or cell types (Havenga, M.J.E. et al., 2002), and therefore, mixing and matching of different adenoviral capsids, i.e., fiber, or penton proteins from various adenoviral serotypes may be advantageous.
  • adenoviral capsids including fiber and penton
  • Modification of the adenoviral capsids, including fiber and penton may result in an adenoviral vector with a tropism that is different from the unmodified adenovirus.
  • Adenovirus vectors that are modified and optimized in their ability to infect target cells may allow for a significant reduction in the therapeutic or prophylactic dose, resulting in reduced local and disseminated toxicity.
  • Viral vector gene delivery systems are commonly used in gene transfer and gene therapy applications. Different viral vector systems have their own unique advantages and disadvantages.
  • Viral vectors that may be used to express the pathogen-derived ligand of the present invention include but are not limited to adenoviral vectors, adeno-associated viral vectors, alphavirus vectors, herpes simplex viral vectors, and retroviral vectors, described in more detail below.
  • adenoviruses are such that the biology of the adenovirus is characterized in detail; the adenovirus is not associated with severe human pathology; the adenovirus is extremely efficient in introducing its DNA into the host cell; the adenovirus may infect a wide variety of cells and has a broad host range; the adenovirus may be produced in large quantities with relative ease; and the adenovirus may be rendered replication defective and/or non-replicating by deletions in the early region 1 ("El") of the viral genome.
  • El early region 1
  • Adenovirus is a non-enveloped DNA virus.
  • the genome of adenovirus is a linear double-stranded DNA molecule of approximately 36,000 base pairs ("bp") with a 55-kDa terminal protein covalently bound to the 5 '-terminus of each strand.
  • the adenovirus DNA contains identical inverted terminal repeats ("ITRs") of about 100 bp, with the exact length depending on the serotype.
  • ITRs inverted terminal repeats
  • the viral origins of replication are located within the ITRs exactly at the genome ends. DNA synthesis occurs in two stages. First, replication proceeds by strand displacement, generating a daughter duplex molecule and a parental displaced strand.
  • the displaced strand is single stranded and may form a "panhandle" intermediate, which allows replication initiation and generation of a daughter duplex molecule.
  • replication may proceed from both ends of the genome simultaneously, obviating the requirement to form the panhandle structure.
  • the viral genes are expressed in two phases: the early phase, which is the period up to viral DNA replication, and the late phase, which coincides with the initiation of viral DNA replication.
  • the early phase only the early gene products, encoded by regions El, E2, E3 and E4, are expressed, which carry out a number of functions that prepare the cell for synthesis of viral structural proteins (Berk, A.J., 1986).
  • the late phase the late viral gene products are expressed in addition to the early gene products and host cell DNA and protein synthesis are shut off. Consequently, the cell becomes dedicated to the production of viral DNA and of viral structural proteins (Tooze, J., 1981).
  • the El region of adenovirus is the first region of adenovirus expressed after infection of the target cell. This region consists of two transcriptional units, the E1A and EIB genes, both of which are required for oncogenic transformation of primary (embryonal) rodent cultures.
  • the main functions of the El A gene products are to induce quiescent cells to enter the cell cycle and resume cellular DNA synthesis, and to transcriptionally activate the EIB gene and the other early regions (E2, E3 and E4) of the viral genome. Transfection of primary cells with the El A gene alone may induce unlimited proliferation (immortalization), but does not result in complete transformation.
  • the EIB encoded proteins assist El A in redirecting the cellular functions to allow viral replication.
  • the EIB 55 kD and E4 33 kD proteins which form a complex that is essentially localized in the nucleus, function in inhibiting the synthesis of host proteins and in facilitating the expression of viral genes. Their main influence is to establish selective transport of viral mRNAs from the nucleus to the cytoplasm, concomitantly with the onset of the late phase of infection.
  • the EIB 21 kD protein is important for correct temporal control of the productive infection cycle, thereby preventing premature death of the host cell before the virus life cycle has been completed.
  • Mutant viruses incapable of expressing the EIB 21 kD gene product exhibit a shortened infection cycle that is accompanied by excessive degradation of host cell chromosomal DNA (deg-phenotype) and in an enhanced cytopathic effect (cyt-phenotype; Telling et al, 1994).
  • the deg and cyt phenotypes are suppressed when in addition the El A gene is mutated, indicating that these phenotypes are a function of El A (White, E. et al., 1988).
  • the EIB 21 kDa protein slows down the rate by which E1A switches on the other viral genes. It is not yet known by which mechanisms EIB 21 kD quenches these El A dependent functions.
  • adenoviruses In contrast to, for example, retroviruses, adenoviruses do not efficiently integrate into the host cell's genome, are able to infect non-dividing cells, and are able to efficiently transfer recombinant genes in vivo (Brody et al., 1994). These features make adenoviruses attractive candidates for in vivo gene transfer of, for example, an antigen or immunogen of interest into cells, tissues or subjects in need thereof.
  • Adenovirus vectors containing multiple deletions are preferred to both increase the carrying capacity of the vector and reduce the likelihood of recombination to generate replication competent adenovirus (RCA).
  • RCA replication competent adenovirus
  • the adenovirus contains multiple deletions, it is not necessary that each of the deletions, if present alone, would result in a replication defective and/or non-replicating adenovirus.
  • the additional deletions may be included for other purposes, e.g., to increase the carrying capacity of the adenovirus genome for heterologous nucleotide sequences.
  • more than one of the deletions prevents the expression of a functional protein and renders the adenovirus replication defective and/or non-replicating and/or attenuated. More preferably, all of the deletions are deletions that would render the adenovirus replication-defective and/or non-replicating and/or attenuated.
  • the invention also encompasses adenovirus and adenovirus vectors that are replication competent and/or wild-type, i.e. comprises all of the adenoviral genes necessary for infection and replication in a subject.
  • Embodiments of the invention employing adenovirus recombinants may include El- defective or deleted, or E3 -defective or deleted, or E4-defective or deleted or adenovirus vectors comprising deletions of El and E3, or El and E4, or E3 and E4, or El, E3, and E4 deleted, or the "gutless" adenovirus vector in which all viral genes are deleted.
  • the adenovirus vectors may comprise mutations in El, E3, or E4 genes, or deletions in these or all adenoviral genes.
  • the El mutation raises the safety margin of the vector because El -defective adenovirus mutants are said to be replication-defective and/or non-replicating in non-permissive cells, and are, at the very least, highly attenuated.
  • the E3 mutation enhances the immunogenicity of the antigen by disrupting the mechanism whereby adenovirus down-regulates MHC class I molecules.
  • the E4 mutation reduces the immunogenicity of the adenovirus vector by suppressing the late gene expression, thus may allow repeated re-vaccination utilizing the same vector.
  • the present invention comprehends adenovirus vectors of any serotype or serogroup that are deleted or mutated in El, or E3, or E4, or El and E3, or El and E4. Deletion or mutation of these adenoviral genes result in impaired or substantially complete loss of activity of these proteins.
  • the "gutless" adenovirus vector is another type of vector in the adenovirus vector family. Its replication requires a helper virus and a special human 293 cell line expressing both Ela and Cre, a condition that does not exist in a natural environment; the vector is deprived of all viral genes, thus the vector as a vaccine carrier is non-immunogenic and may be inoculated multiple times for re-vaccination.
  • the "gutless" adenovirus vector also contains 36 kb space for accommodating antigen or immunogen(s) of interest, thus allowing co-delivery of a large number of antigen or immunogens into cells.
  • Adeno-associated virus is a single-stranded DNA parvovirus which is endogenous to the human population. Although capable of productive infection in cells from a variety of species, AAV is a dependovirus, requiring helper functions from either adenovirus or herpes virus for its own replication. In the absence of helper functions from either of these helper viruses, AAV will infect cells, uncoat in the nucleus, and integrate its genome into the host chromosome, but will not replicate or produce new viral particles.
  • the genome of AAV has been cloned into bacterial plasmids and is well characterized.
  • the viral genome consists of 4682 bases which include two terminal repeats of 145 bases each. These terminal repeats serve as origins of DNA replication for the virus. Some investigators have also proposed that they have enhancer functions.
  • the rest of the genome is divided into two functional domains. The left portion of the genome codes for the rep functions which regulate viral DNA replication and vital gene expression.
  • the right side of the vital genome contains the cap genes that encode the structural capsid proteins VP1, VP2 and VP3. The proteins encoded by both the rep and cap genes function in trans during productive AAV replication.
  • AAV is considered an ideal candidate for use as a transducing vector, and it has been used in this manner.
  • Such AAV transducing vectors comprise sufficient cis-acting functions to replicate in the presence of adenovirus or herpes virus helper functions provided in trans.
  • Recombinant AAV rAAV
  • rAAV Recombinant AAV
  • these vectors the AAV cap and/or rep genes are deleted from the viral genome and replaced with a DNA segment of choice.
  • Current vectors may accommodate up to 4300 bases of inserted DNA.
  • plasmids containing the desired vital construct are transfected into adenovirus-infected cells.
  • a second helper plasmid is cotransfected into these cells to provide the AAV rep and cap genes which are obligatory for replication and packaging of the recombinant viral construct.
  • the rep and cap proteins of AAV act in trans to stimulate replication and packaging of the rAAV construct.
  • rAAV is harvested from the cells along with adenovirus. The contaminating adenovirus is then inactivated by heat treatment.
  • Herpes Simplex Virus 1 (HSV-1) is an enveloped, double-stranded DNA virus with a genome of 153 kb encoding more than 80 genes. Its wide host range is due to the binding of viral envelope glycoproteins to the extracellular heparin sulphate molecules found in cell membranes (WuDunn & Spear, 1989). Internalization of the virus then requires envelope glycoprotein gD and fibroblast growth factor receptor (Kaner, 1990). HSV is able to infect cells lyrically or may establish latency. HSV vectors have been used to infect a wide variety of cell types (Lowenstein, 1994; Huard, 1995; Miyanohara, 1992; Liu, 1996; Goya, 1998).
  • HSV vectors There are two types of HSV vectors, called the recombinant HSV vectors and the amplicon vectors.
  • Recombinant HSV vectors are generated by the insertion of transcription units directly into the HSV genome, through homologous recombination events.
  • the amplicon vectors are based on plasmids bearing the transcription unit of choice, an origin of replication, and a packaging signal.
  • HSV vectors have the obvious advantages of a large capacity for insertion of foreign genes, the capacity to establish latency in neurons, a wide host range, and the ability to confer transgene expression to the CNS for up to 18 months (Carpenter & Stevens, 1996).
  • Retroviruses are enveloped single-stranded RNA viruses, which have been widely used in gene transfer protocols. Retroviruses have a diploid genome of about 7-10 kb, composed of four gene regions termed gag, pro, pol and env. These gene regions encode for structural capsid proteins, viral protease, integrase and viral reverse transcriptase, and envelope glycoproteins, respectively. The genome also has a packaging signal and cz ' s-acting sequences, termed long-terminal repeats (LTRs), at each end, which have a role in transcriptional control and integration.
  • LTRs long-terminal repeats
  • the most commonly used retroviral vectors are based on the Moloney murine leukaemia virus (Mo-MLV) and have varying cellular tropisms, depending on the receptor binding surface domain of the envelope glycoprotein.
  • Mo-MLV Moloney murine leukaemia virus
  • Retroviral vectors are deleted from all retroviral genes, which are replaced with marker or therapeutic genes, or both. To propagate recombinant retroviruses, it is necessary to provide the viral genes, gag, pol and env in trans.
  • Lentiviruses are complex retroviruses that have the ability to infect and express their genes in both mitotic and post-mitotic cells.
  • the most commonly known lentivirus is the human immunodeficiency virus (HIV), which uses the envelope glycoproteins of other viruses to target a broad range of cell types.
  • HIV human immunodeficiency virus
  • Alphaviruses including the prototype Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan equine encephalitis virus (VEE), constitute a group of enveloped viruses containing plus-stranded RNA genomes within icosahedral capsids.
  • the viral vectors of the present invention are useful for the delivery of nucleic acids expressing antigens or immunogens to cells both in vitro and in vivo.
  • the inventive vectors may be advantageously employed to deliver or transfer nucleic acids to cells, more preferably mammalian cells.
  • Nucleic acids of interest include nucleic acids encoding peptides and proteins, preferably therapeutic (e.g., for medical or veterinary uses) or immunogenic (e.g., for vaccines) peptides or proteins.
  • the codons encoding the antigen or immunogen of interest are "optimized" codons, i.e., the codons are those that appear frequently in, e.g.., highly expressed genes in the subject's species, instead of those codons that are frequently used by, for example, an influenza virus.
  • Such codon usage provides for efficient expression of the antigen or immunogen in animal cells.
  • the codon usage pattern is altered to represent the codon bias for highly expressed genes in the organism in which the antigen or immunogen is being expressed. Codon usage patterns are known in the literature for highly expressed genes of many species (e.g., Nakamura et al, 1996; Wang et al, 1998; McEwan et al. 1998).
  • the viral vectors may be used to infect a cell in culture to express a desired gene product, e.g., to produce a protein or peptide of interest.
  • the protein or peptide is secreted into the medium and may be purified therefrom using routine techniques known in the art.
  • Signal peptide sequences that direct extracellular secretion of proteins are known in the art and nucleotide sequences encoding the same may be operably linked to the nucleotide sequence encoding the peptide or protein of interest by routine techniques known in the art.
  • the cells may be lysed and the expressed recombinant protein may be purified from the cell lysate.
  • the cell is an animal cell, more preferably a mammalian cell.
  • cells that are competent for transduction by particular viral vectors of interest include PER.C6 cells, 911 cells, and HEK293 cells.
  • a culture medium for culturing host cells includes a medium commonly used for tissue culture, such as M199-earle base, Eagle MEM (E-MEM), Dulbecco MEM (DMEM), SC- UCM102, UP-SFM (GIBCO BRL), EX-CELL302 (Nichirei), EX-CELL293-S (Nichirei), TFBM-01 (Nichirei), ASF 104, among others.
  • Suitable culture media for specific cell types may be found at the American Type Culture Collection (ATCC) or the European Collection of Cell Cultures (ECACC).
  • Culture media may be supplemented with amino acids such as L-glutamine, salts, anti-fungal or anti-bacterial agents such as Fungizone®, penicillin-streptomycin, animal serum, and the like.
  • the cell culture medium may optionally be serum-free.
  • the present invention also relates to cell lines or transgenic animals which are capable of expressing or overexpressing LITEs or at least one agent useful in the present invention.
  • the cell line or animal expresses or overexpresses one or more LITEs.
  • the transgenic animal is typically a vertebrate, more preferably a rodent, such as a rat or a mouse, but also includes other mammals such as human, goat, pig or cow etc.
  • transgenic animals are useful as animal models of disease and in screening assays for new useful compounds.
  • the effect of such polypeptides on the development of disease may be studied.
  • therapies including gene therapy and various drugs may be tested on transgenic animals.
  • Methods for the production of transgenic animals are known in the art. For example, there are several possible routes for the introduction of genes into embryos. These include (i) direct transfection or retroviral infection of embryonic stem cells followed by introduction of these cells into an embryo at the blastocyst stage of development; (ii) retroviral infection of early embryos; and (iii) direct microinjection of DNA into zygotes or early embryo cells.
  • the gene and/or transgene may also include genetic regulatory elements and/or structural elements known in the art.
  • a type of target cell for transgene introduction is the embryonic stem cell (ES).
  • ES cells may be obtained from pre-implantation embryos cultured in vitro and fused with embryos (Evans et al, 1981, Nature 292: 154-156; Bradley et al, 1984, Nature 309:255-258; Gossler et al, 1986, Proc. Natl. Acad. Sci. USA 83:9065-9069; and Robertson et al, 1986 Nature 322:445- 448).
  • Transgenes may be efficiently introduced into the ES cells by a variety of standard techniques such as DNA transfection, microinjection, or by retrovirus-mediated transduction.
  • the resultant transformed ES cells may thereafter be combined with blastocysts from a non- human animal.
  • the introduced ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal (Jaenisch, 1988, Science 240: 1468-1474).
  • LITEs may also offer valuable temporal precision in vivo.
  • LITEs may be used to alter gene expression during a particular stage of development, for example, by repressing a particular apoptosis gene only during a particular stage of C elegans growth.
  • LITEs may be used to time a genetic cue to a particular experimental window. For example, genes implicated in learning may be overexpressed or repressed only during the learning stimulus in a precise region of the intact rodent or primate brain.
  • LITEs may be used to induce gene expression changes only during particular stages of disease development. For example, an oncogene may be overexpressed only once a tumor reaches a particular size or metastatic stage.
  • proteins suspected in the development of Alzheimer's may be knocked down only at defined time points in the animal's life and within a particular brain region.
  • these examples do not exhaustively list the potential applications of the LITE system, they highlight some of the areas in which LITEs may be a powerful technology.
  • compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders.
  • the effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
  • compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
  • compositions containing compounds identified according to this invention as the active ingredient may be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration.
  • the compounds may be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
  • they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the active agents may be administered concurrently, or they each may be administered at separately staggered times.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the one patient; and the particular compound thereof employed.
  • a physician of ordinary skill may readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • TALEs transcription activator-like effectors
  • the system responds to light in the range of 450nm - 500nm and is capable of inducing a significant increase in the expression of pluripotency factors after stimulation with light at an intensity of 6.2 mW/cm 2 in mammalian cells.
  • Applicants are developing tools for the targeting of a wide range of genes. Applicants believe that a toolbox for the light-mediated control of gene expression would complement the existing optogenetic methods and may in the future help elucidate the timing-, cell type- and concentrationdependent role of specific genes in the brain.
  • TALE transcription activator like effector
  • CRY2 light-sensitive dimerizing protein domains cryptochrome 2
  • CIB1 from Arabidopsis thaliana
  • Applicants show that blue-light stimulation of HEK293FT and Neuro-2a cells transfected with these LITE constructs designed to target the promoter region of KLF4 and Neurog2 results in a significant increase in target expression, demonstrating the functionality of TALE-based optical gene expression modulation technology.
  • FIG. 1 shows a schematic depicting the need for spatial and temporal precision.
  • FIG. 2 shows transcription activator like effectors (TALEs).
  • TALEs consist of 34 aa repeats at the core of their sequence. Each repeat corresponds to a base in the target DNA that is bound by the TALE. Repeats differ only by 2 variable amino acids at positions 12 and 13.
  • the code of this correspondence has been elucidated (Boch, J et al. , Science, 2009 and Moscou, M et al. , Science, 2009) and is shown in this figure.
  • FIG. 3 depicts a design of a LITE: TALE/Cryptochrome transcriptional activation.
  • Each LITE is a two-component system which may comprise a TALE fused to CRY2 and the cryptochrome binding partner CIBl fused to VP64, a transcription activor.
  • the TALE localizes its fused CRY2 domain to the promoter region of the gene of interest.
  • CIBl is unable to bind CRY2, leaving the CIB1-VP64 unbound in the nuclear space.
  • CRY2 Upon stimulation with 488 nm (blue) light, CRY2 undergoes a conformational change, revealing its CIBl binding site (Liu, H et al. , Science, 2008). Rapid binding of CIBl results in recruitment of the fused VP64 domain, which induces transcription of the target gene.
  • FIG. 4 depicts effects of cryptochrome dimer truncations on LITE activity. Truncations known to alter the activity of CRY2 and CIBl () were compared against the full length proteins. A LITE targeted to the promoter of Neurog2 was tested in Neuro-2a cells for each combination of domains. Following stimulation with 488 nm light, transcript levels of Neurog2 were quantified using qPCR for stimulated and unstimulated samples.
  • FIG. 5 depicts a light-intensity dependent response of KLF4 LITE.
  • FIG. 6 depicts activation kinetics of Neurog2 LITE and inactivation kinetics of Neurog2 LITE.
  • LITEs light-inducible transcriptional effectors
  • Inducible gene expression systems have typically been designed to allow for chemically inducible activation of an inserted open reading frame or shR A sequence, resulting in gene overexpression or repression, respectively.
  • Disadvantages of using open reading frames for overexpression include loss of splice variation and limitation of gene size.
  • Gene repression via RNA interference despite its transformative power in human biology, may be hindered by complicated off-target effects.
  • Certain inducible systems including estrogen, ecdysone, and FKBP12/FRAP based systems are known to activate off-target endogenous genes. The potentially deleterious effects of long-term antibiotic treatment may complicate the use of tetracycline transactivator (TET) based systems.
  • TET tetracycline transactivator
  • LITEs are designed to modulate expression of individual endogenous genes in a temporally and spatially precise manner.
  • Each LITE is a two component system consisting of a customized DNA-binding transcription activator like effector (TALE) protein, a light-responsive crytochrome heterodimer from Arabadopsis thaliana, and a transcriptional activation/repression domain.
  • TALE transcription activator like effector
  • the TALE is designed to bind to the promoter sequence of the gene of interest.
  • the TALE protein is fused to one half of the cryptochrome heterodimer (cryptochrome-2 or CIB1), while the remaining cryptochrome partner is fused to a transcriptional effector domain.
  • Effector domains may be either activators, such as VP 16, VP64, or p65, or repressors, such as KRAB, EnR, or SID.
  • activators such as VP 16, VP64, or p65
  • repressors such as KRAB, EnR, or SID.
  • the TALE- cryptochrome2 protein localizes to the promoter of the gene of interest, but is not bound to the CIB1 -effector protein.
  • cryptochrome-2 Upon stimulation of a LITE with blue spectrum light, cryptochrome-2 becomes activated, undergoes a conformational change, and reveals its binding domain.
  • CIB1 binds to cryptochrome-2 resulting in localization of the effector domain to the promoter region of the gene of interest and initiating gene overexpression or silencing.
  • Gene targeting in a LITE is achieved via the specificity of customized TALE DNA binding proteins.
  • a target sequence in the promoter region of the gene of interest is selected and a TALE customized to this sequence is designed.
  • the central portion of the TALE consists of tandem repeats 34 amino acids in length. Although the sequences of these repeats are nearly identical, the 12th and 13th amino acids (termed repeat variable diresidues) of each repeat vary, determining the nucleotide-binding specificity of each repeat.
  • a DNA binding protein specific to the target promoter sequence is created.
  • Light responsiveness of a LITE is achieved via the activation and binding of cryptochrome-2 and CIB1.
  • blue light stimulation induces an activating conformational change in cryptochrome-2, resulting in recruitment of its binding partner CIB1.
  • This binding is fast and reversible, achieving saturation in ⁇ 15 sec following pulsed stimulation and returning to baseline ⁇ 15 min after the end of stimulation.
  • Crytochrome-2 activation is also highly sensitive, allowing for the use of low light intensity stimulation and mitigating the risks of phototoxicity.
  • variable light intensity may be used to control the size of a LITE stimulated region, allowing for greater precision than vector delivery alone may offer.
  • activator and repressor domains may be selected on the basis of species, strength, mechanism, duration, size, or any number of other parameters.
  • the first example is a LITE designed to activate transcription of the mouse gene NEUROG2.
  • the sequence TGAATGATGATAATACGA, located in the upstream promoter region of mouse NEUROG2 was selected as the target and a TALE was designed and synthesized to match this sequence.
  • the TALE sequence was linked to the sequence for cryptochrome-2 via a nuclear localization signal (amino acids: SPKK R VEAS) to facilitate transport of the protein from the cytosol to the nuclear space.
  • a second vector was synthesized comprising the CIB1 domain linked to the transcriptional activator domain VP64 using the same nuclear localization signal.
  • This second vector also a GFP sequence, is separated from the CIB1-VP64 fusion sequence by a 2A translational skip signal.
  • Expression of each construct was driven by a ubiquitous, constitutive promoter (CMV or EFl-a).
  • CMV or EFl-a ubiquitous, constitutive promoter
  • Mouse neuroblastoma cells from the Neuro 2 A cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via qPCR.
  • Truncated versions of cryptochrome-2 and CIB1 were cloned and tested in combination with the full-length versions of cryptochrome-2 and CIB1 in order to determine the effectiveness of each heterodimer pair.
  • the combination of the CRY2PHR domain, consisting of the conserved photoresponsive region of the cryptochrome-2 protein, and the full-length version of CIB1 resulted in the highest upregulation of Neurog2 mRNA levels (-22 fold over YFP samples and -7 fold over unstimulated co-transfected samples).
  • Inactivation kinetics were analyzed by stimulating co-transfected samples for 6 h, at which time stimulation was stopped, and samples were kept in culture for 0 to 12 h to allow for mRNA degradation.
  • Neurog2 mRNA levels peaked at 0.5h after the end of stimulation (-16 fold vs. YFP samples), after which the levels degraded with an -3 h half-life before returning to near baseline levels by 12 h.
  • the second prototypical example is a LITE designed to activate transcription of the human gene KLF4.
  • the TALE sequence was linked to the sequence for CRY2PHR via a nuclear localization signal (amino acids: SPKKKRKVEAS).
  • SPKKKRKVEAS amino acids
  • the identical CIB1-VP64 activator protein described above was also used in this manifestation of the LITE system.
  • Human embryonal kidney cells from the HEK293FT cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via q
  • the light-intensity response of the LITE system was tested by stimulating samples with increased light power (0-9 mW/cm 2 ). Upregulation of KLF4 mRNA levels was observed for stimulation as low as 0.2 mW/cm 2 . KLF4 upregulation became saturated at 5 mW/cm 2 (2.3 fold vs. YFP samples). Cell viability tests were also performed for powers up to 9 mW/cm 2 and showed >98% cell viability. Similarly, the KLF4 LITE response to varying duty cycles of stimulation was tested (1.6-100%). No difference in KLF4 activation was observed between different duty cycles indicating that a stimulation paradigm of as low as 0.25 sec every 15 sec should result in maximal activation.
  • LITEs represent an advantageous choice for gene expression control.
  • LITEs have the advantage of inducing endogenous gene expression with the potential for correct splice variant expression.
  • LITE activation is photoinducible
  • spatially defined light patterns created via masking or rasterized laser scanning, may be used to alter expression levels in a confined subset of cells. For example, by overexpressing or silencing an intercellular signaling molecule only in a spatially constrained set of cells, the response of nearby cells relative to their distance from the stimulation site may help elucidate the spatial characteristics of cell non-autonomous processes.
  • overexpression of sets of transcription factors may be utilized to transform one cell type, such as fibroblasts, into another cell type, such as neurons or cardiomyocytes. Further, the correct spatial distribution of cell types within tissues is critical for proper organotypic function. Overexpression of reprogramming factors using LITEs may be employed to reprogram multiple cell lineages in a spatially precise manner for tissue engineering applications.
  • LITEs may be used to study the dynamics of mRNA splice variant production upon induced expression of a target gene.
  • mRNA degradation studies are often performed in response to a strong extracellular stimulus, causing expression level changes in a plethora of genes.
  • LITEs may be utilized to reversibly induce transcription of an endogenous target, after which point stimulation may be stopped and the degradation kinetics of the unique target may be tracked.
  • LITEs may provide the power to time genetic regulation in concert with experimental interventions.
  • targets with suspected involvement in long-term potentiation may be modulated in organotypic or dissociated neuronal cultures, but only during stimulus to induce LTP, so as to avoid interfering with the normal development of the cells.
  • LTP long-term potentiation
  • targets suspected to be involved in the effectiveness of a particular therapy may be modulated only during treatment.
  • genetic targets may be modulated only during a pathological stimulus. Any number of experiments in which timing of genetic cues to external experimental stimuli is of relevance may potentially benefit from the utility of LITE modulation.
  • LITEs The in vivo context offers equally rich opportunities for the use of LITEs to control gene expression.
  • photoinducibility provides the potential for previously unachievable spatial precision.
  • a stimulating fiber optic lead may be placed in a precise brain region. Stimulation region size may then be tuned by light intensity. This may be done in conjunction with the delivery of LITEs via viral vectors, or, if transgenic LITE animals were to be made available, may eliminate the use of viruses while still allowing for the modulation of gene expression in precise brain regions.
  • LITEs may be used in a transparent organism, such as an immobilized zebrafish, to allow for extremely precise laser induced local gene expression changes.
  • LITEs may also offer valuable temporal precision in vivo.
  • LITEs may be used to alter gene expression during a particular stage of development, for example, by repressing a particular apoptosis gene only during a particular stage of C elegans growth.
  • LITEs may be used to time a genetic cue to a particular experimental window. For example, genes implicated in learning may be overexpressed or repressed only during the learning stimulus in a precise region of the intact rodent or primate brain.
  • LITEs may be used to induce gene expression changes only during particular stages of disease development. For example, an oncogene may be overexpressed only once a tumor reaches a particular size or metastatic stage.
  • proteins suspected in the development of Alzheimer's may be knocked down only at defined time points in the animal's life and within a particular brain region.
  • these examples do not exhaustively list the potential applications of the LITE system, they highlight some of the areas in which LITEs may be a powerful technology.
  • TALE repressor architectures to enable researchers to suppress transcription of endogenous genes.
  • TALE repressors have the potential to suppress the expression of genes as well as non-coding transcripts such as microRNAs, rendering them a highly desirable tool for testing the causal role of specific genetic elements.
  • a TALE targeting the promoter of the human SOX2 gene was used to evaluate the transcriptional repression activity of a collection of candidate repression domains (FIG. 12a).
  • Repression domains across a range of eukaryotic host species were selected to increase the chance of finding a potent synthetic repressor, including the PIE-1 repression domain (PIE-1) (Batchelder, C. et al. Transcriptional repression by the Caenorhabditis elegans germ- line protein PIE-1. Genes Dev. 13, 202-212 (1999)) from Caenorhabditis elegans, the QA domain within the Ubx gene (Ubx-QA) (Tour, E., Hittinger, C.T. & McGinnis, W. Evolutionarily conserved domains required for activation and repression functions of the Drosophila Hox protein Ultrabithorax.
  • PIE-1 repression domain PIE-1 repression domain
  • Ubx-QA the QA domain within the Ubx gene
  • IAA28-RD IAA28 repression domain
  • SID mSin interaction domain
  • Tbx3 repression domain Tbx3-RD
  • Kruppel-associated box KRAB
  • TALEs carrying two widely used mammalian transcriptional repression domains the SID (Ayer, D.E., Laherty, CD., Lawrence, Q.A., Armstrong, A.P. & Eisenman, R.N. Mad proteins contain a dominant transcription repression domain. Mol. Cell. Biol. 16, 5772-5781 (1996)) and KRAB (Margolin, J.F. et al. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci.
  • TALEs may be easily customized to recognize specific sequences on the endogenous genome.
  • a series of screens were conducted to address two important limitations of the TALE toolbox. Together, the identification of a more stringent G-specific RVD with uncompromised activity strength as well as a robust TALE repressor architecture further expands the utility of TALEs for probing mammalian transcription and genome function.
  • SID mSin interaction domain
  • This domain is called SID4X, which is a tandem repeat of four SID domains linked by short peptide linkers.
  • a TALE targeting the promoter of the mouse (Mus musculus) pll (slOOalO) gene was used to evaluate the transcriptional repression activity of a series of candidate TALE repressor architectures (FIG. 13a).
  • TALE Since different truncations of TALE are known to exhibit varying levels of transcriptional activation activity, two different truncations of TALE fused to SID or SID4X domain were tested, one version with 136 and 183 amino acids at N- and C- termini flanking the DNA binding tandem repeats, with another one retaining 240 and 183 amino acids at N- and C-termini (FIG. 13b, c).
  • the candidate TALE repressors were expressed in mouse Neuro2A cells and it was found that TALEs carrying both SID and SID4X domains were able to repress endogenous pll expression up to 4.8 folds, while the GFP-encoding negative control construct had no effect on transcriptional of target gene (FIG. 13b, c).
  • the mSin interaction domain (SID) and SID4X domain were codon optimized for mammalian expression and synthesized with flanking Nhel and Xbal restriction sites (Genscript). Truncation variants of the TALE DNA binding domains are PCR amplified and fused to the SID or the SID4X domain using Nhel and Xbal restriction sites. To control for any effect on transcription resulting from TALE binding, expression vectors carrying the TALE DNA binding domain alone using PCR cloning were constructed. The coding regions of all constructs were completely verified using Sanger sequencing. A comparison of two different types of TALE architecture is seen in FIG. 14.
  • Customized TALEs may be used for a wide variety of genome engineering applications, including transcriptional modulation and genome editing.
  • TALE-TFs custom TALE transcription factors
  • TALENs nucleases
  • This toolbox facilitates affordable and rapid construction of custom TALE-TFs and TALENs within 1 week and may be easily scaled up to construct TALEs for multiple targets in parallel.
  • Applicants also provide details for testing the activity in mammalian cells of custom TALE-TFs and TALENs using quantitative reverse-transcription PCR and Surveyor nuclease, respectively.
  • the TALE toolbox will enable a broad range of biological applications.
  • TALEs are natural bacterial effector proteins used by Xanthomonas sp. to modulate gene transcription in host plants to facilitate bacterial colonization (Boch, J. & Bonas, U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu. Rev. Phytopathol. 48, 419-436 (2010) and Bogdanove, A. J., Schornack, S. & Lahaye, T. TAL effectors: finding plant genes for disease and defense. Curr. Opin. Plant Biol. 13, 394-401 (2010)).
  • the central region of the protein contains tandem repeats of 34-aa sequences (termed monomers) that are required for DNA recognition and binding (Romer, P. et al.
  • TALE-binding sites within plant genomes always begin with a thymine (Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509-1512 (2009) and Moscou, M.J. & Bogdanove, A.J. A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501 (2009)), which is presumably specified by a cryptic signal within the nonrepetitive N terminus of TALEs.
  • the tandem repeat DNA-binding domain always ends with a half-length repeat (0.5 repeat, FIG. 8). Therefore, the length of the DNA sequence being targeted is equal to the number of full repeat monomers plus two.
  • pathogens are often host-specific.
  • Fusarium oxysporum f. sp. lycopersici causes tomato wilt but attacks only tomato
  • Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants.
  • there can be non-host resistance e.g., the host and pathogen are incompatible.
  • Horizontal Resistance e.g., partial resistance against all races of a pathogen, typically controlled by many genes
  • Vertical Resistance e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes.
  • Plant and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance.
  • the sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents.
  • plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in Varieties having desired characteristics or traits employ the present invention to induce the rise of resistance genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs.
  • Applicants have further improved the TALE assembly system with a few optimizations, including maximizing the dissimilarity of ligation adaptors to minimize misligations and combining separate digest and ligation steps into single Golden Gate (Engler, C, Kandzia, R. & Marillonnet, S. A one pot, one step, precision cloning method with high throughput capability.
  • each nucleotide-specific monomer sequence is amplified with ligation adaptors that uniquely specify the monomer position within the TALE tandem repeats. Once this monomer library is produced, it may conveniently be reused for the assembly of many TALEs. For each TALE desired, the appropriate monomers are first ligated into hexamers, which are then amplified via PCR.
  • a second Golden Gate digestion- ligation with the appropriate TALE cloning backbone yields a fully assembled, sequence-specific TALE.
  • the backbone contains a ccdB negative selection cassette flanked by the TALE N and C termini, which is replaced by the tandem repeat DNA-binding domain when the TALE has been successfully constructed.
  • ccdB selects against cells transformed with an empty backbone, thereby yielding clones with tandem repeats inserted (Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011)).
  • TALE-TFs are constructed by replacing the natural activation domain within the TALE C terminus with the synthetic transcription activation domain VP64 (Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 29, 149-153 (2011); FIG. 8). By targeting a binding site upstream of the transcription start site, TALE-TFs recruit the transcription complex in a site-specific manner and initiate gene transcription.
  • TALENs are constructed by fusing a C-terminal truncation (+63 aa) of the TALE DNA-binding domain (Miller, J.C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011)) with the nonspecific Fokl endonuclease catalytic domain (FIG. 14).
  • the +63 -aa C-terminal truncation has also been shown to function as the minimal C terminus sufficient for transcriptional modulation (Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 29, 149-153 (2011)).
  • TALENs form dimers through binding to two target sequences separated by -17 bases. Between the pair of binding sites, the Fokl catalytic domains dimerize and function as molecular scissors by introducing double-strand breaks (DSBs; FIG. 8). Normally, DSBs are repaired by the nonhomologous end-joining (Huertas, P. DNA resection in eukaryotes: deciding how to fix the break. Nat. Struct. Mol. Biol. 17, 11-16 (2010)) pathway (NHEJ), resulting in small deletions and functional gene knockout. Alternatively, TALEN-mediated DSBs may stimulate homologous recombination, enabling site-specific insertion of an exogenous donor DNA template (Miller, J.C.
  • TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011) and Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731-734 (2011)).
  • TALE-TFs being constructed with the VP64 activation domain
  • other embodiments of the invention relate to TALE polypeptides being constructed with the VP 16 and p65 activation domains.
  • a graphical comparison of the effect these different activation domains have on Sox2 mRNA level is provided in FIG. 11.
  • FIG. 17 depicts an effect of cryptochrome2 heterodimer orientation on LITE functionality.
  • Two versions of the Neurogenin 2 (Neurog2) LITE were synthesized to investigate the effects of cryptochrome 2 photo lyase homology region (CRY2PHR)/calcium and integrin-binding protein 1 (CIB1) dimer orientation.
  • the CIB1 domain was fused to the C-terminus of the TALE (Neurog2) domain, while the CRY2PHR domain was fused to the N-terminus of the VP64 domain.
  • the CRY2PHR domain was fused to the C-terminus of the TALE (Neurog2) domain, while the CIB1 domain was fused to the N- terminus of the VP64 domain.
  • TALE Neurogen2
  • CIB1 domain was fused to the N- terminus of the VP64 domain.
  • Each set of plasmids were transfected in Neuro2a cells and stimulated (466 nm, 5 mW/cm 2 , 1 sec pulse per 15 sec, 12 h) before harvesting for qPCR analysis.
  • Stimulated LITE and unstimulated LITE Neurog2 expression levels were normalized to Neurog2 levels from stimulated GFP control samples.
  • the TALE-CRY2PHR/CIB 1 -VP64 LITE exhibited elevated basal activity and higher light induced Neurog2 expression, and suggested its suitability for situations in which higher absolute activation is required. Although the relative light inducible activity of the TALE-CIB 1/CRY2PHR-VP64 LITE was lower that its counterpart, the lower basal activity suggested its utility in applications requiring minimal baseline activation. Further, the TALE-CIB 1 construct was smaller in size, compared to the TALE-CRY2PHR construct, a potential advantage for applications such as viral packaging.
  • FIG. 18 depicts metabotropic glutamate receptor 2 (mGlur2) LITE activity in mouse cortical neuron culture.
  • a mGluR2 targeting LITE was constructed via the plasmids pAAV- human Synapsin I promoter (hSyn)-HA-TALE(mGluR2)-CIBl and pAAV-hSyn-CRY2PHR- VP64-2A-GFP. These fusion constructs were then packaged into adeno associated viral vectors (AAV). Additionally, AAV carrying hSyn-TALE-VP64-2A-GFP and GFP only were produced.
  • Embryonic mouse (El 6) cortical cultures were plated on Poly-L-lysine coated 24 well plates.
  • FIG. 19 depicts transduction of primary mouse neurons with LITE AAV vectors.
  • Primary mouse cortical neuron cultures were co-transduced at 5 days in vitro with AAV vectors encoding hSyn-CRY2PHR-VP64-2A-GFP and hSyn-HA-TALE-CIB 1 , the two components of the LITE system.
  • Left panel at 6 days after transduction, neural cultures exhibited high expression of GFP from the hSyn-CRY2PHR-VP64-2A-GFP vector.
  • FIG. 20 depicts expression of a LITE component in vivo.
  • An AAV vector of seratype 1/2 carrying hSyn-CRY2PHR-VP64 was produced via transfection of HEK293FT cells and purified via heparin column binding. The vector was concentrated for injection into the intact mouse brain. 1 uL of purified AAV stock was injected into the hippocampus and infralimbic cortex of an 8 week old male C57BL/6 mouse by steroeotaxic surgery and injection. 7 days after in vivo transduction, the mouse was euthanized and the brain tissue was fixed by paraformaldehyde perfusion. Slices of the brain were prepared on a vibratome and mounted for imaging. Strong and widespread GFP signals in the hippocampus and infralimbic cortex suggested efficient transduction and high expression of the LITE component CRY2PHR-VP64.
  • Estrogen receptor T2 (ERT2) has a leakage issue.
  • the ERT2 domain would enter the nucleus even in the absence of 4-Hydroxytestosterone (40HT), leading to a background level of activation of target gene by TAL.
  • NES nuclear exporting signal
  • Applicants aim to prevent the entering of ERT2-TAL protein into nucleus in the absence of 40HT, lowering the background activation level due to the "leakage" of the ERT2 domain.
  • FIG. 21 depicts an improved design of the construct where the specific NES peptide sequence used is LDLASLIL.
  • FIG. 22 depicts Sox2 mRNA levels in the absence and presence of 40H tamoxifen.
  • Y-axis is Sox2 mRNA level as measured by qRT-PCR.
  • X-axis is a panel of different construct designs described on top. Plus and minus signs indicate the presence or absence of 0.5uM 40HT.
  • CRISPR clustered regularly interspaced short palindromic repeats
  • adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage.
  • Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells.
  • Cas9 can also be converted into a nicking enzyme to facilitate homology-directed repair with minimal mutagenic activity.
  • multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several sites within the mammalian genome, demonstrating easy programmability and wide applicability of the CRISPR technology.
  • Prokaryotic CRISPR adaptive immune systems can be reconstituted and engineered to mediate multiplex genome editing in mammalian cells.
  • genome-editing technologies such as designer zinc fingers (ZFs) (M. H. Porteus, D. Baltimore, Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763 (May 2, 2003); J. C. Miller et al., An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778 (Jul, 2007); J. D. Sander et al, Selection- free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 8, 67 (Jan, 2011) and A. J.
  • the Streptococcus pyogenes SF370 type II CRISPR locus consists of four genes, including the Cas9 nuclease, as well as two non-coding RNAs: tracrRNA and a pre-crRNA array containing nuclease guide sequences (spacers) interspaced by identical direct repeats (DRs) (FIG. 27) (E. Deltcheva et al, CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602 (Mar 31, 2011)).
  • DRs direct repeats
  • RNA-programmable nuclease system to introduce targeted double stranded breaks (DSBs) in mammalian chromosomes through heterologous expression of the key components. It has been previously shown that expression of tracrRNA, pre-crRNA, host factor RNase III, and Cas9 nuclease are necessary and sufficient for cleavage of DNA in vitro (M. Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012) and G. Gasiunas, R. Barrangou, P. Horvath, V.
  • Siksnys, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria.
  • Proc Natl Acad Sci US A 109, E2579 (Sep 25, 2012)) and in prokaryotic cells R. Sapranauskas et al, The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39, 9275 (Nov, 2011) and A. H. Magadan, M. E. Dupuis, M. Villion, S. Moineau, Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-Cas system.
  • Applicants used the U6 promoter to drive the expression of a pre-crRNA array comprising a single guide spacer flanked by DRs (FIG. 23B).
  • Applicants designed an initial spacer to target a 30-basepair (bp) site (protospacer) in the human EMX1 locus that precedes an NGG, the requisite protospacer adjacent motif (PAM) (FIG. 23C and FIG. 27)
  • PAM protospacer adjacent motif
  • H. Deveau et ah Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol 190, 1390 (Feb, 2008) and F. J. Mojica, C. Diez-Villasenor, J. Garcia-Martinez, C. Almendros, Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733 (Mar, 2009)).
  • Applicants transfected 293FT cells with different combinations of CRISPR components. Since DSBs in mammalian DNA are partially repaired by the indel-forming non-homologous end joining (NHEJ) pathway, Applicants used the SURVEYOR assay (FIG. 29) to detect endogenous target cleavage (FIG.23D and FIG.28B). Co-transfection of all four required CRISPR components resulted in efficient cleavage of the protospacer (FIG. 23D and FIG.
  • Applicants designed an expression vector to drive both pre-crRNA and SpCas9 (FIG. 31).
  • Applicants adapted a chimeric crRNA-tracrRNA hybrid (FIG. 24B, top) design recently validated in vitro (M. Jinek et ah, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012)), where a mature crRNA is fused to a partial tracrRNA via a synthetic stem-loop to mimic the natural crRNA:tracrRNA duplex (FIG. 24B, bottom).
  • cleavage efficiencies of chimeric RNAs were either lower than those of crRNA:tracrRNA duplexes or undetectable. This may be due to differences in the expression and stability of RNAs, degradation by endogenous RNAi machinery, or secondary structures leading to inefficient Cas9 loading or target recognition.
  • Jinek et ah A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012) and R. Sapranauskas et ah, The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39, 9275 (Nov, 2011)). Furthermore, CRISPR is able to mediate genomic cleavage as efficiently as a pair of TALE nucleases (TALEN) targeting the same EMX1 protospacer (FIG. 25, C and D). Targeted modification of genomes ideally avoids mutations arising from the error-prone NHEJ mechanism.
  • TALE nucleases TALEN
  • the wild-type SpCas9 is able to mediate site-specific DSBs, which can be repaired through either NHEJ or homology-directed repair (HDR).
  • HDR homology-directed repair
  • Applicants engineered an aspartate-to-alanine substitution (D10A) in the RuvC I domain of SpCas9 to convert the nuclease into a DNA nickase (SpCas9n, FIG. 26A)
  • D10A aspartate-to-alanine substitution
  • SpCas9n DNA nickase
  • nicked DNA can in rare cases be processed via a DSB intermediate and result in a NHEJ event (M. T. Certo et al., Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods 8, 671 (Aug, 2011)).
  • Applicants then tested Cas9-mediated HDR at the same EMXl locus with a homology repair template to introduce a pair of restriction sites near the protospacer (FIG. 26C).
  • SpCas9 and SpCas9n catalyzed integration of the repair template into EMXl locus at similar levels (FIG. 26D), which Applicants further verified via Sanger sequencing (FIG. 26E).
  • RNA to program sequence-specific DNA cleavage defines a new class of genome engineering tools.
  • S. pyogenes CRISPR system can be heterologously reconstituted in mammalian cells to facilitate efficient genome editing; an accompanying study has independently confirmed high efficiency CRISPR-mediated genome targeting in several human cell lines (Mali et al.).
  • CRISPR system can be further improved to increase its efficiency and versatility.
  • the requirement for an NGG PAM restricts the S. pyogenes CRISPR target space to every 8-bp on average in the human genome (FIG. 33), not accounting for potential constraints posed by crRNA secondary structure or genomic accessibility due to chromatin and DNA methylation states.
  • CRISPR loci are likely to be transplantable into mammalian cells; for example, the Streptococcus thermophilus LMD-9 CRISPRl can also mediate mammalian genome cleavage (FIG. 34).
  • the ability to carry out multiplex genome editing in mammalian cells enables powerful applications across basic science, biotechnology, and medicine (P. A. Carr, G. M. Church, Genome engineering. Nat Biotechnol 27, 1151 (Dec, 2009)).
  • HEK Human embryonic kidney
  • DMEM Dulbecco's modified Eagle's Medium
  • HyClone 10% fetal bovine serum
  • 2mM GlutaMAX 20% GlutaMAX
  • lOOU/mL penicillin 100 ⁇ g/mL streptomycin at 37°C with 5% C02 incubation.
  • Mouse neuro2A (N2A) cell line was maintained with DMEM supplemented with 5% fetal bovine serum (HyClone), 2mM GlutaMAX (Life Technologies), lOOU/mL penicillin, and 100 ⁇ g/mL streptomycin at 37°C with 5% C0 2 .
  • Genomic region surrounding the CRISPR target site for each gene was PCR amplified, and products were purified using QiaQuick Spin Column (Qiagen) following manufacturer's protocol.
  • a total of 400ng of the purified PCR products were mixed with 2 ⁇ 1 10X Taq polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume of 20 ⁇ 1, and subjected to a re-annealing process to enable heteroduplex formation: 95°C for lOmin, 95C to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute.
  • HEK 293FT and N2A cells were transfected with plasmid DNA, and incubated at 37°C for 72 hours before genomic DNA extraction as described above.
  • the target genomic region was PCR amplified using primers outside the homology arms of the homologous recombination (HR) template.
  • PCR products were separated on a 1% agarose gel and extracted with MinElute GelExtraction Kit (Qiagen). Purified products were digested with Hindlll (Fermentas) and analyzed on a 6% Novex TBE poly-acrylamide gel (Life Technologies).
  • RNA extraction and purification HEK 293FT cells were maintained and transfected as stated previously. Cells were harvested by trypsinization followed by washing in phosphate buffered saline (PBS). Total cell RNA was extracted with TRI reagent (Sigma) following manufacturer's protocol. Extracted total RNA was quantified using Naonodrop (Thermo Scientific) and normalized to same concentration. [00312] Northern blot analysis of crRNA and tracrRNA expression in mammalian cells.
  • RNAs were mixed with equal volumes of 2X loading buffer (Ambion), heated to 95°C for 5 min, chilled on ice for 1 min and then loaded onto 8% denaturing polyacrylamide gels (SequaGel, National Diagnostics) after pre-running the gel for at least 30 minutes. The samples were electrophoresed for 1.5 hours at 40 W limit. Afterwards, the RNA was transferred to Hybond N+ membrane (GE Healthcare) at 300 mA in a semi-dry transfer apparatus (Bio-rad) at room temperature for 1.5 hours. The RNA was crosshnked to the membrane using autocrosslink button on Stratagene UV Crosslinker the Stratalinker (Stratagene).
  • the membrane was pre -hybridized in ULTRAhyb-Oligo Hybridization Buffer (Ambion) for 30 min with rotation at 42°C and then probes were added and hybridized overnight. Probes were ordered from IDT and labeled with [gamma-32P] ATP (Perkin Elmer) with T4 polynucleotide kinase (New England Biolabs). The membrane was washed once with pre-warmed (42°C) 2xSSC, 0.5% SDS for 1 min followed by two 30 minute washes at 42°C. The membrane was exposed to phosphor screen for one hour or overnight at room temperature and then scanned with phosphorimager (Typhoon).
  • Table 1 Protospacer sequences and modification efficiencies of mammalian genomic targets.
  • Protospacer targets designed based on Streptococcus pyogenes type II CRISPR and Streptococcus thermophilus CRISPRl loci with their requisite PAMs against three different genes in human and mouse genomes.
  • AAV-promoter-TALE-effector backbone For construction of AAV-promoter-TALE-effector a backbone was cloned by standard subcloning methods. Specifically, the vector contained an antibiotics resistance gene, such as ampicillin resistance and two AAV inverted terminal repeats (itr's) flanking the promoter-TALE-effector insert (sequences, see below). The promoter (hSyn), the effector domain (VP64, SID4X or CIB1 in this example)/ the N- and C-terminal portion of the TALE gene containing a spacer with two typellS restriction sites (Bsal in this instance) were subcloned into this vector.
  • an antibiotics resistance gene such as ampicillin resistance and two AAV inverted terminal repeats (itr's) flanking the promoter-TALE-effector insert (sequences, see below).
  • the promoter (hSyn) the effector domain (VP64, SID4X or CIB1
  • each DNA component was amplified using polymerase-chain reaction and then digested with specific restriction enzymes to create matching DNA sticky ends.
  • the vector was similarily digested with DNA restriction enzymes. All DNA fragments were subsequently allowed to anneal at matching ends and fused together using a ligase enzyme.
  • AAV vectors containing different promoters, effector domains and TALE monomer sequences can be easily constructed.
  • LITEs Light-Inducible Transcriptional Effectors
  • CIB1 a two-hybrid system integrating the customizable TALE DNA-binding domain with the light-sensitive cryptochrome 2 protein and its interacting partner CIB1 from Arabidopsis thaliana.
  • LITEs can be activated within minutes, mediating reversible bidirectional regulation of endogenous mammalian gene expression as well as targeted epigenetic chromatin modifications.
  • Applicants have applied this system in primary mouse neurons, as well as in the brain of awake, behaving mice in vivo.
  • the LITE system establishes a novel mode of optogenetic control of endogenous cellular processes and enables direct testing of the causal roles of genetic and epigenetic regulation.
  • I l l The dynamic nature of gene expression enables cellular programming, homeostasis, and environmental adaptation in living systems. Dissecting the contributions of genes to cellular and organismic function therefore requires an approach that enables spatially and temporally controlled modulation of gene expression.
  • Microbial and plant-derived light-sensitive proteins have been engineered as optogenetic actuators, enabling the use of light - which provides high spatiotemporal resolution - to control many cellular functions (Deisseroth, K. Optogenetics. Nature methods 8, 26-29, doi: 10.1038/nmeth.f.324 (2011); Zhang, F. et al. The microbial opsin family of optogenetic tools.
  • TULIPs tunable, light-controlled interacting protein tags for cell biology. Nature methods 9, 379-384, doi: 10.1038/nmeth.l904 (2012); Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth. l524 (2010); Shimizu-Sato, S., Huq, E., Tepperman, J. M. & Quail, P. H. A light-switchable gene promoter system. Nature biotechnology 20, 1041-1044, doi: 10.1038/nbt734 (2002); Ye, H., Daoud-El Baba, M., Peng, R. W.
  • LITEs Light-Inducible Transcriptional Effectors
  • TALEs transcription activator-like effectors
  • LITEs can be packaged into viral vectors and genetically targeted to probe specific cell populations. Applicants demonstrate the application of this system in primary neurons as well as in the mouse brain in vivo.
  • the LITE system contains two independent components (FIG. 36A):
  • the first component is the genomic anchor and consists of a customized TALE DNA-binding domain fused to the light-sensitive CRY2 protein (TALE-CRY2).
  • TALE-CRY2 The second component consists of CIB1 fused to the desired transcriptional effector domain (CIB1 -effector).
  • NLS nuclear localization signal
  • Illumination with blue light triggers a conformational change in CRY2 and subsequently recruits CIBl -effector (VP64 shown in FIG. 36A) to the target locus to mediate transcriptional modulation.
  • This modular design allows each LITE component to be independently engineered.
  • the same genomic anchor can be combined with activating or repressing effectors (Beerli, R. R., Segal, D. J., Dreier, B. & Barbas, C. F., 3rd.
  • CIBl For CIBl, Applicants tested the full-length protein as well as an N-terminal domain-only fragment (CIBN, amino acids 1-170) (Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi:10.1038/nmeth.l524 (2010)). 3 out of 4 initial LITE pairings produced significant light-induced Neurog2 mRNA upregulation in Neuro 2a cells (p ⁇ 0.001, FIG. 36B). Of these, TALE-CRY2PHR::CIB1-VP64 yielded the highest absolute light-mediated mRNA increase when normalized to either GFP-only control or unstimulated LITE samples (FIG. 36B), and was therefore applied in subsequent experiments.
  • CIBN amino acids 1-170
  • LITE-mediated activation is likely to be limited by the inherent kinetics of transcription.
  • a small-molecule inducible TALE system based on the plant hormone abcisic acid receptor (Liang, F.-S., Ho, W. Q. & Crabtree, G. R.
  • AAV adeno-associated virus
  • the ssDNA-based genome of AAV is less susceptible to recombination, providing an advantage over lentiviral vectors (Holkers, M. et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic acids research 41, e63, doi: 10.1093/nar/gksl446 (2013)).
  • Applicants constructed a panel of TALE-VP64 transcriptional activators targeting 28 murine loci in all, including genes involved in neurotransmission or neuronal differentiation, ion channel subunits, and genes implicated in neurological diseases. DNase I-sensitive regions in the promoter of each target gene provided a guide for TALE binding sequence selections (FIG. 46). Applicants confirmed that TALE activity can be screened efficiently using Applicants' AAV -TALE production process (FIG. 45) and found that TALEs chosen in this fashion and delivered into primary neurons using AAV vectors activated a diverse array of gene targets to varying extents (FIG. 37C).
  • Applicants Having delivered TALE activators into cultured primary neurons, Applicants next sought to use AAV as a vector for the delivery of LITE components. To do so, Applicants needed to ensure that the total viral genome size of each recombinant AAV, with the LITE transgenes included, did not exceed the packaging limit of 4.8 kb (Wu, Z., Yang, H. & Colosi, P. Effect of Genome Size on AAV Vector Packaging. Mol Ther 18, 80-86 (2009)).
  • Applicants shortened the TALE N- and C-termini (keeping 136 aa in the N-terminus and 63 aa in the C- terminus) and exchanged the CRY2PHR (1.5kb) and CIBl (lkb) domains (TALE-CIBl and CRY2PHR-VP64; FIG. 38A).
  • These LITEs were delivered into primary cortical neurons via co- transduction by a combination of two AAV vectors (FIG. 38B; delivery efficiencies of 83-92% for individual components with >80% co-transduction efficiency).
  • CIB1 is a plant transcription factor and may have intrinsic regulatory effects even in mammalian cells (Liu, H. et al. Photoexcited CRY2 Interacts with CIB1 to Regulate Transcription and Floral Initiation in Arabidopsis. Science 322, 1535-1539, doi: 10.1126/science.1163927 (2008)). Applicants sought to eliminate these effects by deleting three CIB 1 regions conserved amongst the basic helix-loop-helix transcription factors of higher plants (FIG. 51).
  • Applicants aimed to prevent TALE-CIBl from binding the target locus in the absence of light.
  • Applicants engineered TALE-CIBl to localize in cytoplasm until light-induced dimerization with the NLS -containing CRY2PHR-VP64 (FIG. 52).
  • Applicants evaluated 73 distinct LITE architectures and identified 12 effector-targeting domain pairs (denoted by the "+" column in FIG. 51 and FIG. 53) with both improved light-induction efficiency and reduced overall baseline (fold mRNA increase in the no-light condition compared with the original LITE 1.0; p ⁇ 0.05).
  • HMTs histone methyltransferases
  • HDACs deacetylases
  • HDACs histone methyltransferases
  • HAT histone acetyltransferase
  • levels of H3K9mel, H4K20me3, H3K27me3, H3K9ac, and H4K8ac were altered by epiTALEs derived from, respectively, KYP (A. thaliana), TgSET8 (T. gondii), NUE and PHF19 (C.
  • LITEs can be used to enable temporally precise, spatially targeted, and bimodal control of endogenous gene expression in cell lines, primary neurons, and in the mouse brain in vivo.
  • the TALE DNA binding component of LITEs can be customized to target a wide range of genomic loci, and other DNA binding domains such as the RNA-guided Cas9 enzyme (Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems.
  • Novel modes of LITE modulation can also be achieved by replacing the effector module with new functionalities such as epigenetic modifying enzymes (de Groote, M. L., Verschure, P. J. & Rots, M. G. Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic acids research 40, 10596-10613, doi: 10.1093/nar/gks863 (2012)). Therefore the LITE system enables a new set of capabilities for the existing optogenetic toolbox and establishes a highly generalizable and versatile platform for altering endogenous gene regulation using light.
  • LITE constructs were transfected into in Neuro 2A cells using GenJet.
  • AAV vectors carrying TALE or LITE constructs were used to transduce mouse primary embryonic cortical neurons as well as the mouse brain in vivo.
  • RNA was extracted and reverse transcribed and mRNA levels were measured using TaqMan-based RT-qPCR.
  • Light emitting diodes or solid-state lasers were used for light delivery in tissue culture and in vivo respectively. 100374
  • Neuro 2a culture and experiments Neuro 2a cells (Sigma-Aldrich) were grown in media containing a 1 : 1 ratio of OptiMEM (Life Technologies) to high-glucose DMEM with GlutaMax and Sodium Pyruvate (Life Technologies) supplemented with 5% HyClone heat- inactivated FBS (Thermo Scientific), 1% penicillin/streptomycin (Life Technologies), and passaged at 1 :5 every 2 days.
  • 120,000 cells were plated in each well of a 24-well plate 18-20 h prior to transfection. 1 h before transfection, media was changed to DMEM supplemented with 5% HyClone heat-inactivated FBS and 1% penicillin/streptomycin.
  • Relative mRNA levels were measured by quantitative realtime PCR (qRT-PCR) using TaqMan probes specific for the targeted gene as well as GAPDH as an endogenous control (Life Technologies, see Table 3 for Taqman probe IDs). AACt analysis was used to obtain fold-changes relative to negative controls transduced with GFP only and subjected to light stimulation. Toxicity experiments were conducted using the LIVE/DEAD assay kit (Life Technologies) according to instructions.
  • AAV vector production 293FT cells (Life Technologies) were grown in antibiotic- free D10 media (DMEM high glucose with GlutaMax and Sodium Pyruvate, 10% heat- inactivated Hyclone FBS, and 1% 1M HEPES) and passaged daily at 1 :2-2.5. The total number of passages was kept below 10 and cells were never grown beyond 85% confluence. The day before transfection, lxl 0 6 cells in 21.5 mL of D10 media were plated onto 15 cm dishes and incubated for 18-22 hours or until -80% confluence.
  • antibiotic- free D10 media DMEM high glucose with GlutaMax and Sodium Pyruvate, 10% heat- inactivated Hyclone FBS, and 1% 1M HEPES
  • PEI "Max” Polysciences
  • 1 mg/mL of PEI "Max” (Polysciences) was dissolved in water and the pH of the solution was adjusted to 7.1.
  • 10.4 ⁇ g of pDF6 helper plasmid, 8.7 ⁇ g of pAAVl serotype packaging vector, and 5.2 ⁇ g of pAAV vector carrying the gene of interest were added to 434 ⁇ ⁇ of serum-free DMEM and 130 ⁇ of PEI "Max” solution was added to the DMEM-diluted DNA mixture.
  • the DNA/DMEM/PEI cocktail was vortexed and incubated at room temperature for 15 min.
  • transfection mixture was added to 22 mL of complete media, vortexed briefly, and used to replace the media for a 15 cm dish of 293FT cells.
  • transfection supernatant was harvested at 48 h, filtered through a 0.45 ⁇ PVDF filter (Millipore), distributed into aliquots, and frozen for storage at -80°C.
  • Cortices were then washed 3 times with 20 mL of warm HBSS containing 1 mL FBS. Cortices were gently triturated in 2 ml of HBSS and plated at 150,000 cells/well in poly-D-lysine coated 24-well plates (BD Biosciences). Neurons were maintained in Neurobasal media (Life Technologies), supplemented with IX B27 (Life Technologies), GlutaMax (Life Technologies) and 1% penicillin/streptomycin.
  • RNA extraction and reverse transcription were performed using the Cells-to-Ct kit according to the manufacturers instructions (Life Technologies). Relative mRNA levels were measured by quantitative real-time PCR (qRT-PCR) using TaqMan probes as described above for Neuro 2a cells.
  • AAV1/2 vectors Production of concentrated and purified AAV1/2 vectors. Production of concentrated and purified AAV for stereotactic injection in- vivo was done using the same initial steps outlined above for production of AAVl supernatant. However, for transfection, equal ratios of AAVl and AAV2 serotype plasmids were used instead of AAVl alone. 5 plates were transfected per construct and cells were harvested with a cell-scraper 48 h post transfection. Purification of AAV 1/2 particles was performed using HiTrap heparin affinity columns (GE Healthcare) (McClure, C, Cole, K. L., Wulff, P., Klugmann, M. & Murray, A. J.
  • Applicants added a second concentration step down to a final volume of 100 ⁇ per construct using an Amicon 500 ⁇ concentration column (100 kDa cutoff, Millipore) to achieve higher viral titers. Titration of AAV was performed by qRT-PCR using a custom Taqman probe for WPRE (Life Technologies). Prior to qRT-PCR, concentrated AAV was treated with DNasel (New England Biolabs) to achieve a measurement of DNasel -resistant particles only. Following DNasel heat-inactivation, the viral envelope was degraded by proteinase K digestion (New England Biolabs). Viral titer was calculated based on a standard curve with known WPRE copy numbers.
  • an optical cannula with fiber Doric Lenses
  • ILC intracranial pressure
  • Cannula with fiber Doric Lenses
  • the cannula was affixed to the skull using Metabond dental cement (Parkell Inc) and Jet denture repair (Lang dental) to build a stable cone around it.
  • the incision was sutured and proper post-operative analgesics were administered for three days following surgery.
  • mice were euthanized using C0 2 and the prefrontal cortices (PFC) were quickly dissected on ice and incubated in RNA later (Qiagen) at 4°C overnight. 200 ⁇ sections were cut in RNA later at 4°C on a vibratome (Leica Biosystems). Sections were then frozen on a glass coverslide on dry ice and virally transduced ILC was identified under a fluorescent stereomicroscope (Leica Ml 65 FC). A 0.35 mm diameter punch of ILC, located directly ventrally to the termination of the optical fiber tract, was extracted (Harris uni-core, Ted Pella).
  • PFC prefrontal cortices
  • the brain punch sample was then homogenized using an RNase-free pellet-pestle grinder (Kimble Chase) in 50 ⁇ Cells-to-Ct RNA lysis buffer and RNA extraction, reverse transcription and qRT-PCR was performed as described for primary neuron samples.
  • RNase-free pellet-pestle grinder Karl Chase
  • Chromatin Immunoprecipitation Neurons or Neuro2a cells were cultured and transduced or transfected as described above. ChIP samples were prepared as previously described (Blecher-Gonen, R. et al. High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. N ' ature protocols 8, 539-554 (2013)) with minor adjustments for the cell number and cell type. Cells were harvested in 24-well format, washed in 96-well format, and transferred to microcentrifuge tubes for lysis. Sample cells were directly lysed by water bath sonication with the Biorupter sonication device for 21 minutes using 30s on/off cycles (Diagenode). qPCR was used to assess enrichment of histone marks at the targeted locus.
  • Example 11 Supplementary Information to Example 10: Optical Control of Endogenous Mammalian
  • Neuro2A cells were grown in a medium containing a 1 : 1 ratio of OptiMEM (Life Technologies) to high-glucose DMEM with GlutaMax and Sodium Pyruvate (Life Technologies) supplemented with 5% HyClone heat-inactivated FBS (Thermo Scientific), 1% penicillin/streptomycin (Life Technologies) and 25mM HEPES (Sigma Aldrich). 150,000 cells were plated in each well of a 24-well plate 18-24 hours prior to transfection. Cells were transfected with 1 ⁇ g total of construct DNA (at equimolar ratios) per well and 2 of Lipofectamine 2000 (Life Technologies) according to the manufacturer's recommended protocols.
  • qRT-PCR quantitative real-time PCR
  • HEK 293FT cells were co-transfected with mutant Cas9 fusion protein and a synthetic guide RNA (sgRNA) using Lipofectamine 2000 (Life Technologies) 24 hours after seeding into a 24 well dish. 72 hours post-transfection, total RNA was purified (RNeasy Plus, Qiagen). lug of RNA was reverse transcribed into cDNA (qScript, Quanta Biosciences).
  • sgRNA synthetic guide RNA
  • Quantitative real-time PCR was done according to the manufacturer's protocol (Life Technologies) and performed in triplicate using TaqMan Assays for hKlf (Hs00358836_ml), hSox2 (Hs01053049_sl), and the endogenous control GAPDH (Hs02758991_gl).
  • the hSpCas9 activator plasmid was cloned into a lentiviral vector under the expression of the hEFla promoter (pLenti-EFla-Cas9-NLS-VP64).
  • the hSpCas9 repressor plasmid was cloned into the same vector (pLenti-EFla-SID4x-NLS-Cas9-NLS).
  • Guide sequences (20bp) targeted to the KLF4 locus are: GCGCGCTCCACACAACTCAC, GCAAAAATAGACAATCAGCA, GAAGGATCTCGGCCAATTTG.
  • Spacer sequences for guide RNAs targeted to the SOX2 locus are: GCTGCCGGGTTTTGCATGAA, CCGGGCCCGCAGCAAACTTC, GGGGCTGTCAGGGAATAAAT.
  • Optogenetic actuators Microbial and plant-derived light-sensitive proteins have been engineered as optogenetic actuators, allowing optical control of cellular functions including membrane potential (Deisseroth, K. Optogenetics. Nature methods 8, 26-29, doi: 10.1038/nmeth.f.324 (2011); Zhang, F. et al. The microbial opsin family of optogenetic tools. Cell 147, 1446-1457, doi: 10.1016/j .cell.2011.12.004 (2011) and Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M. & Deisseroth, K. Optogenetics in neural systems.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

The present invention generally relates to methods and compositions used for the spatial and temporal control of gene expression that may use inducible transcriptional effectors. The invention particularly relates to inducible methods of altering or perturbing expression of a genomic locus of interest in a cell wherein the genomic locus may be contacted with a non- naturally occurring or engineered composition comprising a deoxyribonucleic acid (DNA) binding polypeptide.

Description

INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS
AND APPLICATIONS THEREOF
RELATED APPLICATIONS AND INCORPORATION BY REFERENCE
[0001] This application claims priority to and claims benefit of US provisional patent application Serial Nos. 61/675,778 filed July 25, 2012, 61/721,283 filed November 1, 2012, 61/736,465 filed December 12, 2012, 61/794,458 filed March 15, 2013 and 61/835,973 filed June 17, 2013 titled INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF.
[0002] Reference is also made to US Provisional Application No. 61/565,171 filed November 30, 2011 and US Application Nos. 13/554,922 filed July 30, 2012 and 13/604,945 filed September 6, 2012, titled NUCLEOTIDE-SPECIFIC RECOGNITION SEQUENCES FOR DESIGNER TAL EFFECTORS.
[0003] Reference is also made to US Provisional Application Nos. 61/736,527 filed December 12, 2012; 61/748,427 filed January 2, 2013; 61/757,972 filed January 29, 2013, 61/768,959, filed February 25, 2013 and 61/791,409 filed March 15, 2013, titled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION.
[0004] Reference is also made to US Provisional Application Nos. 61/758,468 filed January 30, 2013 and 61/769,046 filed March 15, 2013, titled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION.
[0005] Reference is also made to US Provisional Application Nos. 61/835,931; 61/835,936; 61/836,080; 61/836,101; 61/836,123 and 61/836,127 filed June 17, 2013.
[0006] Reference is also made to US Provisional Application No. 61/842,322, filed July 2, 2013, titled CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS and US Provisional Application No. 61/847,537, filed July 17, 2013, titled DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND APPLICATIONS.
[0007] The foregoing applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
FIELD OF THE INVENTION
[0008] The present invention generally relates to methods and compositions used for the spatial and temporal control of gene expression, such as genome perturbation, that may use inducible transcriptional effectors.
FEDERAL FUNDING LEGEND
[0009] This invention was made with government support under R01NS073124 and Pioneer Award 1 DP IMH 100706 awarded by the National Institutes of Health. The Government has certain rights in the invention.
BACKGROUND OF THE INVENTION
[0010] Normal gene expression is a dynamic process with carefully orchestrated temporal and spatial components, the precision of which are necessary for normal development, homeostasis, and advancement of the organism. In turn, the dysregulation of required gene expression patterns, either by increased, decreased, or altered function of a gene or set of genes, has been linked to a wide array of pathologies. Technologies capable of modulating gene expression in a spatiotemporally precise fashion will enable the elucidation of the genetic cues responsible for normal biological processes and disease mechanisms. To address this technological need, Applicants developed inducible molecular tools that may regulate gene expression, in particular, light-inducible transcriptional effectors (LITEs), which provide light- mediated control of endogenous gene expression.
[0011] Inducible gene expression systems have typically been designed to allow for chemically induced activation of an inserted open reading frame or shRNA sequence, resulting in gene overexpression or repression, respectively. Disadvantages of using open reading frames for overexpression include loss of splice variation and limitation of gene size. Gene repression via RNA interference, despite its transformative power in human biology, can be hindered by complicated off-target effects. Certain inducible systems including estrogen, ecdysone, and FKBP12/FRAP based systems are known to activate off-target endogenous genes. The potentially deleterious effects of long-term antibiotic treatment can complicate the use of tetracycline transactivator (TET) based systems. In vivo, the temporal precision of these chemically inducible systems is dependent upon the kinetics of inducing agent uptake and elimination. Further, because inducing agents are generally delivered systemically, the spatial precision of such systems is bounded by the precision of exogenous vector delivery.
[0012] US Patent Publication No. 20030049799 relates to engineered stimulus-responsive switches to cause a detectable output in response to a preselected stimulus.
[0013] There is an evident need for methods and compositions that allow for efficient and precise spatial and temporal control of a genomic locus of interest. These methods and compositions may provide for the regulation and modulation of genomic expression both in vivo and in vitro as well as provide for novel treatment methods for a number of disease pathologies.
[0014] Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.
SUMMARY OF THE INVENTION
[0015] In one aspect the invention provides a non-naturally occurring or engineered TALE or CRISPR-Cas system which may comprise at least one switch wherein the activity of said TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch. In an embodiment of the invention the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system may be activated, enhanced, terminated or repressed. The contact with the at least one inducer energy source may result in a first effect and a second effect. The first effect may be one or more of nuclear import, nuclear export, recruitment of a secondary component (such as an effector molecule), conformational change (of protein, DNA or RNA), cleavage, release of cargo (such as a caged molecule or a co-factor), association or dissociation. The second effect may be one or more of activation, enhancement, termination or repression of the control as to the at least one switch or the activity of said TALE or CRISPR- Cas system. In one embodiment the first effect and the second effect may occur in a cascade.
[0016] In another aspect of the invention the TALE or CRISPR-Cas system may further comprise at least one nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation. The one or more of the NLS, the NES or the functional domain may be conditionally activated or inactivated. In another embodiment, the mutation may be one or more of a mutation in a transcription factor homology region, a mutation in a DNA binding domain (such as mutating basic residues of a basic helix loop helix), a mutation in an endogenous NLS or a mutation in an endogenous NES. The invention comprehends that the inducer energy source may be heat, ultrasound, electromagnetic energy or chemical. In a preferred embodiment of the invention, the inducer energy source may be an antibiotic, a small molecule, a hormone, a hormone derivative, a steroid or a steroid derivative. In a more preferred embodiment, the inducer energy source maybe abscisic acid (ABA), doxycycline (DOX), cumate, rapamycin, 4-hydroxytamoxifen (40HT), estrogen or ecdysone. The invention provides that the at least one switch may be selected from the group consisting of antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems. In a more preferred embodiment the at least one switch may be selected from the group consisting of tetracycline (Tet)/DOX inducible systems, light inducible systems, ABA inducible systems, cumate repressor/operator systems, 40HT/estrogen inducible systems, ecdysone-based inducible systems and FKBP12/FRAP (FKBP12-rapamycin complex) inducible systems.
[0017] In one aspect of the invention the inducer energy source is electromagnetic energy. The electromagnetic energy may be a component of visible light having a wavelength in the range of 450nm-700nm. In a preferred embodiment the component of visible light may have a wavelength in the range of 450nm-500nm and may be blue light. The blue light may have an intensity of at least 0.2m W/cm2, or more preferably at least 4mW/cm2. In another embodiment, the component of visible light may have a wavelength in the range of 620-700nm and is red light.
[0018] The invention comprehends systems wherein the at least one functional domain may be selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, histone deribosylase, histone ubiquitinase, histone deubiquitinase, histone biotinase and histone tail protease.
[0019] The invention also provides for use of the system for perturbing a genomic or epigenomic locus of interest. Also provided are uses of the system for the preparation of a pharmaceutical compound.
[0020] In a further aspect, the invention provides a method of controlling a non-naturally occurring or engineered TALE or CRISPR-Cas system, comprising providing said TALE or CRISPR-Cas system comprising at least one switch wherein the activity of said TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch.
[0021] In an embodiment of the invention, the invention provides methods wherein the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system may be activated, enhanced, terminated or repressed. The contact with the at least one inducer energy source may result in a first effect and a second effect. The first effect may be one or more of nuclear import, nuclear export, recruitment of a secondary component (such as an effector molecule), conformational change (of protein, DNA or RNA), cleavage, release of cargo (such as a caged molecule or a co-factor), association or dissociation. The second effect may be one or more of activation, enhancement, termination or repression of the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system. In one embodiment the first effect and the second effect may occur in a cascade.
[0022] In another aspect of the methods of the invention the TALE or CRISPR-Cas system may further comprise at least one nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation. The one or more of the NLS, the NES or the functional domain may be conditionally activated or inactivated. In another embodiment, the mutation may be one or more of a mutation in a transcription factor homology region, a mutation in a DNA binding domain (such as mutating basic residues of a basic helix loop helix), a mutation in an endogenous NLS or a mutation in an endogenous NES. The invention comprehends that the inducer energy source may be heat, ultrasound, electromagnetic energy or chemical. In a preferred embodiment of the invention, the inducer energy source may be an antibiotic, a small molecule, a hormone, a hormone derivative, a steroid or a steroid derivative. In a more preferred embodiment, the inducer energy source maybe abscisic acid (ABA), doxycycline (DOX), cumate, rapamycin, 4-hydroxytamoxifen (40HT), estrogen or ecdysone. The invention provides that the at least one switch may be selected from the group consisting of antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems. In a more preferred embodiment the at least one switch may be selected from the group consisting of tetracycline (Tet)/DOX inducible systems, light inducible systems, ABA inducible systems, cumate repressor/operator systems, 40HT/estrogen inducible systems, ecdysone-based inducible systems and FKBP12/FRAP (FKBP12-rapamycin complex) inducible systems.
[0023] In one aspect of the methods of the invention the inducer energy source is electromagnetic energy. The electromagnetic energy may be a component of visible light having a wavelength in the range of 450nm-700nm. In a preferred embodiment the component of visible light may have a wavelength in the range of 450nm-500nm and may be blue light. The blue light may have an intensity of at least 0.2mW/cm2, or more preferably at least 4mW/cm2. In another embodiment, the component of visible light may have a wavelength in the range of 620-700nm and is red light.
[0024] The invention comprehends methods wherein the at least one functional domain may be selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, histone deribosylase, histone ubiquitinase, histone deubiquitinase, histone biotinase and histone tail protease.
[0025] Further aspects of the invention provides for systems or methods as described herein wherein the TALE system comprises a DNA binding polypeptide comprising: (i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target a locus of interest or
at least one or more effector domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an inducer energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the locus of interest or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the inducer energy source.
[0026] The systems and methods of the invention provide for the DNA binding polypeptide comprising a (a) a N-terminal capping region (b) a DNA binding domain comprising at least 5 to 40 Transcription activator-like effector (TALE) monomers and at least one or more half- monomers specifically ordered to target the locus of interest, and (c) a C-terminal capping region wherein (a), (b) and (c) may be arranged in a predetermined N-terminus to C-terminus orientation, wherein the genomic locus comprises a target DNA sequence 5'-T0NiN2....Nz Nz+i - 3', where T0 and N = A, G, T or C, wherein the target DNA sequence binds to the DNA binding domain, and the DNA binding domain may comprise (Xi_n-Xi2Xi3-Xi4-33 or 34 or 35)z, wherein Xi_ 11 is a chain of 11 contiguous amino acids, wherein Xi2Xi3 is a repeat variable diresidue (RVD), wherein X14-33 or 34 or 35 is a chain of 21, 22 or 23 contiguous amino acids, wherein z may be at least 5 to 40, wherein the polypeptide may be encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to DNA of the locus of interest.
[0027] In a further embodiment, the system or method of the invention provides the N- terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region. In another embodiment, the at least one RVD may be selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS, NN, SN, KN for recognition of guanine (G); (b) NI, KI, RI, HI, SI for recognition of adenine (A); (c) NG, HG, KG, RG for recognition of thymine (T); (d) RD, SD, HD, ND, KD, YG for recognition of cytosine (C); (e) NV, HN for recognition of A or G; and (f) H*, HA, KA, N*, NA, NC, NS, RA, S*for recognition of A or T or G or C, wherein (*) means that the amino acid at X13 is absent.
[0028] In yet another embodiment the at least one RVD may be selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS for recognition of guanine (G); (b) SI for recognition of adenine (A); (c) HG, KG, RG for recognition of thymine (T); (d) RD, SD for recognition of cytosine (C); (e) NV, HN for recognition of A or G and (f) H*, HA, KA, N*, NA, NC, NS, RA, S*for recognition of A or T or G or C, wherein (*) means that the amino acid at XI 3 is absent. In a preferred embodiment, the RVD for the recognition of G is RN, NH, RH or KH; or the RVD for the recognition of A is SI; or the RVD for the recognition of T is KG or RG; and the RVD for the recognition of C is SD or RD. In yet another embodiment, at least one of the following is present [LTLD] or [LTLA] or [LTQV] at XI -4, or [EQHG] or [RDHG] at positions X30-33 or X31-34 or X32-35.
[0029] In an aspect of the invention the TALE system is packaged into a AAV or a lentivirus vector.
[0030] Further aspects of the invention provides for systems or methods as described herein wherein the CRISPR system may comprise a vector system comprising: a) a first regulatory element operably linked to a CRISPR-Cas system guide RNA that targets a locus of interest, b) a second regulatory inducible element operably linked to a Cas protein, wherein components (a) and (b) may be located on same or different vectors of the system, wherein the guide RNA targets DNA of the locus of interest, wherein the Cas protein and the guide RNA do not naturally occur together. In a preferred embodiment of the invention, the Cas protein is a Cas9 enzyme. The invention also provides for the vector being a AAV or a lentivirus.
[0031] The invention particularly relates to inducible methods of altering expression of a genomic locus of interest and to compositions that inducibly alter expression of a genomic locus of interest wherein the genomic locus may be contacted with a non-naturally occurring or engineered composition comprising a deoxyribonucleic acid (DNA) binding polypeptide. [0032] This polypeptide may include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half- monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to an energy sensitive protein or fragment thereof. The energy sensitive protein or fragment thereof may undergo a conformational change upon induction by an energy source allowing it to bind an interacting partner. The polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the energy source. The method may also include applying the energy source and determining that the expression of the genomic locus is altered. In preferred embodiments of the invention the genomic locus may be in a cell.
[0033] The invention also relates to inducible methods of repressing expression of a genomic locus of interest and to compositions that inducibly repress expression of a genomic locus of interest wherein the genomic locus may be contacted with a non-naturally occurring or engineered composition comprising a DNA binding polypeptide.
[0034] The polypeptide may include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or at least one or more repressor domains linked to an energy sensitive protein or fragment thereof. The energy sensitive protein or fragment thereof may undergo a conformational change upon induction by an energy source allowing it to bind an interacting partner. The polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the energy source. The method may also include applying the energy source and determining that the expression of the genomic locus is repressed. In preferred embodiments of the invention the genomic locus may be in a cell.
[0035] The invention also relates to inducible methods of activating expression of a genomic locus of interest and to compositions that inducibly activate expression of a genomic locus of interest wherein the genomic locus may be contacted with a non-naturally occurring or engineered composition comprising a DNA binding polypeptide.
[0036] The polypeptide may include a DNA binding domain comprising at least five or more TALE monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or at least one or more activator domains linked to an energy sensitive protein or fragment thereof. The energy sensitive protein or fragment thereof may undergo a conformational change upon induction by an energy source allowing it to bind an interacting partner. The polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the energy source. The method may also include applying the energy source and determining that the expression of the genomic locus is activated. In preferred embodiments of the invention the genomic locus may be in a cell.
[0037] In another preferred embodiment of the invention, the inducible effector may be a
Light Inducible Transcriptional Effector (LITE). The modularity of the LITE system allows for any number of effector domains to be employed for transcriptional modulation.
[0038] In yet another preferred embodiment of the invention, the inducible effector may be a chemical.
[0039] The present invention also contemplates an inducible multiplex genome engineering using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas systems.
[0040] The present invention also encompasses nucleic acid encoding the polypeptides of the present invention. The nucleic acid may comprise a promoter, advantageously human Synapsin I promoter (hSyn). In a particularly advantageous embodiment, the nucleic acid may be packaged into an adeno associated viral vector (AAV).
[0041] The invention further also relates to methods of treatment or therapy that encompass the methods and compositions described herein.
[0042] Accordingly, it is an object of the invention not to encompass within the invention any previously known product, process of making the product, or method of using the product such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. § 112, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product.
[0043] It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of and "consists essentially of have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
[0044] These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0045] The following detailed description, given by way of example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings.
[0046] FIG. 1 shows a schematic indicating the need for spatial and temporal precision.
[0047] FIG. 2 shows transcription activator like effectors (TALEs). TALEs consist of 34 aa repeats at the core of their sequence. Each repeat corresponds to a base in the target DNA that is bound by the TALE. Repeats differ only by 2 variable amino acids at positions 12 and 13. The code of this correspondence has been elucidated (Boch, J et al. , Science, 2009 and Moscou, M et al. , Science, 2009) and is shown in this figure. Applicants have developed a method for the synthesis of designer TALEs incorporating this code and capable of binding a sequence of choice within the genome (Zhang, F et al. , Nature Biotechnology, 2011).
[0048] FIG. 3 shows a design of a LITE: TALE/Cryptochrome transcriptional activation. Each LITE is a two-component system which may comprise a TALE fused to CRY2 and the cryptochrome binding partner CIB1 fused to VP64, a transcription activor. In the inactive state, the TALE localizes its fused CRY2 domain to the promoter region of the gene of interest. At this point, CIB1 is unable to bind CRY2, leaving the CIB1-VP64 unbound in the nuclear space. Upon stimulation with 488 nm (blue) light, CRY2 undergoes a conformational change, revealing its ClBl binding site (Liu, H et al. , Science, 2008). Rapid binding of ClBl results in recruitment of the fused VP64 domain, which induces transcription of the target gene.
[0049] FIG. 4 shows effects of cryptochrome dimer truncations on LITE activity. Truncations known to alter the activity of CRY2 and ClBl (Kennedy M et al, Nature Methods 2010) were compared against the full length proteins. A LITE targeted to the promoter of Neurog2 was tested in Neuro-2a cells for each combination of domains. Following stimulation with 488 nm light, transcript levels of Neurog2 were quantified using qPCR for stimulated and unstimulated samples.
[0050] FIG. 5 shows a light-intensity dependent response of KLF4 LITE.
[0051] FIG. 6 shows activation kinetics of Neurog2 LITE and inactivation kinetics of
Neurog2 LITE.
[0052] FIG. 7 A shows the base-preference of various RVDs as determined using the Applicants' RVD screening system.
[0053] FIG. 7B shows the base-preference of additional RVDs as determined using the Applicants' RVD screening system.
[0054] FIGS. 8A-D show in (a) Natural structure of TALEs derived from Xanthomonas sp. Each DNA-binding module consists of 34 amino acids, where the RVDs in the 12th and 13th amino acid positions of each repeat specify the DNA base being targeted according to the cipher NG = T, HD = C, NI = A, and NN = G or A. The DNA-binding modules are flanked by nonrepetitive N and C termini, which carry the translocation, nuclear localization (NLS) and transcription activation (AD) domains. A cryptic signal within the N terminus specifies a thymine as the first base of the target site, (b) The TALE toolbox allows rapid and inexpensive construction of custom TALE-TFs and TALENs. The kit consists of 12 plasmids in total: four monomer plasmids to be used as templates for PCR amplification, four TALE-TF and four TALEN cloning backbones corresponding to four different bases targeted by the 0.5 repeat. CMV, cytomegalovirus promoter; N term, nonrepetitive N terminus from the Hax3 TALE; C term, nonrepetitive C terminus from the Hax3 TALE; Bsal, type lis restriction sites used for the insertion of custom TALE DNA-binding domains; ccdB + CmR, negative selection cassette containing the ccdB negative selection gene and chloramphenicol resistance gene; NLS, nuclear localization signal; VP64, synthetic transcriptional activator derived from VP 16 protein of herpes simplex virus; 2A, 2A self-cleavage linker; EGFP, enhanced green fluorescent protein; polyA signal, polyadenylation signal; Fokl, catalytic domain from the Fokl endonuclease. (c) TALEs may be used to generate custom TALE-TFs and modulate the transcription of endogenous genes from the genome. The TALE DNA-binding domain is fused to the synthetic VP64 transcriptional activator, which recruits R A polymerase and other factors needed to initiate transcription, (d) TALENs may be used to generate site-specific double-strand breaks to facilitate genome editing through nonhomologous repair or homology directed repair. Two TALENs target a pair of binding sites flanking a 16-bp spacer. The left and right TALENs recognize the top and bottom strands of the target sites, respectively. Each TALE DNA-binding domain is fused to the catalytic domain of Fokl endonuclease; when Fokl dimerizes, it cuts the DNA in the region between the left and right TALEN-binding sites.
[0055] FIG. 9A-F shows a table listing monomer sequences (excluding the RVDs at positions 12 and 13) and the frequency with which monomers having a particular sequence occur.
[0056] FIG. 10 shows the comparison of the effect of non-RVD amino acid on TALE activity.
[0057] FIG. 11 shows an activator screen comparing levels of activation between VP64, p65 and VP 16.
[0058] FIGS. 12A-D show the development of a TALE transcriptional repressor architecture, (a) Design of SOX2 TALE for TALE repressor screening. A TALE targeting a 14bp sequence within the SOX2 locus of the human genome was synthesized, (b) List of all repressors screened and their host origin (left). Eight different candidate repressor domains were fused to the C-term of the SOX2 TALE, (c) The fold decrease of endogenous SOX2 mRNA is measured using qRTPCR by dividing the SOX2 mRNA levels in mock transfected cells by SOX2 mRNA levels in cells transfected with each candidate TALE repressor, (d) Transcriptional repression of endogenous CACNA1C. TALEs using NN, NK, and NH as the G-targeting RVD were constructed to target a 18 bp target site within the human CACNA1C locus. Each TALE is fused to the SID repression domain. NLS, nuclear localization signal; KRAB, Kruppel-associated box; SID, mSin interaction domain. All results are collected from three independent experiments in HEK 293FT cells. Error bars indicate s.e.m.; n = 3. * p < 0.05, Student's t test. [0059] FIGS. 13A-C shows the optimization of TALE transcriptional repressor architecture using SID and SID4X. (a) Design of pi I TALE for testing of TALE repressor architecture. A TALE targeting a 20bp sequence (pi I TALE binding site) within the pi I (slOOalO) locus of the mouse (Mus musculus) genome was synthesized, (b) Transcriptional repression of endogenous mouse pi I mR A. TALEs targeting the mouse pi I locus harboring two different truncations of the wild type TALE architecture were fused to different repressor domains as indicated on the x-axis. The value in the bracket indicate the number of amino acids at the N- and C- termini of the TALE DNA binding domain flanking the DNA binding repeats, followed by the repressor domain used in the construct. The endogenous pi 1 mRNA levels were measured using qRT-PCR and normalized to the level in the negative control cells transfected with a GFP-encoding construct, (c) Fold of transcriptional repression of endogenous mouse pi I. The fold decrease of endogenous pi I mRNA is measured using qRT-PCR through dividing the pi I mRNA levels in cells transfected with a negative control GFP construct by pi I mRNA levels in cells transfected with each candidate TALE repressors. The labeling of the constructs along the x-axis is the same as previous panel. NLS, nuclear localization signal; SID, mSin interaction domain; SID4X, an optimized four-time tandem repeats of SID domain linked by short peptide linkers. All results are collected from three independent experiments in Neuro2A cells. Error bars indicate s.e.m.; n = 3. *** /? < 0.001, Student's t test.
[0060] FIG. 14 shows a comparison of two different types of TALE architecture.
[0061] FIGS. 15A-C show a chemically inducible TALE ABA inducible system. ABI (ABA insensitive 1) and PYL (PYL protein: pyrabactin resistance (PYR)/PYRl-like (PYL)) are domains from two proteins listed below that will dimerize upon binding of plant hormone Abscisic Acid (ABA). This plant hormone is a small molecule chemical that Applicants used in Applicants' inducible TALE system. In this system, the TALE DNA-binding polypeptide is fused to the ABI domain, whereas the VP64 activation domain or SID repressor domain or any effector domains are linked to the PYL domain. Thus, upon the induction by the presence of ABA molecule, the two interacting domains, ABI and PYL, will dimerize and allow the TALE to be linked to the effector domains to perform its activity in regulating target gene expression.
[0062] FIGS. 16A-B show a chemically inducible TALE 40HT inducible system.
[0063] FIG. 17 depicts an effect of cryptochrome2 heterodimer orientation on LITE functionality. [0064] FIG. 18 depicts mGlur2 LITE activity in mouse cortical neuron culture.
[0065] FIG. 19 depicts transduction of primary mouse neurons with LITE AAV vectors.
[0066] FIG. 20 depicts expression of LITE component in vivo.
[0067] FIG. 21 depicts an improved design of the construct where the specific NES peptide sequence used is LDLASLIL.
[0068] FIG. 22 depicts Sox2 mRNA levels in the absence and presence of 40H tamoxifen.
[0069] FIGS. 23A-E depict a Type II CRISPR locus from Streptococcus pyogenes SF370 can be reconstituted in mammalian cells to facilitate targeted DSBs of DNA. (A) Engineering of SpCas9 and SpRNase III with NLSs enables import into the mammalian nucleus. (B) Mammalian expression of SpCas9 and SpRNase III are driven by the EFla promoter, whereas tracrRNA and pre-crRNA array (DR-Spacer-DR) are driven by the U6 promoter. A protospacer (blue highlight) from the human EMX1 locus with PAM is used as template for the spacer in the pre-crRNA array. (C) Schematic representation of base pairing between target locus and EMX1- targeting crRNA. Red arrow indicates putative cleavage site. (D) SURVEYOR assay for SpCas9-mediated indels. (E) An example chromatogram showing a micro-deletion, as well as representative sequences of mutated alleles identified from 187 clonal amplicons. Red dashes, deleted bases; red bases, insertions or mutations. Scale bar = ΙΟμιη.
[0070] FIGS. 24A-C depict a SpCas9 can be reprogrammed to target multiple genomic loci in mammalian cells. (A) Schematic of the human EMX1 locus showing the location of five protospacers, indicated by blue lines with corresponding PAM in magenta. (B) Schematic of the pre-crRNA:tracrRNA complex (top) showing hybridization between the direct repeat (gray) region of the pre-crRNA and tracrRNA. Schematic of a chimeric RNA design (M. Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012)) (bottom). tracrRNA sequence is shown in red and the 20bp spacer sequence in blue. (C) SURVEYOR assay comparing the efficacy of Cas9-mediated cleavage at five protospacers in the human EMX1 locus. Each protospacer is targeted using either processed pre-crRNA:tracrRNA complex (crRNA) or chimeric RNA (chiRNA).
[0071] FIGS. 25A-D depict an evaluation of the SpCas9 specificity and comparison of efficiency with TALENs. (A) EMX1 -targeting chimeric crRNAs with single point mutations were generated to evaluate the effects of spacer-protospacer mismatches. (B) SURVEYOR assay comparing the cleavage efficiency of different mutant chimeric RNAs. (C) Schematic showing the design of TALENs targeting EMXl. (D) SURVEYOR gel comparing the efficiency of TALEN and SpCas9 (N = 3).
[0072] FIGS. 26A-G depict applications of Cas9 for homologous recombination and multiplex genome engineering. (A) Mutation of the RuvC I domain converts Cas9 into a nicking enzyme (SpCas9n) (B) Co-expression of EMXl -targeting chimeric RNA with SpCas9 leads to indels, whereas SpCas9n does not (N = 3). (C) Schematic representation of the recombination strategy. A repair template is designed to insert restriction sites into EMXl locus. Primers used to amplify the modified region are shown as red arrows. (D) Restriction fragments length polymorphism gel analysis. Arrows indicate fragments generated by HmdIII digestion. (E) Example chromatogram showing successful recombination. (F) SpCas9 can facilitate multiplex genome modification using a crRNA array containing two spacers targeting EMXl and PVALB. Schematic showing the design of the crRNA array (top). Both spacers mediate efficient protospacer cleavage (bottom). (G) SpCas9 can be used to achieve precise genomic deletion. Two spacers targeting EMXl (top) mediated a 118bp genomic deletion (bottom).
[0073] FIG. 27 depicts a schematic of the type II CRISPR-mediated DNA double-strand break. The type II CRISPR locus from Streptococcus pyogenes SF370 contains a cluster of four genes, Cas9, Casl, Cas2, and Csnl, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non- repetitive sequences (spacers, 30bp each) (15-18, 30, 31). Each spacer is typically derived from foreign genetic material (protospacer), and directs the specificity of CRISPR-mediated nucleic acid cleavage. In the target nucleic acid, each protospacer is associated with a protospacer adjacent motif (PAM) whose recognition is specific to individual CRISPR systems (22, 23). The Type II CRISPR system carries out targeted DNA double-strand break (DSB) in sequential steps (M. Jinek et al, Science 337, 816 (Aug 17, 2012); Gasiunas, R. et al. Proc Natl Acad Sci U S A 109, E2579 (Sep 25, 2012); J. E. Garneau et al, Nature 468, 67 (Nov 4, 2010); R. Sapranauskas et al, Nucleic Acids Res 39, 9275 (Nov, 2011); A. H. Magadan et al. PLoS One 7, e40913 (2012)). First, the pre-crRNA array and tracrRNA are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of pre-crRNA and associates with Cas9 as a duplex, which mediates the processing of the pre-crRNA into mature crRNAs containing individual,truncated spacer sequences. Third, the mature crRNA:tracrRNA duplex directs Cas9 to the DNA target consisting of the protospacer and the requisite PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer.
[0074] FIGS. 28A-C depict a comparison of different tracrRNA transcripts for Cas9- mediated gene targeting. (A) Schematic showing the design and sequences of two tracrRNA transcripts tested (short and long). Each transcript is driven by a U6 promoter. Transcription start site is marked as +1 and transcription terminator is as indicated. Blue line indicates the region whose reverse-complement sequence is used to generate northern blot probes for tracrRNA detection. (B) SURVEYOR assay comparing the efficiency of hSpCas9-mediated cleavage of the EMXl locus. Two biological replicas are shown for each tracrRNA transcript. (C) Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying long or short tracrRNA, as well as SpCas9 and DR-E ¥7(1)-DR. Left and right panels are from 293FT cells transfected without or with SpRNase III respectively. U6 indicate loading control blotted with a probe targeting human U6 snRNA. Transfection of the short tracrRNA expression construct led to abundant levels of the processed form of tracrRNA (~75bp) (E. Deltcheva et al., Nature 471, 602 (Mar 31, 2011)). Very low amounts of long tracrRNA are detected on the Northern blot. As a result of these experiments, Applicants chose to use short tracrRNA for application in mammalian cells.
[0075] FIG. 29 depicts a SURVEYOR assay for detection of double strand break-induced micro insertions and deletions (D. Y. Guschin et al. Methods Mol Biol 649, 247 (2010)). Schematic of the SURVEYOR assay used to determine Cas9-mediated cleavage efficiency. First, genomic PCR (gPCR) is used to amplify the Cas9 target region from a heterogeneous population of modified and unmodified cells, and the gPCR products are reannealed slowly to generate heteroduplexes. The reannealed heteroduplexes are cleaved by SURVEYOR nuclease, whereas homoduplexes are left intact. Cas9-mediated cleavage efficiency (% indel) is calculated based on the fraction of cleaved DNA.
[0076] FIG. 30A-B depict a Northern blot analysis of crRNA processing in mammalian cells. (A) Schematic showing the expression vector for a single spacer flanked by two direct repeats (DR-EMX1 (l)-DR). The 30bp spacer targeting the human EMXl locus protospacer 1 (Table 1) is shown in blue and direct repeats are in shown in gray. Orange line indicates the region whose reversecomplement sequence is used to generate northern blot probes for EMXl (I) crRNA detection. (B) Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying DR-E ¥7(1)-DR. Left and right panels are from 293FT cells trans fected without or with SpRNase III respectively. DR-E ¥7(1)-DR was processed into mature crRNAs only in the presence of SpCas9 and short tracrRNA, and was not dependent on the presence of SpRNase III. The mature crRNA detected from transfected 293FT total RNA is ~33bp and is shorter than the 39-42bp mature crRNA from S. pyogenes (E. Deltcheva et al., Nature 471, 602 (Mar 31, 2011)), suggesting that the processed mature crRNA in human 293FT cells is likely different from the bacterial mature crRNA in S. pyogenes.
[0077] FIG. 31A-B depict a bicistronic expression vectors for pre-crRNA array or chimeric crRNA with Cas9. (A) Schematic showing the design of an expression vector for the pre-crRNA array. Spacers can be inserted between two Bbsl sites using annealed oligonucleotides. Sequence design for the oligonucleotides are shown below with the appropriate ligation adapters indicated. (B) Schematic of the expression vector for chimeric crRNA. The guide sequence can be inserted between two Bbsl sites using annealed oligonucleotides. The vector already contains the partial direct repeat (gray) and partial tracrRNA (red) sequences. WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element.
[0078] FIGS. 32A-B depict a selection of protospacers in the human PVALB and mouse Th loci. Schematic of the human PVALB (A) and mouse Th (B) loci and the location of the three protospacers within the last exon of the PVALB and Th genes, respectively. The 30bp protospacers are indicated by black lines and the adjacent PAM sequences are indicated by the magenta bar. Protospacers on the sense and anti-sense strands are indicated above and below the DNA sequences respectively.
[0079] FIGS. 33A-C depict occurrences of PAM sequences in the human genome. Histograms of distances between adjacent Streptococcus pyogenes SF370 locus 1 PAM (NGG) (A) and Streptococcus thermophiles LMD9 locus 1 PAM (NNAGAAW) (B) in the human genome. (C) Distances for each PAM by chromosome. Chr, chromosome. Putative targets were identified using both the plus and minus strands of human chromosomal sequences. Given that there may be chromatin, DNA methylation-, RNA structure, and other factors that may limit the cleavage activity at some protospacer targets, it is important to note that the actual targeting ability might be less than the result of this computational analysis.
[0080] FIGS. 34A-D depict type II CRISPR from Streptococcus thermophilus LMD-9 can also function in eukaryotic cells. (A) Schematic of CRISPR locus 2 from Streptococcus thermophilus LMD-9. (B) Design of the expression system for the S. thermphilus CRISPR system. Human codon-optimized hStCas9 is expressed using a constitutive EFla promoter. Mature versions of tracrRNA and crRNA are expressed using the U6 promoter to ensure precise transcription initiation. Sequences for the mature crRNA and tracrRNA are shown. A single based indicated by the lower case "a" in the crRNA sequence was used to remove the polyU sequence, which serves as a RNA Pol III transcriptional terminator. (C) Schematic showing protospacer and corresponding PAM sequences targets in the human EMX1 locus. Two protospacer sequences are highlighted and their corresponding PAM sequences satisfying the NNAGAAW motif are indicated by magenta lines. Both protospacers are targeting the anti-sense strand. (D) SURVEYOR assay showing StCas9-mediated cleavage in the target locus. RNA guide spacers 1 and 2 induced 14% and 6.4% respectively. Statistical analysis of cleavage activity across biological replica at these two protospacer sites can be found in Table 1.
[0081] FIG. 35 depicts an example of an AAV-promoter-TALE-effector construct, where hSyn = human synapsin 1 promoter, N+136 = TALE N-term, AA +136 truncation, C63 = TALE C-term, AA +63 truncation, vp = VP64 effector domain, GFP = green fluorescent protein, WPRE = Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element, bGH = bovine growth hormone polyA, ITR = AAV inverted terminal repeat and AmpR = ampicillin resistance gene.
[0082] FIG. 36A-C depict design and optimization of the LITE system, (a) A TALE DNA- binding domain is fused to CRY2 and a transcriptional effector domain is fused to CIBl . In the inactive state, TALE-CRY2 binds the promoter region of the target gene while CIBl -effector remains unbound in the nucleus. The VP64 transcriptional activator is shown above. Upon illumination with blue light, TALE-CRY2 and CIBl -effector rapidly dimerize, recruiting CIB1- effector to the target promoter. The effector in turn modulates transcription of the target gene, (b) Light-dependent upregulation of the endogenous target Neurog2 mRNA with LITEs containing functional truncations of its light-sensitive binding partners. LITE -trans fected Neuro- 2a cells were stimulated for 24 h with 466 nm light at an intensity of 5mW/cm2 and a duty cycle of 7%) (I s pulses at 0.066 Hz), (c) Time course of light-dependent Neurog2 upregulation by TALE-CRY2PHR and CIB1-VP64 LITEs. LITE-transfected Neuro-2a cells were stimulated with 466 nm light at an intensity of 5 mW/cm2 and a duty cycle of 7% (I s pulses at 0.066 Hz) and decrease of Neurog2 mRNA levels after 6 h of light stimulation. All Neurog2 mRNA levels were measured relative to expressing GFP control cells (mean ± s.e.m.; n = 3-4) (*, p < 0.05; and ***, /? < 0.001).
[0083] FIG. 37A-F depict in vitro and in vivo AAV-mediated TALE delivery targeting endogenous loci in neurons, (a) General schematic of constitutive TALE transcriptional activator packaged into AAV. Effector domain VP64 highlighted. hSyn: human synapsin promoter; 2A: foot-and-mouth disease-derived 2 A peptide; WPRE: woodchuck hepatitis post-transcriptional response element; bGH pA: bovine growth hormone poly-A signal, (b) Representative images showing transduction with AAV-TALE-VP64 construct from (a) in primary cortical neurons. Cells were stained for GFP and neuronal marker NeuN. Scale bars = 25 μιη. (c) AAV-TALE- VP64 constructs targeting a variety of endogenous loci were screened for transcriptional activation in primary cortical neurons (*, p < 0.05; **, p < 0.01 ; p < 0.001). (d) Efficient delivery of TALE-VP64 by AAV into the ILC of mice. Scale bar = 100 μιη. (Cgl = cingulate cortex, PLC = prelimbic cortex, ILC = infralimbic cortex), (e) Higher magnification image of efficient transduction of neurons in ILC. (f) Grm2 mRNA upregulation by TALE-VP64 in vivo in ILC (mean ± s.e.m.; n = 3 animals per condition), measured using a 300μιη tissue punch.
[0084] FIGS. 38A-I depict LITE-mediated optogenetic modulation of endogenous transcription in primary neurons and in vivo, (a) AAV-LITE activator construct with switched CRY2PHR and CIB1 architecture, (b) Representative images showing co-transduction of AAV- delivered LITE constructs in primary neurons. Cells were stained for GFP, HA-tag, and DAPI. (Scale bars = 25 μιη). (c) Light-induced activation of Grm2 expression in primary neurons after 24 h of stimulation with 0.8% duty cycle pulsed 466 nm light (250 ms pulses at 0.033Hz or 500 ms pulses at 0.016Hz; 5mW/cm2). (d) Upregulation of Grm2 mRNA in primary cortical neurons with and without light stimulation at 4 h and 24 h time points. Expression levels are shown relative to neurons transduced with GFP only, (e) Quantification of mGluR2 protein levels in GFP only control transductions, unstimulated neurons with LITEs, and light-stimulated neurons with LITEs. A representative western blot is shown with β-tubulin-III as a loading control, (f) Schematic showing transduction of ILC with the LITE system, the optical fiber implant, and the 0.35 mm diameter brain punch used for tissue isolation, (g) Representative images of ILC co- transduced with both LITE components. Stains are shown for HA-tag (red), GFP (green), and DAPI (blue). (Scale bar = 25 μιη). (h) Light-induced activation of endogenous Grm2 expression using LITEs transduced into ILC. **, p < 0.05; data generated from 4 different mice for each experimental condition, (i) Fold increases and light induction of Neurog2 expression using LITE 1.0 and optimized LITE 2.0. LITE2.0 provides minimal background while maintaining a high level of activation. NLSa_importin and NLSsv4o, nuclear localization signal from a-importin and simian virus 40 respectively; GS, Gly-Ser linker; NLS*, mutated NLS where the indicated residues have been substituted with Ala to prevent nuclear localization activity; Δ318-334; deletion of a higher plant helix-loop-helix transcription factor homology region.
[0085] FIG. 39A-H depict TALE- and LITE-mediated epigenetic modifications (a) Schematic of LITE epigenetic modifiers (epiLITE). (b) Schematic of engineered epigenetic transcriptional repressor SID4X within an AAV vector. phiLOV2.1 (330bp) was used as a fluorescent marker rather than GFP (800bp) to ensure efficient AAV packaging, (c) epiLITE- mediated repression of endogenous Grm2 expression in primary cortical neurons with and without light stimulation. Fold down regulation is shown relative to neurons transduced with GFP alone, (d) epiLITE-mediated decrease in H3K9 histone residue acetylation at the Grm2 promoter with and without light-stimulation, (e, f) Fold reduction of Grm2 mRNA by epiTALE- methyltransferases (epiTALE-KYP, -TgSET8, and -NUE), and corresponding enrichment of histone methylation marks H3K9mel, H4K20me3, and H3K27me3 at the Grm2 promoter, (g, h) Fold reduction of Grm2 mRNA by epiTALE histone deacetylases (epiTALE-HDAC8, -RPD3, - Sir2a, and -Sin3a), and corresponding decreases in histone residue acetylation marks H4K8Ac and H3K9Ac at the Grm2 promoter. Values shown in all panels are mean ± s.e.m., n = 3-4.
[0086] FIG. 40 depicts an illustration of the absorption spectrum of CRY2 in vitro. Cryptochrome 2 was optimally activated by 350-475 nm light1. A sharp drop in absorption and activation was seen for wavelengths greater than 480 nm. Spectrum was adapted from Banerjee, R. et al. The Signaling State of Arabidopsis Cryptochrome 2 Contains Flavin Semiquinone. Journal of 'Biological Chemistry 282, 14916-14922, doi: 10.1074/jbc.M700616200 (2007).
[0087] FIG. 41 depicts an impact of illumination duty cycle on LITE-mediated gene expression. Varying duty cycles (illumination as percentage of total time) were used to stimulate 293FT cells expressing LITEs targeting the KLF4 gene, in order to investigate the effect of duty cycle on LITE activity. KLF4 expression levels were compared to cells expressing GFP only. Stimulation parameters were: 466 nm, 5 mW/cm2 for 24 h. Pulses were performed at 0.067 Hz with the following durations: 1.7% = 0.25 s pulse, 7% = 1 s pulse, 27% = 4 s pulse, 100%) = constant illumination, (mean ± s.e.m.; n = 3-4). [0088] FIGS. 42A-B depict an impact of light intensity on LITE -mediated gene expression and cell survival, (a) The transcriptional activity of CRY2PHR :: CIB1 LITE was found to vary according to the intensity of 466 nm blue light. Neuro 2a cells were stimulated for 24 h hours at a 7% duty cycle (Is pulses at 0.066Hz) (b) Light-induced toxicity measured as the percentage of cells positive for red- fluorescent ethidium homodimer-1 versus calcein-positive cells. All Neurog2 mRNA levels were measured relative to cells expressing GFP only (mean ± s.e.m.; n = 3-4).
[0089] FIG. 43 depicts an impact of transcriptional activation domains on LITE-mediated gene expression. Neurog2 up-regulation with and without light by LITEs using different transcriptional activation domains (VP 16, VP64, and p65). Neuro-2a cells transfected with LITE were stimulated for 24 h with 466 nm light at an intensity of 5mW/cm2 and a duty cycle of 7% (1 s pulses at 0.066 Hz), (mean ± s.e.m.; n = 3-4)
[0090] FIGS. 44A-C depict chemical induction of endogenous gene transcription, (a) Schematic showing the design of a chemical inducible two hybrid TALE system based on the abscisic acid (ABA) receptor system. ABI and PYL dimerize upon the addition of ABA and dissociates when ABA is withdrawn, (b) Time course of ABA-dependent Neurogl up- regulation. 250 μΜ of ABA was added to HEK 293FT cells expressing T ALE(Neurog2)-AB>\ and PYL-VP64. Fold mRNA increase was measured at the indicated time points after the addition of ABA. (c) Decrease of N ' eurogl mRNA levels after 24 h of ABA stimulation. All Neurogl mRNA levels were measured relative to expressing GFP control cells (mean ± s.e.m.; n = 3-4).
[0091] FIGS. 45A-C depict AAV supernatant production, (a) Lentiviral and AAV vectors carrying GFP were used to test transduction efficiency, (b) Primary embryonic cortical neurons were transduced with 300 and 250 supernatant derived from the same number of AAV or lentivirus-transfected 293FT cells. Representative images of GFP expression were collected at 7 d.p.i. Scale bars = 50 μιη. (c) The depicted process was developed for the production of AAV supernatant and subsequent transduction of primary neurons. 293FT cells were transfected with an AAV vector carrying the gene of interest, the AAVl serotype packaging vector (pAAVl), and helper plasmid (pDF6) using PEL 48 h later, the supernatant was harvested and filtered through a 0.45 μιη PVDF membrane. Primary neurons were then transduced with supernatant and remaining aliquots were stored at -80°C. Stable levels of AAV construct expression were reached after 5-6 days. AAV supernatant production following this process can be used for production of up to 96 different viral constructs in 96-well format (employed for TALE screen in neurons shown in FIG. 37C).
[0092] FIG. 46 depicts selection of TALE target sites guided by DNasel-sensitive chromatin regions. High DNasel sensitivity based on mouse cortical tissue data from ENCODE (http://genome.ucsc.edu) was used to identify open chromatin regions. The peak with the highest amplitude within the region 2 kb upstream of the transcriptional start site was selected for targeting. TALE binding targets were then picked within a 200 bp region at the center of the peak.
[0093] FIG. 47 depicts an impact of light duty cycle on primary neuron health. The effect of light stimulation on primary cortical neuron health was compared for duty cycles of 7%, 0.8%, and no light conditions. Calcein was used to evaluate neuron viability. Bright-field images were captured to show morphology and cell integrity. Primary cortical neurons were stimulated with the indicated duty cycle for 24 h with 5 mW/cm2 of 466 nm light. Representative images, scale bar = 50 μιη. Pulses were performed in the following manner: 7% duty cycle = 1 s pulse at 0.067 Hz, 0.8% duty cycle = 0.5 s pulse at 0.0167 Hz.
[0094] FIG. 48 depicts an image of a mouse during optogenetic stimulation. An awake, freely behaving, LITE-injected mouse is pictured with a stereotactically implanted cannula and optical fiber.
[0095] FIG. 49 depicts co-transduction efficiency of LITE components by AAVl/2 in mouse infralimbic cortex. Cells transduced by TALE(Grm2)-CIBl alone, CRY2PHR-VP64 alone, or co-transduced were calculated as a percentage of all transduced cells.
[0096] FIG. 50 depicts a contribution of individual LITE components to baseline transcription modulation. Grm2 mRNA levels were determined in primary neurons transfected with individual LITE components. Primary neurons expressing Grm2 TALE 1-CIB1 alone led to a similar increase in Grm2 mRNA levels as unstimulated cells expressing the complete LITE system, (mean ± s.e.m.; n = 3-4).
[0097] FIG. 51 depicts effects of LITE Component Engineering on Activation, Background Signal, and Fold Induction. Protein modifications were employed to find LITE components resulting in reduced background transcriptional activation while improving induction ratio by light. Protein alterations are discussed in detail below. In brief, nuclear localization signals and mutations in an endogenous nuclear export signal were used to improve nuclear import of the CRY2PHR-VP64 component. Several variations of CIB1 intended to either reduce nuclear localization or CIB1 transcriptional activation were pursued in order to reduce the contribution of the TALE-CIBI component to background activity. The results of all combinations of CRY2PHR-VP64 and TALE-CIBI which were tested are shown above. The table to the left of the bar graphs indicates the particular combination of domains/mutations used for each condition. Each row of the table and bar graphs contains the component details, Light/No light activity, and induction ratio by light for the particular CRY2PHR/CIB1 combination. Combinations that resulted in both decreased background and increased fold induction compared to LITE 1.0 are highlighted in green in the table column marked "+" (t-test p<0.05). CRY2PHR- VP64 Constructs: Three new constructs were designed with the goal of improving CRY2PHR- VP64 nuclear import. First, the mutations L70A and L74A within a predicted endogenous nuclear export sequence of CRY2PHR were induced to limit nuclear export of the protein (referred to as '*' in the Effector column). Second, the a-importin nuclear localization sequence was fused to the N-terminus of CRY2PHR-VP64 (referred to as 'A' in the Effector column). Third, the SV40 nuclear localization sequence was fused to the C-terminus of CRY2PHR-VP64 (referred to as 'P' in the Effector column). TALE-CIBI Linkers: The SV40 NLS linker between TALE and CIB1 used in LITE 1.0 was replaced with one of several linkers designed to increase nuclear export of the TALE-CIBI protein (The symbols used in the CIB1 Linker column are shown in parentheses): a flexible glycine-serine linker (G), an adenovirus type 5 E1B nuclear export sequence (W), an HIV nuclear export sequence (M), a MAPK nuclear export sequence (K), and a PTK2 nuclear export sequence (P). NLS* Endogenous CIB1 Nuclear Localization Sequence Mutation: A nuclear localization signal exists within the wild type CIB1 sequence. This signal was mutated in NLS* constructs at K92A, R93A, K105A, and K106A in order to diminish TALE-CIBI nuclear localization (referred to as 'N' in the NLS* column). ΔΟΒ1 Transcription Factor Homology Deletions: In an effort to eliminate possible basal CIB 1 transcriptional activation, deletion constructs were designed in which regions of high homology to basic helix-loop-helix transcription factors in higher plants were removed. These deleted regions consisted of Aaa230-256, Aaa276-307, Aaa308-334 (referred to as ' 1 ' '2' and '3' in the ACIBl column). In each case, the deleted region was replaced with a 3 residue GGS link. NES Insertions into CIB1: One strategy to facilitate light-dependent nuclear import of TALE- CIB1 was to insert an NES in CIB1 at its dimerization interface with CRY2PHR such that the signal would be concealed upon binding with CRY2PHR. To this end, an NES was inserted at different positions within the known CRY2 interaction domain CIBN (aa 1-170). The positions are as follows (The symbols used in the NES column are shown in parentheses): aa28 (1), aa52 (2), aa73 (3), aal20 (4), aal40 (5), aal60 (6). *bHLH basic Helix-Loop-Helix Mutation: To reduce direct CIB1-DNA interactions, several basic residues of the basic helix-loop-helix region in CIB 1 were mutated. The following mutations are present in all *bHLH constructs (referred to as 'B' in the *bHLH column of FIG. 51): R175A, G176A, R187A, and R189A.
[0098] FIG. 52 depicts an illustration of light mediated co-dependent nuclear import of TALE-CIBl (a) In the absence of light, the TALE-CIBl LITE component resides in the cytoplasm due to the absence of a nuclear localization signal, NLS (or the addition of a weak nuclear export signal, NES). The CRY2PHR-VP64 component containing a NLS on the other hand is actively imported into the nucleus on its own. (b) In the presence of blue light, TALE- CIBl binds to CRY2PHR. The strong NLS present in CRY2PHR-VP64 now mediates nuclear import of the complex of both LITE components, enabling them to activate transcription at the targeted locus.
[0099] FIG. 53 depicts notable LITE 1.9 combinations. In addition to the LITE 2.0 constructs, several CRY2PHR-VP64 :: TALE-CIBl combinations from the engineered LITE component screen were of particular note. LITE 1.9.0, which combined the a-importin NLS effector construct with a mutated endogenous NLS and Δ276-307 TALE-CIBl construct, exhibited an induction ratio greater than 9 and an absolute light activation of more than 180. LITE 1.9.1, which combined the unmodified CRY2PHR-VP64 with a mutated NLS, Δ318-334, AD5 NES TALE-CIBl construct, achieved an induction ratio of 4 with a background activation of 1.06. A selection of other LITE 1.9 combinations with background activations lower than 2 and induction ratios ranging from 7 to 12 were also highlighted.
[00100] FIGS. 54A-D depict TALE SID4X repressor characterization and application in neurons, a) A synthetic repressor was constructed by concatenating 4 SID domains (SID4X). To identify the optimal TALE -repressor architecture, SID or SID4X was fused to a TALE designed to target the mouse pi I gene, (b) Fold decrease in pi I mRNA was assayed using qRT-PCR. (c) General schematic of constitutive TALE transcriptional repressor packaged into AAV. Effector domain SID4X is highlighted. hSyn: human synapsin promoter; 2A: foot-and-mouth disease- derived 2 A peptide; WPRE: woodchuck hepatitis post-transcriptional response element; bGH pA: bovine growth hormone poly-A signal. phiLOV2.1 (330bp) was chosen as a shorter fluorescent marker to ensure efficient AAV packaging, (d) 2 TALEs targeting the endogenous mouse loci Grm5, and Grm2 were fused to SID4X and virally transduced into primary neurons. The target gene down-regulation via SID4X is shown for each TALE relative to levels in neurons expressing GFP only, (mean ± s.e.m.; n = 3-4).
[00101] FIGS. 55A-B depict a diverse set of epiTALEs mediate transcriptional repression in neurons and euro 2 a cells a) A total o 24 Gnu 2 targeting TALEs fused to different histone effector domains were transduced into primary cortical mouse neurons using AAV. Gnu 2 mRNA levels were measured using RT-qPCR relative to neurons transduced with GFP only. * denotes repression with p < 0.05. b) A total of 32 epiTALEs were transfected into Neuro2A cells. 20 of them mediated significant repression of the targeted Neurog2 locus (* = p<0.05).
[00102] FIGS. 56A-D depict epiTALEs mediating transcriptional repression along with histone modifications in Neuro 2A cells (a) TALEs fused to histone deacetylating epigenetic effectors NcoR and SIRT3 targeting the murine Neurog2 locus in Neuro 2A cells were assayed for repressive activity on Neurog2 transcript levels, (b) ChIP RT-qPCR showing a reduction in H3K.9 acetylation at the Neurog2 promoter for NcoR and SIRT3 epiTALEs. (c) The epigenetic effector PHF19 with known histone methyltransferase binding activity was fused to a TALE targeting Neurog2 mediated repression of Neurog2 mRNA levels, (d) ChIP RT-qPCR showing an increase in H3K27me3 levels at the Neurog2 promoter for the PHF19 epiTALE.
[00103] FIGS. 57A-G depict RNA-guided DNA binding protein Cas9 can be used to target transcription effector domains to specific genomic loci, (a) The RNA-guided nuclease Cas9 from the type II Streptococcus pyogenes CRISPR/Cas system can be converted into a nucleolytically- inactive RNA-guided DNA binding protein (Cas9**) by introducing two alanine substitutions (D10A and H840A). Schematic showing that a synthetic guide RNA (sgRNA) can direct Cas9** -effector fusion to a specific locus in the human genome. The sgRNA contains a 20bp guide sequence at the 5' end which specifies the target sequence. On the target genomic DNA, the 20bp target site needs to be followed by a 5'-NGG PAM motif, (b, c) Schematics showing the sgRNA target sites in the human KLF4 and SOX2 loci respectively. Each target site is indicated by the blue bar and the corresponding PAM sequence is indicated by the magenta bar. (d, e) Schematics of the Cas9**-VP64 transcription activator and SID4X-Cas9** transcription repressor constructs, (f, g) Cas9**-VP64 and SID4X-Cas9** mediated activation of KLF4 and repression of SOX2 respectively. All mRNA levels were measured relative to GFP mock transfected control cells (mean ± s.e.m.; n = 3).
[00104] FIG. 58 depicts 6 TALEs which were designed, with two TALEs targeting each of the endogenous mouse loci Grm5, Grin2a, and Grm2. TALEs were fused to the transcriptional activator domain VP64 or the repressor domain SID4X and virally transduced into primary neurons. Both the target gene upregulation via VP64 and downregulation via SID4X are shown for each TALE relative to levels in neurons expressing GFP only.
[00105] FIGS. 59A-B depict (A) LITE repressor construct highlighting SID4X repressor domain. (B) Light-induced repression of endogenous Grm2 expression in primary cortical neurons using Grm2 Tl-LITE and Grm2 T2-LITE. Fold downregulation is shown relative to neurons transduced with GFP only (mean ± s.e.m.; n = 3-4 for all subpanels).
[00106] FIGS. 60A-B depict exchanging CRY2PHR and CIB1 components. (A) TALE- CIB1 ::CRY2PHR-VP64 was able to activate Ngn2 at higher levels than TALE- CRY2PHR::CIB1-VP64. (B) Fold activation ratios (light versus no light) ratios of Ngn2 LITEs show similar efficiency for both designs. Stimulation parameters were the same as those used in FIG. 36B.
[00107] FIG. 61 depicts Tet Cas9 vector designs for inducible Cas9.
[00108] FIG. 62 depicts a vector and EGFP expression in 293FT cells after Doxycycline induction of Cas9 and EGFP.
DETAILED DESCRIPTION OF THE INVENTION
[00109] The term "nucleic acid" or "nucleic acid sequence" refers to a deoxyribonucleic or ribonucleic oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, i.e., oligonucleotides, containing known analogues of natural nucleotides. The term also encompasses nucleic-acid-like structures with synthetic backbones, see, e.g., Eckstein, 1991; Baserga et al, 1992; Milligan, 1993; WO 97/03211; WO 96/39154; Mata, 1997; Strauss- Soukup, 1997; and Samstag, 1996.
[00110] As used herein, "recombinant" refers to a polynucleotide synthesized or otherwise manipulated in vitro (e.g., "recombinant polynucleotide"), to methods of using recombinant polynucleotides to produce gene products in cells or other biological systems, or to a polypeptide ("recombinant protein") encoded by a recombinant polynucleotide. "Recombinant means" encompasses the ligation of nucleic acids having various coding regions or domains or promoter sequences from different sources into an expression cassette or vector for expression of, e.g., inducible or constitutive expression of polypeptide coding sequences in the vectors of invention.
[00111] The term "heterologous" when used with reference to a nucleic acid, indicates that the nucleic acid is in a cell or a virus where it is not normally found in nature; or, comprises two or more subsequences that are not found in the same relationship to each other as normally found in nature, or is recombinantly engineered so that its level of expression, or physical relationship to other nucleic acids or other molecules in a cell, or structure, is not normally found in nature. A similar term used in this context is "exogenous". For instance, a heterologous nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged in a manner not found in nature; e.g., a human gene operably linked to a promoter sequence inserted into an adenovirus-based vector of the invention. As an example, a heterologous nucleic acid of interest may encode an immunogenic gene product, wherein the adenovirus is administered therapeutically or prophylactically as a carrier or drug-vaccine composition. Heterologous sequences may comprise various combinations of promoters and sequences, examples of which are described in detail herein.
[00112] A "therapeutic ligand" may be a substance which may bind to a receptor of a target cell with therapeutic effects.
[00113] A "therapeutic effect" may be a consequence of a medical treatment of any kind, the results of which are judged by one of skill in the field to be desirable and beneficial. The "therapeutic effect" may be a behavioral or physiologic change which occurs as a response to the medical treatment. The result may be expected, unexpected, or even an unintended consequence of the medical treatment. A "therapeutic effect" may include, for example, a reduction of symptoms in a subject suffering from infection by a pathogen.
[00114] A "target cell" may be a cell in which an alteration in its activity may induce a desired result or response. As used herein, a cell may be an in vitro cell. The cell may be an isolated cell which may not be capable of developing into a complete organism.
[00115] A "ligand" may be any substance that binds to and forms a complex with a biomolecule to serve a biological purpose. As used herein, "ligand" may also refer to an "antigen" or "immunogen". As used herein "antigen" and "immunogen" are used interchangeably.
[00116] "Expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context.
[00117] As used herein, a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. By way of example, some vectors used in recombinant DNA techniques allow entities, such as a segment of DNA (such as a heterologous DNA segment, such as a heterologous cDNA segment), to be transferred into a target cell. The present invention comprehends recombinant vectors that may include viral vectors, bacterial vectors, protozoan vectors, DNA vectors, or recombinants thereof.
[00118] With respect to exogenous DNA for expression in a vector (e.g., encoding an epitope of interest and/or an antigen and/or a therapeutic) and documents providing such exogenous DNA, as well as with respect to the expression of transcription and/or translation factors for enhancing expression of nucleic acid molecules, and as to terms such as "epitope of interest", "therapeutic", "immune response", "immunological response", "protective immune response", "immunological composition", "immunogenic composition", and "vaccine composition", inter alia, reference is made to U.S. Patent No. 5,990,091 issued November 23, 1999, and WO 98/00166 and WO 99/60164, and the documents cited therein and the documents of record in the prosecution of that patent and those PCT applications; all of which are incorporated herein by reference. Thus, U.S. Patent No. 5,990,091 and WO 98/00166 and WO 99/60164 and documents cited therein and documents of record in the prosecution of that patent and those PCT applications, and other documents cited herein or otherwise incorporated herein by reference, may be consulted in the practice of this invention; and, all exogenous nucleic acid molecules, promoters, and vectors cited therein may be used in the practice of this invention. In this regard, mention is also made of U.S. Patents Nos. 6,706,693; 6,716,823; 6,348,450; U.S. Patent Application Serial Nos. 10/424,409; 10/052,323; 10/116,963; 10/346,021; and WO 99/08713, published February 25, 1999, from PCT/US98/16739.
[00119] Aspects of the invention comprehend the TALE and CRISPR-Cas systems of the invention being delivered into an organism or a cell or to a locus of interest via a delivery system. One means of delivery is via a vector, wherein the vector is a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-associated viral vectors, but other means of delivery are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided. In some embodiments, one or more of the viral or plasmid vectors may be delivered via nanoparticles, exosomes, microvesciles, or a gene-gun.
[00120] As used herein, the terms "drug composition" and "drug", "vaccinal composition", "vaccine", "vaccine composition", "therapeutic composition" and "therapeutic-immunologic composition" cover any composition that induces protection against an antigen or pathogen. In some embodiments, the protection may be due to an inhibition or prevention of infection by a pathogen. In other embodiments, the protection may be induced by an immune response against the antigen(s) of interest, or which efficaciously protects against the antigen; for instance, after administration or injection into the subject, elicits a protective immune response against the targeted antigen or immunogen or provides efficacious protection against the antigen or immunogen expressed from the inventive adenovirus vectors of the invention. The term "pharmaceutical composition" means any composition that is delivered to a subject. In some embodiments, the composition may be delivered to inhibit or prevent infection by a pathogen.
[00121] A "therapeutically effective amount" is an amount or concentration of the recombinant vector encoding the gene of interest, that, when administered to a subject, produces a therapeutic response or an immune response to the gene product of interest.
[00122] The term "viral vector" as used herein includes but is not limited to retroviruses, adenoviruses, adeno-associated viruses, alphaviruses, and herpes simplex virus.
[00123] The present invention comprehends spatiotemporal control of endogenous or exogenous gene expression using a form of energy. The form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy. In a preferred embodiment of the invention, the form of energy is electromagnetic radiation, preferably, light energy. Previous approaches to control expression of endogenous genes, such as transcription activators linked to DNA binding zinc finger proteins provided no mechanism for temporal or spatial control. The capacity for photoactivation of the system described herein allows the induction of gene expression modulation to begin at a precise time within a localized population of cells.
[00124] Aspects of control as detailed in this application relate to at least one or more switch(es). The term "switch" as used herein refers to a system or a set of components that act in a coordinated manner to affect a change, encompassing all aspects of biological function such as activation, repression, enhancement or termination of that function. In one aspect the term switch encompasses genetic switches which comprise the basic components of gene regulatory proteins and the specific DNA sequences that these proteins recognize. In one aspect, switches relate to inducible and repressible systems used in gene regulation. In general, an inducible system may be off unless there is the presence of some molecule (called an inducer) that allows for gene expression. The molecule is said to "induce expression". The manner by which this happens is dependent on the control mechanisms as well as differences in cell type. A repressible system is on except in the presence of some molecule (called a corepressor) that suppresses gene expression. The molecule is said to "repress expression". The manner by which this happens is dependent on the control mechanisms as well as differences in cell type. The term "inducible" as used herein may encompass all aspects of a switch irrespective of the molecular mechanism involved. Accordingly a switch as comprehended by the invention may include but is not limited to antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems. In preferred embodiments the switch may be a tetracycline (Tet)/DOX inducible system, a light inducible systems, a Abscisic acid (ABA) inducible system, a cumate repressor/operator system, a 40HT/estrogen inducible system, an ecdysone-based inducible systems or a FKBP12/FRAP (FKBP12-rapamycin complex) inducible system.
[00125] In one aspect of the invention at least one switch may be associated with a TALE or CRISPR-Cas system wherein the activity of the TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch. The term "contact" as used herein for aspects of the invention refers to any associative relationship between the switch and the inducer energy source, which may be a physical interaction with a component (as in molecules or proteins which bind together) or being in the path or being struck by energy emitted by the energy source (as in the case of absorption or reflection of light, heat or sound). In some aspects of the invention the contact of the switch with the inducer energy source is brought about by application of the inducer energy source. The invention also comprehends contact via passive feedback systems. This includes but is not limited to any passive regulation mechanism by which the TALE or CRISPR-Cas system activity is controlled by contact with an inducer energy source that is already present and hence does not need to be applied. For example this energy source may be a molecule or protein already existent in the cell or in the cellular environment. Interactions which bring about contact passively may include but are not limited to receptor/ligand binding, receptor/chemical ligand binding, receptor/protein binding, antibody/protein binding, protein dimerization, protein heterodimerization, protein multimerization, nuclear receptor/ligand binding, post-translational modifications such as phosphorylation, dephosphorylation, ubiquitination or deubiquitination.
[00126] Two key molecular tools were leveraged in the design of the photoresponsive transcription activator-like (TAL) effector system. First, the DNA binding specificity of engineered TAL effectors is utilized to localize the complex to a particular region in the genome. Second, light-induced protein dimerization is used to attract an activating or repressing domain to the region specified by the TAL effector, resulting in modulation of the downstream gene.
[00127] Inducible effectors are contemplated for in vitro or in vivo application in which temporally or spatially specific gene expression control is desired. In vitro examples: temporally precise induction/suppression of developmental genes to elucidate the timing of developmental cues, spatially controlled induction of cell fate reprogramming factors for the generation of cell- type patterned tissues. In vivo examples: combined temporal and spatial control of gene expression within specific brain regions.
[00128] In a preferred embodiment of the invention, the inducible effector is a Light Inducible Transcriptional Effector (LITE). The modularity of the LITE system allows for any number of effector domains to be employed for transcriptional modulation. In a particularly advantageous embodiment, transcription activator like effector (TALE) and the activation domain VP64 are utilized in the present invention.
[00129] LITEs are designed to modulate or alter expression of individual endogenous genes in a temporally and spatially precise manner. Each LITE may comprise a two component system consisting of a customized DNA-binding transcription activator like effector (TALE) protein, a light-responsive cryptochrome heterodimer from Arabadopsis thaliana, and a transcriptional activation/repression domain. The TALE is designed to bind to the promoter sequence of the gene of interest. The TALE protein is fused to one half of the cryptochrome heterodimer (cryptochrome-2 or CIB1), while the remaining cryptochrome partner is fused to a transcriptional effector domain. Effector domains may be either activators, such as VP 16, VP64, or p65, or repressors, such as KRAB, EnR, or SID. In a LITE'S unstimulated state, the TALE- cryptochrome2 protein localizes to the promoter of the gene of interest, but is not bound to the CIB1 -effector protein. Upon stimulation of a LITE with blue spectrum light, cryptochrome-2 becomes activated, undergoes a conformational change, and reveals its binding domain. CIB1, in turn, binds to cryptochrome-2 resulting in localization of the effector domain to the promoter region of the gene of interest and initiating gene overexpression or silencing.
[00130] Activator and repressor domains may selected on the basis of species, strength, mechanism, duration, size, or any number of other parameters. Preferred effector domains include, but are not limited to, a transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-protein recruiting domain, cellular uptake activity associated domain, nucleic acid binding domain or antibody presentation domain.
[00131] Gene targeting in a LITE or in any other inducible effector may be achieved via the specificity of customized TALE DNA binding proteins. A target sequence in the promoter region of the gene of interest is selected and a TALE customized to this sequence is designed. The central portion of the TALE consists of tandem repeats 34 amino acids in length. Although the sequences of these repeats are nearly identical, the 12th and 13th amino acids (termed repeat variable diresidues) of each repeat vary, determining the nucleotide-binding specificity of each repeat. Thus, by synthesizing a construct with the appropriate ordering of TALE monomer repeats, a DNA binding protein specific to the target promoter sequence is created.
[00132] In advantageous embodiments of the invention, the methods provided herein use isolated, non-naturally occurring, recombinant or engineered DNA binding proteins that comprise TALE monomers or TALE monomers or half monomers as a part of their organizational structure that enable the targeting of nucleic acid sequences with improved efficiency and expanded specificity.
[00133] Naturally occurring TALEs or "wild type TALEs" are nucleic acid binding proteins secreted by numerous species of proteobacteria. TALE polypeptides contain a nucleic acid binding domain composed of tandem repeats of highly conserved monomer polypeptides that are predominantly 33, 34 or 35 amino acids in length and that differ from each other mainly in amino acid positions 12 and 13. In advantageous embodiments the nucleic acid is DNA. As used herein, the term "polypeptide monomers", "TALE monomers" or "monomers" will be used to refer to the highly conserved repetitive polypeptide sequences within the TALE nucleic acid binding domain and the term "repeat variable di-residues" or "RVD" will be used to refer to the highly variable amino acids at positions 12 and 13 of the polypeptide monomers. A general representation of a TALE monomer which is comprised within the DNA binding domain is Xi_ n-(X12X13)-X14-33 or 34 or 35, where the subscript indicates the amino acid position and X represents any amino acid. X12X13 indicate the RVDs. In some polypeptide monomers, the variable amino acid at position 13 is missing or absent and in such monomers, the RVD consists of a single amino acid. In such cases the RVD may be alternatively represented as X*, where X represents X12 and (*) indicates that X13 is absent. The DNA binding domain comprises several repeats of TALE monomers and this may be represented as (Xi_n-(Xi2Xi3)-Xi4-33 or 34 or 35)z, where in an advantageous embodiment, z is at least 5 to 40. In a further advantageous embodiment, z is at least 10 to 26.
[00134] The TALE monomers have a nucleotide binding affinity that is determined by the identity of the amino acids in its RVD. For example, polypeptide monomers with an RVD of NI preferentially bind to adenine (A), monomers with an RVD of NG preferentially bind to thymine (T), monomers with an RVD of HD preferentially bind to cytosine (C) and monomers with an RVD of NN preferentially bind to both adenine (A) and guanine (G). In yet another embodiment of the invention, monomers with an RVD of IG preferentially bind to T. Thus, the number and order of the polypeptide monomer repeats in the nucleic acid binding domain of a TALE determines its nucleic acid target specificity. In still further embodiments of the invention, monomers with an RVD of NS recognize all four base pairs and may bind to A, T, G or C. The structure and function of TALEs is further described in, for example, Moscou et al, Science 326: 1501 (2009); Boch et al, Science 326:1509-1512 (2009); and Zhang et al, Nature Biotechnology 29: 149-153 (2011), each of which is incorporated by reference in its entirety.
[00135] The polypeptides used in methods of the invention are isolated, non-naturally occurring, recombinant or engineered nucleic acid-binding proteins that have nucleic acid or DNA binding regions containing polypeptide monomer repeats that are designed to target specific nucleic acid sequences.
[00136] As described herein, polypeptide monomers having an RVD of FIN or NH preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In a preferred embodiment of the invention, polypeptide monomers having RVDs RN, N, NK, SN, NH, KN, HN, NQ, HH, RG, KH, RH and SS preferentially bind to guanine. In a much more advantageous embodiment of the invention, polypeptide monomers having RVDs RN, NK, NQ, HH, KH, RH, SS and SN preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In an even more advantageous embodiment of the invention, polypeptide monomers having RVDs HH, KH, NH, NK, NQ, RH, RN and SS preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In a further advantageous embodiment, the RVDs that have high binding specificity for guanine are RN, NH RH and KH. Furthermore, polypeptide monomers having an RVD of NV preferentially bind to adenine and guanine. In more preferred embodiments of the invention, monomers having RVDs of H*, HA, KA, N*, NA, NC, NS, RA, and S* bind to adenine, guanine, cytosine and thymine with comparable affinity.
[00137] In even more advantageous embodiments of the invention the RVDs that have a specificity for adenine are NI, RI, KI, HI, and SI. In more preferred embodiments of the invention, the RVDs that have a specificity for adenine are HN, SI and RI, most preferably the RVD for adenine specificity is SI. In even more preferred embodiments of the invention the RVDs that have a specificity for thymine are NG, HG, RG and KG. In further advantageous embodiments of the invention, the RVDs that have a specificity for thymine are KG, HG and RG, most preferably the RVD for thymine specificity is KG or RG. In even more preferred embodiments of the invention the RVDs that have a specificity for cytosine are HD, ND, KD, RD, HH, YG and SD. In a further advantageous embodiment of the invention, the RVDs that have a specificity for cytosine are SD and RD. Refer to FIG. 7B for representative RVDs and the nucleotides they target to be incorporated into the most preferred embodiments of the invention. In a further advantageous embodiment the variant TALE monomers may comprise any of the RVDs that exhibit specificity for a nucleotide as depicted in FIG. 7A. All such TALE monomers allow for the generation of degenerative TALE polypeptides able to bind to a repertoire of related, but not identical, target nucleic acid sequences. In still further embodiments of the invention, the RVD NT may bind to G and A. In yet further embodiments of the invention, the RVD NP may bind to A, T and C. In more advantageous embodiments of the invention, at least one selected RVD may be NI, HD, NG, N, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, KI, HI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA or NC.
[00138] The predetermined N-terminal to C-terminal order of the one or more polypeptide monomers of the nucleic acid or DNA binding domain determines the corresponding predetermined target nucleic acid sequence to which the polypeptides of the invention will bind. As used herein the monomers and at least one or more half monomers are "specifically ordered to target" the genomic locus or gene of interest. In plant genomes, the natural TALE-binding sites always begin with a thymine (T), which may be specified by a cryptic signal within the non- repetitive N-terminus of the TALE polypeptide; in some cases this region may be referred to as repeat 0. In animal genomes, TALE binding sites do not necessarily have to begin with a thymine (T) and polypeptides of the invention may target DNA sequences that begin with T, A, G or C. The tandem repeat of TALE monomers always ends with a half-length repeat or a stretch of sequence that may share identity with only the first 20 amino acids of a repetitive full length TALE monomer and this half repeat may be referred to as a half-monomer (FIG. 8). Therefore, it follows that the length of the nucleic acid or DNA being targeted is equal to the number of full monomers plus two.
[00139] For example, nucleic acid binding domains may be engineered to contain 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more polypeptide monomers arranged in a N-terminal to C-terminal direction to bind to a predetermined 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotide length nucleic acid sequence. In more advantageous embodiments of the invention, nucleic acid binding domains may be engineered to contain 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or more full length polypeptide monomers that are specifically ordered or arranged to target nucleic acid sequences of length 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28 nucleotides, respectively. In certain embodiments the polypeptide monomers are contiguous. In some embodiments, half-monomers may be used in the place of one or more monomers, particularly if they are present at the C-terminus of the TALE polypeptide.
[00140] Polypeptide monomers are generally 33, 34 or 35 amino acids in length. With the exception of the RVD, the amino acid sequences of polypeptide monomers are highly conserved or as described herein, the amino acids in a polypeptide monomer, with the exception of the RVD, exhibit patterns that effect TALE activity, the identification of which may be used in preferred embodiments of the invention. Representative combinations of amino acids in the monomer sequence, excluding the RVD, are shown by the Applicants to have an effect on TALE activity (FIG. 10). In more preferred embodiments of the invention, when the DNA binding domain comprises (Xi_n-Xi2Xi3-Xi4-33 or 34 or 35)z, wherein X1-n is a chain of 1 1 contiguous amino acids, wherein Xi2Xi3 is a repeat variable diresidue (RVD), wherein Xi4_33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids, wherein z is at least 5 to 26, then the preferred combinations of amino acids are [LTLD] or [LTLA] or [LTQV] at X1-4, or [EQHG] or [RDHG] at positions X30-33 or X3i_34 or X32_35. Furthermore, other amino acid combinations of interest in the monomers are [LTPD] at Xi_4 and [NQALE] at Xi6-2o and [DHG] at X32_34 when the monomer is 34 amino acids in length. When the monomer is 33 or 35 amino acids long, then the corresponding shift occurs in the positions of the contiguous amino acids [NQALE] and [DHG]; preferably, embodiments of the invention may have [NQALE] at Xi5_i9 or Xi7_2i and [DHG] at
Figure imgf000039_0001
[00141] In still further embodiments of the invention, amino acid combinations of interest in the monomers, are [LTPD] at Xi_4 and [KRALE] at Xi6-2o and [AHG] at X32_34 or [LTPE] at Xi_4 and [KRALE] at Xi6-2o and [DHG] at X32_34 when the monomer is 34 amino acids in length. When the monomer is 33 or 35 amino acids long, then the corresponding shift occurs in the positions of the contiguous amino acids [KRALE], [AHG] and [DHG]. In preferred embodiments, the positions of the contiguous amino acids may be ([LTPD] at Xi_4 and [KRALE] at Xi5_i9 and [AHG] at X31-33) or ([LTPE] at Xi_4 and [KRALE] at Xi5_i9 and [DHG] at X31-33) or ([LTPD] at Xi_4 and [KRALE] at Xi7_2i and [AHG] at X33-35) or ([LTPE] at Xi_4 and [KRALE] at Xi7_2i and [DHG] at X33_35). In still further embodiments of the invention, contiguous amino acids [NGKQALE] are present at positions Xi4-2o or X13-19 or X15-21. These representative positions put forward various embodiments of the invention and provide guidance to identify additional amino acids of interest or combinations of amino acids of interest in all the TALE monomers described herein (FIGs .9A-F and 10).
[00142] Provided below are exemplary amino acid sequences of conserved portions of polypeptide monomers. The position of the RVD in each sequence is represented by XX or by X* (wherein (*) indicates that the RVD is a single amino acid and residue 13 (X13) is absent).
L T P A Q V V A I A S X X G G K Q A L E T V Q R L L P V L C Q D H G L T P A Q V V A I A S X * G G K Q A L E T V Q R L L P V L C Q D H G
L T P D Q V V A I A N X X G G K Q A L A T V Q R L L P V L C Q D H G
L T P D Q V V A I A N X X G G K Q A L E T L Q R L L P V L C Q D H G
L T P D Q V V A I A N X X G G K Q A L E T V Q R L L P V L C Q D H G
L T P D Q V V A I A S X X G G K Q A L A T V Q R L L P V L C Q D H G
L T P D Q V V A I A S X X G G K Q A L E T V Q R L L P V L C Q D H G
L T P D Q V V A I A S X X G G K Q A L E T V Q R V L P V L C Q D H G
L T P E Q V V A I A S X X G G K Q A L E T V Q R L L P V L C Q A H G
L T P Y Q V V A I A S X X G S K Q A L E T V Q R L L P V L C Q D H G
L T R E Q V V A I A S X X G G K Q A L E T V Q R L L P V L C Q D H G
L S T A Q V V A I A S X X G G K Q A L E G I G E Q L L K L R T A P Y
L S T A Q V V A V A S X X G G K P A L E A V R A Q L L A L R A A P Y
[00143] A further listing of TALE monomers excluding the RVDs which may be denoted in a sequence (X1-n-X14-34 or Χι_ιι-Χι4_35), wherein X is any amino acid and the subscript is the amino acid position is provided in FIG.9A-F. The frequency with which each monomer occurs is also indicated.
[00144] As described in Zhang et al, Nature Biotechnology 29:149-153 (2011), TALE polypeptide binding efficiency may be increased by including amino acid sequences from the "capping regions" that are directly N-terminal or C-terminal of the DNA binding region of naturally occurring TALEs into the engineered TALEs at positions N-terminal or C-terminal of the engineered TALE DNA binding region. Thus, in certain embodiments, the TALE polypeptides described herein further comprise an N-terminal capping region and/or a C-terminal capping region.
[00145] An exemplary amino acid sequence of a N-terminal capping region is:
M D P I R S R T P S P A R E L L S G P Q P D G V Q P T A D R G V S P P A G G P L D G L P A R R T M S R T R L P S P P A P S P A F S A D S F S D L L R Q F D P S L F N T S L F D S L P P F G A H H T E A A T G E W D E V Q S G L R A A D A P P P T M R V A V T A A R P P R A K P A P R R R A A Q P S D A S P A A Q V D L R T L G Y S Q Q Q Q E K I K P K V R S T V A Q H H E A L V G H G F T H A H I V A L S Q H P A A L G T V A V K Y Q D M I A A L P E A T H E A I V G V G K Q W S G A R A L E A L L T V A G E L R G P P L Q L D T G Q L L K I A K R G G V T A V E A V H A W R N A L T G A P L N
[00146] An exemplary amino acid sequence of a C-terminal capping region is:
R P A L E S I V A Q L S R P D P A L A A L T N D H L V A L A C L G G R P A L D A V K K G L P H A P A L I K R T N R R I P E R T S H R V A D H A Q V V R V L G F F Q C H S H P A Q A F D D A M T Q F G M S R H G L L Q L F R R V G V T E L E A R S G T L P P A S Q R W D R I L Q A S G M K R A K P S P T S T Q T P D Q A S L H A F A D S L E R D L D A P S P M H E G D Q T R A S
[00147] As used herein the predetermined "N-terminus" to "C terminus" orientation of the N-terminal capping region, the DNA binding domain comprising the repeat TALE monomers and the C-terminal capping region provide structural basis for the organization of different domains in the d-TALEs or polypeptides of the invention.
[00148] The entire N-terminal and/or C-terminal capping regions are not necessary to enhance the binding activity of the DNA binding region. Therefore, in certain embodiments, fragments of the N-terminal and/or C-terminal capping regions are included in the TALE polypeptides described herein.
[00149] In certain embodiments, the TALE polypeptides described herein contain a N- terminal capping region fragment that included at least 10, 20, 30, 40, 50, 54, 60, 70, 80, 87, 90, 94, 100, 102, 110, 117, 120, 130, 140, 147, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260 or 270 amino acids of an N-terminal capping region. In certain embodiments, the N- terminal capping region fragment amino acids are of the C-terminus (the DNA-binding region proximal end) of an N-terminal capping region. As described in Zhang et al., Nature Biotechnology 29:149-153 (2011), N-terminal capping region fragments that include the C- terminal 240 amino acids enhance binding activity equal to the full length capping region, while fragments that include the C-terminal 147 amino acids retain greater than 80% of the efficacy of the full length capping region, and fragments that include the C-terminal 117 amino acids retain greater than 50% of the activity of the full-length capping region.
[00150] In some embodiments, the TALE polypeptides described herein contain a C-terminal capping region fragment that included at least 6, 10, 20, 30, 37, 40, 50, 60, 68, 70, 80, 90, 100, 110, 120, 127, 130, 140, 150, 155, 160, 170, 180 amino acids of a C-terminal capping region. In certain embodiments, the C-terminal capping region fragment amino acids are of the N-terminus (the DNA-binding region proximal end) of a C-terminal capping region. As described in Zhang et al, Nature Biotechnology 29: 149-153 (2011), C-terminal capping region fragments that include the C-terminal 68 amino acids enhance binding activity equal to the full length capping region, while fragments that include the C-terminal 20 amino acids retain greater than 50% of the efficacy of the full length capping region.
[00151] In certain embodiments, the capping regions of the TALE polypeptides described herein do not need to have identical sequences to the capping region sequences provided herein. Thus, in some embodiments, the capping region of the TALE polypeptides described herein have sequences that are at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%), 98%o or 99% identical or share identity to the capping region amino acid sequences provided herein. Sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences. In some preferred embodiments, the capping region of the TALE polypeptides described herein have sequences that are at least 95% dentical or share identity to the capping region amino acid sequences provided herein.
[0100] Sequence homologies may be generated by any of a number of computer programs known in the art, which include but are not limited to BLAST or FASTA. Suitable computer program for carrying out alignments like the GCG Wisconsin Bestfit package may also be used. Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.
[00152] In advantageous embodiments described herein, the TALE polypeptides of the invention include a nucleic acid binding domain linked to the one or more effector domains. The terms "effector domain" or "regulatory and functional domain" refer to a polypeptide sequence that has an activity other than binding to the nucleic acid sequence recognized by the nucleic acid binding domain. By combining a nucleic acid binding domain with one or more effector domains, the polypeptides of the invention may be used to target the one or more functions or activities mediated by the effector domain to a particular target DNA sequence to which the nucleic acid binding domain specifically binds. Ther terms "effector domain" and "functional domain" are used interchangeably throughout this application.
[00153] In some embodiments of the TALE polypeptides described herein, the activity mediated by the effector domain is a biological activity. For example, in some embodiments the effector domain is a transcriptional inhibitor (i.e., a repressor domain), such as an mSin interaction domain (SID). SID4X domain or a Kruppel-associated box (KRAB) or fragments of the KRAB domain. In some embodiments the effector domain is an enhancer of transcription (i.e. an activation domain), such as the VP 16, VP64 or p65 activation domain. A graphical comparison of the effect these different activation domains have on Sox2 mRNA level is provided in FIG. 11.
[00154] As used herein, VP 16 is a herpesvirus protein. It is a very strong transcriptional activator that specifically activates viral immediate early gene expression. The VP 16 activation domain is rich in acidic residues and has been regarded as a classic acidic activation domain (AAD). As used herein, VP64 activation doamin is a tetrameric repeat of VP16's minimal activation domain. As used herein, p65 is one of two proteins that the NF-kappa B transcription factor complex is composed of. The other protein is p50. The p65 activation domain is a part of the p65 subunit is a potent transcriptional activator even in the absence of p50. In certain embodiments, the effector domain is a mammalian protein or biologically active fragment thereof. Such effector domains are referred to as "mammalian effector domains."
[00155] In some embodiments, the nucleic acid binding is linked, for example, with an effector domain or functional domain that includes but is not limited to transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, histone deribosylase, histone ubiquitinase, histone deubiquitinase, histone biotinase and histone tail protease. [00156] In some embodiments, the effector domain is a protein domain which exhibits activities which include but are not limited to transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity, nuclease activity, nuclear-localization signaling activity, transcriptional repressor activity, transcriptional activator activity, transcription factor recruiting activity, or cellular uptake signaling activity. Other preferred embodiments of the invention may include any combination the activities described herein.
[00157] As described in Zhang et al, Nature Biotechnology 29: 149-153 (2011), a TALE polypeptide having a nucleic acid binding domain and an effector domain may be used to target the effector domain's activity to a genomic position having a predetermined nucleic acid sequence recognized by the nucleic acid binding domain. In some embodiments of the invention described herein, TALE polypeptides are designed and used for targeting gene regulatory activity, such as transcriptional or translational modifier activity, to a regulatory, coding, and/or intergenic region, such as enhancer and/or repressor activity, that may affect transcription upstream and downstream of coding regions, and may be used to enhance or repress gene expression. For example, TALEs polypeptide may comprise effector domains having DNA- binding domains from transcription factors, effector domains from transcription factors (activators, repressors, co-activators, co-repressors), silencers, nuclear hormone receptors, and/or chromatin associated proteins and their modifiers (e.g., methylases, kinases, phosphatases, acetylases and deacetylases). In a preferred embodiment, the TALE polypeptide may comprise a nuclease domain. In a more preferred embodiment the nuclease domain is a non-specific Fokl endonucleases catalytic domain.
[00158] In a further embodiment, useful domains for regulating gene expression may also be obtained from the gene products of oncogenes. In yet further advantageous embodiments of the invention, effector domains having integrase or transposase activity may be used to promote integration of exogenous nucleic acid sequence into specific nucleic acid sequence regions, eliminate (knock-out) specific endogenous nucleic acid sequence, and/or modify epigenetic signals and consequent gene regulation, such as by promoting DNA methyltransferase, DNA demethylase, histone acetylase and histone deacetylase activity. In other embodiments, effector domains having nuclease activity may be used to alter genome structure by nicking or digesting target sequences to which the polypeptides of the invention specifically bind, and may allow introduction of exogenous genes at those sites. In still further embodiments, effector domains having invertase activity may be used to alter genome structure by swapping the orientation of a DNA fragment.
[00159] In particularly advantageous embodiments, the polypeptides used in the methods of the invention may be used to target transcriptional activity. As used herein, the term "transcription factor" refers to a protein or polypeptide that binds specific DNA sequences associated with a genomic locus or gene of interest to control transcription. Transcription factors may promote (as an activator) or block (as a repressor) the recruitment of RNA polymerase to a gene of interest. Transcription factors may perform their function alone or as a part of a larger protein complex. Mechanisms of gene regulation used by transcription factors include but are not limited to a) stabilization or destabilization of RNA polymerase binding, b) acetylation or deacetylation of histone proteins and c) recruitment of co-activator or co-repressor proteins. Furthermore, transcription factors play roles in biological activities that include but are not limited to basal transcription, enhancement of transcription, development, response to intercellular signaling, response to environmental cues, cell-cycle control and pathogenesis. With regards to information on transcriptional factors, mention is made of Latchman and DS (1997) Int. J. Biochem. Cell Biol. 29 (12): 1305-12; Lee TI, Young RA (2000) Annu. Rev. Genet. 34: 77-137and Mitchell PJ, Tjian R (1989) Science 245 (4916): 371-8, herein incorporated by reference in their entirety.
[00160] Light responsiveness of a LITE is achieved via the activation and binding of cryptochrome-2 and CIB1. As mentioned above, blue light stimulation induces an activating conformational change in cryptochrome-2, resulting in recruitment of its binding partner CIB1. This binding is fast and reversible, achieving saturation in <15 sec following pulsed stimulation and returning to baseline <15 min after the end of stimulation. These rapid binding kinetics result in a LITE system temporally bound only by the speed of transcription/translation and transcript/protein degradation, rather than uptake and clearance of inducing agents. Crytochrome-2 activation is also highly sensitive, allowing for the use of low light intensity stimulation and mitigating the risks of phototoxicity. Further, in a context such as the intact mammalian brain, variable light intensity may be used to control the size of a LITE stimulated region, allowing for greater precision than vector delivery alone may offer. [00161] The modularity of the LITE system allows for any number of effector domains to be employed for transcriptional modulation. Thus, activator and repressor domains may be selected on the basis of species, strength, mechanism, duration, size, or any number of other parameters.
[00162] Applicants next present two prototypical manifestations of the LITE system. The first example is a LITE designed to activate transcription of the mouse gene NEUROG2. The sequence TGAATGATGATAATACGA, located in the upstream promoter region of mouse NEUROG2, was selected as the target and a TALE was designed and synthesized to match this sequence. The TALE sequence was linked to the sequence for cryptochrome-2 via a nuclear localization signal (amino acids: SPKK R VEAS) to facilitate transport of the protein from the cytosol to the nuclear space. A second vector was synthesized comprising the CIB1 domain linked to the transcriptional activator domain VP64 using the same nuclear localization signal. This second vector, also a GFP sequence, is separated from the CIB1-VP64 fusion sequence by a 2A translational skip signal. Expression of each construct was driven by a ubiquitous, constitutive promoter (CMV or EFl-a). Mouse neuroblastoma cells from the Neuro 2 A cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via qPCR.
[00163] Truncated versions of cryptochrome-2 and CIB1 were cloned and tested in combination with the full-length versions of cryptochrome-2 and CIB1 in order to determine the effectiveness of each heterodimer pair. The combination of the CRY2PHR domain, consisting of the conserved photoresponsive region of the cryptochrome-2 protein, and the full-length version of CIB1 resulted in the highest upregulation of Neurog2 mRNA levels (~22 fold over YFP samples and ~7 fold over unstimulated co-transfected samples). The combination of full-length cryptochrome-2 (CRY2) with full-length CIB1 resulted in a lower absolute activation level (~4.6 fold over YFP), but also a lower baseline activation (-1.6 fold over YFP for unstimulated co- transfected samples). These cryptochrome protein pairings may be selected for particular uses depending on absolute level of induction required and the necessity to minimize baseline "leakiness" of the LITE system. [00164] Speed of activation and reversibility are critical design parameters for the LITE system. To characterize the kinetics of the LITE system, constructs consisting of the Neurog2 TALE-CRY2PHR and CIB1-VP64 version of the system were tested to determine its activation and inactivation speed. Samples were stimulated for as little as 0.5 h to as long as 24 h before extraction. Upregulation of Neurog2 expression was observed at the shortest, 0.5 h, time point (~5 fold vs YFP samples). Neurog2 expression peaked at 12 h of stimulation (-19 fold vs YFP samples). Inactivation kinetics were analyzed by stimulating co-transfected samples for 6 h, at which time stimulation was stopped, and samples were kept in culture for 0 to 12 h to allow for mRNA degradation. Neurog2 mRNA levels peaked at 0.5h after the end of stimulation (~16 fold vs. YFP samples), after which the levels degraded with an ~3 h half-life before returning to near baseline levels by 12 h.
[00165] The second prototypical example is a LITE designed to activate transcription of the human gene KLF4. The sequence TTCTTACTTATAAC, located in the upstream promoter region of human KLF4, was selected as the target and a TALE was designed and synthesized to match this sequence. The TALE sequence was linked to the sequence for CRY2PHR via a nuclear localization signal (amino acids: SPKKKRKVEAS). The identical CIB1-VP64 activator protein described above was also used in this manifestation of the LITE system. Human embryonal kidney cells from the HEK293FT cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via qPCR.
[00166] The light-intensity response of the LITE system was tested by stimulating samples with increased light power (0-9 mW/cm2). Upregulation of KLF4 mRNA levels was observed for stimulation as low as 0.2 mW/cm2. KLF4 upregulation became saturated at 5 mW/cm2 (2.3 fold vs. YFP samples). Cell viability tests were also performed for powers up to 9 mW/cm2 and showed >98% cell viability. Similarly, the KLF4 LITE response to varying duty cycles of stimulation was tested (1.6-100%). No difference in KLF4 activation was observed between different duty cycles indicating that a stimulation paradigm of as low as 0.25 sec every 15 sec should result in maximal activation. [00167] The invention contemplates energy sources such as electromagnetic radiation, sound energy or thermal energy. Advantageously, the electromagnetic radiation is a component of visible light. In a preferred embodiment, the light is a blue light with a wavelength of about 450 to about 495 nm. In an especially preferred embodiment, the wavelength is about 488 nm. In another preferred embodiment, the light stimulation is via pulses. The light power may range from about 0-9 mW/cm2. In a preferred embodiment, a stimulation paradigm of as low as 0.25 sec every 15 sec should result in maximal activation.
[00168] The invention particularly relates to inducible methods of perturbing a genomic or epigenomic locus or altering expression of a genomic locus of interest in a cell wherein the genomic or epigenomic locus may be contacted with a non-naturally occurring or engineered composition comprising a deoxyribonucleic acid (DNA) binding polypeptide.
[00169] The cells of the present invention may be a prokaryotic cell or a eukaryotic cell, advantageously an animal cell, more advantageously a mammalian cell.
[00170] This polypeptide may include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half- monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to a chemical sensitive protein or fragment thereof. The chemical or energy sensitive protein or fragment thereof may undergo a conformational change upon induction by the binding of a chemical source allowing it to bind an interacting partner. The polypeptide may also include a DNA binding domain comprising at least one or more variant TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the chemical or energy sensitive protein or fragment thereof may bind to the interacting partner upon induction by the chemical source. The method may also include applying the chemical source and determining that the expression of the genomic locus is altered.
[00171] There are several different designs of this chemical inducible system: 1. ABI-PYL based system inducible by Abscisic Acid (ABA) (see, e.g., http://stke.sciencemag.org/cgi/content/abstract/sigtrans;4/164/rs2), 2. FKBP-FRB based system inducible by rapamycin (or related chemicals based on rapamycin) (see, e.g., http://www.nature.com/nmeth/joumal/v2/n6/full/nmeth763.html), 3. GID1-GAI based system inducible by Gibberellin (GA) (see, e.g., http://www.nature.com/nchembio/joumal/v8/n5/full/nchembio.922.htm
[00172] Another system contemplated by the present invention is a chemical inducible system based on change in sub-cellular localization. Applicants also developed a system in which the polypeptide include a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest linked to at least one or more effector domains are further linker to a chemical or energy sensitive protein. This protein will lead to a change in the sub-cellular localization of the entire polypeptide (i.e. transportation of the entire polypeptide from cytoplasm into the nucleus of the cells) upon the binding of a chemical or energy transfer to the chemical or energy sensitive protein. This transportation of the entire polypeptide from one sub-cellular compartments or organelles, in which its activity is sequestered due to lack of substrate for the effector domain, into another one in which the substrate is present would allow the entire polypeptide to come in contact with its desired substrate (i.e. genomic DNA in the mammalian nucleus) and result in activation or repression of target gene expression.
[00173] This type of system could also be used to induce the cleavage of a genomic locus of interest in a cell when the effector domain is a nuclease.
[00174] The designs for this chemical inducible system is an estrogen receptor (ER) based system inducible by 4-hydroxytamoxifen (40HT) (see, e.g., http://www.pnas.Org/content/104/3/1027.abstract). A mutated ligand-binding domain of the estrogen receptor called ERT2 translocates into the nucleus of cells upon binding of 4- hydroxytamoxifen. Two tandem ERT2 domains were linked together with a flexible peptide linker and then fused to the TALE protein targeting a specific sequence in the mammalian genome and linked to one or more effector domains. This polypeptide will be in the cytoplasm of cells in the absence of 40HT, which renders the TALE protein linked to the effector domains inactive. In the presence of 40HT, the binding of 40HT to the tandem ERT2 domain will induce the transportation of the entire peptide into nucleus of cells, allowing the TALE protein linked to the effector domains become active.
[00175] In another embodiment of the estrogen receptor (ER) based system inducible by 4- hydroxytamoxifen (40HT), the present invention may comprise a nuclear exporting signal (NES). Advantageously, the NES may have the sequence of LDLASLIL. In further embodiments of the invention any naturally occurring or engineered derivative of any nuclear receptor, thyroid hormone receptor, retinoic acid receptor, estrogren receptor, estrogen-related receptor, glucocorticoid receptor, progesterone receptor, androgen receptor may be used in inducible systems analogous to the ER based inducible system.
[00176] Another inducible system is based on the design using Transient receptor potential (TRP) ion channel based system inducible by energy, heat or radio-wave (see, e.g., http://www.sciencemag.org/content/336/6081/604). These TRP family proteins respond to different stimuli, including light and heat. When this protein is activated by light or heat, the ion channel will open and allow the entering of ions such as calcium into the plasma membrane. This inflex of ions will bind to intracellular ion interacting partners linked to a polypeptide include TALE protein and one or more effector domains, and the binding will induce the change of subcellular localization of the polypeptide, leading to the entire polypeptide entering the nucleus of cells. Once inside the nucleus, the TALE protein linked to the effector domains will be active and modulating target gene expression in cells.
[00177] This type of system could also be used to induce the cleavage of a genomic locus of interest in a cell when the effector domain is a nuclease. The light could be generated with a laser or other forms of energy sources. The heat could be generated by raise of temperature results from an energy source, or from nano-particles that release heat after absorbing energy from an energy source delivered in the form of radio-wave.
[00178] While light activation may be an advantageous embodiment, sometimes it may be disadvantageous especially for in vivo applications in which the light may not penetrate the skin or other organs. In this instance, other methods of energy activation are contemplated, in particular, electric field energy and/or ultrasound which have a similar effect. If necessary, the proteins pairings of the LITE system may be altered and/or modified for maximal effect by another energy source.
[00179] Electric field energy is preferably administered substantially as described in the art, using one or more electric pulses of from about 1 Volt/cm to about 10 kVolts/cm under in vivo conditions. Instead of or in addition to the pulses, the electric field may be delivered in a continuous manner. The electric pulse may be applied for between 1 and 500 milliseconds, preferably between 1 and 100 milliseconds. The electric field may be applied continuously or in a pulsed manner for 5 about minutes. [00180] As used herein, 'electric field energy' is the electrical energy to which a cell is exposed. Preferably the electric field has a strength of from about 1 Volt/cm to about 10 kVolts/cm or more under in vivo conditions (see WO97/49450).
[00181] As used herein, the term "electric field" includes one or more pulses at variable capacitance and voltage and including exponential and/or square wave and/or modulated wave and/or modulated square wave forms. References to electric fields and electricity should be taken to include reference the presence of an electric potential difference in the environment of a cell. Such an environment may be set up by way of static electricity, alternating current (AC), direct current (DC), etc, as known in the art. The electric field may be uniform, non-uniform or otherwise, and may vary in strength and/or direction in a time dependent manner.
[00182] Single or multiple applications of electric field, as well as single or multiple applications of ultrasound are also possible, in any order and in any combination. The ultrasound and/or the electric field may be delivered as single or multiple continuous applications, or as pulses (pulsatile delivery).
[00183] Electroporation has been used in both in vitro and in vivo procedures to introduce foreign material into living cells. With in vitro applications, a sample of live cells is first mixed with the agent of interest and placed between electrodes such as parallel plates. Then, the electrodes apply an electrical field to the cell/implant mixture. Examples of systems that perform in vitro electroporation include the Electro Cell Manipulator ECM600 product, and the Electro Square Porator T820, both made by the BTX Division of Genetronics, Inc (see U.S. Pat. No 5,869,326).
[00184] The known electroporation techniques (both in vitro and in vivo) function by applying a brief high voltage pulse to electrodes positioned around the treatment region. The electric field generated between the electrodes causes the cell membranes to temporarily become porous, whereupon molecules of the agent of interest enter the cells. In known electroporation applications, this electric field comprises a single square wave pulse on the order of 1000 V/cm, of about 100 .mu.s duration. Such a pulse may be generated, for example, in known applications of the Electro Square Porator T820.
[00185] Preferably, the electric field has a strength of from about 1 V/cm to about 10 kV/cm under in vitro conditions. Thus, the electric field may have a strength of 1 V/cm, 2 V/cm, 3 V/cm, 4 V/cm, 5 V/cm, 6 V/cm, 7 V/cm, 8 V/cm, 9 V/cm, 10 V/cm, 20 V/cm, 50 V/cm, 100 V/cm, 200 V/cm, 300 V/cm, 400 V/cm, 500 V/cm, 600 V/cm, 700 V/cm, 800 V/cm, 900 V/cm, 1 kV/cm, 2 kV/cm, 5 kV/cm, 10 kV/cm, 20 kV/cm, 50 kV/cm or more. More preferably from about 0.5 kV/cm to about 4.0 kV/cm under in vitro conditions. Preferably the electric field has a strength of from about 1 V/cm to about 10 kV/cm under in vivo conditions. However, the electric field strengths may be lowered where the number of pulses delivered to the target site are increased. Thus, pulsatile delivery of electric fields at lower field strengths is envisaged.
[00186] Preferably the application of the electric field is in the form of multiple pulses such as double pulses of the same strength and capacitance or sequential pulses of varying strength and/or capacitance. As used herein, the term "pulse" includes one or more electric pulses at variable capacitance and voltage and including exponential and/or square wave and/or modulated wave/square wave forms.
[00187] Preferably the electric pulse is delivered as a waveform selected from an exponential wave form, a square wave form, a modulated wave form and a modulated square wave form.
[00188] A preferred embodiment employs direct current at low voltage. Thus, Applicants disclose the use of an electric field which is applied to the cell, tissue or tissue mass at a field strength of between lV/cm and 20V/cm, for a period of 100 milliseconds or more, preferably 15 minutes or more.
[00189] Ultrasound is advantageously administered at a power level of from about 0.05 W/cm2 to about 100 W/cm2. Diagnostic or therapeutic ultrasound may be used, or combinations thereof.
[00190] As used herein, the term "ultrasound" refers to a form of energy which consists of mechanical vibrations the frequencies of which are so high they are above the range of human hearing. Lower frequency limit of the ultrasonic spectrum may generally be taken as about 20 kHz. Most diagnostic applications of ultrasound employ frequencies in the range 1 and 15 MHz' (From Ultrasonics in Clinical Diagnosis, P. N. T. Wells, ed., 2nd. Edition, Publ. Churchill Livingstone [Edinburgh, London & NY, 1977]).
[00191] Ultrasound has been used in both diagnostic and therapeutic applications. When used as a diagnostic tool ("diagnostic ultrasound"), ultrasound is typically used in an energy density range of up to about 100 mW/cm2 (FDA recommendation), although energy densities of up to 750 mW/cm2 have been used. In physiotherapy, ultrasound is typically used as an energy source in a range up to about 3 to 4 W/cm2 (WHO recommendation). In other therapeutic applications, higher intensities of ultrasound may be employed, for example, HIFU at 100 W/cm up to 1 kW/cm2 (or even higher) for short periods of time. The term "ultrasound" as used in this specification is intended to encompass diagnostic, therapeutic and focused ultrasound.
[00192] Focused ultrasound (FUS) allows thermal energy to be delivered without an invasive probe (see Morocz et al 1998 Journal of Magnetic Resonance Imaging Vol.8, No. 1, pp.136-142. Another form of focused ultrasound is high intensity focused ultrasound (HIFU) which is reviewed by Moussatov et al in Ultrasonics (1998) Vol.36, No.8, pp.893-900 and TranHuuHue et al in Acustica (1997) Vol.83, No.6, pp.1103-1106.
[00193] Preferably, a combination of diagnostic ultrasound and a therapeutic ultrasound is employed. This combination is not intended to be limiting, however, and the skilled reader will appreciate that any variety of combinations of ultrasound may be used. Additionally, the energy density, frequency of ultrasound, and period of exposure may be varied.
[00194] Preferably the exposure to an ultrasound energy source is at a power density of from about 0.05 to about 100 Wcm"2. Even more preferably, the exposure to an ultrasound energy source is at a power density of from about 1 to about 15 Wcm"2.
[00195] Preferably the exposure to an ultrasound energy source is at a frequency of from about 0.015 to about 10.0 MHz. More preferably the exposure to an ultrasound energy source is at a frequency of from about 0.02 to about 5.0 MHz or about 6.0 MHz. Most preferably, the ultrasound is applied at a frequency of 3 MHz.
[00196] Preferably the exposure is for periods of from about 10 milliseconds to about 60 minutes. Preferably the exposure is for periods of from about 1 second to about 5 minutes. More preferably, the ultrasound is applied for about 2 minutes. Depending on the particular target cell to be disrupted, however, the exposure may be for a longer duration, for example, for 15 minutes.
[00197] Advantageously, the target tissue is exposed to an ultrasound energy source at an acoustic power density of from about 0.05 Wcm"2 to about 10 Wcm"2 with a frequency ranging from about 0.015 to about 10 MHz (see WO 98/52609). However, alternatives are also possible, for example, exposure to an ultrasound energy source at an acoustic power density of above 100 Wcm"2, but for reduced periods of time, for example, 1000 Wcm"2 for periods in the millisecond range or less. [00198] Preferably the application of the ultrasound is in the form of multiple pulses; thus, both continuous wave and pulsed wave (pulsatile delivery of ultrasound) may be employed in any combination. For example, continuous wave ultrasound may be applied, followed by pulsed wave ultrasound, or vice versa. This may be repeated any number of times, in any order and combination. The pulsed wave ultrasound may be applied against a background of continuous wave ultrasound, and any number of pulses may be used in any number of groups.
[00199] Preferably, the ultrasound may comprise pulsed wave ultrasound. In a highly preferred embodiment, the ultrasound is applied at a power density of 0.7 Wcm-2 or 1.25 Wcm-2 as a continuous wave. Higher power densities may be employed if pulsed wave ultrasound is used.
[00200] Use of ultrasound is advantageous as, like light, it may be focused accurately on a target. Moreover, ultrasound is advantageous as it may be focused more deeply into tissues unlike light. It is therefore better suited to whole-tissue penetration (such as but not limited to a lobe of the liver) or whole organ (such as but not limited to the entire liver or an entire muscle, such as the heart) therapy. Another important advantage is that ultrasound is a non-invasive stimulus which is used in a wide variety of diagnostic and therapeutic applications. By way of example, ultrasound is well known in medical imaging techniques and, additionally, in orthopedic therapy. Furthermore, instruments suitable for the application of ultrasound to a subject vertebrate are widely available and their use is well known in the art.
[00201] The rapid transcriptional response and endogenous targeting of LITEs make for an ideal system for the study of transcriptional dynamics. For example, LITEs may be used to study the dynamics of mRNA splice variant production upon induced expression of a target gene. On the other end of the transcription cycle, mRNA degradation studies are often performed in response to a strong extracellular stimulus, causing expression level changes in a plethora of genes. LITEs may be utilized to reversibly induce transcription of an endogenous target, after which point stimulation may be stopped and the degradation kinetics of the unique target may be tracked.
[00202] The temporal precision of LITEs may provide the power to time genetic regulation in concert with experimental interventions. For example, targets with suspected involvement in long-term potentiation (LTP) may be modulated in organotypic or dissociated neuronal cultures, but only during stimulus to induce LTP, so as to avoid interfering with the normal development of the cells. Similarly, in cellular models exhibiting disease phenotypes, targets suspected to be involved in the effectiveness of a particular therapy may be modulated only during treatment. Conversely, genetic targets may be modulated only during a pathological stimulus. Any number of experiments in which timing of genetic cues to external experimental stimuli is of relevance may potentially benefit from the utility of LITE modulation.
[00203] The in vivo context offers equally rich opportunities for the use of LITEs to control gene expression. As mentioned above, photoinducibility provides the potential for previously unachievable spatial precision. Taking advantage of the development of optrode technology, a stimulating fiber optic lead may be placed in a precise brain region. Stimulation region size may then be tuned by light intensity. This may be done in conjunction with the delivery of LITEs via viral vectors or the molecular sleds of US Provisional Patent application no. 61/671,615, or, if transgenic LITE animals were to be made available, may eliminate the use of viruses while still allowing for the modulation of gene expression in precise brain regions. LITEs may be used in a transparent organism, such as an immobilized zebrafish, to allow for extremely precise laser induced local gene expression changes.
[00204] The present invention also contemplates a multiplex genome engineering using CRISPPv/Cas sytems. Functional elucidation of causal genetic variants and elements requires precise genome editing technologies. The type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats) adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage. Applicants engineered two different type II CRISPR systems and demonstrate that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells. Cas9 can also be converted into a nicking enzyme to facilitate homology-directed repair with minimal mutagenic activity. Finally, multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several sites within the mammalian genome, demonstrating easy programmability and wide applicability of the CRISPR technology.
[00205] In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus. In some embodiments, one or more elements of a CRISPR system is derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). In the context of formation of a CRISPR complex, "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell.
[00206] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. Without wishing to be bound by theory, all or a portion of the tracr sequence may also form part of a CRISPR complex, such as by hybridization to all or a portion of a tracr mate sequence that is operably linked to the guide sequence. In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to ("upstream" of) or 3' with respect to ("downstream" of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or all in a single intron). In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.
[00207] In some embodiments, a vector comprises one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site"). In some embodiments, one or more insertion sites (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and/or downstream of one or more sequence elements of one or more vectors. In some embodiments, a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that following insertion of a guide sequence into the insertion site and upon expression the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell. In some embodiments, a vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to allow insertion of a guide sequence at each site. In such an arrangement, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these. When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell. For example, a single vector may comprise about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequence-containing vectors may be provided, and optionally delivered to a cell.
[00208] In some embodiments, a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4, homologues thereof, or modified versions thereof. In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. As a further example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III) may be mutated to produce a mutated Cas9 substantially lacking all DNA cleavage activity. In some embodiments, a D10A mutation is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity. In some embodiments, a CRISPR enzyme is considered to substantially lack all DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%>, 1%>, 0.1 %>, 0.01%, or lower with respect to its non- mutated form.
[00209] In some embodiments, an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate. In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database" available at www.kazusa.orjp/codon/ (visited Jul. 9, 2002), and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000"Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, PA), are also available. In some embodiments, one or more codons (e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.
[00210] In some embodiments, a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs. In some embodiments, the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy-terminus, or a combination of these (e.g. one or more NLS at the amino-terminus and one or more NLS at the carboxy terminus). When more than one NLS is present, each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies. In some embodiments, an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus. Non- limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV; the NLS from nucleoplasmin (e.g. the nucleoplasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK); the c-myc NLS having the amino acid sequence PAAKRVKLD or RQRRNELKRSP; the hRNPAl M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY; the sequence
RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV of the IBB domain from importin-alpha; the sequences VSRKRPRP and PPKKARED of the myoma T protein; the sequence POPKKKPL of human p53; the sequence SALIKKKKKMAP of mouse c-abl IV; the sequences DRLRR and PKQKKRK of the influenza virus NSl; the sequence RKLKKKIKKL of the Hepatitis virus delta antigen; the sequence REKKKFLKRR of the mouse Mxl protein; the sequence KRKGDEVDGVDEVAKKKSKK of the human poly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK of the steroid hormone receptors (human) glucocorticoid.
[00211] In general, the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In general, strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors. Detection of accumulation in the nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be visualized, such as in combination with a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI). Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR enzyme activity), as compared to a control no exposed to the CRISPR enzyme or complex, or exposed to a CRISPR enzyme lacking the one or more NLSs.
[00212] In another embodiment of the present invention, the invention relates to an inducible CRISPR which may comprise an inducible Cas9.
[00213] The CRISPR system may be encoded within a vector system which may comprise one or more vectors which may comprise I. a first regulatory element operably linked to a CRISPR/Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence may comprise (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme which may comprise at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3 Orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex may comprise the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the enzyme coding sequence encoding the CRISPR enzyme further encodes a heterologous functional domain.
[00214] In an advantageous embodiment, the inducible Cas9 may be prepared in a lentivirus. For example, FIG. 61 depicts Tet Cas9 vector designs and FIG. 62 depicts a vector and EGFP expression in 293FT cells. In particular, an inducible tetracycline system is contemplated for an inducible CRISPR..The vector may be designed as described in Markusic et al, Nucleic Acids Research, 2005, Vol. 33, No. 6 e63. The tetracycline-dependent transcriptional regulatory system is based on the Escherichia coli TnlO Tetracycline resistance operator consisting of the tetracycline repressor protein (TetR) and a specific DNA-binding site, the tetracycline operator sequence (TetO). In the absence of tetracycline, TetR dimerizes and binds to the TetO. Tetracycline or doxycycline (a tetracycline derivative) can bind and induce a conformational change in the TetR leading to its disassociation from the TetO. In an advantageous embodiment, the vector may be a single Tet-On lentiviral vector with autoregulated rtTA expression for regulated expression of the CRISPR complex. Tetracycline or doxycycline may be contemplated for activating the inducible CRISPR complex.
[00215] In another embodiment, a cumate gene-switch system is contemplated for an inducible CRISPR. A similar system as described in Mullick et al., BMC Biotechnology 2006, 6:43 doi: 10.1186/1472-6750-6-43. The inducible cumate system involves regulatory mechanisms of bacterial operons (cmt and cym) to regulate gene expression in mammalian cells using three different strategies. In the repressor configuration, regulation is mediated by the binding of the repressor (CymR) to the operator site (CuO), placed downstream of a strong constitutive promoter. Addition of cumate, a small molecule, relieves the repression. In the transactivator configuration, a chimaeric transactivator (cTA) protein, formed by the fusion of CymR with the activation domain of VP 16, is able to activate transcription when bound to multiple copies of CuO, placed upstream of the CMV minimal promoter. Cumate addition abrogates DNA binding and therefore transactivation by cTA. The invention also contemplates a reverse cumate activator (rcTA), which activates transcription in the presence rather than the absence of cumate. CymR may be used as a repressor that reversibly blocks expression from a strong promoter, such as CMV. Certain aspects of the Cumate repressor/operator system are further described in US patent No. 7745592.
[00216] Other inducible systems are contemplated such as, but not limited to, regulation by heavy-metals [Mayo KE et al, Cell 1982, 29:99-108; Searle PF et al, Mol Cell Biol 1985, 5: 1480-1489 and Brinster RL et al, Nature (London) 1982, 296:39-42], steroid hormones [Hynes NE et al, Proc Natl Acad Sci USA 1981, 78:2038-2042; Klock G et al, Nature (London) 1987, 329:734-736 and Lee F et al, Nature (London) 1981, 294:228-232.], heat shock [Nouer L: Heat Shock Response. Boca Raton, FL: CRC; 1991] and other reagents have been developed [Mullick A, Massie B: Transcription, translation and the control of gene expression. In Encyclopedia of Cell Technology Edited by: Speir RE. Wiley; 2000: 1140-1164 and Fussenegger M, . Biotechnol Prog 2001, 17: 1-51]. However, there are limitations with these inducible mammalian promoters such as "leakiness" of the "off state and pleiotropic effects of inducers (heat shock, heavy metals, glucocorticoids etc.). The use of insect hormones (ecdysone) has been proposed in an attempt to reduce the interference with cellular processes in mammalian cells [No D et al., Proc Natl Acad Sci USA 1996, 93:3346-3351]. Another elegant system uses rapamycin as the inducer [Rivera VM et al, Nat Med 1996, 2: 1028-1032] but the role of rapamycin as an immunosuppressant was a major limitation to its use in vivo and therefore it was necessary to find a biologically inert compound [Saez E et al., Proc Natl Acad Sci USA 2000, 97: 14512- 14517] for the control of gene expression.
[00217] The present invention also encompasses nucleic acid encoding the polypeptides of the present invention. The nucleic acid may comprise a promoter, advantageously human Synapsin I promoter (hSyn). In a particularly advantageous embodiment, the nucleic acid may be packaged into an adeno associated viral vector (AAV).
[00218] Also contemplated by the present invention are recombinant vectors and recombinant adenoviruses that may comprise subviral particles from more than one adenovirus serotype. For example, it is known that adenovirus vectors may display an altered tropism for specific tissues or cell types (Havenga, M.J.E. et al., 2002), and therefore, mixing and matching of different adenoviral capsids, i.e., fiber, or penton proteins from various adenoviral serotypes may be advantageous. Modification of the adenoviral capsids, including fiber and penton may result in an adenoviral vector with a tropism that is different from the unmodified adenovirus. Adenovirus vectors that are modified and optimized in their ability to infect target cells may allow for a significant reduction in the therapeutic or prophylactic dose, resulting in reduced local and disseminated toxicity.
[00219] Viral vector gene delivery systems are commonly used in gene transfer and gene therapy applications. Different viral vector systems have their own unique advantages and disadvantages. Viral vectors that may be used to express the pathogen-derived ligand of the present invention include but are not limited to adenoviral vectors, adeno-associated viral vectors, alphavirus vectors, herpes simplex viral vectors, and retroviral vectors, described in more detail below.
[00220] Additional general features of adenoviruses are such that the biology of the adenovirus is characterized in detail; the adenovirus is not associated with severe human pathology; the adenovirus is extremely efficient in introducing its DNA into the host cell; the adenovirus may infect a wide variety of cells and has a broad host range; the adenovirus may be produced in large quantities with relative ease; and the adenovirus may be rendered replication defective and/or non-replicating by deletions in the early region 1 ("El") of the viral genome.
[00221] Adenovirus is a non-enveloped DNA virus. The genome of adenovirus is a linear double-stranded DNA molecule of approximately 36,000 base pairs ("bp") with a 55-kDa terminal protein covalently bound to the 5 '-terminus of each strand. The adenovirus DNA contains identical inverted terminal repeats ("ITRs") of about 100 bp, with the exact length depending on the serotype. The viral origins of replication are located within the ITRs exactly at the genome ends. DNA synthesis occurs in two stages. First, replication proceeds by strand displacement, generating a daughter duplex molecule and a parental displaced strand. The displaced strand is single stranded and may form a "panhandle" intermediate, which allows replication initiation and generation of a daughter duplex molecule. Alternatively, replication may proceed from both ends of the genome simultaneously, obviating the requirement to form the panhandle structure.
[00222] During the productive infection cycle, the viral genes are expressed in two phases: the early phase, which is the period up to viral DNA replication, and the late phase, which coincides with the initiation of viral DNA replication. During the early phase, only the early gene products, encoded by regions El, E2, E3 and E4, are expressed, which carry out a number of functions that prepare the cell for synthesis of viral structural proteins (Berk, A.J., 1986). During the late phase, the late viral gene products are expressed in addition to the early gene products and host cell DNA and protein synthesis are shut off. Consequently, the cell becomes dedicated to the production of viral DNA and of viral structural proteins (Tooze, J., 1981).
[00223] The El region of adenovirus is the first region of adenovirus expressed after infection of the target cell. This region consists of two transcriptional units, the E1A and EIB genes, both of which are required for oncogenic transformation of primary (embryonal) rodent cultures. The main functions of the El A gene products are to induce quiescent cells to enter the cell cycle and resume cellular DNA synthesis, and to transcriptionally activate the EIB gene and the other early regions (E2, E3 and E4) of the viral genome. Transfection of primary cells with the El A gene alone may induce unlimited proliferation (immortalization), but does not result in complete transformation. However, expression of El A, in most cases, results in induction of programmed cell death (apoptosis), and only occasionally is immortalization obtained (Jochemsen et al., 1987). Co-expression of the EIB gene is required to prevent induction of apoptosis and for complete morphological transformation to occur. In established immortal cell lines, high-level expression of E1A may cause complete transformation in the absence of EIB (Roberts, B.E. et al, 1985).
[00224] The EIB encoded proteins assist El A in redirecting the cellular functions to allow viral replication. The EIB 55 kD and E4 33 kD proteins, which form a complex that is essentially localized in the nucleus, function in inhibiting the synthesis of host proteins and in facilitating the expression of viral genes. Their main influence is to establish selective transport of viral mRNAs from the nucleus to the cytoplasm, concomitantly with the onset of the late phase of infection. The EIB 21 kD protein is important for correct temporal control of the productive infection cycle, thereby preventing premature death of the host cell before the virus life cycle has been completed. Mutant viruses incapable of expressing the EIB 21 kD gene product exhibit a shortened infection cycle that is accompanied by excessive degradation of host cell chromosomal DNA (deg-phenotype) and in an enhanced cytopathic effect (cyt-phenotype; Telling et al, 1994). The deg and cyt phenotypes are suppressed when in addition the El A gene is mutated, indicating that these phenotypes are a function of El A (White, E. et al., 1988). Furthermore, the EIB 21 kDa protein slows down the rate by which E1A switches on the other viral genes. It is not yet known by which mechanisms EIB 21 kD quenches these El A dependent functions. [00225] In contrast to, for example, retroviruses, adenoviruses do not efficiently integrate into the host cell's genome, are able to infect non-dividing cells, and are able to efficiently transfer recombinant genes in vivo (Brody et al., 1994). These features make adenoviruses attractive candidates for in vivo gene transfer of, for example, an antigen or immunogen of interest into cells, tissues or subjects in need thereof.
[00226] Adenovirus vectors containing multiple deletions are preferred to both increase the carrying capacity of the vector and reduce the likelihood of recombination to generate replication competent adenovirus (RCA). Where the adenovirus contains multiple deletions, it is not necessary that each of the deletions, if present alone, would result in a replication defective and/or non-replicating adenovirus. As long as one of the deletions renders the adenovirus replication defective or non-replicating, the additional deletions may be included for other purposes, e.g., to increase the carrying capacity of the adenovirus genome for heterologous nucleotide sequences. Preferably, more than one of the deletions prevents the expression of a functional protein and renders the adenovirus replication defective and/or non-replicating and/or attenuated. More preferably, all of the deletions are deletions that would render the adenovirus replication-defective and/or non-replicating and/or attenuated. However, the invention also encompasses adenovirus and adenovirus vectors that are replication competent and/or wild-type, i.e. comprises all of the adenoviral genes necessary for infection and replication in a subject.
[00227] Embodiments of the invention employing adenovirus recombinants may include El- defective or deleted, or E3 -defective or deleted, or E4-defective or deleted or adenovirus vectors comprising deletions of El and E3, or El and E4, or E3 and E4, or El, E3, and E4 deleted, or the "gutless" adenovirus vector in which all viral genes are deleted. The adenovirus vectors may comprise mutations in El, E3, or E4 genes, or deletions in these or all adenoviral genes. The El mutation raises the safety margin of the vector because El -defective adenovirus mutants are said to be replication-defective and/or non-replicating in non-permissive cells, and are, at the very least, highly attenuated. The E3 mutation enhances the immunogenicity of the antigen by disrupting the mechanism whereby adenovirus down-regulates MHC class I molecules. The E4 mutation reduces the immunogenicity of the adenovirus vector by suppressing the late gene expression, thus may allow repeated re-vaccination utilizing the same vector. The present invention comprehends adenovirus vectors of any serotype or serogroup that are deleted or mutated in El, or E3, or E4, or El and E3, or El and E4. Deletion or mutation of these adenoviral genes result in impaired or substantially complete loss of activity of these proteins.
[00228] The "gutless" adenovirus vector is another type of vector in the adenovirus vector family. Its replication requires a helper virus and a special human 293 cell line expressing both Ela and Cre, a condition that does not exist in a natural environment; the vector is deprived of all viral genes, thus the vector as a vaccine carrier is non-immunogenic and may be inoculated multiple times for re-vaccination. The "gutless" adenovirus vector also contains 36 kb space for accommodating antigen or immunogen(s) of interest, thus allowing co-delivery of a large number of antigen or immunogens into cells.
[00229] Adeno-associated virus (AAV) is a single-stranded DNA parvovirus which is endogenous to the human population. Although capable of productive infection in cells from a variety of species, AAV is a dependovirus, requiring helper functions from either adenovirus or herpes virus for its own replication. In the absence of helper functions from either of these helper viruses, AAV will infect cells, uncoat in the nucleus, and integrate its genome into the host chromosome, but will not replicate or produce new viral particles.
[00230] The genome of AAV has been cloned into bacterial plasmids and is well characterized. The viral genome consists of 4682 bases which include two terminal repeats of 145 bases each. These terminal repeats serve as origins of DNA replication for the virus. Some investigators have also proposed that they have enhancer functions. The rest of the genome is divided into two functional domains. The left portion of the genome codes for the rep functions which regulate viral DNA replication and vital gene expression. The right side of the vital genome contains the cap genes that encode the structural capsid proteins VP1, VP2 and VP3. The proteins encoded by both the rep and cap genes function in trans during productive AAV replication.
[00231] AAV is considered an ideal candidate for use as a transducing vector, and it has been used in this manner. Such AAV transducing vectors comprise sufficient cis-acting functions to replicate in the presence of adenovirus or herpes virus helper functions provided in trans. Recombinant AAV (rAAV) have been constructed in a number of laboratories and have been used to carry exogenous genes into cells of a variety of lineages. In these vectors, the AAV cap and/or rep genes are deleted from the viral genome and replaced with a DNA segment of choice. Current vectors may accommodate up to 4300 bases of inserted DNA. [00232] To produce rAAV, plasmids containing the desired vital construct are transfected into adenovirus-infected cells. In addition, a second helper plasmid is cotransfected into these cells to provide the AAV rep and cap genes which are obligatory for replication and packaging of the recombinant viral construct. Under these conditions, the rep and cap proteins of AAV act in trans to stimulate replication and packaging of the rAAV construct. Three days after transfection, rAAV is harvested from the cells along with adenovirus. The contaminating adenovirus is then inactivated by heat treatment.
[00233] Herpes Simplex Virus 1 (HSV-1) is an enveloped, double-stranded DNA virus with a genome of 153 kb encoding more than 80 genes. Its wide host range is due to the binding of viral envelope glycoproteins to the extracellular heparin sulphate molecules found in cell membranes (WuDunn & Spear, 1989). Internalization of the virus then requires envelope glycoprotein gD and fibroblast growth factor receptor (Kaner, 1990). HSV is able to infect cells lyrically or may establish latency. HSV vectors have been used to infect a wide variety of cell types (Lowenstein, 1994; Huard, 1995; Miyanohara, 1992; Liu, 1996; Goya, 1998).
[00234] There are two types of HSV vectors, called the recombinant HSV vectors and the amplicon vectors. Recombinant HSV vectors are generated by the insertion of transcription units directly into the HSV genome, through homologous recombination events. The amplicon vectors are based on plasmids bearing the transcription unit of choice, an origin of replication, and a packaging signal.
[00235] HSV vectors have the obvious advantages of a large capacity for insertion of foreign genes, the capacity to establish latency in neurons, a wide host range, and the ability to confer transgene expression to the CNS for up to 18 months (Carpenter & Stevens, 1996).
[00236] Retroviruses are enveloped single-stranded RNA viruses, which have been widely used in gene transfer protocols. Retroviruses have a diploid genome of about 7-10 kb, composed of four gene regions termed gag, pro, pol and env. These gene regions encode for structural capsid proteins, viral protease, integrase and viral reverse transcriptase, and envelope glycoproteins, respectively. The genome also has a packaging signal and cz's-acting sequences, termed long-terminal repeats (LTRs), at each end, which have a role in transcriptional control and integration. [00237] The most commonly used retroviral vectors are based on the Moloney murine leukaemia virus (Mo-MLV) and have varying cellular tropisms, depending on the receptor binding surface domain of the envelope glycoprotein.
[00238] Recombinant retroviral vectors are deleted from all retroviral genes, which are replaced with marker or therapeutic genes, or both. To propagate recombinant retroviruses, it is necessary to provide the viral genes, gag, pol and env in trans.
[00239] Lentiviruses are complex retroviruses that have the ability to infect and express their genes in both mitotic and post-mitotic cells. The most commonly known lentivirus is the human immunodeficiency virus (HIV), which uses the envelope glycoproteins of other viruses to target a broad range of cell types.
[00240] Alphaviruses, including the prototype Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan equine encephalitis virus (VEE), constitute a group of enveloped viruses containing plus-stranded RNA genomes within icosahedral capsids.
[00241] The viral vectors of the present invention are useful for the delivery of nucleic acids expressing antigens or immunogens to cells both in vitro and in vivo. In particular, the inventive vectors may be advantageously employed to deliver or transfer nucleic acids to cells, more preferably mammalian cells. Nucleic acids of interest include nucleic acids encoding peptides and proteins, preferably therapeutic (e.g., for medical or veterinary uses) or immunogenic (e.g., for vaccines) peptides or proteins.
[00242] Preferably, the codons encoding the antigen or immunogen of interest are "optimized" codons, i.e., the codons are those that appear frequently in, e.g.., highly expressed genes in the subject's species, instead of those codons that are frequently used by, for example, an influenza virus. Such codon usage provides for efficient expression of the antigen or immunogen in animal cells. In other embodiments, for example, when the antigen or immunogen of interest is expressed in bacteria, yeast or another expression system, the codon usage pattern is altered to represent the codon bias for highly expressed genes in the organism in which the antigen or immunogen is being expressed. Codon usage patterns are known in the literature for highly expressed genes of many species (e.g., Nakamura et al, 1996; Wang et al, 1998; McEwan et al. 1998).
[00243] As a further alternative, the viral vectors may be used to infect a cell in culture to express a desired gene product, e.g., to produce a protein or peptide of interest. Preferably, the protein or peptide is secreted into the medium and may be purified therefrom using routine techniques known in the art. Signal peptide sequences that direct extracellular secretion of proteins are known in the art and nucleotide sequences encoding the same may be operably linked to the nucleotide sequence encoding the peptide or protein of interest by routine techniques known in the art. Alternatively, the cells may be lysed and the expressed recombinant protein may be purified from the cell lysate. Preferably, the cell is an animal cell, more preferably a mammalian cell. Also preferred are cells that are competent for transduction by particular viral vectors of interest. Such cells include PER.C6 cells, 911 cells, and HEK293 cells.
[00244] A culture medium for culturing host cells includes a medium commonly used for tissue culture, such as M199-earle base, Eagle MEM (E-MEM), Dulbecco MEM (DMEM), SC- UCM102, UP-SFM (GIBCO BRL), EX-CELL302 (Nichirei), EX-CELL293-S (Nichirei), TFBM-01 (Nichirei), ASF 104, among others. Suitable culture media for specific cell types may be found at the American Type Culture Collection (ATCC) or the European Collection of Cell Cultures (ECACC). Culture media may be supplemented with amino acids such as L-glutamine, salts, anti-fungal or anti-bacterial agents such as Fungizone®, penicillin-streptomycin, animal serum, and the like. The cell culture medium may optionally be serum- free.
[00245] The present invention also relates to cell lines or transgenic animals which are capable of expressing or overexpressing LITEs or at least one agent useful in the present invention. Preferably the cell line or animal expresses or overexpresses one or more LITEs.
[00246] The transgenic animal is typically a vertebrate, more preferably a rodent, such as a rat or a mouse, but also includes other mammals such as human, goat, pig or cow etc.
[00247] Such transgenic animals are useful as animal models of disease and in screening assays for new useful compounds. By specifically expressing one or more polypeptides, as defined above, the effect of such polypeptides on the development of disease may be studied. Furthermore, therapies including gene therapy and various drugs may be tested on transgenic animals. Methods for the production of transgenic animals are known in the art. For example, there are several possible routes for the introduction of genes into embryos. These include (i) direct transfection or retroviral infection of embryonic stem cells followed by introduction of these cells into an embryo at the blastocyst stage of development; (ii) retroviral infection of early embryos; and (iii) direct microinjection of DNA into zygotes or early embryo cells. The gene and/or transgene may also include genetic regulatory elements and/or structural elements known in the art. A type of target cell for transgene introduction is the embryonic stem cell (ES). ES cells may be obtained from pre-implantation embryos cultured in vitro and fused with embryos (Evans et al, 1981, Nature 292: 154-156; Bradley et al, 1984, Nature 309:255-258; Gossler et al, 1986, Proc. Natl. Acad. Sci. USA 83:9065-9069; and Robertson et al, 1986 Nature 322:445- 448). Transgenes may be efficiently introduced into the ES cells by a variety of standard techniques such as DNA transfection, microinjection, or by retrovirus-mediated transduction. The resultant transformed ES cells may thereafter be combined with blastocysts from a non- human animal. The introduced ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal (Jaenisch, 1988, Science 240: 1468-1474).
[00248] LITEs may also offer valuable temporal precision in vivo. LITEs may be used to alter gene expression during a particular stage of development, for example, by repressing a particular apoptosis gene only during a particular stage of C elegans growth. LITEs may be used to time a genetic cue to a particular experimental window. For example, genes implicated in learning may be overexpressed or repressed only during the learning stimulus in a precise region of the intact rodent or primate brain. Further, LITEs may be used to induce gene expression changes only during particular stages of disease development. For example, an oncogene may be overexpressed only once a tumor reaches a particular size or metastatic stage. Conversely, proteins suspected in the development of Alzheimer's may be knocked down only at defined time points in the animal's life and within a particular brain region. Although these examples do not exhaustively list the potential applications of the LITE system, they highlight some of the areas in which LITEs may be a powerful technology.
[00249] Therapeutic or diagnostic compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
[00250] The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
[00251] Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents may be desirable. [00252] The present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compositions containing compounds identified according to this invention as the active ingredient may be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compounds may be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
[00253] Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
[00254] For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents may be administered concurrently, or they each may be administered at separately staggered times.
[00255] The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the one patient; and the particular compound thereof employed. A physician of ordinary skill may readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. [00256] Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations may be made herein without departing from the spirit and scope of the invention as defined in the appended claims.
[00257] The present invention will be further illustrated in the following Examples which are given for illustration purposes only and are not intended to limit the invention in any way.
Examples
Example 1
[00258] The ability to directly modulate gene expression from the endogenous mammalian genome is critical for elucidating normal gene function and disease mechanism. Advances that further refine the spatial and temporal control of gene expression within cell populations have the potential to expand the utility of gene modulation. Applicants previously developed transcription activator-like effectors (TALEs) from Xanthamonas oryze to enable the rapid design and construction of site-specific DNA binding proteins. Applicants developed a set of molecular tools for enabling light-regulated gene expression in the endogenous mammalian genome. The system consists of engineered artificial transcription factors linked to light-sensitive dimerizing protein domains from Arabidopsis thaliana. The system responds to light in the range of 450nm - 500nm and is capable of inducing a significant increase in the expression of pluripotency factors after stimulation with light at an intensity of 6.2 mW/cm2 in mammalian cells. Applicants are developing tools for the targeting of a wide range of genes. Applicants believe that a toolbox for the light-mediated control of gene expression would complement the existing optogenetic methods and may in the future help elucidate the timing-, cell type- and concentrationdependent role of specific genes in the brain.
[00259] The ability to directly modulate gene expression from the endogenous mammalian genome is critical for elucidating normal gene function and disease mechanisms. Applicants present the development of a set of molecular tools for enabling light-regulated gene expression in the endogenous mammalian genome. This system consists of a transcription activator like effector (TALE) and the activation domain VP64 linked to the light-sensitive dimerizing protein domains cryptochrome 2 (CRY2) and CIB1 from Arabidopsis thaliana. Applicants show that blue-light stimulation of HEK293FT and Neuro-2a cells transfected with these LITE constructs designed to target the promoter region of KLF4 and Neurog2 results in a significant increase in target expression, demonstrating the functionality of TALE-based optical gene expression modulation technology.
[00260] FIG. 1 shows a schematic depicting the need for spatial and temporal precision.
[00261] FIG. 2 shows transcription activator like effectors (TALEs). TALEs consist of 34 aa repeats at the core of their sequence. Each repeat corresponds to a base in the target DNA that is bound by the TALE. Repeats differ only by 2 variable amino acids at positions 12 and 13. The code of this correspondence has been elucidated (Boch, J et al. , Science, 2009 and Moscou, M et al. , Science, 2009) and is shown in this figure. Applicants developed a method for the synthesis of designer TALEs incorporating this code and capable of binding a sequence of choice within the genome (Zhang, F et al. , Nature Biotechnology, 2011).
[00262] FIG. 3 depicts a design of a LITE: TALE/Cryptochrome transcriptional activation. Each LITE is a two-component system which may comprise a TALE fused to CRY2 and the cryptochrome binding partner CIBl fused to VP64, a transcription activor. In the inactive state, the TALE localizes its fused CRY2 domain to the promoter region of the gene of interest. At this point, CIBl is unable to bind CRY2, leaving the CIB1-VP64 unbound in the nuclear space. Upon stimulation with 488 nm (blue) light, CRY2 undergoes a conformational change, revealing its CIBl binding site (Liu, H et al. , Science, 2008). Rapid binding of CIBl results in recruitment of the fused VP64 domain, which induces transcription of the target gene.
[00263] FIG. 4 depicts effects of cryptochrome dimer truncations on LITE activity. Truncations known to alter the activity of CRY2 and CIBl () were compared against the full length proteins. A LITE targeted to the promoter of Neurog2 was tested in Neuro-2a cells for each combination of domains. Following stimulation with 488 nm light, transcript levels of Neurog2 were quantified using qPCR for stimulated and unstimulated samples.
[00264] FIG. 5 depicts a light-intensity dependent response of KLF4 LITE.
[00265] FIG. 6 depicts activation kinetics of Neurog2 LITE and inactivation kinetics of Neurog2 LITE.
Example 2
[00266] Normal gene expression is a dynamic process with carefully orchestrated temporal and spatial components, the precision of which are necessary for normal development, homeostasis, and advancement of the organism. In turn, the dysregulation of required gene expression patterns, either by increased, decreased, or altered function of a gene or set of genes, has been linked to a wide array of pathologies. Technologies capable of modulating gene expression in a spatiotemporally precise fashion will enable the elucidation of the genetic cues responsible for normal biological processes and disease mechanisms. To address this technological need, Applicants developed light-inducible transcriptional effectors (LITEs), which provide light-mediated control of endogenous gene expression.
[00267] Inducible gene expression systems have typically been designed to allow for chemically inducible activation of an inserted open reading frame or shR A sequence, resulting in gene overexpression or repression, respectively. Disadvantages of using open reading frames for overexpression include loss of splice variation and limitation of gene size. Gene repression via RNA interference, despite its transformative power in human biology, may be hindered by complicated off-target effects. Certain inducible systems including estrogen, ecdysone, and FKBP12/FRAP based systems are known to activate off-target endogenous genes. The potentially deleterious effects of long-term antibiotic treatment may complicate the use of tetracycline transactivator (TET) based systems. In vivo, the temporal precision of these chemically inducible systems is dependent upon the kinetics of inducing agent uptake and elimination. Further, because inducing agents are generally delivered systemically, the spatial precision of such systems is bounded by the precision of exogenous vector delivery.
[00268] In response to these limitations, LITEs are designed to modulate expression of individual endogenous genes in a temporally and spatially precise manner. Each LITE is a two component system consisting of a customized DNA-binding transcription activator like effector (TALE) protein, a light-responsive crytochrome heterodimer from Arabadopsis thaliana, and a transcriptional activation/repression domain. The TALE is designed to bind to the promoter sequence of the gene of interest. The TALE protein is fused to one half of the cryptochrome heterodimer (cryptochrome-2 or CIB1), while the remaining cryptochrome partner is fused to a transcriptional effector domain. Effector domains may be either activators, such as VP 16, VP64, or p65, or repressors, such as KRAB, EnR, or SID. In a LITE'S unstimulated state, the TALE- cryptochrome2 protein localizes to the promoter of the gene of interest, but is not bound to the CIB1 -effector protein. Upon stimulation of a LITE with blue spectrum light, cryptochrome-2 becomes activated, undergoes a conformational change, and reveals its binding domain. CIB1, in turn, binds to cryptochrome-2 resulting in localization of the effector domain to the promoter region of the gene of interest and initiating gene overexpression or silencing. [00269] Gene targeting in a LITE is achieved via the specificity of customized TALE DNA binding proteins. A target sequence in the promoter region of the gene of interest is selected and a TALE customized to this sequence is designed. The central portion of the TALE consists of tandem repeats 34 amino acids in length. Although the sequences of these repeats are nearly identical, the 12th and 13th amino acids (termed repeat variable diresidues) of each repeat vary, determining the nucleotide-binding specificity of each repeat. Thus, by synthesizing a construct with the appropriate ordering of TALE monomer repeats, a DNA binding protein specific to the target promoter sequence is created.
[00270] Light responsiveness of a LITE is achieved via the activation and binding of cryptochrome-2 and CIB1. As mentioned above, blue light stimulation induces an activating conformational change in cryptochrome-2, resulting in recruitment of its binding partner CIB1. This binding is fast and reversible, achieving saturation in <15 sec following pulsed stimulation and returning to baseline <15 min after the end of stimulation. These rapid binding kinetics result in a LITE system temporally bound only by the speed of transcription/translation and transcript/protein degradation, rather than uptake and clearance of inducing agents. Crytochrome-2 activation is also highly sensitive, allowing for the use of low light intensity stimulation and mitigating the risks of phototoxicity. Further, in a context such as the intact mammalian brain, variable light intensity may be used to control the size of a LITE stimulated region, allowing for greater precision than vector delivery alone may offer.
[00271] The modularity of the LITE system allows for any number of effector domains to be employed for transcriptional modulation. Thus, activator and repressor domains may be selected on the basis of species, strength, mechanism, duration, size, or any number of other parameters.
[00272] Applicants next present two prototypical manifestations of the LITE system. The first example is a LITE designed to activate transcription of the mouse gene NEUROG2. The sequence TGAATGATGATAATACGA, located in the upstream promoter region of mouse NEUROG2, was selected as the target and a TALE was designed and synthesized to match this sequence. The TALE sequence was linked to the sequence for cryptochrome-2 via a nuclear localization signal (amino acids: SPKK R VEAS) to facilitate transport of the protein from the cytosol to the nuclear space. A second vector was synthesized comprising the CIB1 domain linked to the transcriptional activator domain VP64 using the same nuclear localization signal. This second vector, also a GFP sequence, is separated from the CIB1-VP64 fusion sequence by a 2A translational skip signal. Expression of each construct was driven by a ubiquitous, constitutive promoter (CMV or EFl-a). Mouse neuroblastoma cells from the Neuro 2 A cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via qPCR.
[00273] Truncated versions of cryptochrome-2 and CIB1 were cloned and tested in combination with the full-length versions of cryptochrome-2 and CIB1 in order to determine the effectiveness of each heterodimer pair. The combination of the CRY2PHR domain, consisting of the conserved photoresponsive region of the cryptochrome-2 protein, and the full-length version of CIB1 resulted in the highest upregulation of Neurog2 mRNA levels (-22 fold over YFP samples and -7 fold over unstimulated co-transfected samples). The combination of full-length cryptochrome-2 (CRY2) with full-length CIB1 resulted in a lower absolute activation level (~4.6 fold over YFP), but also a lower baseline activation (-1.6 fold over YFP for unstimulated co- transfected samples). These cryptochrome protein pairings may be selected for particular uses depending on absolute level of induction required and the necessity to minimize baseline "leakiness" of the LITE system.
[00274] Speed of activation and reversibility are critical design parameters for the LITE system. To characterize the kinetics of the LITE system, constructs consisting of the Neurog2 TALE-CRY2PHR and CIB1-VP64 version of the system were tested to determine its activation and inactivation speed. Samples were stimulated for as little as 0.5 h to as long as 24 h before extraction. Upregulation of Neurog2 expression was observed at the shortest, 0.5 h, time point (~5 fold vs YFP samples). Neurog2 expression peaked at 12 h of stimulation (-19 fold vs YFP samples). Inactivation kinetics were analyzed by stimulating co-transfected samples for 6 h, at which time stimulation was stopped, and samples were kept in culture for 0 to 12 h to allow for mRNA degradation. Neurog2 mRNA levels peaked at 0.5h after the end of stimulation (-16 fold vs. YFP samples), after which the levels degraded with an -3 h half-life before returning to near baseline levels by 12 h.
[00275] The second prototypical example is a LITE designed to activate transcription of the human gene KLF4. The sequence TTCTTACTTATAAC, located in the upstream promoter region of human KLF4, was selected as the target and a TALE was designed and synthesized to match this sequence. The TALE sequence was linked to the sequence for CRY2PHR via a nuclear localization signal (amino acids: SPKKKRKVEAS). The identical CIB1-VP64 activator protein described above was also used in this manifestation of the LITE system. Human embryonal kidney cells from the HEK293FT cell line were co-transfected with the two vectors. After incubation to allow for vector expression, samples were stimulated by periodic pulsed blue light from an array of 488 nm LEDs. Unstimulated co-tranfected samples and samples transfected only with the fluorescent reporter YFP were used as controls. At the end of each experiment, mRNA was purified from the samples analyzed via qPCR.
[00276] The light-intensity response of the LITE system was tested by stimulating samples with increased light power (0-9 mW/cm2). Upregulation of KLF4 mRNA levels was observed for stimulation as low as 0.2 mW/cm2. KLF4 upregulation became saturated at 5 mW/cm2 (2.3 fold vs. YFP samples). Cell viability tests were also performed for powers up to 9 mW/cm2 and showed >98% cell viability. Similarly, the KLF4 LITE response to varying duty cycles of stimulation was tested (1.6-100%). No difference in KLF4 activation was observed between different duty cycles indicating that a stimulation paradigm of as low as 0.25 sec every 15 sec should result in maximal activation.
[00277] There are potential applications for which LITEs represent an advantageous choice for gene expression control. There exist a number of in vitro applications for which LITEs are particularly attractive. In all these cases, LITEs have the advantage of inducing endogenous gene expression with the potential for correct splice variant expression.
[00278] Because LITE activation is photoinducible, spatially defined light patterns, created via masking or rasterized laser scanning, may be used to alter expression levels in a confined subset of cells. For example, by overexpressing or silencing an intercellular signaling molecule only in a spatially constrained set of cells, the response of nearby cells relative to their distance from the stimulation site may help elucidate the spatial characteristics of cell non-autonomous processes. Additionally, recent advances in cell reprogramming biology have shown that overexpression of sets of transcription factors may be utilized to transform one cell type, such as fibroblasts, into another cell type, such as neurons or cardiomyocytes. Further, the correct spatial distribution of cell types within tissues is critical for proper organotypic function. Overexpression of reprogramming factors using LITEs may be employed to reprogram multiple cell lineages in a spatially precise manner for tissue engineering applications.
[00279] The rapid transcriptional response and endogenous targeting of LITEs make for an ideal system for the study of transcriptional dynamics. For example, LITEs may be used to study the dynamics of mRNA splice variant production upon induced expression of a target gene. On the other end of the transcription cycle, mRNA degradation studies are often performed in response to a strong extracellular stimulus, causing expression level changes in a plethora of genes. LITEs may be utilized to reversibly induce transcription of an endogenous target, after which point stimulation may be stopped and the degradation kinetics of the unique target may be tracked.
[00280] The temporal precision of LITEs may provide the power to time genetic regulation in concert with experimental interventions. For example, targets with suspected involvement in long-term potentiation (LTP) may be modulated in organotypic or dissociated neuronal cultures, but only during stimulus to induce LTP, so as to avoid interfering with the normal development of the cells. Similarly, in cellular models exhibiting disease phenotypes, targets suspected to be involved in the effectiveness of a particular therapy may be modulated only during treatment. Conversely, genetic targets may be modulated only during a pathological stimulus. Any number of experiments in which timing of genetic cues to external experimental stimuli is of relevance may potentially benefit from the utility of LITE modulation.
[00281] The in vivo context offers equally rich opportunities for the use of LITEs to control gene expression. As mentioned above, photoinducibility provides the potential for previously unachievable spatial precision. Taking advantage of the development of optrode technology, a stimulating fiber optic lead may be placed in a precise brain region. Stimulation region size may then be tuned by light intensity. This may be done in conjunction with the delivery of LITEs via viral vectors, or, if transgenic LITE animals were to be made available, may eliminate the use of viruses while still allowing for the modulation of gene expression in precise brain regions. LITEs may be used in a transparent organism, such as an immobilized zebrafish, to allow for extremely precise laser induced local gene expression changes.
[00282] LITEs may also offer valuable temporal precision in vivo. LITEs may be used to alter gene expression during a particular stage of development, for example, by repressing a particular apoptosis gene only during a particular stage of C elegans growth. LITEs may be used to time a genetic cue to a particular experimental window. For example, genes implicated in learning may be overexpressed or repressed only during the learning stimulus in a precise region of the intact rodent or primate brain. Further, LITEs may be used to induce gene expression changes only during particular stages of disease development. For example, an oncogene may be overexpressed only once a tumor reaches a particular size or metastatic stage. Conversely, proteins suspected in the development of Alzheimer's may be knocked down only at defined time points in the animal's life and within a particular brain region. Although these examples do not exhaustively list the potential applications of the LITE system, they highlight some of the areas in which LITEs may be a powerful technology.
Example 3
Development of mammalian TALE transcriptional repressors
[00283] Applicants developed mammalian TALE repressor architectures to enable researchers to suppress transcription of endogenous genes. TALE repressors have the potential to suppress the expression of genes as well as non-coding transcripts such as microRNAs, rendering them a highly desirable tool for testing the causal role of specific genetic elements. In order to identify a suitable repression domain for use with TALEs in mammalian cells, a TALE targeting the promoter of the human SOX2 gene was used to evaluate the transcriptional repression activity of a collection of candidate repression domains (FIG. 12a). Repression domains across a range of eukaryotic host species were selected to increase the chance of finding a potent synthetic repressor, including the PIE-1 repression domain (PIE-1) (Batchelder, C. et al. Transcriptional repression by the Caenorhabditis elegans germ- line protein PIE-1. Genes Dev. 13, 202-212 (1999)) from Caenorhabditis elegans, the QA domain within the Ubx gene (Ubx-QA) (Tour, E., Hittinger, C.T. & McGinnis, W. Evolutionarily conserved domains required for activation and repression functions of the Drosophila Hox protein Ultrabithorax. Development 132, 5271-5281 (2005)) from Drosophila melanogaster, the IAA28 repression domain (IAA28-RD)(4) from Arabidopsis thaliana, the mSin interaction domain (SID) (Ayer, D.E., Laherty, CD., Lawrence, Q.A., Armstrong, A.P. & Eisenman, R.N. Mad proteins contain a dominant transcription repression domain. Mol. Cell. Biol. 16, 5772-5781 (1996)), Tbx3 repression domain (Tbx3-RD), and the Kruppel-associated box (KRAB) (Margolin, J.F. et al. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci. U S A 91, 4509-4513 (1994)) repression domain from Homo Sapiens. Since different truncations of KRAB have been known to exhibit varying levels of transcriptional repression (Margolin, J.F. et al. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci. U S A 91, 4509-4513 (1994)), three different truncations of KRAB were tested (FIG. 12c). These candidate TALE repressors were expressed in HEK 293FTcells and it was found that TALEs carrying two widely used mammalian transcriptional repression domains, the SID (Ayer, D.E., Laherty, CD., Lawrence, Q.A., Armstrong, A.P. & Eisenman, R.N. Mad proteins contain a dominant transcription repression domain. Mol. Cell. Biol. 16, 5772-5781 (1996)) and KRAB (Margolin, J.F. et al. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci. U S A 91, 4509-4513 (1994)) domains, were able to repress endogenous SOX2 expression, while the other domains had little effect on transcriptional activity (FIG. 12c). To control for potential perturbation of SOX2 transcription due to TALE binding, expression of the SOX2 -targeting TALE DNA binding domain alone without any effector domain had no effect (similar to mock or expression of GFP) on the transcriptional activity of SOX2 (FIG. 12c, Null condition). Since the SID domain was able to achieve 26% more transcriptional repression of the endogenous SOX2 locus than the KRAB domain (FIG. 12c), it was decided to use the SID domain for subsequent studies.
[00284] To further test the effectiveness of the SID repressor domain for down regulating endogenous transcription, SID was combined with CACNAlC-target TALEs from the previous experiment (FIG. 12d). Using qRT-PCR, it was found that replacement of the VP64 domain on CACNAlC-targeting TALEs with SID was able to repress CACNA1C transcription. The NH- containing TALE repressor was able to achieve a similar level of transcriptional repression as the NN-containing TALE (~4 fold repression), while the TALE repressor using NK was significantly less active (~2 fold repression) (FIG. 12d). These data demonstrate that SID is indeed a suitable repression domain, while also further supporting NH as a more suitable G- targeting RVD than NK.
[00285] TALEs may be easily customized to recognize specific sequences on the endogenous genome. Here, a series of screens were conducted to address two important limitations of the TALE toolbox. Together, the identification of a more stringent G-specific RVD with uncompromised activity strength as well as a robust TALE repressor architecture further expands the utility of TALEs for probing mammalian transcription and genome function. [00286] After identifying SID (mSin interaction domain) as a robust novel repressor domain to be used with TALEs, more active repression domain architecture based on SID domain for use with TALEs in mammalian cells were further designed and verified. This domain is called SID4X, which is a tandem repeat of four SID domains linked by short peptide linkers. For testing different TALE repressor architectures, a TALE targeting the promoter of the mouse (Mus musculus) pll (slOOalO) gene was used to evaluate the transcriptional repression activity of a series of candidate TALE repressor architectures (FIG. 13a). Since different truncations of TALE are known to exhibit varying levels of transcriptional activation activity, two different truncations of TALE fused to SID or SID4X domain were tested, one version with 136 and 183 amino acids at N- and C- termini flanking the DNA binding tandem repeats, with another one retaining 240 and 183 amino acids at N- and C-termini (FIG. 13b, c). The candidate TALE repressors were expressed in mouse Neuro2A cells and it was found that TALEs carrying both SID and SID4X domains were able to repress endogenous pll expression up to 4.8 folds, while the GFP-encoding negative control construct had no effect on transcriptional of target gene (FIG. 13b, c). To control for potential perturbation of pll transcription due to TALE binding, expression of the pi 1 -targeting TALE DNA binding domain (with the same N- and C- termini truncations as the tested constructs) without any effector domain had no effect on the transcriptional activity of endogenous pll (FIG. 13b, c, null constructs).
[00287] Because the constructs harboring SID4X domain were able to achieve 167% and 66% more transcriptional repression of the endogenous pll locus than the SID domain depending on the truncations of TALE DNA binding domain (FIG. 13c), it was concluded that a truncated TALE DNA binding domain, bearing 136 and 183 amino acids at N- and C- termini respectively, fused to the SID4X domain is a potent TALE repressor architecture that enables down-regulation of target gene expression and is more active than the previous design employing SID domain.
[00288] The mSin interaction domain (SID) and SID4X domain were codon optimized for mammalian expression and synthesized with flanking Nhel and Xbal restriction sites (Genscript). Truncation variants of the TALE DNA binding domains are PCR amplified and fused to the SID or the SID4X domain using Nhel and Xbal restriction sites. To control for any effect on transcription resulting from TALE binding, expression vectors carrying the TALE DNA binding domain alone using PCR cloning were constructed. The coding regions of all constructs were completely verified using Sanger sequencing. A comparison of two different types of TALE architecture is seen in FIG. 14.
Example 4
Development of mammalian TALE transcriptional activators and nucleases
[00289] Customized TALEs may be used for a wide variety of genome engineering applications, including transcriptional modulation and genome editing. Here, Applicants describe a toolbox for rapid construction of custom TALE transcription factors (TALE-TFs) and nucleases (TALENs) using a hierarchical ligation procedure. This toolbox facilitates affordable and rapid construction of custom TALE-TFs and TALENs within 1 week and may be easily scaled up to construct TALEs for multiple targets in parallel. Applicants also provide details for testing the activity in mammalian cells of custom TALE-TFs and TALENs using quantitative reverse-transcription PCR and Surveyor nuclease, respectively. The TALE toolbox will enable a broad range of biological applications.
TALEs are natural bacterial effector proteins used by Xanthomonas sp. to modulate gene transcription in host plants to facilitate bacterial colonization (Boch, J. & Bonas, U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu. Rev. Phytopathol. 48, 419-436 (2010) and Bogdanove, A. J., Schornack, S. & Lahaye, T. TAL effectors: finding plant genes for disease and defense. Curr. Opin. Plant Biol. 13, 394-401 (2010)). The central region of the protein contains tandem repeats of 34-aa sequences (termed monomers) that are required for DNA recognition and binding (Romer, P. et al. Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene. Science 318, 645-648 (2007); Kay, S., Hahn, S., Marois, E., Hause, G. & Bonas, U. A bacterial effector acts as a plant transcription factor and induces a cell size regulator. Science 318, 648-651 (2007); Kay, S., Hahn, S., Marois, E., Wieduwild, R. & Bonas, U. Detailed analysis of the DNA recognition motifs of the Xanthomonas type III effectors AvrBs3 and AvrBs3Deltarepl6. Plant J. 59, 859-871 (2009) and Romer, P. et al. Recognition of AvrBs3-like proteins is mediated by specific binding to promoters of matching pepper Bs3 alleles. Plant Physiol. 150, 1697-1712 (2009).) (FIG. 8). Naturally occurring TALEs have been found to have a variable number of monomers, ranging from 1.5 to 33.5 (Boch, J. & Bonas, U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu. Rev. Phytopathol. 48, 419-436 (2010)). Although the sequence of each monomer is highly conserved, they differ primarily in two positions termed the repeat variable diresidues (RVDs, 12th and 13th positions). Recent reports have found that the identity of these two residues determines the nucleotide -binding specificity of each TALE repeat and that a simple cipher specifies the target base of each RVD (NI = A, HD = C, NG = T, NN = G or A) (Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509-1512 (2009) and Moscou, M.J. & Bogdanove, A.J. A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501 (2009)). Thus, each monomer targets one nucleotide and the linear sequence of monomers in a TALE specifies the target DNA sequence in the 5' to 3' orientation. The natural TALE-binding sites within plant genomes always begin with a thymine (Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509-1512 (2009) and Moscou, M.J. & Bogdanove, A.J. A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501 (2009)), which is presumably specified by a cryptic signal within the nonrepetitive N terminus of TALEs. The tandem repeat DNA-binding domain always ends with a half-length repeat (0.5 repeat, FIG. 8). Therefore, the length of the DNA sequence being targeted is equal to the number of full repeat monomers plus two.
[00290] In plants, pathogens are often host-specific. For example, Fusarium oxysporum f. sp. lycopersici causes tomato wilt but attacks only tomato, and F. oxysporum f. dianthii Puccinia graminis f. sp. tritici attacks only wheat. Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants. In plants there can be non-host resistance, e.g., the host and pathogen are incompatible. There can also be Horizontal Resistance, e.g., partial resistance against all races of a pathogen, typically controlled by many genes and Vertical Resistance, e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes. In a Gene-for-Gene level, plants and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance. The sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents. Using the present invention, plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in Varieties having desired characteristics or traits employ the present invention to induce the rise of resistance genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs.
[00291] Applicants have further improved the TALE assembly system with a few optimizations, including maximizing the dissimilarity of ligation adaptors to minimize misligations and combining separate digest and ligation steps into single Golden Gate (Engler, C, Kandzia, R. & Marillonnet, S. A one pot, one step, precision cloning method with high throughput capability. PLoS ONE 3, e3647 (2008); Engler, C, Gruetzner, R., Kandzia, R. & Marillonnet, S. Golden gate shuffling: a one -pot DNA shuffling method based on type lis restriction enzymes. PLoS ONE 4, e5553 (2009) and Weber, E., Engler, C, Gruetzner, R., Werner, S. & Marillonnet, S. A modular cloning system for standardized assembly of multigene constructs. PLoS ONE 6, el6765 (2011)) reactions. Briefly, each nucleotide-specific monomer sequence is amplified with ligation adaptors that uniquely specify the monomer position within the TALE tandem repeats. Once this monomer library is produced, it may conveniently be reused for the assembly of many TALEs. For each TALE desired, the appropriate monomers are first ligated into hexamers, which are then amplified via PCR. Then, a second Golden Gate digestion- ligation with the appropriate TALE cloning backbone (FIG. 8) yields a fully assembled, sequence-specific TALE. The backbone contains a ccdB negative selection cassette flanked by the TALE N and C termini, which is replaced by the tandem repeat DNA-binding domain when the TALE has been successfully constructed. ccdB selects against cells transformed with an empty backbone, thereby yielding clones with tandem repeats inserted (Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011)).
[00292] Assemblies of monomeric DNA-binding domains may be inserted into the appropriate TALE-TF or TALEN cloning backbones to construct customized TALE-TFs and TALENs. TALE-TFs are constructed by replacing the natural activation domain within the TALE C terminus with the synthetic transcription activation domain VP64 (Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 29, 149-153 (2011); FIG. 8). By targeting a binding site upstream of the transcription start site, TALE-TFs recruit the transcription complex in a site-specific manner and initiate gene transcription. TALENs are constructed by fusing a C-terminal truncation (+63 aa) of the TALE DNA-binding domain (Miller, J.C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011)) with the nonspecific Fokl endonuclease catalytic domain (FIG. 14). The +63 -aa C-terminal truncation has also been shown to function as the minimal C terminus sufficient for transcriptional modulation (Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 29, 149-153 (2011)). TALENs form dimers through binding to two target sequences separated by -17 bases. Between the pair of binding sites, the Fokl catalytic domains dimerize and function as molecular scissors by introducing double-strand breaks (DSBs; FIG. 8). Normally, DSBs are repaired by the nonhomologous end-joining (Huertas, P. DNA resection in eukaryotes: deciding how to fix the break. Nat. Struct. Mol. Biol. 17, 11-16 (2010)) pathway (NHEJ), resulting in small deletions and functional gene knockout. Alternatively, TALEN-mediated DSBs may stimulate homologous recombination, enabling site-specific insertion of an exogenous donor DNA template (Miller, J.C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011) and Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731-734 (2011)).
[00293] Along with the TALE-TFs being constructed with the VP64 activation domain, other embodiments of the invention relate to TALE polypeptides being constructed with the VP 16 and p65 activation domains. A graphical comparison of the effect these different activation domains have on Sox2 mRNA level is provided in FIG. 11.
Example 5
[00294] FIG. 17 depicts an effect of cryptochrome2 heterodimer orientation on LITE functionality. Two versions of the Neurogenin 2 (Neurog2) LITE were synthesized to investigate the effects of cryptochrome 2 photo lyase homology region (CRY2PHR)/calcium and integrin-binding protein 1 (CIB1) dimer orientation. In one version, the CIB1 domain was fused to the C-terminus of the TALE (Neurog2) domain, while the CRY2PHR domain was fused to the N-terminus of the VP64 domain. In the converse version, the CRY2PHR domain was fused to the C-terminus of the TALE (Neurog2) domain, while the CIB1 domain was fused to the N- terminus of the VP64 domain. Each set of plasmids were transfected in Neuro2a cells and stimulated (466 nm, 5 mW/cm2, 1 sec pulse per 15 sec, 12 h) before harvesting for qPCR analysis. Stimulated LITE and unstimulated LITE Neurog2 expression levels were normalized to Neurog2 levels from stimulated GFP control samples. The TALE-CRY2PHR/CIB 1 -VP64 LITE exhibited elevated basal activity and higher light induced Neurog2 expression, and suggested its suitability for situations in which higher absolute activation is required. Although the relative light inducible activity of the TALE-CIB 1/CRY2PHR-VP64 LITE was lower that its counterpart, the lower basal activity suggested its utility in applications requiring minimal baseline activation. Further, the TALE-CIB 1 construct was smaller in size, compared to the TALE-CRY2PHR construct, a potential advantage for applications such as viral packaging.
[00295] FIG. 18 depicts metabotropic glutamate receptor 2 (mGlur2) LITE activity in mouse cortical neuron culture. A mGluR2 targeting LITE was constructed via the plasmids pAAV- human Synapsin I promoter (hSyn)-HA-TALE(mGluR2)-CIBl and pAAV-hSyn-CRY2PHR- VP64-2A-GFP. These fusion constructs were then packaged into adeno associated viral vectors (AAV). Additionally, AAV carrying hSyn-TALE-VP64-2A-GFP and GFP only were produced. Embryonic mouse (El 6) cortical cultures were plated on Poly-L-lysine coated 24 well plates. After 5 days in vitro neural cultures were co-trasnduced with a mixture of TALE(mGluR2)-CIBl and CRY2PHR-VP64 AAV stocks. Control samples were transduced with either TALE(mGluR2)-VP64 AAV or GFP AAV. 6 days after AAV transduction, experimental samples were stimulated using either of two light pulsing paradigms: 0.5 s per min and 0.25 sec per 30 sec. Neurons were stimulated for 24 h and harvested for qPCR analysis. All mGluR2 expression levels were normalized to the respective stimulated GFP control. The data suggested that the LITE system could be used to induce the light-dependent activation of a target gene in primary neuron cultures in vitro.
[00296] FIG. 19 depicts transduction of primary mouse neurons with LITE AAV vectors. Primary mouse cortical neuron cultures were co-transduced at 5 days in vitro with AAV vectors encoding hSyn-CRY2PHR-VP64-2A-GFP and hSyn-HA-TALE-CIB 1 , the two components of the LITE system. Left panel: at 6 days after transduction, neural cultures exhibited high expression of GFP from the hSyn-CRY2PHR-VP64-2A-GFP vector. Right panel: Co-transduced neuron cultures were fixed and stained with an antibody specific to the HA epitope on the N- terminus of the TALE domain in hSyn-HA-TALE-CIBl . Red signal indicated HA expression, with particularly strong nuclear signal (DNA stained by DAPI in blue channel). Together these images suggested that the expression of each LITE component could be achieved in primary mouse neuron cultures, (scale bars=50 um).
[00297] FIG. 20 depicts expression of a LITE component in vivo. An AAV vector of seratype 1/2 carrying hSyn-CRY2PHR-VP64 was produced via transfection of HEK293FT cells and purified via heparin column binding. The vector was concentrated for injection into the intact mouse brain. 1 uL of purified AAV stock was injected into the hippocampus and infralimbic cortex of an 8 week old male C57BL/6 mouse by steroeotaxic surgery and injection. 7 days after in vivo transduction, the mouse was euthanized and the brain tissue was fixed by paraformaldehyde perfusion. Slices of the brain were prepared on a vibratome and mounted for imaging. Strong and widespread GFP signals in the hippocampus and infralimbic cortex suggested efficient transduction and high expression of the LITE component CRY2PHR-VP64.
Example 6
Improved design by using NES element
[00298] Estrogen receptor T2 (ERT2) has a leakage issue. The ERT2 domain would enter the nucleus even in the absence of 4-Hydroxytestosterone (40HT), leading to a background level of activation of target gene by TAL. NES (nuclear exporting signal) is a peptide signal that targets a protein to the cytoplasm of a living cell. By adding NES to an existing construct, Applicants aim to prevent the entering of ERT2-TAL protein into nucleus in the absence of 40HT, lowering the background activation level due to the "leakage" of the ERT2 domain.
[00299] FIG. 21 depicts an improved design of the construct where the specific NES peptide sequence used is LDLASLIL.
[00300] FIG. 22 depicts Sox2 mRNA levels in the absence and presence of 40H tamoxifen. Y-axis is Sox2 mRNA level as measured by qRT-PCR. X-axis is a panel of different construct designs described on top. Plus and minus signs indicate the presence or absence of 0.5uM 40HT.
Example 7
Multiplex Genome Engineering Using CRISPR/Cas Systems
[00301] Functional elucidation of causal genetic variants and elements requires precise genome editing technologies. The type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats) adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage. Applicants engineered two different type II CRISPR systems and demonstrate that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells. Cas9 can also be converted into a nicking enzyme to facilitate homology-directed repair with minimal mutagenic activity. Finally, multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several sites within the mammalian genome, demonstrating easy programmability and wide applicability of the CRISPR technology.
[00302] Prokaryotic CRISPR adaptive immune systems can be reconstituted and engineered to mediate multiplex genome editing in mammalian cells.
Precise and efficient genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements. Although genome-editing technologies such as designer zinc fingers (ZFs) (M. H. Porteus, D. Baltimore, Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763 (May 2, 2003); J. C. Miller et al., An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778 (Jul, 2007); J. D. Sander et al, Selection- free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 8, 67 (Jan, 2011) and A. J. Wood et al, Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (Jul 15, 2011)), transcription activator-like effectors (TALEs) (A. J. Wood et al, Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (Jul 15, 2011); M. Christian et al., Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757 (Oct, 2010); F. Zhang et al, Efficient construction of sequence- specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 29, 149 (Feb, 2011); J. C. Miller et al., A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29, 143 (Feb, 2011); D. Reyon et al, FLASH assembly of TALENs for high- throughput genome editing. Nat Biotechnol 30, 460 (May, 2012); J. Boch et al., Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509 (Dec 11, 2009) and M. J. Moscou, A. J. Bogdanove, A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501 (Dec 11, 2009)), and homing meganucleases (B. L. Stoddard, Homing endonuclease structure and function. Quarterly reviews of biophysics 38, 49 (Feb, 2005)) have begun to enable targeted genome modifications, there remains a need for new technologies that are scalable, affordable, and easy to engineer. Here, Applicants report the development of a new class of precision genome engineering tools based on the RNA-guided Cas9 nuclease (M. Jinek et al, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012); G. Gasiunas, R. Barrangou, P. Horvath, V. Siksnys, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109, E2579 (Sep 25, 2012) and J. E. Garneau et al, The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67 (Nov 4, 2010)) from the type II prokaryotic CRISPR adaptive immune system (H. Deveau, J. E. Garneau, S. Moineau, CRISPR/Cas system and its role in phage- bacteria interactions. Annual review of microbiology 64, 475 (2010); P. Horvath, R. Barrangou, CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167 (Jan 8, 2010); K. S. Makarova et al., Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9, 467 (Jun, 2011) and D. Bhaya, M. Davison, R. Barrangou, CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45, 273 (2011)).
The Streptococcus pyogenes SF370 type II CRISPR locus consists of four genes, including the Cas9 nuclease, as well as two non-coding RNAs: tracrRNA and a pre-crRNA array containing nuclease guide sequences (spacers) interspaced by identical direct repeats (DRs) (FIG. 27) (E. Deltcheva et al, CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602 (Mar 31, 2011)). Applicants sought to harness this prokaryotic RNA-programmable nuclease system to introduce targeted double stranded breaks (DSBs) in mammalian chromosomes through heterologous expression of the key components. It has been previously shown that expression of tracrRNA, pre-crRNA, host factor RNase III, and Cas9 nuclease are necessary and sufficient for cleavage of DNA in vitro (M. Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012) and G. Gasiunas, R. Barrangou, P. Horvath, V. Siksnys, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci US A 109, E2579 (Sep 25, 2012)) and in prokaryotic cells (R. Sapranauskas et al, The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39, 9275 (Nov, 2011) and A. H. Magadan, M. E. Dupuis, M. Villion, S. Moineau, Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-Cas system. PLoS One 7, e40913 (2012)). Applicants codon optimized the S. pyogenes Cas9 (SpCas9) and RNase III (SpRNase III) and attached nuclear localization signals (NLS) to ensure nuclear compartmentalization in mammalian cells. Expression of these constructs in human 293FT cells revealed that two NLSs are required for targeting SpCas9 to the nucleus (FIG. 23A). To reconstitute the non-coding RNA components of CRISPR, Applicants expressed an 89- nucleotide (nt) tracrRNA (FIG. 28) under the RNA polymerase III U6 promoter (FIG. 23B). Similarly, Applicants used the U6 promoter to drive the expression of a pre-crRNA array comprising a single guide spacer flanked by DRs (FIG. 23B). Applicants designed an initial spacer to target a 30-basepair (bp) site (protospacer) in the human EMX1 locus that precedes an NGG, the requisite protospacer adjacent motif (PAM) (FIG. 23C and FIG. 27) (H. Deveau et ah, Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol 190, 1390 (Feb, 2008) and F. J. Mojica, C. Diez-Villasenor, J. Garcia-Martinez, C. Almendros, Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733 (Mar, 2009)).
To test whether heterologous expression of the CRISPR system (SpCas9, SpRNase III, tracrRNA, and pre-crRNA) can achieve targeted cleavage of mammalian chromosomes, Applicants transfected 293FT cells with different combinations of CRISPR components. Since DSBs in mammalian DNA are partially repaired by the indel-forming non-homologous end joining (NHEJ) pathway, Applicants used the SURVEYOR assay (FIG. 29) to detect endogenous target cleavage (FIG.23D and FIG.28B). Co-transfection of all four required CRISPR components resulted in efficient cleavage of the protospacer (FIG. 23D and FIG. 28B), which is subsequently verified by Sanger sequencing (FIG.23E). Interestingly, SpRNase III was not necessary for cleavage of the protospacer (FIG. 23D), and the 89-nt tracrRNA is processed in its absence (FIG. 28C). Similarly, maturation of pre-crRNA does not require RNase III (FIG. 23D and FIG. 30), suggesting that there may be endogenous mammalian RNases that assist in pre- crRNA maturation (M. Jinek, J. A. Doudna, A three-dimensional view of the molecular machinery of RNA interference. Nature 457, 405 (Jan 22, 2009); C. D. Malone, G. J. Hannon, Small RNAs as guardians of the genome. Cell 136, 656 (Feb 20, 2009) and G. Meister, T. Tuschl, Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343 (Sep 16, 2004)). Removing any of the remaining RNA or Cas9 components abolished the genome cleavage activity of the CRISPR system (FIG. 23D). These results define a minimal three- component system for efficient CRISPR-mediated genome modification in mammalian cells. [00303] Next, Applicants explored the generalizability of CRISPR-mediated cleavage in eukaryotic cells by targeting additional protospacers within the EMX1 locus (FIG. 24A). To improve co-delivery, Applicants designed an expression vector to drive both pre-crRNA and SpCas9 (FIG. 31). In parallel, Applicants adapted a chimeric crRNA-tracrRNA hybrid (FIG. 24B, top) design recently validated in vitro (M. Jinek et ah, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012)), where a mature crRNA is fused to a partial tracrRNA via a synthetic stem-loop to mimic the natural crRNA:tracrRNA duplex (FIG. 24B, bottom). Applicants observed cleavage of all protospacer targets when SpCas9 is co-expressed with pre-crRNA (DR-spacer-DR) and tracrRNA. However, not all chimeric RNA designs could facilitate cleavage of their genomic targets (FIG. 24C, Table 1). Applicants then tested targeting of additional genomic loci in both human and mouse cells by designing pre-crRNAs and chimeric RNAs targeting the human PVALB and the mouse Th loci (FIG. 32). Applicants achieved efficient modification at all three mouse Th and one PVALB targets using the crRNA:tracrRNA design, thus demonstrating the broad applicability of the CRISPR system in modifying different loci across multiple organisms (Table 1). For the same protospacer targets, cleavage efficiencies of chimeric RNAs were either lower than those of crRNA:tracrRNA duplexes or undetectable. This may be due to differences in the expression and stability of RNAs, degradation by endogenous RNAi machinery, or secondary structures leading to inefficient Cas9 loading or target recognition.
[00304] Effective genome editing requires that nucleases target specific genomic loci with both high precision and efficiency. To investigate the specificity of CRISPR-mediated cleavage, Applicants analyzed single-nucleotide mismatches between the spacer and its mammalian protospacer target (FIG. 25 A). Applicants observed that single-base mismatch up to 12-bp 5' of the PAM completely abolished genomic cleavage by SpCas9, whereas spacers with mutations farther upstream retained activity against the protospacer target (FIG. 25B). This is consistent with previous bacterial and in vitro studies of Cas9 specificity (M. Jinek et ah, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012) and R. Sapranauskas et ah, The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39, 9275 (Nov, 2011)). Furthermore, CRISPR is able to mediate genomic cleavage as efficiently as a pair of TALE nucleases (TALEN) targeting the same EMX1 protospacer (FIG. 25, C and D). Targeted modification of genomes ideally avoids mutations arising from the error-prone NHEJ mechanism. The wild-type SpCas9 is able to mediate site-specific DSBs, which can be repaired through either NHEJ or homology-directed repair (HDR). Applicants engineered an aspartate-to-alanine substitution (D10A) in the RuvC I domain of SpCas9 to convert the nuclease into a DNA nickase (SpCas9n, FIG. 26A) (M. Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (Aug 17, 2012); G. Gasiunas, R. Barrangou, P. Horvath, V. Siksnys, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A 109, E2579 (Sep 25, 2012) and R. Sapranauskas et al, The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39, 9275 (Nov, 2011)), because nicked genomic DNA is typically repaired either seamlessly or through high- fidelity HDR. SURVEYOR (FIG. 26B) and sequencing of 327 amplicons did not detect any indels induced by SpCas9n. However, it is worth noting that nicked DNA can in rare cases be processed via a DSB intermediate and result in a NHEJ event (M. T. Certo et al., Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods 8, 671 (Aug, 2011)). Applicants then tested Cas9-mediated HDR at the same EMXl locus with a homology repair template to introduce a pair of restriction sites near the protospacer (FIG. 26C). SpCas9 and SpCas9n catalyzed integration of the repair template into EMXl locus at similar levels (FIG. 26D), which Applicants further verified via Sanger sequencing (FIG. 26E). These results demonstrate the utility of CRISPR for facilitating targeted genomic insertions. Given the 14-bp (12-bp from the seed sequence and 2-bp from PAM) target specificity (FIG. 25B) of the wild type SpCas9, the use of a nickase may reduce off-target mutations.
[00305] Finally, the natural architecture of CRISPR loci with arrayed spacers (FIG. 27) suggests the possibility of multiplexed genome engineering. Using a single CRISPR array encoding a pair of EMXl- and PV ALB -tSiXgQtmg spacers, Applicants detected efficient cleavage at both loci (FIG. 26F). Applicants further tested targeted deletion of larger genomic regions through concurrent DSBs using spacers against two targets within EMXl spaced by 119-bp, and observed a 1.6% deletion efficacy (3 out of 182 amplicons; FIG. 26G), thus demonstrating the CRISPR system can mediate multiplexed editing within a single genome.
The ability to use RNA to program sequence-specific DNA cleavage defines a new class of genome engineering tools. Here, Applicants have shown that the S. pyogenes CRISPR system can be heterologously reconstituted in mammalian cells to facilitate efficient genome editing; an accompanying study has independently confirmed high efficiency CRISPR-mediated genome targeting in several human cell lines (Mali et al.). However, several aspects of the CRISPR system can be further improved to increase its efficiency and versatility. The requirement for an NGG PAM restricts the S. pyogenes CRISPR target space to every 8-bp on average in the human genome (FIG. 33), not accounting for potential constraints posed by crRNA secondary structure or genomic accessibility due to chromatin and DNA methylation states. Some of these restrictions may be overcome by exploiting the family of Cas9 enzymes and its differing PAM requirements (H. Deveau et al., Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol 190, 1390 (Feb, 2008) and F. J. Mojica, C. Diez-Villasenor, J. Garcia- Martinez, C. Almendros, Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733 (Mar, 2009)) across the microbial diversity (K. S. Makarova et al., Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9, 467 (Jun, 2011)). Indeed, other CRISPR loci are likely to be transplantable into mammalian cells; for example, the Streptococcus thermophilus LMD-9 CRISPRl can also mediate mammalian genome cleavage (FIG. 34). Finally, the ability to carry out multiplex genome editing in mammalian cells enables powerful applications across basic science, biotechnology, and medicine (P. A. Carr, G. M. Church, Genome engineering. Nat Biotechnol 27, 1151 (Dec, 2009)).
Example 8
Multiplex Genome Engineering Using CRISPR/Cas Systems: Supplementary Material
[00306] Cell culture and transfection. Human embryonic kidney (HEK) cell line 293FT (Life Technologies) was maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2mM GlutaMAX (Life Technologies), lOOU/mL penicillin, and 100μg/mL streptomycin at 37°C with 5% C02 incubation. Mouse neuro2A (N2A) cell line (ATCC) was maintained with DMEM supplemented with 5% fetal bovine serum (HyClone), 2mM GlutaMAX (Life Technologies), lOOU/mL penicillin, and 100μg/mL streptomycin at 37°C with 5% C02.
[00307] 293FT or N2A cells were seeded into 24-well plates (Corning) one day prior to transfection at a density of 200,000 cells per well. Cells were transfected using Lipofectamine 2000 (Life Technologies) following the manufacturer's recommended protocol. For each well of a 24-well plate a total of 800ng plasmids was used.
[00308] Suveryor assay and sequencing analysis for genome modification. 293FT or N2A cells were transfected with plasmid DNA as described above. Cells were incubated at 37°C for 72 hours post transfection before genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA extraction kit (Epicentre) following the manufacturer's protocol. Briefly, cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes.
[00309] Genomic region surrounding the CRISPR target site for each gene was PCR amplified, and products were purified using QiaQuick Spin Column (Qiagen) following manufacturer's protocol. A total of 400ng of the purified PCR products were mixed with 2μ1 10X Taq polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume of 20μ1, and subjected to a re-annealing process to enable heteroduplex formation: 95°C for lOmin, 95C to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute. After reannealing, products were treated with SURVEYOR nuclease and SURVEYOR enhancer S (Transgenomics) following the manufacturer's recommended protocol, and analyzed on 4-20 Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Biorad). Quantification was based on relative band intensities.
[00310] Restriction fragment length polymorphism assay for detection of homologous recombination. HEK 293FT and N2A cells were transfected with plasmid DNA, and incubated at 37°C for 72 hours before genomic DNA extraction as described above. The target genomic region was PCR amplified using primers outside the homology arms of the homologous recombination (HR) template. PCR products were separated on a 1% agarose gel and extracted with MinElute GelExtraction Kit (Qiagen). Purified products were digested with Hindlll (Fermentas) and analyzed on a 6% Novex TBE poly-acrylamide gel (Life Technologies).
[00311] RNA extraction and purification. HEK 293FT cells were maintained and transfected as stated previously. Cells were harvested by trypsinization followed by washing in phosphate buffered saline (PBS). Total cell RNA was extracted with TRI reagent (Sigma) following manufacturer's protocol. Extracted total RNA was quantified using Naonodrop (Thermo Scientific) and normalized to same concentration. [00312] Northern blot analysis of crRNA and tracrRNA expression in mammalian cells. RNAs were mixed with equal volumes of 2X loading buffer (Ambion), heated to 95°C for 5 min, chilled on ice for 1 min and then loaded onto 8% denaturing polyacrylamide gels (SequaGel, National Diagnostics) after pre-running the gel for at least 30 minutes. The samples were electrophoresed for 1.5 hours at 40 W limit. Afterwards, the RNA was transferred to Hybond N+ membrane (GE Healthcare) at 300 mA in a semi-dry transfer apparatus (Bio-rad) at room temperature for 1.5 hours. The RNA was crosshnked to the membrane using autocrosslink button on Stratagene UV Crosslinker the Stratalinker (Stratagene). The membrane was pre -hybridized in ULTRAhyb-Oligo Hybridization Buffer (Ambion) for 30 min with rotation at 42°C and then probes were added and hybridized overnight. Probes were ordered from IDT and labeled with [gamma-32P] ATP (Perkin Elmer) with T4 polynucleotide kinase (New England Biolabs). The membrane was washed once with pre-warmed (42°C) 2xSSC, 0.5% SDS for 1 min followed by two 30 minute washes at 42°C. The membrane was exposed to phosphor screen for one hour or overnight at room temperature and then scanned with phosphorimager (Typhoon).
[00313] Table 1. Protospacer sequences and modification efficiencies of mammalian genomic targets. Protospacer targets designed based on Streptococcus pyogenes type II CRISPR and Streptococcus thermophilus CRISPRl loci with their requisite PAMs against three different genes in human and mouse genomes. Cells were transfected with Cas9 and either precrRNA/ tracrRNA or chimeric RNA. Cells were analyzed 72 hours after transfection. Percent indels are calculated based on SURVEYOR assay results from indicated cell lines, N = 3 for all protospacer targets, errors are S.E.M. N.D., not detectable using the SURVEYOR assay; N.T., not tested in this study.
Figure imgf000096_0001
[00314] Table 2. Sequences for primers and probes used for SURVEYOR assay, RFLP assay, genomic sequencing, and Northern blot.
Figure imgf000097_0001
[00315] Supplementary Sequences
[00316] > U6-short tracrRNA (Streptococcus pyogenes SF370) [00317] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGGAACCATTCAAAACAGCATAGCAAGTTAA
AATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT
[00318] > U6-long tracrRNA (Streptococcus pyogenes SF370)
[00319] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGGTAGTATTAAGTATTGTTTTATGGCTGATA
AATTTCTTTGAATTTCTCCTTGATTATTTGTTATAAAAGTTATAAAATAATCTTGTTG
GAACCATTCAAAACAGCATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGA
AAAAGTGGCACCGAGTCGGTGCTTTTTTT
[00320] > U6-DR-BbsI backbone-DR (Streptococcus pyogenes SF370)
[00321] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGGGTTTTAGAGCTATGCTGTTTTGAATGGTC
CCAAAACGGGTCTTCGAGAAGACGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAA
AC
[00322] > U6-chimeric RNA-BbsI backbone (Streptococcus pyogenes SF370)
[00323] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGGGTCTTCGAGAAGACCTGTTTTAGAGCTA
GAAATAGCAAGTTAAAATAAGGCTAGTCCG
[00324] > 3xFLAG-NLS-SpCas9-NLS [00325] ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTA
CAAAGACGATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCAC
GGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTC
TGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGG
TGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTG
TTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAA
GATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAG
ATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGA
AGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGG
CCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGC
ACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTC
CGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAA
GCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAA
CGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGAC
GGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGC
AACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTG
GCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAA
CCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCT
GTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGG
CCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACC
CTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTC
GACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAG
AGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTG
CTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGG
CAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGG
AAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACC
TTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGG
ATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGA
CAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACC
TGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGT
ATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTC CTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAA
AGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACT
CCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCAC
GATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGA
CATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGA
GGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGA
AGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATC
CGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGC
CAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACA
TCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAAT
CTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGA
CGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGG
CCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAA
GCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCC
GTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGG
GCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATG
TGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGC
TGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGT
CGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC
AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGAT
AAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGT
GGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGA
TCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAG
GATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCC
TACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAG
CGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGA
GCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATG
AACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCT
GATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTG
CCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAG
GTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAA GCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCC
CCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAG
AAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTT
CGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGG
ACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAG
AGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTC
CAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCC
CGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACG
AGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAAT
CTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCA
GGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTT
CAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGC
TGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGAC
CTGTCTCAGCTGGGAGGCGACAAGCGTCCTGCTGCTACTAAGAAAGCTGGTCAAGCT
AAGAAAAAGAAA
[00326] > SpRNase3-mCherry-NLS
[00327] ATGAAGCAGCTGGAGGAGTTACTTTCTACCTCTTTCGACATCCAGTTTAAT
GACCTGACCCTGCTGGAAACCGCCTTCACTCACACCTCCTACGCGAATGAGCACCGC
CTACTGAATGTGAGCCACAACGAGCGCCTGGAGTTTCTGGGGGATGCTGTCTTACAG
CTGATCATCTCTGAATATCTGTTTGCCAAATACCCTAAGAAAACCGAAGGGGACATG
TCAAAGCTGCGCTCCATGATAGTCAGGGAAGAGAGCCTGGCGGGCTTTAGTCGTTTT
TGCTCATTCGACGCTTATATCAAGCTGGGAAAAGGCGAAGAGAAGTCCGGCGGCAG
GAGGCGCGATACAATTCTGGGCGATCTCTTTGAAGCGTTTCTGGGCGCACTTCTACT
GGACAAAGGGATCGACGCAGTCCGCCGCTTTCTGAAACAAGTGATGATCCCTCAGG
TCGAAAAGGGAAACTTCGAGAGAGTGAAGGACTATAAAACATGTTTGCAGGAATTT
CTCCAGACCAAGGGAGATGTAGCAATAGATTATCAGGTAATAAGTGAGAAAGGACC
AGCTCACGCCAAACAATTCGAAGTTAGCATCGTTGTTAATGGCGCAGTGTTGTCGAA
GGGCTTGGGTAAATCAAAAAAACTGGCCGAGCAGGACGCTGCTAAAAACGCCCTCG
CTCAGCTCAGCGAGGTAGGATCCGTGAGCAAGGGCGAGGAGGATAACATGGCCATC
ATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGA
GTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCA AGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTC
AGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACT
TGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGAC
GGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTA
CAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGA
AGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTG
AAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTG
AGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAAC
GTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACA
GTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGA
AGCGTCCTGCTGCTACTAAGAAAGCTGGTCAAGCTAAGAAAAAGAAA
[00328] > 3xFLAG-NLS-SpCas9n-NLS (the D 1 OA nickase mutation is underlined)
[00329] ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTA
CAAAGACGATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCAC
GGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGCCATCGGCACCAACTC
TGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGG
TGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTG
TTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAA
GATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAG
ATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGA
AGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGG
CCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGC
ACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTC
CGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAA
GCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAA
CGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGAC
GGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGC
AACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTG
GCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAA
CCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCT
GTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGG CCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACC
CTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTC
GACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAG
AGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTG
CTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGG
CAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGG
AAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACC
TTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGG
ATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGA
CAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACC
TGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGT
ATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTC
CTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAA
AGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACT
CCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCAC
GATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGA
CATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGA
GGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGA
AGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATC
CGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGC
CAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACA
TCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAAT
CTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGA
CGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGG
CCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAA
GCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCC
GTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGG
GCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATG
TGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGC
TGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGT
CGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGAT
AAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGT
GGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGA
TCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAG
GATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCC
TACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAG
CGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGA
GCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATG
AACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCT
GATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTG
CCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAG
GTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAA
GCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCC
CCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAG
AAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTT
CGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGG
ACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAG
AGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTC
CAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCC
CGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACG
AGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAAT
CTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCA
GGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTT
CAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGC
TGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGAC
CTGTCTCAGCTGGGAGGCGACAAGCGTCCTGCTGCTACTAAGAAAGCTGGTCAAGCT
AAGAAAAAGAAA
[00330] > hEMXl-HRTemplate-Hindlll-Nhel
[00331] GAATGCTGCCCTCAGACCCGCTTCCTCCCTGTCCTTGTCTGTCCAAGGAGA
ATGAGGTCTCACTGGTGGATTTCGGACTACCCTGAGGAGCTGGCACCTGAGGGACA
AGGCCCCCCACCTGCCCAGCTCCAGCCTCTGATGAGGGGTGGGAGAGAGCTACATG AGGTTGCTAAGAAAGCCTCCCCTGAAGGAGACCACACAGTGTGTGAGGTTGGAGTC
TCTAGCAGCGGGTTCTGTGCCCCCAGGGATAGTCTGGCTGTCCAGGCACTGCTCTTG
ATATAAACACCACCTCCTAGTTATGAAACCATGCCCATTCTGCCTCTCTGTATGGAA
AAGAGCATGGGGCTGGCCCGTGGGGTGGTGTCCACTTTAGGCCCTGTGGGAGATCA
TGGGAACCCACGCAGTGGGTCATAGGCTCTCTCATTTACTACTCACATCCACTCTGT
GAAGAAGCGATTATGATCTCTCCTCTAGAAACTCGTAGAGTCCCATGTCTGCCGGCT
TCCAGAGCCTGCACTCCTCCACCTTGGCTTGGCTTTGCTGGGGCTAGAGGAGCTAGG
ATGCACAGCAGCTCTGTGACCCTTTGTTTGAGAGGAACAGGAAAACCACCCTTCTCT
CTGGCCCACTGTGTCCTCTTCCTGCCCTGCCATCCCCTTCTGTGAATGTTAGACCCAT
GGGAGCAGCTGGTCAGAGGGGACCCCGGCCTGGGGCCCCTAACCCTATGTAGCCTC
AGTCTTCCCATCAGGCTCTCAGCTCAGCCTGAGTGTTGAGGCCCCAGTGGCTGCTCT
GGGGGCCTCCTGAGTTTCTCATCTGTGCCCCTCCCTCCCTGGCCCAGGTGAAGGTGT
GGTTCCAGAACCGGAGGACAAAGTACAAACGGCAGAAGCTGGAGGAGGAAGGGCC
TGAGTCCGAGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCA
CGAAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACaagcttgctagcGGTGG
GCAACCACAAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCCAGGCCCCTGCGT
GGGCCCAAGCTGGACTCTGGCCACTCCCTGGCCAGGCTTTGGGGAGGCCTGGAGTC
ATGGCCCCACAGGGCTTGAAGCCCGGGGCCGCCATTGACAGAGGGACAAGCAATGG
GCTGGCTGAGGCCTGGGACCACTTGGCCTTCTCCTCGGAGAGCCTGCCTGCCTGGGC
GGGCCCGCCCGCCACCGCAGCCTCCCAGCTGCTCTCCGTGTCTCCAATCTCCCTTTTG
TTTTGATGCATTTCTGTTTTAATTTATTTTCCAGGCACCACTGTAGTTTAGTGATCCCC
AGTGTCCCCCTTCCCTATGGGAATAATAAAAGTCTCTCTCTTAATGACACGGGCATC
CAGCTCCAGCCCCAGAGCCTGGGGTGGTAGATTCCGGCTCTGAGGGCCAGTGGGGG
CTGGTAGAGCAAACGCGTTCAGGGCCTGGGAGCCTGGGGTGGGGTACTGGTGGAGG
GGGTCAAGGGTAATTCATTAACTCCTCTCTTTTGTTGGGGGACCCTGGTCTCTACCTC
CAGCTCCACAGCAGGAGAAACAGGCTAGACATAGGGAAGGGCCATCCTGTATCTTG
AGGGAGGACAGGCCCAGGTCTTTCTTAACGTATTGAGAGGTGGGAATCAGGCCCAG
GTAGTTCAATGGGAGAGGGAGAGTGCTTCCCTCTGCCTAGAGACTCTGGTGGCTTCT
CCAGTTGAGGAGAAACCAGAGGAAAGGGGAGGATTGGGGTCTGGGGGAGGGAACA
CCATTCACAAAGGCTGACGGTTCCAGTCCGAAGTCGTGGGCCCACCAGGATGCTCA
CCTGTCCTTGGAGAACCGCTGGGCAGGTTGAGACTGCAGAGACAGGGCTTAAGGCT GAGCCTGCAACCAGTCCCCAGTGACTCAGGGCCTCCTCAGCCCAAGAAAGAGCAAC
GTGCCAGGGCCCGCTGAGCTCTTGTGTTCACCTG
[00332] > NLS-StCsnl-NLS
[00333] ATGAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAA AAGTCCGACCTGGTACTTGGACTGGATATTGGTATCGGTTCGGTGGGAGTCGGAATC CTCAACAAGGTCACGGGGGAGATCATTCACAAGAACTCGCGGATCTTCCCCGCAGC TCAGGCTGAGAACAACTTGGTGCGGAGAACG
[00334] AATAGGCAGGGCAGGCGACTGGCGAGGAGGAAGAAACACAGGAGAGTC
CGATTGAACCGGCTGTTCGAGGAGTCCGGTTTGATCACCGACTTTACGAAAATCTCG
ATTAACCTTAATCCCTATCAGCTTCGGGTGAAAGGCCTGACAGACGAACTTTCGAAT
GAGGAACTTTTCATCGCGCTGAAAAACATGGTCAAGCACAGAGGGATTTCCTACCTC
GATGACGCCTCGGATGACGGAAATTCCTCAGTAGGAGATTATGCACAGATCGTGAA
AGAGAACTCAAAGCAACTGGAAACAAAGACACCGGGGCAGATCCAACTTGAAAGA
TACCAGACATACGGACAGCTCAGAGGAGATTTTACGGTGGAGAAGGACGGTAAAAA
GCACAGACTCATTAACGTATTTCCCACGTCGGCGTACAGATCCGAAGCGCTCCGCAT
CCTTCAGACTCAACAGGAGTTCAACCCGCAAATTACTGATGAGTTCATCAACCGCTA
TTTGGAAATCTTGACCGGAAAGCGCAAGTATTATCATGGGCCGGGTAATGAGAAAT
CCAGAACAGATTACGGCCGATACAGAACTTCGGGGGAAACCTTGGATAACATCTTT
GGTATTTTGATTGGAAAGTGCACCTTTTACCCGGACGAGTTTCGAGCGGCCAAGGCG
TCATACACAGCACAAGAGTTTAATCTCTTGAATGATTTGAACAACTTGACGGTCCCC
ACGGAGACAAAGAAGCTCTCCAAAGAGCAAAAGAACCAAATCATCAACTACGTCA
AGAACGAGAAGGCTATGGGGCCAGCGAAGCTGTTCAAGTATATCGCTAAACTTCTC
AGCTGTGATGTGGCGGACATCAAAGGGTACCGAATCGACAAGTCGGGAAAAGCGGA
AATTCACACGTTTGAAGCATATCGAAAGATGAAAACGTTGGAAACACTGGACATTG
AGCAGATGGACCGGGAAACGCTCGACAAACTGGCATACGTGCTCACGTTGAATACT
GAACGAGAGGGAATCCAAGAGGCCCTTGAACATGAGTTCGCCGATGGATCGTTCAG
CCAGAAGCAGGTCGACGAACTTGTGCAATTCCGCAAGGCGAATAGCTCCATCTTCG
GGAAGGGATGGCACAACTTTTCGGTCAAACTCATGATGGAGTTGATCCCAGAACTTT
ATGAGACTTCGGAGGAGCAAATGACGATCTTGACGCGCTTGGGGAAACAGAAAACG
ACAAGCTCATCGAACAAAACTAAGTACATTGATGAGAAATTGCTGACGGAAGAAAT
CTATAATCCGGTAGTAGCGAAATCGGTAAGACAAGCGATCAAAATCGTGAACGCGG CGATCAAGGAATATGGTGACTTTGATAACATCGTAATTGAAATGGCTAGAGAGACG
AACGAAGATGACGAGAAAAAGGCAATCCAGAAGATCCAGAAGGCCAACAAGGATG
AAAAAGATGCAGCGATGCTTAAAGCGGCCAACCAATACAATGGAAAGGCGGAGCT
GCCCCATTCAGTGTTTCACGGTCATAAACAGTTGGCGACCAAGATCCGACTCTGGCA
TCAGCAGGGTGAGCGGTGTCTCTACACCGGAAAGACTATCTCCATCCATGACTTGAT
TAACAATTCGAACCAGTTTGAAGTGGATCATATTCTGCCCCTGTCAATCACCTTTGA
CGACTCGCTTGCGAACAAGGTGCTCGTGTACGCAACGGCAAATCAGGAGAAAGGCC
AGCGGACTCCGTATCAGGCGCTCGACTCAATGGACGATGCGTGGTCATTCCGGGAG
CTGAAGGCGTTCGTACGCGAGAGCAAGACACTGAGCAACAAAAAGAAAGAGTATCT
GCTGACAGAGGAGGACATCTCGAAATTCGATGTCAGGAAGAAGTTCATCGAGCGGA
ATCTTGTCGACACTCGCTACGCTTCCAGAGTAGTACTGAACGCGCTCCAGGAACACT
TTAGAGCGCACAAAATTGACACGAAGGTGTCAGTGGTGAGAGGGCAGTTCACATCC
CAACTCCGCCGACATTGGGGCATCGAAAAGACGCGGGACACATATCACCATCATGC
GGTGGACGCGCTGATTATTGCCGCTTCGTCCCAGTTGAATCTCTGGAAAAAGCAGAA
GAACACGCTGGTGTCGTATTCGGAGGATCAGCTTTTGGACATCGAAACCGGGGAGC
TGATTTCCGACGATGAATACAAAGAATCGGTGTTTAAGGCACCATATCAGCATTTCG
TGGACACGCTGAAGAGCAAAGAGTTTGAGGACAGCATCCTCTTTTCGTACCAAGTG
GACTCGAAGTTTAATCGCAAGATTTCAGACGCCACAATCTACGCGACGAGGCAGGC
GAAGGTGGGCAAAGATAAAGCAGATGAAACCTACGTCCTTGGTAAAATCAAGGACA
TCTACACTCAGGACGGGTACGATGCGTTCATGAAAATCTACAAGAAGGATAAGTCG
AAGTTTCTCATGTACCGCCACGATCCACAGACTTTCGAAAAAGTCATTGAGCCTATT
TTGGAGAACTACCCTAACAAGCAAATCAACGAGAAAGGGAAAGAAGTCCCGTGCAA
CCCCTTTCTGAAGTACAAGGAAGAGCACGGTTATATCCGCAAATACTCGAAGAAAG
GAAATGGGCCTGAGATTAAGTCGCTTAAGTATTACGACTCAAAGTTGGGTAACCAC
ATCGACATTACCCCGAAAGACTCCAACAACAAAGTCGTGTTGCAGTCCGTCTCGCCC
TGGCGAGCAGATGTGTATTTTAATAAGACGACCGGCAAATATGAGATCCTTGGACTC
AAATACGCAGACCTTCAATTCGAAAAGGGGACGGGCACTTATAAGATTTCACAAGA
GAAGTACAACGACATCAAGAAAAAGGAAGGGGTCGATTCAGATTCGGAGTTCAAAT
TCACCCTCTACAAAAACGACCTCCTGCTTGTGAAGGACACAGAAACGAAGGAGCAG
CAGCTCTTTCGGTTCCTCTCACGCACGATGCCCAAACAAAAACATTACGTCGAACTT
AAACCTTACGATAAGCAAAAGTTTGAAGGGGGAGAGGCACTGATCAAAGTATTGGG TAACGTAGCCAATAGCGGACAGTGTAAGAAAGGGCTGGGAAAGTCCAATATCTCGA
TCTATAAAGTACGAACAGATGTATTGGGAAACCAGCATATCATCAAAAATGAGGGG
GATAAACCCAAACTCGATTTCAAGCGTCCTGCTGCTACTAAGAAAGCTGGTCAAGCT
AAGAAAAAGAAATAA
[00335] > U6-St_tracrR A(7-97)
[00336] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGTTACTTAAATCTTGCAGAAGCTACAAAGA
TAAGGCTTCATGCCGAAATCAACACCCTGTCATTTTATGGCAGGGTGTTTTCGTTATT
TAA
[00337] >EMX 1 _T ALEN Left
[00338] ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTA
CAAAGACGATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCAC
GGAGTCCCAGCAGCCGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGA
AAAGATCAAGCCCAAAGTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGG
GTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCCTGCAGCCCTTG
GCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACAT
GAGGCGATCGTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCT
GTTGACGGTCGCGGGAGAGCTGAGAGGGCCTCCCCTTCAGCTGGACACGGGCCAGT
TGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGG
CGCAATGCGCTCACGGGAGCACCCCTCAACCTGACCCCAGAGCAGGTCGTGGCAAT
TGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTG
TGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCAAC
CACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCA
AGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACATCGGGGGAA
AGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGG
TTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACT
CGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAG
AGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTC CAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGT
GGCAATTGCGAGCAACATCGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGC
TGCCTGTGCTGTGCCAAGCGCACGGACTTACACCCGAACAAGTCGTGGCAATTGCG
AGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCT
GTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACG
GGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCG
C AC GG ACT AAC CCC AG AGC AGGTC GTGGC AATTGC G AGC AAC ATC GGGGG AAAGC A
GGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTGA
CCCCAGAGCAGGTCGTGGCAATTGCGAGCAACATCGGGGGAAAGCAGGCACTCGAA
ACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAGAGCA
GGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGA
GGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCA
ATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCC
TGTGCTGTGCCAAGCGCACGGACTCACGCCTGAGCAGGTAGTGGCTATTGCATCCAA
CAACGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCCAGCTTTCGAGGCCGGACC
CCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGAC
GACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAG
CGGACCAACAGAAGGATTCCCGAGAGGACATCACATCGAGTGGCAGGTTCCCAACT
CGTGAAGAGTGAACTTGAGGAGAAAAAGTCGGAGCTGCGGCACAAATTGAAATACG
TACCGCATGAATACATCGAACTTATCGAAATTGCTAGGAACTCGACTCAAGACAGA
ATCCTTGAGATGAAGGTAATGGAGTTCTTTATGAAGGTTTATGGATACCGAGGGAAG
CATCTCGGTGGATCACGAAAACCCGACGGAGCAATCTATACGGTGGGGAGCCCGAT
TGATTACGGAGTGATCGTCGACACGAAAGCCTACAGCGGTGGGTACAATCTTCCCAT
CGGGCAGGCAGATGAGATGCAACGTTATGTCGAAGAAAATCAGACCAGGAACAAA
CACATCAATCCAAATGAGTGGTGGAAAGTGTATCCTTCATCAGTGACCGAGTTTAAG
TTTTTGTTTGTCTCTGGGCATTTCAAAGGCAACTATAAGGCCCAGCTCACACGGTTG
AATCACATTACGAACTGCAATGGTGCGGTTTTGTCCGTAGAGGAACTGCTCATTGGT
GGAGAAATGATCAAAGCGGGAACTCTGACACTGGAAGAAGTCAGACGCAAGTTTAA
CAATGGCGAGATCAATTTCCGCTCA
[00339] >EMX 1 _T ALEN Right [00340] ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTA
CAAAGACGATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCAC
GGAGTCCCAGCAGCCGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGA
AAAGATCAAGCCCAAAGTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGG
GTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCCTGCAGCCCTTG
GCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACAT
GAGGCGATCGTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCT
GTTGACGGTCGCGGGAGAGCTGAGAGGGCCTCCCCTTCAGCTGGACACGGGCCAGT
TGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGG
CGCAATGCGCTCACGGGAGCACCCCTCAACCTGACCCCAGAGCAGGTCGTGGCAAT
TGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTG
TGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCAAC
CACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCA
AGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGA
AAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGG
GTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACATCGGGGGAAAGCAGGCAC
TCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAG
AGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTC
CAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGT
GGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGC
TGCCTGTGCTGTGCCAAGCGCACGGACTTACACCCGAACAAGTCGTGGCAATTGCG
AGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCT
GTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACG
GGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCG
CACGGACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGC
AGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTG
ACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCG
AAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAGAG
CAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCA
GAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGG
CAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTG CCTGTGCTGTGCCAAGCGCACGGACTCACGCCTGAGCAGGTAGTGGCTATTGCATCC
AACGGAGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCCAGCTTTCGAGGCCGGA
CCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGG
ACGACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTA
AGCGGACCAACAGAAGGATTCCCGAGAGGAATCACATCGAGTGGCAGGTTCCCAAC
TCGTGAAGAGTGAACTTGAGGAGAAAAAGTCGGAGCTGCGGCACAAATTGAAATAC
GTACCGCATGAATACATCGAACTTATCGAAATTGCTAGGAACTCGACTCAAGACAG
AATCCTTGAGATGAAGGTAATGGAGTTCTTTATGAAGGTTTATGGATACCGAGGGAA
GCATCTCGGTGGATCACGAAAACCCGACGGAGCAATCTATACGGTGGGGAGCCCGA
TTGATTACGGAGTGATCGTCGACACGAAAGCCTACAGCGGTGGGTACAATCTTCCCA
TCGGGCAGGCAGATGAGATGCAACGTTATGTCGAAGAAAATCAGACCAGGAACAAA
CACATCAATCCAAATGAGTGGTGGAAAGTGTATCCTTCATCAGTGACCGAGTTTAAG
TTTTTGTTTGTCTCTGGGCATTTCAAAGGCAACTATAAGGCCCAGCTCACACGGTTG
AATCACATTACGAACTGCAATGGTGCGGTTTTGTCCGTAGAGGAACTGCTCATTGGT
GGAGAAATGATCAAAGCGGGAACTCTGACACTGGAAGAAGTCAGACGCAAGTTTAA
CAATGGCGAGATCAATTTCCGCTCA
Example 9
Cloning (construction) of AA V constructs
[00341] construction of AAV-promoter-TALE-effector backbone. For construction of AAV-promoter-TALE-effector a backbone was cloned by standard subcloning methods. Specifically, the vector contained an antibiotics resistance gene, such as ampicillin resistance and two AAV inverted terminal repeats (itr's) flanking the promoter-TALE-effector insert (sequences, see below). The promoter (hSyn), the effector domain (VP64, SID4X or CIB1 in this example)/ the N- and C-terminal portion of the TALE gene containing a spacer with two typellS restriction sites (Bsal in this instance) were subcloned into this vector. To achieve subcloning, each DNA component was amplified using polymerase-chain reaction and then digested with specific restriction enzymes to create matching DNA sticky ends. The vector was similarily digested with DNA restriction enzymes. All DNA fragments were subsequently allowed to anneal at matching ends and fused together using a ligase enzyme.
[00342] Assembly of individual TALEs into AAV-promoter-TALE-effector backbone.
For incorporating different TALE monomer sequences into the AAV-promoter-TALE-effector backbone described above, a strategy based on restriction of individual monomers with type IIS restriction enzymes and ligation of their unique overhangs to form an assembly of 12 to 16 monomers to form the final TALE and ligate it into the AAV-promoter-TALE-effector backbone by using the type IIS sites present in the spacer between the N- and C-term (termed golden gate assembly). This method of TALE monomer assembly has previously been described by us (NE Sanjana, L Cong, Y Zhou, M M Cunniff, G Feng & F Zhang A transcription activator-like effector toolbox for genome engineering Nature Protocols 7, 171-192 (2012) doi: 10.1038/nprot.2011.431)
[00343] By using the general cloning strategy outlined above, AAV vectors containing different promoters, effector domains and TALE monomer sequences can be easily constructed.
[00344] Nucleotide Sequences:
[00345] Left AAV ITR
[00346] cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcc cggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct
[00347] Right AAV ITR
[00348] Aggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgc ccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagg
[00349] hSyn promoter
[00350] gtgtctagactgcagagggccctgcgtatgagtgcaagtgggttttaggaccaggatgaggcggggtgggggtgcctac ctgacgaccgaccccgacccactggacaagcacccaacccccattccccaaattgcgcatcccctatcagagagggggaggggaaaca ggatgcggcgaggcgcgtgcgcactgccagcttcagcaccgcggacagtgccttcgcccccgcctggcggcgcgcgccaccgccgcc tcagcactgaaggcgcgctgacgtcactcgccggtcccccgcaaactccccttcccggccaccttggtcgcgtccgcgccgccgccggc ccagccggaccgcaccacgcgaggcgcgagataggggggcacgggcgcgaccatctgcgctgcggcgccggcgactcagcgctgc ctcagtctgcggtgggcagcggaggagtcgtgtcgtgcctgagagcgcagtcgagaa
[00351] TALE N-term (+136 AA truncation)
[00352] GTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAA
GCCCAAAGTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGT
TTACACATGCCCACATCGTAGCCTTGTCGCAGCACCCTGCAGCCCTTGGCACGGTCG
CCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATC
GTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGT
CGCGGGAGAGCTGAGAGGGCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGA TCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGGCGCAATGC
GCTCACGGGAGCACCCCTCAAC
[00353] TALE C-term (+63 AA truncation)
[00354] CGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCC TGCCTCGGCGGACGACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCC TGCATTGATTAAGCGGACCAACAGAAGGATTCCCGAGAGGACATCACATCGAGTGG CA
[00355] Ampicillin resistance gene
[00356] atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtga aagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgcccc gaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgcc gcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtg ctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatg ggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagca atggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagtt gcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgca gcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatc gctgagataggtgcctcactgattaagcattgg
Example 10
Optical Control of Endogenous Mammalian Transcription
[00357] The ability to directly modulate transcription of the endogenous mammalian genome is critical for elucidating normal gene function and disease mechanisms. Here, Applicants describe the development of Light-Inducible Transcriptional Effectors (LITEs), a two-hybrid system integrating the customizable TALE DNA-binding domain with the light-sensitive cryptochrome 2 protein and its interacting partner CIB1 from Arabidopsis thaliana. LITEs can be activated within minutes, mediating reversible bidirectional regulation of endogenous mammalian gene expression as well as targeted epigenetic chromatin modifications. Applicants have applied this system in primary mouse neurons, as well as in the brain of awake, behaving mice in vivo. The LITE system establishes a novel mode of optogenetic control of endogenous cellular processes and enables direct testing of the causal roles of genetic and epigenetic regulation.
I l l [00358] The dynamic nature of gene expression enables cellular programming, homeostasis, and environmental adaptation in living systems. Dissecting the contributions of genes to cellular and organismic function therefore requires an approach that enables spatially and temporally controlled modulation of gene expression. Microbial and plant-derived light-sensitive proteins have been engineered as optogenetic actuators, enabling the use of light - which provides high spatiotemporal resolution - to control many cellular functions (Deisseroth, K. Optogenetics. Nature methods 8, 26-29, doi: 10.1038/nmeth.f.324 (2011); Zhang, F. et al. The microbial opsin family of optogenetic tools. Cell 147, 1446-1457, doi: 10.1016/j .cell.2011.12.004 (2011); Levskaya, A., Weiner, O. D., Lim, W. A. & Voigt, C. A. Spatiotemporal control of cell signalling using a light- switchable protein interaction. Nature 461, 997-1001, doi: 10.1038/nature08446 (2009); Yazawa, M., Sadaghiani, A. M., Hsueh, B. & Dolmetsch, R. E. Induction of protein-protein interactions in live cells using light. Nature biotechnology 27, 941- 945, doi: 10.1038/nbt. l569 (2009); Strickland, D. et al. TULIPs: tunable, light-controlled interacting protein tags for cell biology. Nature methods 9, 379-384, doi: 10.1038/nmeth.l904 (2012); Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth. l524 (2010); Shimizu-Sato, S., Huq, E., Tepperman, J. M. & Quail, P. H. A light-switchable gene promoter system. Nature biotechnology 20, 1041-1044, doi: 10.1038/nbt734 (2002); Ye, H., Daoud-El Baba, M., Peng, R. W. & Fussenegger, M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 332, 1565-1568, doi:10.1126/science.1203535 (2011); Polstein, L. R. & Gersbach, C. A. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. Journal of the American Chemical Society 134, 16480-16483, doi: 10.1021/ja3065667 (2012); Bugaj, L. J., Choksi, A. T., Mesuda, C. K., Kane, R. S. & Schaffer, D. V. Optogenetic protein clustering and signaling activation in mammalian cells. Nature methods (2013) and Zhang, F. et al. Multimodal fast optical interrogation of neural circuitry. Nature 446, 633-639, doi: 10.1038/nature05744 (2007)). However, versatile and robust technologies to directly modulate endogenous transcriptional regulation using light remain elusive.
[00359] Here, Applicants report the development of Light-Inducible Transcriptional Effectors (LITEs), a modular optogenetic system that enables spatiotemporally precise control of endogenous genetic and epigenetic processes in mammalian cells. LITEs combine the programmable DNA-binding domain of transcription activator-like effectors (TALEs) (Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509-1512, doi: 10.1126/science.l 178811 (2009) and Moscou, M. J. & Bogdanove, A. J. A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501, doi: 10.1126/science.1178817 (2009)) from Xanthomonas sp. with the light-inducible heterodimeric proteins cryptochrome 2 (CRY2) and CIB1 from Arabidopsis thaliana (Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth.l524 (2010) and Liu, H. et al. Photoexcited CRY2 interacts with CIB1 to regulate transcription and floral initiation in Arabidopsis. Science 322, 1535-1539, doi: 10.1126/science. l 163927 (2008)). They do not require the introduction of heterologous genetic elements, do not depend on exogenous chemical co-factors, and exhibit fast and reversible dimerization kinetics (Levskaya, A., Weiner, O. D., Lim, W. A. & Voigt, C. A. Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature 461, 997-1001, doi: 10.1038/nature08446 (2009); Yazawa, M., Sadaghiani, A. M., Hsueh, B. & Dolmetsch, R. E. Induction of protein-protein interactions in live cells using light. Nature biotechnology 27, 941-945, doi: 10.1038/nbt.l569 (2009), Kennedy, M. J. et al. Rapid blue-light- mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth. l524 (2010); Shimizu-Sato, S., Huq, E., Tepperman, J. M. & Quail, P. H. A light-switchable gene promoter system. Nature biotechnology 20, 1041-1044, doi: 10.1038/nbt734 (2002) and Liu, H. et al. Photoexcited CRY2 interacts with CIB1 to regulate transcription and floral initiation in Arabidopsis. Science 322, 1535-1539, doi: 10.1126/science. l 163927 (2008)). Like other optogenetic tools, LITEs can be packaged into viral vectors and genetically targeted to probe specific cell populations. Applicants demonstrate the application of this system in primary neurons as well as in the mouse brain in vivo.
[00360] The LITE system contains two independent components (FIG. 36A): The first component is the genomic anchor and consists of a customized TALE DNA-binding domain fused to the light-sensitive CRY2 protein (TALE-CRY2). The second component consists of CIB1 fused to the desired transcriptional effector domain (CIB1 -effector). To ensure effective nuclear targeting, Applicants attached a nuclear localization signal (NLS) to both modules. In the absence of light (inactive state), TALE-CRY2 binds the promoter region of the target gene while CIB1 -effector remains free within the nuclear compartment. Illumination with blue light (peak -450 nm) triggers a conformational change in CRY2 and subsequently recruits CIBl -effector (VP64 shown in FIG. 36A) to the target locus to mediate transcriptional modulation. This modular design allows each LITE component to be independently engineered. For example, the same genomic anchor can be combined with activating or repressing effectors (Beerli, R. R., Segal, D. J., Dreier, B. & Barbas, C. F., 3rd. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proceedings of the National Academy of Sciences of the United States of America 95, 14628-14633 (1998) and Cong, L., Zhou, R., Kuo, Y.-c, Cunniff, M. & Zhang, F. Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun 3, 968) to exert positive and negative transcriptional control over the same endogenous genomic locus.
[00361] In order to identify the most effective LITE architecture, Applicants fused TALE and the transcriptional activator VP64 (Beerli, R. R., Segal, D. J., Dreier, B. & Barbas, C. F., 3rd. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proceedings of the National Academy of Sciences of the United States of America 95, 14628-14633 (1998); Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 29, 149-153, doi: 10.1038/nbt. l775 (2011); Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nature biotechnology 29, 143- 148, doi: 10.1038/nbt. l755 (2011) and Hsu, P. D. & Zhang, F. Dissecting neural function using targeted genome engineering technologies. ACS chemical neuroscience 3, 603-610, doi: 10.1021/cn300089k (2012).) to different truncations (Kennedy, M. J. et al. Rapid blue-light- mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth.l524 (2010)) of CRY2 and CIBl, respectively, and assessed the efficacy of each design by measuring blue light illumination induced transcriptional changes of the neural lineage-specifying transcription factor neurogenin 2 {Neurogl) (FIG. 36B). Applicants evaluated full-length CRY2 as well as a truncation consisting of the photolyase homology region alone (CRY2PHR, amino acids 1-498) (Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth. l524 (2010)). For CIBl, Applicants tested the full-length protein as well as an N-terminal domain-only fragment (CIBN, amino acids 1-170) (Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi:10.1038/nmeth.l524 (2010)). 3 out of 4 initial LITE pairings produced significant light-induced Neurog2 mRNA upregulation in Neuro 2a cells (p < 0.001, FIG. 36B). Of these, TALE-CRY2PHR::CIB1-VP64 yielded the highest absolute light-mediated mRNA increase when normalized to either GFP-only control or unstimulated LITE samples (FIG. 36B), and was therefore applied in subsequent experiments.
[00362] Having established an effective LITE architecture, Applicants systematically optimized light stimulation parameters, including wavelength (FIG. 40), duty cycle (FIG. 41), and light intensity (FIG. 42 and Example 11) (Banerjee, R. et al. The signaling state of Arabidopsis cryptochrome 2 contains flavin semiquinone. The Journal of biological chemistry 282, 14916-14922, doi: 10.1074/jbc.M700616200 (2007)). Applicants also compared the activation domains VP 16 and p65 in addition to VP64 to test the modularity of the LITE CIB1- effector component. All three domains produced a significant light-dependent Neurog2 mRNA upregulation (p < 0.001, FIG. 43). Applicants selected VP64 for subsequent experiments due to its lower basal activity in the absence of light-stimulation.
[00363] Manipulation of endogenous gene expression presents various challenges, as the rate of expression depends on many factors, including regulatory elements, mRNA processing, and transcript stability (Moore, M. J. & Proudfoot, N. J. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136, 688-700, doi: 10.1016/j.cell.2009.02.001 (2009) and Proudfoot, N. J., Furger, A. & Dye, M. J. Integrating mRNA processing with transcription. Cell 108, 501-512 (2002)). Although the interaction between CRY2 and CIB1 occurs on a subsecond timescale (Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth.l524 (2010)), LITE- mediated activation is likely to be limited by the inherent kinetics of transcription. Applicants investigated the on-kinetics of LITE -mediated Neurogl expression by measuring mRNA levels during a time course of light stimulation from 30 min to 24 h (FIG. 36C). Relative levels of Neurogl mRNA increased considerably as early as 30 min after the onset of light stimulation and rose steadily until saturating at 12 h with a roughly 20-fold upregulation compared to GFP- transfected negative controls. Similarly, Applicants assessed the off-kinetics of the system by stimulating cells for 6 h and measuring the level of Neurogl transcripts at multiple time points after ceasing illumination (FIG. 36D). Neurogl mRNA levels briefly increased up to 30 min post-stimulation, an effect that may have resulted from residual CRY2PHR-CIB 1 dimerization or from previously recruited RNA polymerases. Thereafter, Neurog2 expression declined with a half-life of ~3 h, demonstrating that transcripts return to natural levels in the absence of light stimulation. In contrast, a small-molecule inducible TALE system based on the plant hormone abcisic acid receptor (Liang, F.-S., Ho, W. Q. & Crabtree, G. R. Engineering the ABA Plant Stress Pathway for Regulation of Induced Proximity. Sci. Signal. 4, rs2-, doi: 10.1126/scisignal.2001449 (2011)) exhibited slower on- and off-kinetics (FIG. 44), potentially limited by drug diffusion, metabolism, or clearance.
[00364] Applicants next explored the utility of LITEs for neuronal applications via viral transduction. Applicants developed an adeno-associated virus (AAV)-based vector for the delivery of TALE genes and a simplified process for AAV production (FIGS. 37A and B, FIG. 45, and Example 11). The ssDNA-based genome of AAV is less susceptible to recombination, providing an advantage over lentiviral vectors (Holkers, M. et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic acids research 41, e63, doi: 10.1093/nar/gksl446 (2013)).
[00365] To characterize AAV-mediated TALE delivery for modulating transcription in primary mouse cortical neurons, Applicants constructed a panel of TALE-VP64 transcriptional activators targeting 28 murine loci in all, including genes involved in neurotransmission or neuronal differentiation, ion channel subunits, and genes implicated in neurological diseases. DNase I-sensitive regions in the promoter of each target gene provided a guide for TALE binding sequence selections (FIG. 46). Applicants confirmed that TALE activity can be screened efficiently using Applicants' AAV -TALE production process (FIG. 45) and found that TALEs chosen in this fashion and delivered into primary neurons using AAV vectors activated a diverse array of gene targets to varying extents (FIG. 37C). Moreover, stereotactic delivery of AAV- TALEs mediated robust expression in vivo in the mouse prefrontal cortex (FIG. 37D, E). Expression of TALE(Grm2)-VP64 in the mouse infralimbic cortex (ILC) induced a 2.5-fold increase in Grm2 mRNA levels compared to GFP-injected controls (FIG. 37F).
[00366] Having delivered TALE activators into cultured primary neurons, Applicants next sought to use AAV as a vector for the delivery of LITE components. To do so, Applicants needed to ensure that the total viral genome size of each recombinant AAV, with the LITE transgenes included, did not exceed the packaging limit of 4.8 kb (Wu, Z., Yang, H. & Colosi, P. Effect of Genome Size on AAV Vector Packaging. Mol Ther 18, 80-86 (2009)). Applicants shortened the TALE N- and C-termini (keeping 136 aa in the N-terminus and 63 aa in the C- terminus) and exchanged the CRY2PHR (1.5kb) and CIBl (lkb) domains (TALE-CIBl and CRY2PHR-VP64; FIG. 38A). These LITEs were delivered into primary cortical neurons via co- transduction by a combination of two AAV vectors (FIG. 38B; delivery efficiencies of 83-92% for individual components with >80% co-transduction efficiency). Applicants tested a Grm2- targeted LITE at 2 light pulsing frequencies with a reduced duty cycle of 0.8%> to ensure neuron health (FIG. 47). Both stimulation conditions achieved a ~7-fold light-dependent increase in Grm2 mRNA levels (FIG. 38C). Further study verified that substantial target gene expression increases could be attained quickly (4-fold upregulation within 4 h; FIG. 38D). In addition, Applicants observed significant upregulation of mGluR2 protein after stimulation, demonstrating that changes effected by LITEs at the mRNA level translate to the protein level (p < 0.01 vs GFP control, p < 0.05 vs no-light condition; FIG. 38E).
[00367] To apply the LITE system in vivo, Applicants stereotactically delivered a 1 : 1 mixture of high concentration AAV vectors (1012 DNAsel resistant particles/mL) carrying the Grm2- targeting TALE-CIBl and CRY2PHR-VP64 LITE components into ILC of wildtype C57BL/6 mice. To provide optical stimulation of LITE-expressing neurons in vivo, Applicants implanted a fiber optic cannula at the injection site (FIG. 38F and FIG. 48) (Zhang, F. et al. Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. Nat Protoc 5, 439-456, doi: 10.1038/nprot.2009.226 (2010)). Neurons at the injection site were efficiently co-transduced by both viruses, with >80%> of transduced cells expressing both TALE(Grm2)- CIB1 and CRY2PHR-VP64 (FIG. 38G and FIG. 49). 8 days post-surgery, Applicants stimulated the ILC of behaving mice by connecting a solid-state 473 nm laser to the implanted fiber cannula. Following a 12 h stimulation period (5 mW, 0.8%> duty cycle using 0.5 s light pulses at 0.0167 Hz), brain tissue from the fiber optic cannula implantation site was analyzed (FIG. 38H) for changes in Grm2 mRNA. Applicants observed a significant increase in Grm2 mRNA after light stimulation compared with unstimulated ILC (p < 0.01). Taken together, these results confirm that LITEs enable optical control of endogenous gene expression in cultured neurons and in vivo.
[00368] Due to the persistence of basal up-regulation observed in the no-light condition of in vivo LITE activators, Applicants undertook another round of optimization, aiming to identify and attenuate the source of the background and improve the efficiency of light-mediated gene induction (light/no-light ratio of gene expression). Neurons expressing only the LITE targeting component TALE-CIBl produced Grm2 mRNA increases similar to those found in unstimulated neurons expressing both LITE components (both p < 0.001 versus GFP controls), while the effector component CRY2PHR-VP64 alone did not significantly affect transcription (p > 0.05, FIG. 50), implying that the background transcriptional activation caused by LITE could arise solely from the DNA targeting component.
[00369] Accordingly, Applicants carried out a comprehensive screen to reduce the basal target up-regulation caused by TALE-CIBl (FIG. 51). The optimization focused on two strategies: First, CIB1 is a plant transcription factor and may have intrinsic regulatory effects even in mammalian cells (Liu, H. et al. Photoexcited CRY2 Interacts with CIB1 to Regulate Transcription and Floral Initiation in Arabidopsis. Science 322, 1535-1539, doi: 10.1126/science.1163927 (2008)). Applicants sought to eliminate these effects by deleting three CIB 1 regions conserved amongst the basic helix-loop-helix transcription factors of higher plants (FIG. 51). Second, Applicants aimed to prevent TALE-CIBl from binding the target locus in the absence of light. To achieve this, Applicants engineered TALE-CIBl to localize in cytoplasm until light-induced dimerization with the NLS -containing CRY2PHR-VP64 (FIG. 52). To test both strategies independently or in combination, Applicants evaluated 73 distinct LITE architectures and identified 12 effector-targeting domain pairs (denoted by the "+" column in FIG. 51 and FIG. 53) with both improved light-induction efficiency and reduced overall baseline (fold mRNA increase in the no-light condition compared with the original LITE 1.0; p < 0.05). One architecture incorporating both strategies, designated LITE2.0, demonstrated the highest light induction (light/no-light = 20.4) and resulted in greater than 6-fold reduction of background activation compared with the original architecture (FIG. 381). Another - LITE 1.9.1 - produced a minimal background mRNA increase (1.06) while maintaining four- fold light induction (FIG. 53).
[00370] Applicants sought to further expand the range of processes accessible by TALE and LITE modulation. Endogenous transcriptional repression is often mediated by chromatin modifying enzymes such as histone methyltransferases (HMTs) and deacetylases (HDACs). Applicants have previously shown that the mSin3 interaction domain (SID), part of the mSin3- HDAC complex, can be fused with TALE in order to down regulate target genes in 293FT cells (Beerli, R. R., Segal, D. J., Dreier, B. & Barbas, C. F., 3rd. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proceedings of the National Academy of Sciences of the United States of America 95, 14628-14633 (1998) and Cong, L., Zhou, R., Kuo, Y.-c, Cunniff, M. & Zhang, F. Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun 3, 968,
Figure imgf000121_0001
Hoping to further improve this TALE repressor, Applicants reasoned that four repeats of SID - analogous to the quadruple VP16 tandem repeat architecture of VP64 (Beerli, R. R., Segal, D. J., Dreier, B. & Barbas, C. F., 3rd. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proceedings of the National Academy of Sciences of the United States of America 95, 14628-14633 (1998)) - might augment its potency to repress gene transcription. Indeed, TALE-SID4X constructs were twice as effective as TALE-SID in 293FT cells (FIG. 54 A and 54B) and also mediated efficient gene repression in neurons (FIG. 54C and 54D).
[00371] Applicants hypothesized that TALE-mediated targeting of histone effectors to endogenous loci could induce specific epigenetic modifications, enabling the interrogation of epigenetic as well as transcriptional dynamics (FIG. 39A). Applicants generated CRY2PHR- SID4X constructs and demonstrated light-mediated transcription repression of Grm2 in neurons (FIG. 39B and FIG. 39C), concomitant with ~2-fold reduction in H3K9 acetylation at the targeted Grm2 promoter (FIG. 39D). In an effort to expand the diversity of histone residue targets for locus specific histone modification, Applicants derived a set of repressive histone effector domains from the literature (Table 6). Drawn from across a wide phylogenetic spectrum, the domains included HDACs, histone methyltransferases (HMTs), and histone acetyltransferase (HAT) inhibitors, as well as HDAC and HMT recruiting proteins. Preference was given to proteins and functional truncations of small size to facilitate efficient AAV packaging. The resulting epigenetic-modifying TALE-histone effector fusion constructs (epiTALEs) were tested in primary neurons and Neuro 2a cells for their ability to repress Grm2 and Neurog2 transcription, respectively (FIG. 39E, FIG. 39F and FIG. 55). In primary neurons, 23 out of 24 epiTALEs successfully repressed transcription of grm2 using the statistical criteria of p < 0.05. Similarly, epiTALE expression in Neuro 2a cells led to decreased Neurog2 expression for 20 of the 32 histone effector domains tested (p < 0.05). A subset of promising epiTALEs were expressed in primary neurons and Neuro 2a cells and relative histone residue mark levels in the targeted endogenous promoter were quantified by ChlP-RT-qPCR (FIG. 39G, FIG. 39H and FIG. 56). In primary neurons or Neuro 2a cells, levels of H3K9mel, H4K20me3, H3K27me3, H3K9ac, and H4K8ac were altered by epiTALEs derived from, respectively, KYP (A. thaliana), TgSET8 (T. gondii), NUE and PHF19 (C. trachomatis and H. sapiens), Sin3a, Sirt3 and NcoR, (all H. sapiens) and hdac8, RPD3, and Sir2a (X laevis, S cerevisiae, P falciparum). These domains provide a ready source of epigenetic effectors to expand the range of transcriptional and epigenetic controls by LITE.
[00372] The ability to achieve spatiotemporally precise in vivo gene regulation in heterogeneous tissues such as the brain would allow researchers to ask questions about the role of dynamic gene regulation in processes as diverse as development, learning, memory, and disease progression. LITEs can be used to enable temporally precise, spatially targeted, and bimodal control of endogenous gene expression in cell lines, primary neurons, and in the mouse brain in vivo. The TALE DNA binding component of LITEs can be customized to target a wide range of genomic loci, and other DNA binding domains such as the RNA-guided Cas9 enzyme (Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819- 823 (2013)) may be used in lieu of TALE to enable versatile locus-specific targeting (FIG. 57). Novel modes of LITE modulation can also be achieved by replacing the effector module with new functionalities such as epigenetic modifying enzymes (de Groote, M. L., Verschure, P. J. & Rots, M. G. Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic acids research 40, 10596-10613, doi: 10.1093/nar/gks863 (2012)). Therefore the LITE system enables a new set of capabilities for the existing optogenetic toolbox and establishes a highly generalizable and versatile platform for altering endogenous gene regulation using light.
[00373] Methods Summary. LITE constructs were transfected into in Neuro 2A cells using GenJet. AAV vectors carrying TALE or LITE constructs were used to transduce mouse primary embryonic cortical neurons as well as the mouse brain in vivo. RNA was extracted and reverse transcribed and mRNA levels were measured using TaqMan-based RT-qPCR. Light emitting diodes or solid-state lasers were used for light delivery in tissue culture and in vivo respectively. 100374| Design and construction of LITEs. All LITE constructs sequences can be found in Example 11.
[00375] Neuro 2a culture and experiments. Neuro 2a cells (Sigma-Aldrich) were grown in media containing a 1 : 1 ratio of OptiMEM (Life Technologies) to high-glucose DMEM with GlutaMax and Sodium Pyruvate (Life Technologies) supplemented with 5% HyClone heat- inactivated FBS (Thermo Scientific), 1% penicillin/streptomycin (Life Technologies), and passaged at 1 :5 every 2 days. 120,000 cells were plated in each well of a 24-well plate 18-20 h prior to transfection. 1 h before transfection, media was changed to DMEM supplemented with 5% HyClone heat-inactivated FBS and 1% penicillin/streptomycin. Cells were transfected with 1.0 μg total of construct DNA (at equimolar ratios) per well with 1.5 μΐ, of GenJet (SignaGen Laboratories) transfection reagent according to the manufacturer's instructions. Media was exchanged 24 h and 44 h post-transfection and light stimulation was started at 48 h. Stimulation parameters were: 5 mW/cm2, 466 nm, 7 % duty cycle (1 s light pulse 0.067 Hz) for 24 h unless indicated otherwise in figure legends. RNA was extracted using the RNeasy kit (Qiagen) according to manufacturer's instructions and 1 μg of RNA per sample was reverse-transcribed using qScript (Quanta Biosystems). Relative mRNA levels were measured by quantitative realtime PCR (qRT-PCR) using TaqMan probes specific for the targeted gene as well as GAPDH as an endogenous control (Life Technologies, see Table 3 for Taqman probe IDs). AACt analysis was used to obtain fold-changes relative to negative controls transduced with GFP only and subjected to light stimulation. Toxicity experiments were conducted using the LIVE/DEAD assay kit (Life Technologies) according to instructions.
[00376] AAV vector production. 293FT cells (Life Technologies) were grown in antibiotic- free D10 media (DMEM high glucose with GlutaMax and Sodium Pyruvate, 10% heat- inactivated Hyclone FBS, and 1% 1M HEPES) and passaged daily at 1 :2-2.5. The total number of passages was kept below 10 and cells were never grown beyond 85% confluence. The day before transfection, lxl 06 cells in 21.5 mL of D10 media were plated onto 15 cm dishes and incubated for 18-22 hours or until -80% confluence. For use as a transfection reagent, 1 mg/mL of PEI "Max" (Polysciences) was dissolved in water and the pH of the solution was adjusted to 7.1. For AAV production, 10.4 μg of pDF6 helper plasmid, 8.7 μg of pAAVl serotype packaging vector, and 5.2 μg of pAAV vector carrying the gene of interest were added to 434 μΐ^ of serum-free DMEM and 130 μί of PEI "Max" solution was added to the DMEM-diluted DNA mixture. The DNA/DMEM/PEI cocktail was vortexed and incubated at room temperature for 15 min. After incubation, the transfection mixture was added to 22 mL of complete media, vortexed briefly, and used to replace the media for a 15 cm dish of 293FT cells. For supernatant production, transfection supernatant was harvested at 48 h, filtered through a 0.45 μιη PVDF filter (Millipore), distributed into aliquots, and frozen for storage at -80°C.
[00377] Primary cortical neuron culture. Dissociated cortical neurons were prepared from C57BL/6N mouse embryos on E16 (Charles River Labs). Cortical tissue was dissected in ice- cold HBSS - (50 mL lOx HBSS, 435 mL dH20, 0.3 M HEPES pH 7.3, and 1% penicillin/streptomycin). Cortical tissue was washed 3X with 20 mL of ice-cold HBSS and then digested at 37°C for 20 min in 8 mL of HBSS with 240 of 2.5% trypsin (Life Technologies). Cortices were then washed 3 times with 20 mL of warm HBSS containing 1 mL FBS. Cortices were gently triturated in 2 ml of HBSS and plated at 150,000 cells/well in poly-D-lysine coated 24-well plates (BD Biosciences). Neurons were maintained in Neurobasal media (Life Technologies), supplemented with IX B27 (Life Technologies), GlutaMax (Life Technologies) and 1% penicillin/streptomycin.
[00378] Primary neuron transduction and light stimulation experiments. Primary cortical neurons were transduced with 250 of AAVl supernatant on DIV 5. The media and supernatant were replaced with regular complete neurobasal the following day. Neurobasal was exchanged with Minimal Essential Medium (Life Technologies) containing IX B27, GlutaMax (Life Technologies) and 1% penicillin/streptomycin 6 days after AAV transduction to prevent formation of phototoxic products from HEPES and riboflavin contained in Neurobasal during light stimulation.
[00379] Light stimulation was started 6 days after AAV transduction (DIV 11) with an intensity of 5 mW/cm2, duty cycle of 0.8% (250 ms pulses at 0.033Hz or 500 ms pulses at 0.016Hz), 466 nm blue light for 24 h unless indicated otherwise in figure legends. RNA extraction and reverse transcription were performed using the Cells-to-Ct kit according to the manufacturers instructions (Life Technologies). Relative mRNA levels were measured by quantitative real-time PCR (qRT-PCR) using TaqMan probes as described above for Neuro 2a cells.
[00380] Immunohistochemistry of primary neurons. For immunohistochemistry of primary neurons, cells were plated on poly-D-lysine/laminin coated coverslips (BD Biosciences) after harvesting. AAV 1 -transductions were performed as described above. Neurons were fixed 7 days post-transduction with 4% paraformaldehyde (Sigma Aldrich) for 15 min at RT. Blocking and permeabilization were performed with 10% normal goat serum (Life Technologies) and 0.5% Triton-XlOO (Sigma-Aldrich) in DPBS (Life Technologies) for 1 h at room temperature. Neurons were incubated with primary antibodies overnight at 4°C, washed 3X with DPBS and incubated with secondary antibodies for 90 min at RT. For antibody providers and concentrations used, see Table 4. Covers lips were finally mounted using Prolong Gold Antifade Reagent with DAPI (Life Technologies) and imaged on an Axio Scope A. l (Zeiss) with an X-Cite 120Q light source (Lumen Dynamics). Image were acquired using an AxioCam MRm camera and Axio Vision 4.8.2.
[00381] Western Blots. For preparation of total protein lysates, primary cortical neurons were harvested after light stimulation (see above) in ice-cold lysis buffer (RIP A, Cell Signaling; 0.1 % SDS, Sigma-Aldrich; and cOmplete ultra protease inhibitor mix, Roche Applied Science). Cell lysates were sonicated for 5 min at 'M' setting in a Bioruptor sonicator (Diagenode) and centrifuged at 21,000 x g for 10 min at 4°C. Protein concentration was determined using the RC DC protein assay (Bio-Rad). 30-40 μg of total protein per lane was separated under non- reducing conditions on 4-15% Tris-HCl gels (Bio-Rad) along with Precision Plus Protein Dual Color Standard (Bio-Rad) After wet electrotransfer to polyvinylidene difluoride membranes (Millipore) and membrane blocking for 45 min in 5% BLOT-QuickB locker (Millipore) in Tris- buffered saline (TBS, Bio-Rad), western blots were probed with anti-mGluR2 (Abeam, 1 : 1.000) and anti-a-tubulin (Sigma-Aldrich 1 :20,000) overnight at 4°C, followed by washing and anti- mouse-IgG HRP antibody incubation (Sigma-Aldrich, 1 :5,000 - 1 : 10,000). For further antibody details see Table 4. Detection was performed via ECL Western blot substrate (SuperSignal West Femto Kit, Thermo Scientific). Blots were imaged with an Alphalmager (Innotech) system, and quantified using ImageJ software 1.46r.
[00382] Production of concentrated and purified AAV1/2 vectors. Production of concentrated and purified AAV for stereotactic injection in- vivo was done using the same initial steps outlined above for production of AAVl supernatant. However, for transfection, equal ratios of AAVl and AAV2 serotype plasmids were used instead of AAVl alone. 5 plates were transfected per construct and cells were harvested with a cell-scraper 48 h post transfection. Purification of AAV 1/2 particles was performed using HiTrap heparin affinity columns (GE Healthcare) (McClure, C, Cole, K. L., Wulff, P., Klugmann, M. & Murray, A. J. Production and titering of recombinant adeno-associated viral vectors. J Vis Exp, e3348, doi: 10.3791/3348 (2011)). Applicants added a second concentration step down to a final volume of 100 μΐ per construct using an Amicon 500 μΐ concentration column (100 kDa cutoff, Millipore) to achieve higher viral titers. Titration of AAV was performed by qRT-PCR using a custom Taqman probe for WPRE (Life Technologies). Prior to qRT-PCR, concentrated AAV was treated with DNasel (New England Biolabs) to achieve a measurement of DNasel -resistant particles only. Following DNasel heat-inactivation, the viral envelope was degraded by proteinase K digestion (New England Biolabs). Viral titer was calculated based on a standard curve with known WPRE copy numbers.
[00383] Stereotactic injection of AAV1/2 and optical implant. All animal procedures were approved by the MIT Committee on Animal Care. Adult (10-14 weeks old) male C57BL/6N mice were anaesthetized by intraperitoneal (i.p.) injection of Ketamine/Xylazine (100 mg/kg Ketamine and 10 mg/kg Xylazine) and pre-emptive analgesia was given (Buprenex, 1 mg/kg, i.p.). Craniotomy was performed according to approved procedures and Ιμΐ of AAVl/2 was injected into ILC at 0.35/1.94/-2.94 (lateral, anterior and inferior coordinates in mm relative to bregma). During the same surgical procedure, an optical cannula with fiber (Doric Lenses) was implanted into ILC unilaterally with the end of the optical fiber located at 0.35/1.94/-2.64 relative to bregma. The cannula was affixed to the skull using Metabond dental cement (Parkell Inc) and Jet denture repair (Lang dental) to build a stable cone around it. The incision was sutured and proper post-operative analgesics were administered for three days following surgery.
[00384] Immunohistochemistry on ILC brain sections. Mice were injected with a lethal dose of Ketamine/Xylazine anaesthetic and transcardially perfused with PBS and 4% paraformaldehyde (PFA). Brains were additionally fixed in 4% PFA at 4°C overnight and then transferred to 30% sucrose for cryoprotection overnight at room temperature. Brains were then transferred into Tissue -Tek Optimal Cutting Temperature (OCT) Compound (Sakura Finetek) and frozen at -80°C. 18 μιη sections were cut on a cryostat (Leica Biosystems) and mounted on Superfrost Plus glass slides (Thermo Fischer). Sections were post-fixed with 4% PFA for 15 min, and immunohistochemistry was performed as described for primary neurons above.
[00385] Light stimulation and mRNA level analysis in ILC. 8 days post-surgery, awake and freely moving mice were stimulated using a 473 nm laser source (OEM Laser Systems) connected to the optical implant via fiber patch cables and a rotary joint. Stimulation parameters were the same as used on primary neurons: 5 mW (total output), 0.8% duty cycle (500 ms light pulses at 0.016 Hz) for a total of 12 h. Experimental conditions, including transduced constructs and light stimulation are listed in Table 5.
[00386] After the end of light stimulations, mice were euthanized using C02 and the prefrontal cortices (PFC) were quickly dissected on ice and incubated in RNA later (Qiagen) at 4°C overnight. 200 μιη sections were cut in RNA later at 4°C on a vibratome (Leica Biosystems). Sections were then frozen on a glass coverslide on dry ice and virally transduced ILC was identified under a fluorescent stereomicroscope (Leica Ml 65 FC). A 0.35 mm diameter punch of ILC, located directly ventrally to the termination of the optical fiber tract, was extracted (Harris uni-core, Ted Pella). The brain punch sample was then homogenized using an RNase- free pellet-pestle grinder (Kimble Chase) in 50 μΐ Cells-to-Ct RNA lysis buffer and RNA extraction, reverse transcription and qRT-PCR was performed as described for primary neuron samples.
[00387] Chromatin Immunoprecipitation. Neurons or Neuro2a cells were cultured and transduced or transfected as described above. ChIP samples were prepared as previously described (Blecher-Gonen, R. et al. High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. N ' ature protocols 8, 539-554 (2013)) with minor adjustments for the cell number and cell type. Cells were harvested in 24-well format, washed in 96-well format, and transferred to microcentrifuge tubes for lysis. Sample cells were directly lysed by water bath sonication with the Biorupter sonication device for 21 minutes using 30s on/off cycles (Diagenode). qPCR was used to assess enrichment of histone marks at the targeted locus.
[00388] Statistical analysis. All experiments were performed with a minimum of two independent biological replicates. Statistical analysis was performed with Prism (GraphPad) using Student's two-tailed t-test when comparing two conditions, ANOVA with Tukey's post- hoc analysis when comparing multiple samples with each other, and ANOVA with Dunnett's post-hoc analysis when comparing multiple samples to the negative control.
Example 11 Supplementary Information to Example 10: Optical Control of Endogenous Mammalian
Transcription
100389| Photostim illation Hardware - in vitro. In vitro light stimulation experiments were performed using a custom built LED photostimulation device. All electronic elements were mounted on a custom printed circuit board (ExpressPCB). Blue LEDs with peaks 466 nm (model #: YSL-R542B5C-A11, China Young Sun LED Technology; distributed by SparkFun Electronics as 'LED - Super Bright Blue' COM-00529), were arrayed in groups of three aligned with the wells of a Corning 24-well plate. LED current flow was regulated by a 25 mA DynaOhm driver (LEDdymanics #4006-025). Columns of the LED array were addressed by TTL control (Fairchild Semiconductor PN2222BU-ND) via an Arduino UNO microcontroller board. Light output was modulated via pulse width modulation. Light output was measured from a distance of 80 mm above the array utilizing a Thorlabs PM100D power meter and S120VC photodiode detector. In order to provide space for ventilation and to maximize light field uniformity, an 80 mm tall ventilation spacer was placed between the LED array and the 24-well sample plate. Fans (Evercool EC5015M12CA) were mounted along one wall of the spacer unit, while the opposite wall was fabricated with gaps to allow for increased airflow.
[00390] Quantification of LIVE/DEAD® assay using ImageJ software. Images of LIVE/DEAD (Life Technologies) stained cells were captured by fluorescence microscopy and processed as follows: Background was subtracted {Process -> Subtract Background). A threshold based on fluorescence area was set to ensure accurate identification of cell state {Image Adjust Threshold). A segmentation analysis was performed to enable automated counting of individual cells {Process -> Binary -> Watershed). Finally, debris signals were filtered and cells were counted {Analyze -> Analyze Particles). Toxicity was determined as the percentage of dead cells.
[00391] Chemically-inducible TALEs. Neuro2A cells were grown in a medium containing a 1 : 1 ratio of OptiMEM (Life Technologies) to high-glucose DMEM with GlutaMax and Sodium Pyruvate (Life Technologies) supplemented with 5% HyClone heat-inactivated FBS (Thermo Scientific), 1% penicillin/streptomycin (Life Technologies) and 25mM HEPES (Sigma Aldrich). 150,000 cells were plated in each well of a 24-well plate 18-24 hours prior to transfection. Cells were transfected with 1 μg total of construct DNA (at equimolar ratios) per well and 2 of Lipofectamine 2000 (Life Technologies) according to the manufacturer's recommended protocols. Media was exchanged 12 hours post-transfection. For the kinetics test, chemical induction was started 24 hours post-transfection, when abscisic acid (ABA, Sigma Aldrich) was added to fresh media to a final concentration of 250 μΜ. RNA was extracted using the RNeasy kit (Qiagen) according to manufacturer's instructions and 1 μg of RNA per sample was reverse- transcribed using qScript (Quanta Biosystems). Relative mRNA levels were measured by quantitative real-time PCR (qRT-PCR) using Taqman probes specific for the targeted gene as well as mouse GAPDH as an endogenous control (Life Technologies, see Supplementary Table 2 for Taqman probe IDs). AACt analysis was used to obtain fold-changes relative to negative controls where cells were subjected to mock transfection with GFP.
[00392] Cas9 transcriptional effectors. HEK 293FT cells were co-transfected with mutant Cas9 fusion protein and a synthetic guide RNA (sgRNA) using Lipofectamine 2000 (Life Technologies) 24 hours after seeding into a 24 well dish. 72 hours post-transfection, total RNA was purified (RNeasy Plus, Qiagen). lug of RNA was reverse transcribed into cDNA (qScript, Quanta Biosciences). Quantitative real-time PCR was done according to the manufacturer's protocol (Life Technologies) and performed in triplicate using TaqMan Assays for hKlf (Hs00358836_ml), hSox2 (Hs01053049_sl), and the endogenous control GAPDH (Hs02758991_gl).
[00393] The hSpCas9 activator plasmid was cloned into a lentiviral vector under the expression of the hEFla promoter (pLenti-EFla-Cas9-NLS-VP64). The hSpCas9 repressor plasmid was cloned into the same vector (pLenti-EFla-SID4x-NLS-Cas9-NLS). Guide sequences (20bp) targeted to the KLF4 locus are: GCGCGCTCCACACAACTCAC, GCAAAAATAGACAATCAGCA, GAAGGATCTCGGCCAATTTG. Spacer sequences for guide RNAs targeted to the SOX2 locus are: GCTGCCGGGTTTTGCATGAA, CCGGGCCCGCAGCAAACTTC, GGGGCTGTCAGGGAATAAAT.
[00394] Optogenetic actuators: Microbial and plant-derived light-sensitive proteins have been engineered as optogenetic actuators, allowing optical control of cellular functions including membrane potential (Deisseroth, K. Optogenetics. Nature methods 8, 26-29, doi: 10.1038/nmeth.f.324 (2011); Zhang, F. et al. The microbial opsin family of optogenetic tools. Cell 147, 1446-1457, doi: 10.1016/j .cell.2011.12.004 (2011) and Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M. & Deisseroth, K. Optogenetics in neural systems. Neuron 71, 9-34, doi: 10.1016/j.neuron.2011.06.004 (2011)), intracellular biochemical signaling (Airan, R. D., Thompson, K. R., Fenno, L. E., Bernstein, H. & Deisseroth, K. Temporally precise in vivo control of intracellular signalling. Nature 458, 1025-1029, doi:10.1038/nature07926 (2009))_, protein interactions (Levskaya, A., Weiner, O. D., Lim, W. A. & Voigt, C. A. Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature 461, 997-1001, doi: 10.1038/nature08446 (2009); Yazawa, M., Sadaghiani, A. M., Hsueh, B. & Dolmetsch, R. E. Induction of protein-protein interactions in live cells using light. Nat Biotechnol 27, 941-945, doi: 10.1038/nbt. l569 (2009); Strickland, D. et al. TULIPs: tunable, light-controlled interacting protein tags for cell biology. Nature methods 9, 379-384, doi: 10.1038/nmeth.l904 (2012) and Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth. l524 (2010)), and heterologous gene expression (Yazawa, M., Sadaghiani, A. M., Hsueh, B. & Dolmetsch, R. E. Induction of protein-protein interactions in live cells using light. Nat Biotechnol 27, 941-945, doi: 10.1038/nbt.l569 (2009); Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nature methods 7, 973-975, doi: 10.1038/nmeth.l524 (2010); Shimizu-Sato, S., Huq, E., Tepperman, J. M. & Quail, P. H. A light-switchable gene promoter system. Nat Biotechnol 20, 1041-1044, doi: 10.1038/nbt734 (2002); Ye, H., Daoud-El Baba, M., Peng, R. W. & Fussenegger, M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 332, 1565-1568, doi:10.1126/science.1203535 (2011); Wang, X., Chen, X. & Yang, Y. Spatiotemporal control of gene expression by a light-switchable transgene system. Nature methods 9, 266-269, doi: 10.1038/nmeth. l892 (2012) and Polstein, L. R. & Gersbach, C. A. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. J Am Chem Soc 134, 16480-16483, doi: 10.1021/ja3065667 (2012)).
[00395] Ambient light exposure: All cells were cultured at low light levels (<0.01 mW/cm2) at all times except during stimulation. These precautions were taken as ambient light in the room (0.1-0.2 mW/cm2) was found to significantly activate the LITE system (FIG. 36D). No special precautions were taken to shield animals from light during in vivo experiments - even assuming ideal propagation within the implanted optical fiber, an estimation of light transmission at the fiber terminal due to ambient light was <0.01 mW (based on 200 μιη fiber core diameter and 0.22 numerical aperture).
[00396] Optimization of light stimulation parameters in Neuro2A cells: To minimize near- UV induced cytotoxicity, Applicants selected 466 nm blue LEDs to activate TALE-CRY2, a wavelength slightly red- shifted from the CRY2 absorption maxima of 450 nm but still maintaining over 80% activity (Banerjee, R. et al. The signaling state of Arabidopsis cryptochrome 2 contains flavin semiquinone. J Biol Chem 282, 14916-14922, doi: 10.1074/jbc.M700616200 (2007)) (FIG. 42). To minimize light exposure, Applicants selected a mild stimulation protocol (I s light pulses at 0.067 Hz, -7% duty cycle). This was based on Applicants' finding that light duty cycle had no significant effect on LITE-mediated transcriptional activation over a wide range of duty cycle parameters (1.7% to 100%) duty cycles, FIG. 41). Illumination with a range of light intensities from 0 to 10 mW/cm2 revealed that Ngn2 mRNA levels increased as a function of intensity up to 5 mW/cm2. However, increases in Ngn2 mRNA levels declined at 10 mW/cm2 (FIG. 36C), suggesting that higher intensity light may have detrimental effects on either LITE function or on cell physiology. To better characterize this observation, Applicants performed an ethidium homodimer-1 cytotoxicity assay with a calcein counterstain for living cells and found a significantly higher percentage of ethidium- positive cells at the higher stimulation intensity of 10 mW/cm2. Conversely, the ethidium- positive cell count from 5 mW/cm2 stimulation was indistinguishable from unstimulated controls. Thus 5 mW/cm2 appeared to be optimal for achieving robust LITE activation while maintaining low cytotoxicity.
[00397] Reduction of light-induced toxicity in primary neurons: Initial application of LITEs in neurons revealed that cultured neurons were much more sensitive to blue light than Neuro 2a cells. Stimulation parameters that Applicants previously optimized for Neuro 2a cells (466 nm, 5 mW/cm2 intensity, 7% duty cycle with 1 s light pulse at 0.067 Hz for a total of 24 h) caused >50% toxicity in primary neurons. Applicants therefore tested survival with a lower duty cycle, as Applicants had previously observed that a wide range of duty cycles had little effect on LITE-mediated transcriptional activation (FIG. 41). A reduced duty cycle of 0.8%> (0.5 s light pulses at 0.0167 Hz) at the same light intensity (5 mW/cm2) was sufficient to maintain a high survival rate that was indistinguishable from that of unstimulated cultures (FIG. 47).
[00398] Light propagation and toxicity in in vivo experiments: Previous studies have investigated the propagation efficiency of different wavelengths of light in brain tissue. For 473 nm light (wavelength used in this study), there was a >90%> attenuation after passing through 0.35 mm of tissue (Witten, liana B. et al. Recombinase-Driver Rat Lines: Tools, Techniques, and Optogenetic Application to Dopamine-Mediated Reinforcement. Neuron 72, 721-733, doi:http://dx.doi.org/l 0.1016/j .neiiron.201 1.10.028 (2011)). An estimated 5 mW/cm2 light power density was estimated based on a tissue depth of 0.35 mm of tissue (the diameter of brain punch used in this study) and a total power output of 5 mW. The light stimulation duty cycle used in vivo was the same (0.8%, 0.5 s at 0.0167 Hz) as that used for primary neurons (FIG 47).
[00399] CRY2 absorption spectrum: An illustration of the absorption spectrum of CRY2 was shown in FIG. 42. The spectrum showed a sharp drop in absorption above 480 nm (Banerjee, R. et al. The Signaling State of Arabidopsis Cryptochrome 2 Contains Flavin Semiquinone. Journal of Biological Chemistry 282, 14916-14922, doi: 10.1074/jbc.M700616200 (2007)). Wavelengths > 500 nm were virtually not absorbed, which could be useful for future multimodal optical control with yellow or red-light sensitive proteins.
[00400] Development of AAVl supernatant process: Traditional AAV particle generation required laborious production and purification processes, and made testing many constructs in parallel impractical (Grieger, J. C, Choi, V. W. & Samulski, R. J. Production and characterization of adeno-associated viral vectors. Nat Protoc 1, 1412-1428, doi: 10.1038/nprot.2006.207 (2006)). In this study, a simple yet highly effective process of AAV production using filtered supernatant from transfected 293FT cells (FIG. 43). Recent reported indicate that AAV particles produced in 293FT cells could be found not only it the cytoplasm but also at considerable amounts in the culture media (Lock M, A. M., Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM. Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale. Human Gene Therapy 21, 1259-1271, doi: 10.1089/hum.2010.055 (2010)). The ratio of viral particles between the supernatant and cytosol of host cells varied depending on the AAV serotype, and secretion was enhanced if polyethylenimine (PEI) was used to transfect the viral packaging plasmids (Lock M, A. M., Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM. Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale. Human Gene Therapy 21, 1259-1271, doi: 10.1089/hum.2010.055 (2010)). In the current study, it was found that 2xl05 293FT cells transfected with AAV vectors carrying TALEs (FIG. 38A) and packaged using AAVl serotype were capable of producing 250 μΐ of AAVl at a concentration of 5.6 ± 0.24 x 1010 DNAsel resistant genome copies (gc) per mL. 250 μΐ of filtered supernatant was able to transduce 150,000 primary cortical neurons at efficiencies of 80-90% (FIG. 38B and FIG. 43). This process was also successfully adapted to a 96-well format, enabling the production of 125 ul AAVl supernatant from up to 96 different constructs in parallel. 35ul of supernatant can then be used to transduce one well of primary neurons cultured in 96-well format, enabling the transduction in biological triplicate from a single well.
[00401] Table 3 | Product information for all Taqman probes (Life Technologies)
Target Species Probe #
Ngn2 mouse Mm00437603 gl
Grm5 (mGluR5) mouse Mm00690332_ml
Grm.2 (mGluR2) mouse Mm01235831_ml
Grin2a (NMDAR2A) mouse Mm00433802 ml
GAPD (GAPDH) mouse 4352932E
KLF4 human Hs00358836 ml
GAPD (GAPDH) human 4352934E
WPRE custom
5-HT1A mouse Mm00434106_sl
5-HT1B mouse Mm00439377_sl
5-HTT mouse Mm00439391_ml
Arc mouse Mm00479619_gl
BDNF mouse Mm04230607_sl c-Fos mouse Mm00487425_ml
CBP/P300 mouse Mm01342452_ml
CREB mouse Mm00501607_ml
CRHR1 mouse Mm00432670_ml
DNMT1 mouse Mm01151063_ml
DNMT3a mouse Mm00432881_ml
DNMT3b mouse Mm01240113_ml
egr-1 (zif-268) mouse Mm00656724_ml
Gad65 mouse Mm00484623_ml
Gad67 mouse Mm00725661_sl
GR (GCR, NR3C1 ) mouse Mm00433832_ml
HAT I mouse Mm00509140_ml
HCRTR1 mouse Mm01185776_ml
HCRTR2 mouse Mm01179312_ml
HDAC1 mouse Mm02391771_gl
HDAC2 mouse Mm00515108_ml
HDAC4 mouse Mm01299557_ml
JMJD2A mouse Mm00805000_ml
Ml (CHRM1) mouse Mm00432509_sl
MCH-R1 mouse Mm00653044_ml
NET (SLC6A2) mouse Mm00436661_ml
NR2B subunit mouse Mm00433820_ml
OXTR mouse Mm01182684_ml
Sen la mouse Mm00450580_ml
SIRT1 mouse Mm00490758 ml Tetl mouse MmOl 169087 ml
Tet2 mouse Mm00524395_ml
Tet3 mouse Mm00805756_ml
[00402] Table 4 Clone, product numbers and concentrations for antibodies used in this study
Primary Antibodies
Target Host Clone # Manufacturer Product # IsoType Concentration mGluR2 mouse mG2Na-s Abeam Ab 15672 IgG 1 : 1000 a-tubulin mouse B-5-1-2 Sigma-Aldrich T5168 IgGl 1 :20000
NeuN mouse A60 Millipore MAB377 IgGl 1 :200
HA (Alexa mouse 6E2 Cell Signaling 3444 IgGl 1 : 100
GFP chicken polyclonal Aves Labs GFP- 1020 IgY 1 :500
Target Host Conjugate Manufacturer Product # Concentration mouse IgG goat HRP Sigma-Aldrich A9917 1 :5000-10000 mouse IgG goat Alexa Fluor Life A1 1005 1 : 1000
594 Technologies
chicken IgG Goat Alexa Fluor Life A1 1039 1 : 1000
488 Technologies
Target Host Epitope Manufacturer Product # IsoType Concentration
H3K9mel mouse 1- 18 Millipore 17-680 IgG 2 μΙ/ΙΡ
H3K9me2 mouse 1- 18 Millipore 17-681 IgG 4 μΙ/ΙΡ
H3K9Ac rabbit polyclonal Millipore 17-658 IgG 3
H4K20mel rabbit 15-24 Millipore 17-651 IgG 4
H4K8Ac rabbit polyclonal Millipore 17-10099 IgG 1.5 μΙ/ΙΡ
H4K20me3 rabbit 18-22 Millipore 17-671 IgG 7 μΙ/ΙΡ
H3K27me3 rabbit polyclonal Millipore 17-622 IgG 4 μg/IP
[00403] Table 5 qPCR primers used for CHIP-qPCR
Figure imgf000134_0001
Myt-1 promoter control Cell Signaling Technologies SimpleChlP® Mouse MYT-1 Promoter
Primers #8985
RPL30 Intron 2 control Cell Signaling Technologies SimpleChlP® Mouse RPL30 Intron 2
Primers #7015
[00404] Table 6 genomic sequences targeted by TALEs
Figure imgf000135_0001
[00405] Table 7 Viral transduction and light stimulation parameters for in vivo LITE-mediated activation of Grm2 in the mouse infralimbic cortex (ILC). Grm2 mRNA levels in the ipsilateral LITE-expressing hemisphere are compared with the contralateral mCherry-expressing control hemisphere for all three experimental conditions shown in FIG. 39J.
Experimental ILC Hemisphere (ipsilateral) ILC Hemisphere condition (contralateral)
AAV vector Light AAV vector stimulation
GFP GFP yes mCherry
LITEs / no Light TALE-CIB 1 : :CRY2PHR- no mCherry
VP64
LITEs / + Light TALE-CIB 1 : :CRY2PHR- yes mCherry
VP64
[00406] Table 8 HDAC Recruiter Effector Domains
Figure imgf000136_0001
Nan, X. et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389 (1998).
Boeke, J., Ammerpohl, O., Kegel, S., Moehren, U. & Renkawitz, R. The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to
Sin3A. Journal of Biological Chemistry 275, 34963-34967 (2000).
Laherty, C D. et al. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89, 349-356 (1997).
Zhang, J., Kalkum, M., Chait, B. T. & Roeder, R. G. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2.
Molecular cell 9, 611-623 (2002).
Lauberth, S. M. & Rauchman, M. A conserved 12-amino acid motif in Salll recruits the
nucleosome remodeling and deacetylase corepressor complex. Journal of Biological
Chemistry 281, 23922-23931 (2006).
Gu, H. & Roizman, B. Herpes simplex virus-infected cell protein 0 blocks the silencing of viral
DNA by dissociating histone deacetylases from the CoREST, AiREST complex.
Ouyang, J., Shi, Y., Valin, A., Xuan, Y. & Gill, G. Direct binding of CoRESTl to SUMO-2/3 contributes to gene-specific repression by the LSDl/CoRESTl/HDAC complex.
Molecular cell 34, 145-154 (2009)
[00407] Table 9 HDAC Effector Domains
Figure imgf000136_0002
Figure imgf000137_0001
Vannier, D., Balderes, D. & Shore, D. Evidence that the transcriptional regulators SIN3 and RPD3, and a novel gene (SDS3) with similar functions, are involved in transcriptional silencing in S. cerevisiae. Genetics 144, 1343-1353 (1996).
Gregoretti, I., Lee, Y.-M. & Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. Journal of molecular biology 338, 17-31 (2004).
Gao, L., Cueto, M. A., Asselbergs, F. & Atadja, P. Cloning and functional characterization of
HDAC 11 , a novel member of the human histone deacetylase family. Journal of
Biological Chemistry 277, 25748-25755 (2002).
Wu, K., Tian, L., Malik, K., Brown, D. & Miki, B. Functional analysis of HD2 histone
deacetylase homologues in Arabidopsis thaliana. The Plant Journal 22, 19-27 (2000). Scher, M. B., Vaquero, A. & Reinberg, D. SirT3 is a nuclear NAD+-dependent histone
deacetylase that translocates to the mitochondria upon cellular stress. Genes &
development 21, 920-928 (2007).
Hnisz, D., SchwarznW°ller, T. & Kuchler, K. Transcriptional loops meet chromatin: a
dual,Aelayer network controls white, Aiopaque switching in Candida albicans. Molecular microbiology 74, 1-15 (2009).
Landry, J. et al. The silencing protein SIR2 and its homologs are NAD-dependent protein
deacetylases. Proceedings of the National Academy of Sciences 97, 5807-5811 (2000). Wilson, J. M., Le, V. Q., Zimmerman, C, Marmorstein, R. & Pillus, L. Nuclear export
modulates the cytoplasmic Sir2 homologue Hst2. EMBO reports 7, 1247-1251 (2006). Gertz, M. & Steegborn, C. Function and regulation of the mitochondrial Sirtuin isoform Sirt5 in
Mammalia. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1804, 1658-
1665 (2010).
Zhu, A. Y. et al. Plasmodium falciparum Sir2A preferentially hydro lyzes medium and long chain fatty acyl lysine. ACS chemical biology 7, 155-159 (2011). Tennen, R. I., Berber, E. & Chua, K. F. Functional dissection of SIRT6: identification of domains that regulate histone deacetylase activity and chromatin localization.
Mechanisms of ageing and development 131, 185-192 (2010).
[00408] Table 10 Histone Methyltransferase (HMT) Effector Domains
Figure imgf000138_0001
Pennini, M. E., Perrinet, S. p., Dautry-Varsat, A. & Subtil, A. Histone methylation by NUE, a novel nuclear effector of the intracellular pathogen Chlamydia trachomatis. PLoS pathogens 6, el000995 (2010).
Mujtaba, S. et al. Epigenetic transcriptional repression of cellular genes by a viral SET protein.
Nature cell biology 10, 1114-1122 (2008).
Tachibana, M., Matsumura, Y., Fukuda, M., Kimura, H. & Shinkai, Y. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. The EMBO journal 27, 2681-2690 (2008).
Snowden, A. W., Gregory, P. D., Case, C. C. & Pabo, C. O. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Current biology 12, 2159-2166
(2002).
Rathert, P., Zhang, X., Freund, C, Cheng, X. & Jeltsch, A. Analysis of the substrate specificity of the Dim-5 histone lysine methyltransferase using peptide arrays. Chemistry & biology 15, 5-11 (2008).
Jackson, J. P. et al. Dimethylation of histone H3 lysine 9 is a critical mark for DNA methylation and gene silencing in Arabidopsis thaliana. Chromosoma 112, 308-315 (2004). Thorstensen, T. et al. The Arabidopsis SUVR4 protein is a nucleolar histone methyltransferase with preference for monomethylated H3K9. Nucleic acids research 34, 5461-5470 (2006).
Vielle, A. et al. H4K20mel Contributes to Downregulation of X-Linked Genes for C. elegans
Dosage Compensation. PLoS Genetics 8, el002933 (2012).
Couture, J.-F., Collazo, E., Brunzelle, J. S. & Trievel, R. C. Structural and functional analysis of
SET8, a histone H4 Lys-20 methyltransferase. Genes & development 19, 1455-1465
(2005).
Sautel, C. 1. F. et al. SET8-mediated methylations of histone H4 lysine 20 mark silent
heterochromatic domains in apicomplexan genomes. Molecular and cellular biology 27, 5711-5724 (2007).
[00409] Table 11 Histone Methyltransferase (HMT) Recruiter Effector Domains
Figure imgf000139_0001
Hathaway, N. A. et al. Dynamics and memory of heterochromatin in living cells. Cell (2012). Ballare, C. et al. Phfl9 links methylated Lys36 of histone H3 to regulation of Poly comb activity.
Nature structural & molecular biology 19, 1257-1265 (2012).
Jin, Q. et al. The protein phosphatase-1 (PP1) regulator, nuclear inhibitor of PP1 (NIPP1),
interacts with the polycomb group protein, embryonic ectoderm development (EED), and functions as a transcriptional repressor. Journal of Biological Chemistry 278, 30677-
30685 (2003).
[00410] Table 12 Histone Acetyltransferase Inhibitor Effector Domains
Figure imgf000139_0002
Cervoni, N., Detich, N., Seo, S.-B., Chakravarti, D. & Szyf, M. The oncoprotein Set/TAF-1(E< an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. Journal of Biological Chemistry 277, 25026-25031 (2002)
[00411] Supplementary Sequences
[00412] > TALE(Ngn2)- LS-C Y2
[00413] MSRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGAHHTEAATG EWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGY SQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALP EATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVH AWRNALTGAPLNLTPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASN
GGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS NGGKQALETVQRLLPVLCQAHGLT
PEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV
LCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS NGGKQA
LETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAI
ASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS NGGKQALETVQRLLPVLCQAH
GLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQR
LLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGK
QALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQV
VAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGRPALESIVAQLSRPDPA
LAALTNDHLVALACLGGRPALDAVK GLPHAPALIKRTNRRIPERTSHRVADHAQVVR
VLGFFQCHSHPAQAFDDAMTQFGMSRHGLLQLFRRVGVTELEARSGTLPPASQRWDRI
LQASGMKRAKPSPTSTQTPDQASLHAFADSLERDLDAPSPMHEGDQTRAS : S ; ; .
MKQSLAeLSQSLKALGSDLTLI THNllSAiLDCIR\ GATKVVFNHLYDPVSL'VRDHTV ! KV)^<(dS\ QS N:G !.!A \ F l L G i-TSFNSYYV Kk'C. i !)ViS!!.Sv\1i P pWk; ΡΪΤΑΑΑΕΑ1 WACSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLLNEFiEKQLIDYA
NS KVVG STSLI,SPYniFGE]SVRT:iVFQCARMK.QnWARD SEGEESADLFLR.GIGLR
EYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKF AWRQGRTGYPLVDAG RELWATG
^nlH RIRViVSSFAYK-FLLLPWKWGMKYFWDTLLDADLECDiLGWQYiSGSiPDGHEL
Figure imgf000140_0001
K-PIVDIDTARELLA AISRTREAQiMJGAAPDEiVADSFEALGANTiiEPGLCPSVSS DQ
QVPSAVRYN 3S RVKPE-EEEERDM KSRGFDERELFSTAESSSSSSVFFVSQSCSLASEG
KNXEGiQDSSDQITTSLGKNG
[00414] > TALE(Ngn2)- LS-CRY2PHR
[00415] MSRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGAHHTEAATG
EWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGY
SQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALP
EATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVH
AWRNALTGAPLNLTPEQVVAIAS NGGKQALETVQRLLPVLCQAHGLTPEQVVAIASN
GGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS NGGKQALETVQRLLPVLCQAHGLT PEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV
LCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS NGGKQA
LETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAI
ASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS NGGKQALETVQRLLPVLCQAH
GLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQR
LLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGK
QALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQV
VAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGRPALESIVAQLSRPDPA
LAALTNDHLVALACLGGRPALDAVK GLPHAPALIKRTNRRIPERTSHRVADHAQVVR
VLGFFQCHSHPAQAFDDAMTQFGMSRHGLLQLFRRVGVTELEARSGTLPPASQRWDRI
LQASGMKRAKPSPTSTQTPDQASLHAFADSLERDLDAPSPM
v? ·:·:!< 1:Μ !< TIV\ HG nUUn H:FF<;QFY kASk\V\V
MKQSLAHLSQSLKLA^LGSDLTLiKTHNTiSAILDCiRVTGAT VVFN LYDPVSLVRDHTV
KEKLVERiHSVQSYNGDLLYEPWEIYCEKGKPFTSFNSYW CLD SIESVMLPPPmL
MPJTAAAEAIWACSIEELGLE EAE PSNALLTi AWSPGWS AD LLNEFi EKQ1JDYAK SKKVTGNSTSLLSPYLHFGr^SVRIWFQCA KQHWARDKNSEGEESADLFLRGiGLR
EYS!lYiCFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPLVDAGM!lEL ATG
WMHNmVIVSSFAVKFIJJJP^
DRLDNPALQGA YDPEGEYIRQWLPELARLPTEWiHHPWDAPLTVLKASGVELGTNYA PIVDIDTARELLAKAISRTREAQIMIGAAP
[00416] > CIB1- LS-VP64_2A_GFP
[00417] MNGAIGGDLLLNFPDMSVLERQRAHL YLNPTFDSPLAGFFADSSMITGGEM SYl ¾ ] .\ :| XU'VI YGhTTY GDSkLSiSF yii (GX-XFK R KH Π'ι.Ί KiX NF KKKVH M^!RDDLVEEGEEE S FIEQN GSTKSI KMKHKAKKEEN FSNDSS VT ELE TDY1 FiVRARRGQATDSFiSIAERVRRE iSERM FLQDLVPGCDKlTGKAGMLDEilNYVQSLQ RQ] EFLSMKLAlVNPRPDFDMDDiFA EVASTPMTVVPSPEMVLSGYSHE VFJSGYSSE MVlsTSGYUWNPMQQVls SSDPLSCF^
B SGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDM
LINSRGSGEGRGSLLTCGDVEENPGPVSKGEELFTGVVPILVELDGDVNGH FSVSGEGE G ATYGKLn.kTK TT KJ iGIAV!G ΥΥΤΓΓΓΥ<Λ OC r S F Y H >j{ γ] Qi! I >FF S VII M ;( · Y VQERTIFFKDDGNY TRAEVKFEGDTLVNRIEL GiDF EDGNiLGHBLEYNYNSHNVYI MADKQ NGiKVNFKIRH JEDGSVQLADHYQQNTPiGDGPVLLPD'NHYLSTQSALSKDP
NEKi DPIMVLLEFVTAAGPrLG IlELYK
[00418] > CIBN- LS-VP64_2A_GFP
[00419] MNGAIGGDLLLNFPDMSVLERQRAHL YLNPTFDSPLAGFFADSSMITGGEM SYi .STAGI G\PYIY1 Y(; Γ1ΑΊ YYOSkLSiSPLl' i 1 <G'(-\Fk R KH >'Π·.Ί KiX Yi KKKYH MNRDDLVEEGEEE SKITEQNNGST SI AlKilKAKXEE NFS DSSKVT ELE TDYI ASPK KK RRVEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSD ALDDFDLDMLINSRGSGEGRGSLLTCGDVEENPGPVSKGEELFTGVVP1LVELDGDVNG FiKFSVSGEGF.GDATYGKI.TI,KPICTTGKIPVPWPTiA' Ti. YGVQCFSRYPDEIM .Qi-iDF FKSAMPEGYVQER11FFK DGNYKTRAEV EEGD11,A RIELKG[DFKEDGNRA3F]:KLE YNYNSH VYIMAD Q NGI VNF IRFiNIEDGSVQLADHYQQNTPIGDGPVLLPDNHY
Figure imgf000142_0001
[00420] > C1B1-NLB-VP16_2A_GFP
[00421] M GAIGGDLI .NFPI MSVLEM QRAHL YLNPLL:DSPLAGFFADSSMITGGEM
DSYLSTAGL LP M YGETTVEGDSRLSISPETTLGTGNF KRKFDTETKDC E KKKMT
MNRDDIAEEGEEEKSKJTEQNNGSTKS] K MKHKAKKEE NFS DSS VTKELEKTDYI
HVRARRGQATDSHSIAERVIULE ISERM FXQDLVTGCDKITGKAGMLDEONYVQSLQ
RQIEFI,S KJ:AIVNPRJ5DFD DDIFA EVASTPMTVVPSPEM;VF,SGYSFFEMV]-ISGYSSE
MYNSGYLF{VNPMQQYNI:'SSDPLSCFNNGEAPSMWDSHVQNLYGNLGVASPKK_KRKA
EASAPPTDVSLGDELHLDGEDVAMAHADALDDFDLDMLGDGDSPGPGFTPHDSAPYG
ALDMADFEFEQMFTDALGIDEYGGEFPGIRRSRGSGEGRGSLLTCGDVEENPGPVSK( E
EEETGVVPIFAELDGDVNGH: FSVSGEGEGDATYGKI;II.KPICTTG E VPWPTLVTTLT
Y OnSRY! Hi KO!HJHXSA
ELKGiDFKEDGNiLGHKLEY YNSHNVYIMAD QK GiKVNF JRHNiEDGSVQLADHY QQ TPiGDGPVIJ.PD FiYLSTQSAi.S DPNT RDFi Vi.LEFVTAAGiTLG DELYK.
[00422] > CIBl- LS-p65_2A_GFP
[00423] M GAJGGDLi^LNFPDMSVLERQRAHL YLNPTFDSPi^AGFFADSS ITGGE SYi .STAGI G JAIY1 Y(; ΊΑ (P)SkLSiSPE1'i 1 <GXEG;kKR KH >'Π·.Ί KiX YE KKKYH MNRDDLVEEGEEEKSKITEQNNGST SI KAlKilKAKXEE NFS DSSKVT ELE TDYI EiVRAJlRGQATOSFiSIAERVRRE iSERM FLQDLVPGCDKjTGKAGMLDEilNYVQSLQ RQIEFLSMKPAIVNPRPDFDMDDIFAKPVASTPMTVVPSPEMVLSGYSHEMVFISGYSSE
Figure imgf000143_0001
PSGOISNQAI.AI.APSSAPVI.AO VlVPSSAVlVPI.AO APAPVI.IPGPPOSI.SAPVPK STQAGEGTLSEALLHLQFDADEDLGALLGNSTDPGVFTDLASVDNSEFQQLLNQGVSMS HSTAEPMLMEYPEAITRLVTGSQRPPDPAPTPLGTSGLPNGLSGDEDFSSIADMDFSALLS
QISSSGQSRGSGEGRGSLLTCGDVEENPGPVSKC:H^B].F]X}VVP][,VELDi DVNi eKJ::SVS
GEGEGDATYG LTL FJCTTG LPVPWPTLVTTLTYGVQCFSRYPDHM QHDFF SAM
PEGYVQERTIFF DDGNY TRAEV FEGDTi.VNRiEIJ^GIDF EDGNILGiKIJiYNYNS
HNVYiMADKQKNGI VNF iRH iEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSA
I^S DPNB RDeMVIIJi-FVTAAGrriXiMDEIY
[00424] > HA-TALE(12mer)-NLS-VP64_2A_GFP
[00425] MYPYDVPDYAVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHI
V AL S QHP AALGT V AVKYQDMI AALPE ATHE AI VG VGKQ WS G ARALE ALLT V AGELRGP PLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPEQVVAIASXXGGKQALET VQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASX XGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLT PEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLP VLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQ ALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVV AIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQ AHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGRPALESI VAQLSRPDPALAALTNDHLVALACLGGRPALDAVK GLPHAPALIKRTNRRIPERTSHR VAASP R VEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLG SDALDDn>LD LI SRGSGEGRGSLLTCGDVEENPGPVSKGEELFTGVVPILVELDGDV NGHKFSVSGEGEGDAlTGKLTl FlCllOKLPVPWPl'LVIi:i;iTGVQCFSRYPDH Q HDFFKSAMPEGYrVQERTiFFKDDGNY TRAEV FEGDTL\TSTRiELKGiDFKEDGNi∑^GH KLEY Y SHNVYIMAD Q NGiKV FKJRHNiEDGSVQLADHYQQNTPiGDGPVLLPDN HYLSTQSA∑JS DPNE RDHMVLLEF\TAAG]TLGMDELY
[00426] > HA-TALE(12mer)- LS-SID4X_2A_ph.iLOV2..1
[00427] MYPYDVPDYAVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHI
V AL S QHP AALGT V AVKYQDMI AALPE ATHE AIVG VGKQ WS G ARALE ALLT V AGELRGP PLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPEQVVAIASXXGGKQALET VQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASX
XGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLT
PEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLP
VLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQ
ALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVV
AIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQ
AHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGRPALESI
VAQLSRPDPALAALTNDHLVALACLGGRPALDAVK GLPHAPALIKRTNRRIPERTSHR
YA ALK KK;. v LA ALK KK;. v LA AiSi i XiOvlU ί : A A. ; ) V I J J K I I . A 1 :Π( s V Λ S Ml ( ·
SGMNIQ LLEAADYLER E EAEHGYAS LPGSGMNIQ LLEAADYLE E EAEHG
YASMLPGSGMNiQMLLEAADYLERREREAEHGYASMLPSRSRGSGEGRGSLLTCGDVE
ENPGPn;;K ;Vm>PRLPDYP:nFASDGFn
DAIRDQRETTVQLINYT SG FW LLHLQPVRDR GGLQYFIGVQLVGSDHV
[00428] > HA-TALE(12mer)-NLS-CIB1
[00429] MYPYDVPDYAVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHI
V AL S QHP AALGT V AVKYQDMI AALPE ATHE AI VG VGKQ WS G ARALE ALLT V AGELRGP
PLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPEQVVAIASXXGGKQALET
VQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASX
XGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLT
PEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLP
VLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQ
ALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVV
AIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQ
AHGLTPEQVVAIASXXGGKQALETVQRLLPVLCQAHGLTPEQVVAIASXXGGRPALESI
VAQLSRPDPALAALTNDHLVALACLGGRPALDAVK GLPHAPALIKRTNRRIPERTSHR
VAASP KKR YEASNGAIGGDLLL FPDMSVLERQRAHL YLNPIPDSPLAGFFADSS
ITGGEMDSYLSTAGLNLPMMYGETT\'TGDSRLSiSPETTLGTGNFKKR .FDTETKDCNE
Figure imgf000144_0001
LEKTDYieVRARIlGQATDSHSIAEIWRREKISERM FLQDLVPGCDKFrGKAGMLDEIIN
VVQSFQkQlFJI Sv! !.AlV\P P!)ri)V:i)FH!- VAS!P VA PSPL Vj S YSHiY! v!i
SGYSSEMV SGYLHVNPMQQVNTSSDPLSCFNNGEAPSMWDSHVQNLYGNLGV [00430] > CRY2PHR- LS-VP64_2A_GFP
[00431] M MD KTIVWFRRDLRIED PAT.AAAAHEGSVFPVFIWCPEEEGQFYPGRAS K\\ \\ Y1KQS1 Λ I n.SQSI ΚΛ1 GSIH I 1 JKYl VilSAii j }i*!R YTGAT V Y i '\Ί 11 Y r YSi YR DlU \^ U ! ^:=K^SVQSY\(H)!.i VLlAVHiVC UK KPiAAFXSY VKkCi DVfMLSVVH.pp
Figure imgf000145_0001
DYAK SBK GNSTSLLSPYLHFGEiSVRHVFQCARMKQHWARD NSEGEESADLFLR GIG∑^REY¾RY]CFNFPFTHEQSII^SFiLRFFPWDADVDKFKA\^.QGRTGYPLVDA.GM EL WATGWMHNRIRViVSSFAV FLLLPWKWGM YFWDTLLDADLECDlLGWQYiSGSiPD
Figure imgf000145_0002
TNYAKPiVDIDTARELLAKAiSRTI EAQiMIGAAPASP KXRKVEASGSGRADALDDFDL DMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRGSGEGRGSLLTC GDVEENPGPVS GEELFTGVVPILVELDGDVNGiiKFSVSGEGEGDATYGKLTLKFiCTr GBLPVPWPTXVT LTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKT
pΛl vKF!:(k) Ί Y\KllJ Κ(5Π} Κ!;ΐ)(<\πχ<1Π· : 1 Y\Y\SΠYVY! vlAI>KQK\(:ik\ \Pk!
RHKf EDGSVQLADHYQQ TPIGDGPV'LLPD HYLSTQSALS DP EKLRDH VLLEFVTA AGITLGM DEL Y V
[00432] > CRY2PHR-NLS-SID4X_2AjphiLOV2.1
[00433] M MDKKTlVWFRRDLRIEDNPALAAAAHEGSVFPVFiWCPEEEGQFYPGRAS R MKQSLAHLSQSL ALGSDLTLI THNTiSAlLDCiRVTGAT V^'FNFiLYDPVSLVR DHTVKEKIA/ERGISVQSYNGDLLYEPWEIYCE G PFTSFNSYWKR LDMSIESVMLPP PWi AIPf i'A AA FA1\YA< 'Si Li J X.Ai .AAA FKPSY l F TR A\YSP< VSX nK FFYi FI KQFi DYAKNS3 WGNSTSLLSPYLHFGEISVRHVFQCARIvl QnWARDiCNSEGEESADLFLR GKO-IUiYS YK NFPFTIiEQS LLS ffi,RF FP W
WATGWMHNRIRV^VSSFAV FLLLP KWGMKYFWDTLLDADLECDILG QYiSGSiPD
GFiEi^DRI NPAi^QGAK O EGEYiRQWi^PEi RI TEWn^irlP^OAPL VI^ASGVFJ-
TNYA PIVDIDTARELLA AiSRTREAQiMlGAAPAS XKRKVEASGSGMNIQMLLEAA
DYLERREREAEHGYASMLPGSGMNIQMLLEAADYLERREREAEHGYASMLPGSGMNIQ
MLLEAADYLERREREAEHGYASMLPGSGMNIQMLLEAADYLERREREAEHGYASMLP
SRSRGSGEGRGSLLTCGDVEENPGPIE SFVITDPRLPDYPIIFASDGFLELTEYSREEIMG
R ARFLQGPETDQATVQ JRDAiRDQRE TV'QLINYT SG KirWNLLHLQPVRDR GGL
QYFiGVQLVGSDHV [00434] > TALE( X 4)-NLS-OY2PFIR
[00435] MSRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGAHHTEAATG
EWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGY
SQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALP
EATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVH
AWRNALTGAPLNLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIASH
DGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLT
PEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLP
VLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQ
ALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVV
AIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQA
HGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQ
RLLPVLCQAHGLTPEQVVAIASHDGGRPALESIVAQLSRPDPALAALTNDHLVALACLG
GRPALDAVK GLPHAPALIKRTNRRIPERTSHRVADHAQVVRVLGFFQCHSHPAQAFDD
AMTQFGMSRHGLLQLFRRVGVTELEARSGTLPPASQRWDRILQASGMKRAKPSPTSTQ
TPDQ ASLHAF ADSLERDLD APSPMHEGDQTRAS A S P RKRK YE A S MDKK.T I V W PR RD
LRIEDNPALAAAAHEGSVFPVFl WCPEEEGQFYPGRASRWVVM QSLAIILSQSLKALGS
DLTLIK NTJSAJLDCIRA' GATKVVFNHLYDPVSi^VRDHTVKE LVERGlSVQSYNGD J Yi:P\VH) V('|; (i PI; I SF\SY WRKC UYvtSniSY tU xYR!A P! ! AAAfLAi Y Ai SH-HL
GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLiDYAKNS3£KWGNSTSLLSPYL
EiFGEISVRHVFQCARMKQHWAilJD SEGEESADLFLRGiGLREYSRYiCiTSiFPFl iEQSL
LSHLRFFPWDADVD F AWRQGRTGYPLVDAGMRELWATGWMHNRIRViVSSFAV F
Figure imgf000146_0001
EYIRQ LPELARLPTEWIHHPWDAPLTVLKASGV LGTNYAKPIVDiDTARELLAKAiSR
TREAQ!MIGAAP
[00436] > HA- LS-TALE(pi /, N 136}-SID
[00437] MYPYDVPDYASP KKR !VIiASVDLRTLGYSQQQQEKJKPKVRSTVAQffi-iEA IA G!iG!- i HA!UX Ai SQj ίΡΑΛΙ ;ΤΥΑΥΚΥΟί> ίΛΑί.!;ΗΛ'1 j Ι ί ν(5ν(Π ( ^ S(;AIIA1 HA LLTVAGELRGPPLQLDTGQIJ^ JAKRGGVTAVEAVeAWRNAIYrGAPLNLTPEQVVAIA SNNGGKQALEn QRLLPVLCQAFIGLTPEQVVAIASHDGGKQALEn QRLLPVLCQAFIG LTPEQVVAIASHDGGKQALEWQRLLPVLCQAHGLTPEQVVAiASNGGGKQALETVQR LLPVLCQAHGLTPEQVVAlASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAiASHDGG
KQALETVQRI .PVLCQAHGLTPEQVVAJASeDGGKQALETVQRLLPVLCQAHGLTPEQ
VVAIASHDGG QAi ri QRLLPVLCQAHGLTPEQVVAIASNGGG QAi n QRLLPVL
CQAHGLTPEQVVAIASHDGG QALETVQRLLPVLCQAHGLTPEQVVAIASHDGG QAL
Ί'νθΚΙ! PVl ('QAHGl Ί PPQVVAlASX!G(:kOAi FTVOPLLPYPC OA; KHPTPLQYVAIA
SN GGKQALETVQRLLPVLCQAHGLTPEQVVAiASN GGKQALETVQRLLPVLCQAHG
FT!^QYVAjASBDGGKQALH vQRU PYi 'QAnGGlPHQY VAiASXGGGKQAI.L'i vQK
LLPVLCQAHGLTPEQV^^AL\SHDGG QALETVQRLLPVLCQAHGLTPEQVVAiASHDGG QALE QRLLPVLCQAHGLTPEQVVAIASHDGGRPALES1VA.QLSRPDPALAALTNDH
LVALACLGGRPALDAV GLPHAPALIKRTORRIPERTSHRVADHAQVVRVLGFFQCHS
HPAQAFDDAMTQFGMSRHGLLQLFRRVG\7TELEARSGTLPPASQRWDRILQASGM RA
KPSPl'SI^QlI ^QASIJiAP'ADSI-.ERDLDAPSPM EijDQll^ASASGSGMNIQMLLEAADYL
ERREREAEHGYASMLP.
[00438] > HA- LS-TALE(p/i, N136)-SID4X
[00439] MYPYDVPDYASP KR VEASVDLRTLGYSQQQQEKLI P VRSTVAQHHEA
LVG GFTHAH]VALSQHPAALGTVAA7 YQDMiAALPEATHEAIVGVG QWSGARALEA
LL AGELRGPPLQLDTGQLL IAKRGGVTAV AVHAWRNALTGAPLNLTPEQVVAiA
SXAGGKQA!AI vQK) P \ I.C 'GAB EIPHGYv Ai Si IDGGKQA!AI vQK) FPYLC 'GAHG
LTPEQ VV Al ASHDGGKQ ALETVQRLLPYLC. ;Q AHGLTPEQ VVAI ASNGGGKQALE1 A QR
LLPVLCQAHGLTPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGG
KQAPLl YQkFl YiXQ ! I i rPkQYV IASI iDGGKQALi.l vQkPP vLrOAn Gf kQ
WAiASBDGGKQALETVQRLL VLCQAHGLTPEQWAiASNGGGKQALETVQRLLPVL
(•QAn( ;r!' QV AP\Sni) (PvC^\LiG VQRj.i.PYi.C Q A I K = Ρ1Ί : Q\ P \S Π 1 )(R · EC) A ί
ETVQRLLPVLCQAHGLTPEQVVAIAS iGGKQALEWQRLLPVLCQAHGLTPEQVVAiA
SN GG QALE QRLLPVLCQAHGLTPEQVVAIASN GG QALE QRLLPVLCQAHG
LTPEQVVAIASHDGGKQALEIAQRLLPVLCQA GL1PEQVVAIASNGGGKQALE1'VQR
IIJ5VI :QABGi;PPEQVVAIASFfDC: iK.ClA:[,ETVQRIIJ5VLCQABGI. PEQVVAIASBDGG
KOAPkTYQPLPPVi ( QA! iGi.l PPOVX A! AS! H H RdlPALPSi VAQi SPPDPALAAf 'i'XGl i
[A/AEACLGGRPALDAVKKGLPHAPALIKR NRRIPERTSFIRVADHAQVVRVLGFFQCFIS
HP QAFDDAMTQFGMSRHGLLQLFRRVG\TO^^^
KPSPTSTQTPDQASLBAFADSLERDLDAPSPMHEGDQTRASASGSGMNIQMLLEAADYL ERREREAEHGYASMLPGSGMNIQMLLEAADYLERREREAEHGYASMLPGSGMNIQML LEAADYLERREREAEHGYASMLPGSGMNIQMLLEAADYLERREREAEHGYASMLPSR
[00440] >HA-TALE(?jgl C63i-GS-cibl-r- RNLS
[00441] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA
; Π ΓΠ.ΑΛΊ GR DRVQSCR JIAARR\PRP1 M 11 Λ V 1 Λ Λ R RPR A K. R A R R R R A AO PS I > A SPA Λ
QVDLRTLGYSQQQQE IKPKVRSTVAQ HEALVGHGFTHAHIVALSQ PAALGTVAVK
Figure imgf000148_0001
G\ AVEAVHA RNALTGAPLNLTPEQVVAIASNGGG QALETVQRLLP'VLCQAHGLTP
EQVVAIASN GG QALE QRLLPVLCQAFiGLTPEQVVAIASNiGGKQALETVQRi.LPV
LCQAHGLTPEQVVA]ASNiGG .QALETVQRLLPVLCQAEIGLTPEQVVAiAS GGG .QAL
ETVQRLLPVLCQAHGLTPEQVVAIASN^GG QALETVQRLLPVLCQAHGLTPEQVVAiA
S G KQAR! TYQRi RPYR< 'OA j ( j/i'PHOV I ASXGGGKQ i J IA;Qk ί RPYR< 'QA! K;R
TPEQVVAIASNNGG QALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLL
PVf ( ( AMCR •! lR:QVVA!AS\(RKR<OARR rVQRRR!'V i ( QA! R 'i RRQ A AsASAKR KQ
ALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA
iASXGG KQAi.L 1 YQkRRPYRAQAi A'RHQYV A RASA iGkQAi H YYQRRRRVS ί ΟΑΠ
GLTPEQVVAiASHDGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAV .
GLPEIAPAI.I RTNRR.IPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR
AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNF AAKPDTETKDCNEAAKKMTMNRDDLVEEGEEEKSKITEQISnSiGSTKSIKK
MKHK^AKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF
LQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAS
TPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEA
PSMWDSHVQNLYGNLGV
[00442] > HA-TALE(«g2, C63)- NES-cibl-rm;RN L8
[00443] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HiiTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAA QYDL rLGYSQQQQEIOK KA^
YQDMiAALPEATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLL ]AKRG
G\ AVELAVHAWRNALTGAPLNLTPEQVVAL\SNGGG QALETVQRLLPVLCQAHGLTP
EQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV LCQAHGLTPEQVVAiAS GGKQALETVQRLLPVLCQAFfGLTPEQVVAlASNGGGKQAL
ETVQRII VLCQAHGLTPEQVVAiASN GG QA∑ iTVQRJJ. VI QAHGLTPEQVVAIA
S GGKQAI J.'i YQki 1 PYPX 'OA j (Gh Π'ΗΟΥ ΥΛ I SXGGGKQ i J IA;Qk ί l.PYLi "QAi ;GL
TPEQVVAIASNNGG QALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLL
Figure imgf000149_0001
ALETVQRLLPVLCQAHGLTPEQWAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA
lASNGGGKQAEETVQRIXPVLCQAHGLTPEQVVAIAS
Gl/rPEQVVAlASHDGGRPALESIVAQLSRPDPALAALI^NDHLVALACLGGRPALDAV K GLPiiAPAIJ TNRRIPERTSiiRVAASiA E i. Rii^TNGAIGGDLLLNFPDMSVLERQRA HLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPET TLGTGNFK KFDTETKDCNE
KHKAKKEE NFSND S SKVTKELEKTD YIH VRARRGQ ATD SH SI AERVRREKI SERMKFL QDLVPGCDKITGKAGMLDEIF YVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAST PMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEAP SMWDSHVQNLYGNLGV
[00444] > HA-TALE(«g2, C63)-mNES-cibl-muiNLS
[00445] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HiiTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAA QVDLRTLGYSQQQQE JKPKVRSTVAQHBEALVGBGFTBABIV'ALSQHPAALGTVAV
YQDMiAALPEATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLL ]AKRG
G\ AVELAVHAWRNALTGAPLNLTPEQVVALASNGGG QALETVQRLLPVLCQAHGLTP
EQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV
!\C (AAMCd•! l :QVVA!AS\K:GKQA!J: 'VORLi PV1 QOAnGl . nXOVAYGASNGGGKQA I.
ETVQRLLPVLCQAHGLTPEQVVAiAS NGGKQALETVQRLLPVLCQAeGLl EQVVAIA
SNKXiKQAEETYQRIXPVLCQAHGLTPEQVVA
TPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAiASNIGGKQALETVQRLL PVLCQAHGLTPEQV^^AIASNGGG QA∑ i QRJJ. VLCQAFiGLTPEQVVAIASNiGG .Q Λ1 TVQRiJ PVi ( OAiiGi 1 PLOV\ A!AS\K-GRQAI J 1 Y Qk 1 1 ΡΧ .< 'Q HG i .T kQY V A iASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAJASNIGG QALETVQRLLPVLCQAH
Figure imgf000149_0002
GLPHAPALI RTNRRIPERTSHRVAASLQLPPLERLTLNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNFKAAKFDTETKDCNE AKKMTMNRDDLVEEGEEEKSKITEQNNGSTKSIKK
MKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF
LQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAS
TPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEA
PSMWDSHVQNLYGNLGV
[00446] > HA-TALE(«g2, C63)-ptic2NES-cibl-m¾i LS
[00447] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA
HiiTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAA
QVDLRTLGYSQQQQE JKPKVRSTVAQHBEALVGBGFTBABIV'ALSQHPAALGTVAV'
YQDMiAALPEATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLL ]AKRG
G\ AVELAVHAW NALTGAPLNLTPEQVVAL\SNGGG QALETVQRLLPVLCQAHGLTP
EQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV
Figure imgf000150_0001
ETVQRLLPVLCQAHGLTPEQVVAiAS NGGKQALETVQRLLPVLCQAeGLl EQVVAIA
SMGiiKQALL 1 νί,ίΚΐ 1 r\ KC'QAl K n;HQY V A L^SAiiGii QALL 1 νί,ίΚΐ 1 PM.C'QAI sK
TPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAiASNIGGKQALETVQRLL
PVLCQAHGLTPEQV^^AIASNGGG QA∑ i QRJJ. VL€QAFiGLTPEQVVAIASNiGG .Q
ALETVQilLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA iASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAJASNIGG QALETVQRLLPVLCQAH
GLTH ^VVAIAS; 1Π = ΡΡ Ι J^Si v AQI SRi )i L l.'Γ\l)l ΗΛΆί.Λί ί Gki'Ai DAY K
GLPHAPALI RTNRRIPERTSHRVAASLDLASLiLNGAIGGDLLLNFPDMSVLERQRAHL
KYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPETTL
Figure imgf000150_0002
KAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKFLQD LVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVASTPM TVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEAPSM WDSHVQNLYGNLGV
[00448] > HA-TALE(/ig2, C63)-mapkkNES-cibl-imitNIA
[00449] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HHTEAATGEWDEVQSGLRAADAPPPTNIRVAVTAARPPRAKPAPRRRAAQPSDASPAA QVDL TLGYSQQQQE JKPKVRSTVAQHBEALVGBGF1¾AB1V'ALSQHPAALGTVAV' S QGMiAAi PLAY! UYAI GYGLQ\VS AKALLAi.L ; Y AG PL K PR) QL YGOL; K!A PG G\ AVELAVHAWRNALTGAPLNLTPEQV^
EQVVA1ASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV
LC (X\n<d•!l :QVVA!AS\ :GKQA!J:'!'VOkLi PV1 ('QAHGl Ί P^OVVΛl S^ (: KQ i.
E QRLLPVLCQAHGLTPEQVVAIASNTSTGG QALETVQRLLPVLCQAHGLTPEQVVAIA
SNiGGKQALL 1 νί,ίΚΐ 1 P\ PC'Q I K3 n;IYJY VALASYGGGKQALL 1 νί,ίΚΐ 1 PX'PC'Q I KsL
TPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAiASNIGGKQALETVQRLL
PVLCQAHGLTPEQV^^AIASNGGG QA∑ i QRiJ. VLCQAHGLTPEQVVAIASNiGG .Q
ALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA
iASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAJASNIGG QALETVQRLLPVLCQAH
<d•!l :QYV !ASnn (:RP !J:Siv AQf SPPi)PALAA ί GGkPAi DAY K
GLPHAPALI RTNRRIPERTSHRVAASLQKJ LEELELNGAIGGDLLLNFPDMSVLERQRA
HLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPET
TLGTGNFKAAKEDTC
KHKAKKEE NFSND S SKVTKELEKTD YIH VRARRGQ ATD SH SI AERVRREKI SERMKFL QDLVPGCDKITGKAGMLDEILNYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAST PMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEAP SMWDSHVQNLYGNLGV
[00450] > HA-TALE(/ig2, C63)-GS-ciblA3-miuNLS
[00451] YPYD DYASRTRLPSPPAPSPAFSADSI^DLLRQFDPSLFNTSLFDSLPPFGA HHTEAATGEWDEVQSGLRAADAPPPTNIRVAVTAARPPRAKPAPRRRAAQPSDASPAA QYGLkl LGYSC >QlXn<H<YRSTYAOn
YQD liAALPEATHEAiV lV l .QWSGAiL\LEALLTVAGELRGPPLQLDTGQLL IAKRG G AVF VHAWRNAI GAPLNLTPEQVVAIASNGGGK.QALETVQRLL VLCQAHGLTP EQVVAiAS NGGKQALETVQRLLPVLCQAeGLTPEQV'VAIAS'NIGGKQALE Qi LLP'V
Figure imgf000151_0001
LYYQkLi PY1 COWi SGI RLOYYAI S YGGRQALL YYQki 1.PYI.COA j iGLTPHOYYA IA SNiGGKQALEWQRLLPVLCQAHGLTPEQVVAJASNGGGKQALEWQRLLPVLCQAHGL TPEQVVAiASNNGG QALErVQRI PViX:QAHGUrPEQVVAiAS :iGGKQALE'rVQRLL PVLCQAHGLTPEQVVAIASNGGG QALETVQRLLPVLCQAHGLTPEQVVAiASNiGGKQ ALETVQilLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQ LLPVLCQAHGLTPEQVVA iAS GGGKQALETVQRLLPVLCQAHGLTPEQWA^^
Figure imgf000152_0001
GLPHAPALI RTNRRIPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE TTLGTGNFKAA^
MKHK^AKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF LQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAS TPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSS
[00452] > HA-TALE(jjg2, C63)-wNLS-ciblA3-mui LS
[00453] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA iiKrELA.ATGEWiDEVQSGiJ AADAPPPTMRVAVTAARPPRA PAJ^RRAAQPSDASPAA
QVDLRTLGYSQQQQEKI P VRSTVAQH EALVGHGFT A IVALSQHPAALGTVAVK.
Figure imgf000152_0002
GVTAVEAVHAWRNALTGAPLNLTPEQVVAIAS'NGGGKQALETVQRLLPVLCQAHGLTP
EQWAIASNNGGKQALETVQRi VLCQATriGLTPEQVVAJAS GG QALE QRLLPV
LCQAHGLTPEQVVAlASN!GG QALETVQRELPVLCQAHGl/rPEQVVAlAS GGG QAL
Figure imgf000152_0003
SNlGG QALElTQRLLPVLCQAHGLI'PEQVVAIASNGGGKQALE':rVQRLLPVLCQAHGL
TPEQVVAIASNNGGKQALETVQRLLPVLCQABGLTPEQVVAIAS IGG QALETVQRLL
PVLCQAi iLlTEQVVAiASNGGG QALETVQRLiJ^LCQAI- iLTPEQVVAIASNIGG Q
ALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQWA
! S\(: (:KO ! 1· rVQPIJ JA'I ( QA! Ka/i PPQ A Ai SNKi KQALP rVQRi ! PYLCQAM
GLTPEQVVAIASHDGGRPALESIVAQLSRPDPALAALl'NDeLVALACLGGRPALDAVK
C .:P]-iAPA.iJKRTNRRiPERTSi:IRVAASI,YPERI;RRII,TNGAIGGDLLLNFPDMSVLERQRA
HLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPET
TLGTGNFK AKTDTETKT>CNE
KHKAKKEE NFSND S SKVTKELEKTD YIH VRARRGQ ATD SH SI AERVRREKI SERMKFL QDLVPGCDKITGKAGMLDEIF YVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAST PMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSS
[00454] > HA-TALE(«g2, C63)-mNLS-ciblA3-.mui LS [00455] YPYDVPDYASRT LPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA ill EAATGEWDEVQSGIJ AADAPPPTMRAAVTAARPPRA PAPRRRAAC^PSDASPAA QVDLRTLGYSQQQQE I P YRSϊVAQί:IHEAL GHGFΊΉAHIVALSQί:IPAAI 3Ί ?AVK YQDMIAALPEATeEAlVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLL IA RG ; Y" (A v L A V Π A \Y R\ Λ ί 1 ( LX!:r!' QV iAS?x(RH5KC^Ll1 vQKi LPX'l.i *θ Π(·ΡΤΡ
EQVVA:LASNNGG QAIXTVQRL:LPVIX:QAHGLTPEQVVAIASNIGGKQALETVQRLLPV
! ( VAHii! -r EOVv AlASN! CdxOAl ΙΠΑ ΟΚΕΐ. νΙ.ί QANGU PLi.A ΥΛ! ASAG G!XOA)
ETVQilLLPVLCQAHGLIPEQVA^¾]ASN GG QALE1A7QilLLPVXCQAHGLI'PEQVVAIA
S IGGKQAi iTVQRJXPVI QA
TPEQVA^AiASNNGG QALETVQRLLPVLCQAHGLTPEQVVAiASNIGGKQALETVQRLL
PVLCQAHGLTPEQWAiASNGGGKQALEWQRLLPVLCQAHGLTPEQVVAJASNIGG Q
Figure imgf000153_0001
lASNGGGKQALETVQRLLPVLCQAeGLTPEQVVAIASNlGGKQALETVQRLLPVLCQAH
GLlTEQVVAiASiiDGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGi^ALDAV K
GLPHAPALIKRT RRIPERISHRVAASSPK KRKVEASNGAIGGDLLLNFPDMSVLERQR
AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNF AA.KPDTETKDCNEAAKKMTMNRDDLVEEGEEEKSKITEQ]SnSiGSTKSIKK
MKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF
LQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAS
TPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSS
[00456] > ΙΙΛ-Ί ί.ΙΑν-.; C63)-GS-cibl-m¾i I..S-mut MI.i;!
[00457] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA ΠΠΓΙΑΛΊ <:!AV!)EVOS(:L!lAAf>A ΡΡΡΊ I 11 A V 1 A A K P Pk A k Λ P K K A AO PS I > A SPA A QVDLRTLGYSQQQQE JKPKVRSTVAQHBEALVGBGFrBAFJlV'ALSQHPAALGTVAV S QDMiAAi PLAY! 1PAIYGYGLQA S AKALLALL ; Y AGPLR Pi QL Y QY; K!AKPG G\ AVEAVHA RNALTGAPLNLTPEQVVAIASNGGG QALETVQRLLPVLCQAHGLTP EQVVAIASN GG QALE QRLLPVLCQAFiGLTPEQVVAIASNiGGKQALETVQRi.LPV
Figure imgf000153_0002
ETVQRLLPVLCQAHGLTPEQVVAIASN^GG QALETVQRLLPVLCQAHGLTPEQVVAiA S G KQAPLYYQRi LPYP< 'QA! i kl lA^V V Λ I ASXGGGKQ LLYvQki LPYPrQAM P TPEQVVAIASNNGG QALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLL PVLCQAHGLlPEQVVA]ASNGGG QALE1 QilLLPVXCQAHGLI'PEQVVAIASNiGG .Q
ALETVQ i ^VLCQAHGLTPEQVVAJAS GG QALE QRLLPVLCQAHGLTPEQVVA iASNGCXi QALETVQRLLPVLCQAHGLTPEQVVAIA^^GG QAi n QRLLPVLCQAH
GLTPEQWAIASHDGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAV K
GLPI1APALI RTNRRH>ERTSHRVAASGGGGSGGGGSNGAIGGDLLL FPDMSVLERQR
AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNF AAKEDTETKDCNEAAKKMTMNRDDLVEEGEEEKSKITEQISnSiGSTKSIKK
MKHKAKKEE NF SND S SKVTKELEKTD YIH VRAR A A Q ATD SH SI AE A V AREKI SERMK
FLQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVA
STPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGE
APSMWDSHVQNLYGNLGV
[00458] > I ΙΛ-ΊΆί,! C63)-wNES-cibl-rmu LS-m¾tbB LH
[00459] SRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGAHHTEAATGE
WDE-VQSGLilAAJDAI^PTMRVAV AARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYS
QQQQE IKPKVRS AQHHEALVGHGFTHAHIVALSQePAALGTVAVKYQDMIAALPE
A Ml AiX G\ G QWSGA A; UA!J i V ACUJ R PH.QJ m QU iAKKGi -v ί ΑΥΓΑΥΊ §A
WR ALTGAPLNX PEQVVAIASNGGG QALETVQRLLPVLCQAHGLTPEQVVAIASN
GG QALE QRJJ.PVI QAHGI. PEQVVAIASNiGGKQALETVQRi .PVLCQAHGLTPE
QVVAIAS IGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVL
CQAeGLTPEQVVAIASNNGGKQALETVQRLLPVLCQAeGLTPEQVVAIASNIGG QALE
TVQRLLPVLCQAHGLTPEQVVAIASM
N^GGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGL
Figure imgf000154_0001
PVLCQAHGLlPEQVVAiAS IGGKQALETVQRLLPVLCQAHGLTPEQVVAlASNGGGKQ ALETVQRi ^VLCQAHGLTPEQVVAJASNIGG QALE QRLLPVLCQAHGLTPEQVVA lASHDGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRi'ALDAV GLPHAPALI KRTNRRIPERTSHRVAASI.'YPERi^RRIL.TNGAIGGDLLLNFPDMSVLERQRAHLKYLNPT FDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPETTLGTGNFK KFDTETKDCNE KKMTMNPJ)DLVEEGEEEKSKITEQ N
ElSnSiFSNDSSKVTKELEKTDYIFIVRARAAQATDSHSIAEAVAREKISERMKFLQDLVPGC DKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVASTPMTVVPS PEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEAPSMWDSH VQNLYGNLGV
[00460] > 11 A-Y,\ij :(;;.;.; C63)-GS-ciblAl-mui LS
[00461] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA
; Π ΓΠ.ΑΛΊ GR DRVQSCR JIAAPR\PRP1 M ! I Λ V 1 Λ Λ R RPR A k R A R R R R A AC) PS I > A S R A Λ
QVDLRTLGYSQQQQE IKPKVRSTVAQ HEALVGHGFTHAHIVALSQ PAALGTVAVK
S QDMiAA) R! ·! lRA!V(A(d^O\VS< ^RAL! !JA^ AiRil.RGPPi QR Y QR; KAAKRG
G\ AVEAVHA RNALTGAPLNLTPEQVVAIASNGGG QALETVQRLLP'VLCQAHGLTP
EQVVAIASN GG QALE QRLLPVLCQAFiGLTPEQVVAIASNiGGKQALETVQRi.LPV
LCQAHGLTPEQVVA]ASNiGG .QALETVQRLLPVLCQAHGLTPEQVVAiAS GGG .QAL
ETVQRLLPVLCQAHGLTPEQVVAIASN^GG QALETVQRLLPVLCQAHGLTPEQVVAiA
SAlG KQARRTYQRi EPYR< 'OA j s ;R FP1R \ Α \SA K- ;KQAf L i \'QR ί EPYR< 'QA! K;R
TPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLL
PvRC QA; IGRYRRQv YAR\S\G GKOAREYY PR RvRi QA! KR.YRRC vA AR\S\1GGKQ
ALETVQRLLFVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA
iASXGG KQAi.L 1 \ QRR1 PXRA'Q l R A'PEQY VARASA iGRQAi EYYQPRRRVR ί ΟΑΠ
GLTPEQVVAiASHDGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAV .
GLP IAPAI.I R.TNRR.IPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR
AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNF AAKEDTETKDCNEAAKKMTMNRDDLVEEGEEEKSKITEQISnSiGSTKSIKK
MKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF
LQDLVPGCDKITGKAGMLDEIINYVQSLQRGGSVASTPMTVVPSPEMVLSGYSHEMVHS
GYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00462] > HA-TALE(jjg2, C63)-wNLS-ciblAl-mut LS
[00463] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLF TSLFDSLPPFGA HHTEAATGEW'DEVQSGLRAADAPPPTMRVAVTAAi^PilA J'APRRIlAAQPSDASPAA
QVOLRTLGYSQQQQF.K1 P VRSTVAQHHEALVGBGFTHAH1VA.LSQHPAALGTVA.V
Figure imgf000155_0001
GVTAVEAVFIAWRNALTGAPLNLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTP
Figure imgf000155_0002
LCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQWAiAS GGGKQAL ETVQRLLPVLCQAHGLTPEQVVAiAS NGG .QALETVQRLLPVLCQAHGLTPEQVVAIA SMGGKQALP 1 vQKlJ.PVPi'QAi K n;HQY VA! ASXGGGKQAI.P 1 νί,ίΚΐ 1 PM.C'QAI KsP TPEQVVAiASNNGG QALETVQRI PViX:QAHGi rPEQVVAIAS :iGGKQALE'rVQRLL PVLCQAHGLTPEQVVAIASNGGG QALETVQRLLPVLCQAHGLTPEQVVAiASNiGGKQ Al.HTVQRi.U'Vi ( ΟΛΠΟί 1 PLQVYAiASN!GGKQALL') YQk 11 ΡΧ .< 'O HG i .T k Y V A iASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAJASNIGG QALETVQRLLPVLCQAH
Figure imgf000156_0001
GLPH APA L! KRTN RRIPERTSBR VAAS LY PERLRPd LTNGAIGGDLLLNFPDMSVLERQRA HLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPET TLGTGNFKAAKFDTETKDCNEA
KHKAKKEE NFSND S SKVTKELEKTD YIH VRAR GQ ATD SH SI AERVR EKI SERMKFL
QDLVPGCDKITGKAGMLDEIINYVQSLQRGGSGEEEKSKITEQNNGSTKSIKKMKHKAK
KEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVR EKISERMKFLQDLVP
GCDKITGKAGMLDEIINYVQSLQRGGSVASTPMTVVPSPEMVLSGYSHEMVHSGYSSE
MVNSGYLHVNPMQQVNTSSDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00464] > HA-TALE(«g2, C63)-GS-ciblA2-muiNLS
[00465] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HiiTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAA QVDLRTLGYSQQQQE JKPKVRSTVAQHBEALVGBGFTBABIV'ALSQHPAALGTVAV
YQDMiAALPEATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLL ]AKRG G\ AVELAVHAWRNALTGAPLNLTPEQVVAL\SNGGG QALETVQRLLPVLCQAHGLTP EQVV AIA .SNNGGKQ ALETVQRLLPVLCQAHGLTPEQV VAI A SNI GGKQALETVQRLLP V PC (Α Π<^•! l :QVVA! S\ : KQA!J: 'VO : ί PV1 ('QAHGl Ί PPQVVA1ASNG(:GKQAL E VQRLLPVLCQAHGLTPEQVVA1AS NGG .QALETVQRLLPVLCQAHGLTPEQVVAIA
Figure imgf000156_0002
TPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAiASNIGGKQALETVQRLL PVLCQAHGLTPEQV^^AIASNGGG QA∑ i QRJJ. VI QAHGLTPEQVVAIASNiGG .Q Al.HTVQRi.U'Vi ( OAiiGi 1 PLOVX A! AS\K-GKQAf J 1 ΥίΑκΡΡΡΥ Γ ΠΟ Ϊ Ρ Υ VA iASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAJASNIGG QALETVQRLLPVLCQAH GPYPPQYYAP\SnnGGPPAPPSPYAOPSP 1 GGRPAl DAY K
GLPHAPALI RTNRRIPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNFKAAKFDTETKDCNEA AKKMTMNRDDLVEEGEEEKSKITEQNNGSTKSIKK
MKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF
LQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAS
TPMTVVPSPEMVLSGYGGSPLSCF NGEAPSMWDSHVQNLYGNLGV
[00466] > HA-IALE(/igA C63)-wNES-ciblA2-rm;i L8
[00467] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLL QFDPSLFNTSLFDSLPPFGA
HHTEAATGEW'DEVQSGLRAADAPPPTM RVAVTAARPPRAK APRRRAAQPSDASPAA
QVOLRTLGYSQQQQEK1 P VRSTVAQHHEALVG GFTHAH1VA.LSQHPAALGTVA.V
YQD liAALPEATHEAiV lV l .QWSGAiL\LEALLTVAGELRGPPLQLDTGQLL IAKRG
GVTAVEAVFIAWRNALTGAPLNLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTP
Figure imgf000157_0001
LCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQWAiAS GGGKQAL
Γ! YQRU PV1 <X) i I 1 PPQY ΥΛ1ΑΒΧΛΟ ΟΑί\ί ΑΧ)Κί 1 ;ΑΊΧΧ)ΛΠί ATP!-QYYA!A
SNlGG QALElAQRLliALCQAHGl/rPEQVVAIASNGGGKQALElAQRLLPVLCQAHGL
TPF.QVVALASNNGG QAT..F VQRLLPV∑ QAHG∑,TPF.QVV^iAS ]GGKQALETVQRLL
PVLCQAHGLTPEQVVAiAS GGGKQALETVQRLLPVLCQAeGLTPEQVVAIAS iGGKQ
ALETVQRLLPVLCQAHGLTPEQWAIASNI^
JASNGGGKQALEWQRLLPVLCQAHGLTPEQVVAIASNiGGKQALETVQRLLPVLCQAe GLTPEQ AIASHDGGRPALESIVAQLSRPDPALAALT DHLVALACLGGRPALDAViiX G LP!∑ APA U KR TNR EJ E R IS BR V A ASI Y PERLRR Π NGAIGGDLLLNFPDMS VLERQRA HLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPET TLGTGNFKAAKFDTETKDCNEA AKKMTMNRDDLVEEGEEEKSKITEQ NGSTKSIKKM KHKAKKEE NFSND S SKVTKELEKTD YIH VRARRGQ ATD SH SI AERVRREKI SERMKFL QDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAST PMTVVPSPEMVLSGYGGSPLSCFNNGEAPSMWDSHVQNLYGNLGV
[00468] > HA-TALE(«g2, C63)-NLS-cibl-rmu LS-m¾†.bHLH
[00469] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HHTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRA PAPRRRAAQPSDASPAA QVDLRTLGYSQQQQE I P YRSTVAQi:IHEALYGHGFraAHIVALSQi:IPAAIX31A?AVK
YQDMIAALPEATeEAlVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLL IA RG GVTAVEAVHAWRNALTGAPLNLTPEQVVAIAS'NGGGKQALETVQRLLPVLCQAHGLTP
EQWAIASNNGGKQALETVQRi VLCQAHGLTPEQVVAJAS GG QALE QRLLPV
LCQAE iLlTEQVVAiAS iGG QALE QRLLPVLCQAHGLlPEQVVAIAS GGG QAL
ETVQRLL VLCQAHGLTPEQVVAiASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAJA
SX!GC-KQA! rVQR!J !A ( QA! X Pi!QVA A (ASNGGG QAi J nAQ(XU; X( QAHGL
TPEQVVAIASNNGGKQALETVQRLLPVLCQAeGLTPEQVVAIAS IGG QALETVQRLL
PV! ^AHii! 'r EOVvAl SXiiC i QALLi vQkl j PX -Q ! i!/r EQX' V j SX! C-!xQ
ALETVQRLLPVLCQAHGLTPEQVVAIAS IGG QALETVQRLLPVLCQAHGLTPEQVVA
Figure imgf000158_0001
GLTPEQVVAIASHDGGRPALESIVAQLSRPDPALAALl'ND LVALACLGGRPALDAVK
GLPHAPALI RTNRRjPERTSHRVAASSPKXKP VEASNGAIGGDLLLNFPDMSVLERQR
AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNFKA AKFDTETKDCNEA KKMTMNRDDLVEEGEEEKSKITEQ NGSTKSIKK
MKHKAKKEE NFSNDSSKVTKELEKTDYIHVRA AAQATDSHSIAEA V AREKISERMK
FLQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVA
STPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGE
APSMWDSHVQNLYGNLGV
[00470] > HA-TALE(«g2, C63)- LS-ciblAl-rauf LS
[00471] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HHTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRA PAPRRRAAQPSDASPAA QVDLRTLGYSQQQQE I P YRSϊVAQί5HE L GHGFΊΉAHIVALSQί5 AAI I ?AVK
YQDMIAALPEATeEAjVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLL IA RG ; Y" f A v L A V Π A \Y RX A ί 10Λ ί ί Π;ΗΟΥ VA lASXGGGKQAiXI vQKi LPX'l.i "Q il iAP
EQVVAIASNNGGKQALEI QRLLPVLCQAHGLl'PEQVVAIASNIGGKQALEl'VQRLLPV
LCQAi: iLTPEQVV iAS ]GG QALET\'TQRTXPVXCQAHC.:TPEQVA'^4IASNGGG QA∑,
ETVQilLLPVLCQAHGLIPEQVVAiASN GG QALEI QilLLPVXCQAHGLI'PEQVVAIA
SNKX3KQALETVQRLLPVLCQAPKiLTPI^
T!XQY VAE\SXXGGkQAU-A VQRj.i.PYXC QAi I L H iQ VAI SxiGG OA IXTYOiUX PVLCQAHGLTPEQWAiASNGGGKQALEWQRLLPVLCQAHGLTPEQVVAJASNIGG Q ΑΠ.Ί YQki ί^Υί ΥΑΑΠ ί/Π'ΗΟΥ ( OAHGi 1 PLQVYA lASNGGGKQALETVQRLLPVLCQAeGLTPEQVVAIASNlGGKQALETVQRLLPVLCQAH GLTPEQVVAIASHDGGRPALESIVAQLSRPDPALAALl'ND LVALACLGGRPALDAV GIPIiAPAjJ RTNRRJPERTSeRVAASSP KKR VEASNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE TTLGTGNFKA AKFDTETKDCNEAAKKMTMNRDDLVEEGEEEKSKITEQ NGSTKSIKK MKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF LQDLVPGCDKITGKAGMLDEIINYVQSLQRGGSVASTPMTVVPSPEMVLSGYSHEMVHS GYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00472] > HA-TALE(«g2, C63)-NLS-ciblA2-mutNLS
[00473] YPYDVPDYASR.TRLPSPPAPSPAFSADSFSDLLR.QFDPS∑,FNTSLFDSLPPFGA. HHTEAAI'GEWDEVQSGLRAADAPPP'T RVAVIAARPPRAKPAPRRRAAQPSDASPAA QVDLRTLGYSQQQQE IKPKVRSTVAQ HEALVGHGFTHAHIVALSQ PAALGTVAVK YQUYliAA! LAmPAiV V KOWS
GVTAVEAVeAWRNALTGAPLNLTPEQVVAIASNGGG QALETVQRLLPVLCQAHGLTP
I:QV AiASXA C-KQAl J rVQRiJ PVi ( QA!KA l i )V\'AIAS\K- KQAf J 1 YQki .l . PY
LCQAHGLTPEQVVA]ASNiGG .QALETVQRLLPVLCQAHGLTPEQVVAiAS GGG .QAL
ETVQRII VLCQAHGLTPEQVVAIASN GG QA∑ iTVQRJJ. VI QAFiGL PEQVVAIA
SN[GGKQALE'rVQRLLPVLCQAeGL':rPEQVVAIASNGGGKQALE'rVQRLLPVLCQAeGL
TPF^WAlASNNGGKQALriWQRLLPVLCQAHGLTPEQVTAlASNIGG QALETVQRLL
PVl 'QAHGl/rPEQVVAlASNGGG QALElTQRLli'Vl 'QAHGLI'PEQVVAIASNIGGKQ
ALETVQRLLPVLCQAHGLTPEQWAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA
iASNGCXi QALETVQRLLPVLCQAHGLTPEQVVAIA^^GG QAi n QRLLPVLCQAFi
GLT EQWAIASHDGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAV K
GLPHAPALIKRTNRRIPERT SI! RVAASL YPER LRRI L TNGAIGGDLLLNFPDMSVLERQRA
HLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPET
TLGTGNFK K^
KHKAKKEE NFSND S SKVTKELEKTD YIH VRARRGQ ATD SH SI AERVRREKI SERMKFL QDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAST PMTVVPSPEMVLSGYGGSPLSCFNNGEAPSMWDSHVQNLYGNLGV
[00474] > F£A-TALE(/ig2, C63)-GS-iNESl-cibl-y.rsui LS
[00475] YPYD DYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA
IIHTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRA PAPRRRAAQPSDASPAA QVDL TLGYSQQQQE JKPKVRSTVAQHBEALVGBGF1¾AB1V'ALSQHPAALGTVAV'
YQDMIAALPEATHEAIVGVGKQWSGAi AEEALE^^^
GVIY EAVHAWR ALTGAPENLI^EQVVAIASNGGG
EQVVA1ASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV PC (Α Π<^•!l :QYVA!AS\ : KQ !J 'YOkLi i>Vl ('QAHGl Ί P^OVvΛl S^ (: KQ i. E QRLLPVLCQAHGLTPEQVVAIASNTSTGG QALETVQRLLPVLCQAHGLTPEQVVAIA SYIGGKQALH vQPU.P PrQ n P YHiQY^^
TPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAiASNIGGKQALETVQRLL
PVLCQAHGLTPEQV^^AIASNGGG QA∑ i QRiJ. VLCQAHGLTPEQVVAIASNiGG .Q
ALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA
iASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAJASNIGG QALETVQRLLPVLCQAH
Figure imgf000160_0001
GLPHAPALI RTNRRIPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR
AHLKYLLYPERLRRILTNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETT
VEGDSRLSISPETTLGTGNFKAAKEDTETKDCNEAAKKMTMNRDDLVEEGEEEKSKITE
Q NGSTKSIK MKHKAKKEENNFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERV
RREKISERMKFLQDLVPGCDKITGKAGMLDEIF YVQSLQRQIEFLSMKLAIVNPRPDFD
MDDIFAKEVASTPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTS
SDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00476] > HA-TALE(/ig2, C63)-GS-iNES2-cibl-raui LS
[00477] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HHTEAATGEWDEVQSGLRAADAPPPTNIRVAVTAARPPRAKPAPRRRAAQPSDASPAA
Figure imgf000160_0002
YQD liAALPEATHEAiVlVl .QWSGAiL\LEALLTVAGELRGPPLQLDTGQLL IAKRG G AVF VHAWRNAI GAPLNLTPEQVVAIASNGGGK.QALETVQRLL VLCQAHGLTP EQVVAIASNNGGKQALEl'YQRLLPVLCQAeGLI^PEQVVAjASNIGG QALEIA'QRLLPV !.( QA; !<·!. I PLiYvN'AI ASYR-GKQAL!. I YQkl U>YPa !GPYPPQY v AlASYGGGKQAL PYYQkLi ^ l CO i SGI TPPOYYAIAS YGGRQALP TYQki 1 PYLCOAi H sPTPPOYv AiA
SN:IGGKQAIXTVQRIJ,PVLCQAHGLTPEQVVA:LASNGGG QALETVQRI.,;LPVLCQAHGL
TPEQVVAiASNNGG QALErVQRI PViX:QAHGUrPEQVVAiAS :iGGKQALE'rVQRLL PVLCQAHGLTPEQVVAIASNGGG QALETVQRLLPVLCQAHGLTPEQVVAiASNiGGKQ ALETVQilLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQ LLPVLCQAHGLTPEQVVA iAS GGGKQALETVQRLLPVLCQAHGLTPEQ
GLTp QY y,\IAS; 1Π = ΡΡ Ι J^Si v AQI SRi )i LΛ l.'Γ\l)l ΠΛΆΙ.Λ( ί kPAi DAY K GLPHAPALI RTNRRIPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDLYPERLRRILTSYLSTAGLNLPMMYGETT VEGDSRLSISPETTLGTGNFKAAKTDTETKTC
Q NGSTKSIKKMKHKAKKEENNFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERV
RREKISERMKFLQDLVPGCDKITGKAGMLDEir YVQSLQRQIEFLSMKLAIVNPRPDFD
MDDIFAKEVASTPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTS
SDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00478] > HA-TALE(/ig2, C63)-GS-iNES3-cibl-y.rsui LS
[00479] YPYD DYASRTRLPSPPAPSPAFSADSI¾DLLRQi^)PSLFNTSLFDSLPPFGA HHTEAATGEWDEVQSGLRAADAPPPTNIRVAVTAARPPRAKPAPRRRAAQPSDASPAA QVDLi XSYSQQQQEKJKPKVRSTVAQHHEALVG^^^^
YQD liAALPEATHEAiVlVl .QWSGAiL\LEALLTVAGELRGPPLQLDTGQLL IAKRG
G AVF VHAWR AI GAPLNLTPEQVVAIASNGGGK.QALETVQRLL VLCQAHGLTP
EQVVAiAS NGGKQALETVQRLLPVLCQAeGLTPEQV'VAIAS'NIGGKQALE Qi LLP'V
LCQAFiGLTPEQV^^AIASNIGGKQALETVQRII-vPVLCQAir iLTPEQVV iAS GGG QAL
ETVQRLLPVLCQAHGLTPEQVVAiAS NGGKQALETVQRLLPVLCQAeGLl EQVVAIA
SNiGGKQALEWQRLLPVLCQAHGLTPEQVVAJASNGGGKQALEWQRLLPVLCQAHGL
TPEQVVAiASNNGG QALErVQRI PViX:QAHGUrPEQVVAiAS :iGGKQALEWQRLL
PVLCQAHGLTPEQVVAIASNGGG QALETVQRLLPVLCQAHGLTPEQVVAiASNiGGKQ
Al TVQRiJ PVi ( OAiiGi 1 PLQVYAiASN!GGKQALL') YQk 1 1 ΡΧ .< 'OA Hi > i .T kQY V A
JASNGGGKQALEWQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAE GLTPI:X>VVAIASIID<;K]RPALI VAQLSR
GLPHAPALI RTNRRLPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR
AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGLYPERLRR
ILTDSRLSISPETTLGTGNFK KEDTC NGSTKSIKXMKHKAKXEE NFSNDSSKVTKE!LEKTDYIHVRARRGQATDSHSIAERVR REKISERMKFLQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDM DDIFAKEVASTPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTSSD
PLSCF NGEAPSMWDSHVQNLYGNLGV
[00480] > ΗΑ-Ί ALE(ng2, C63)-GS-iNES4-cibl-myf I.S
[00481] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA
Figure imgf000162_0001
QVDLRTLGYSQQQQE IKPKVRSTVAQ HEALVGFJGFTHAHIVALSQ PAALGTVAVK
S QDMiAA) ! ·! Π: !V(A(d^O\VS< ^KAL! !JA^ AidiLR ! Q!J)'!'GQ!J K!AKPG
G\ AVEAVHA RNALTGAPLNLTPEQVVAIASNGGG QALETVQRLLP'VLCQAHGLTP
EQVVAIASN GG QALE QRLLPVLCQAFiGLTPEQVVAIASNiGGKQALETVQRi.LPV
LCQAHGLTPEQVVA]ASNiGG .QALETVQRLLPVLCQAEIGLTPEQVVAiAS GGG .QAL
ETVQRLLPVLCQAHGLTPEQVVAIASN^GG QALETVQRLLPVLCQAHGLTPEQVVAiA
S GGKQAL! YQki Ι ΡΧΊ 'QA j (Gh I HQ A I ASXGGGKQAi J l YQk ί 1.P L<* 'QA M L
TPEQVVAIASNNGG QALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLL
PYPC QA; K-f 1 X>\A1\IAS\(-(K-K0A] j rVQ I J JA;L( QAi KXi Pi iv YAiAS GGKQ
ALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA IAS GGGKQALF/TVQRLLPVLCQAHGLTPE
GLTPEQVVAIASHDGGRPALESIVAQLS PDPALAALTNDHLVALACLGGRPALDAV . GLP IAPAI.I TNRR.IPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE TTLGTGNFKAAKFDTET
EQ NGSTKSIKKMKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAER VRREKISERMKFLQDLVPGCDKITGKAGMLDEIR YVQSLQRQIEFLSMKLAIVNPRPDF DMDDIFAKEVASTPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNT SSDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00482] > I ΙΛ- 1 A !.!.(;;- A C63)-GS-iNES5-cibl-m† LN
[00483] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HiiTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAA QVDLRTLGYSQQQQEKJKPKVRSTVAQHHEAL^
YQDMiAALPEATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLL ]AKRG
G\ AVELAVHAWRNALTGAPLNLTPEQVVAL\SNGGG QALETVQRLLPVLCQAHGLTP
EQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV LCQAHGLTPEQVVA]ASNiGG .QALETVQRLLPVLCQAHGLTPEQVVAiAS GGG .QAL
ETVQRII VLCQAHGLTPEQVVAiASN GG QA∑ iTVQRJJ. VI QAHGLTPEQVVAIA
S GGKQAi.i.TYQRi 1 PYL< 'OA j (Gh Π'ΗΟΥ v Λ I SXGGGKQ i J IA;Q ί Ι.ΡΥί,ί "QAi ;GL
TPEQVVAIASNNGG QALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLL
PYLC ( Π<^ 'il ^VVAIASNCH RcKOA! jrrVQR!JJ-vLi QAi K-LTH v ΥΛ; AS\K AQ Q
ALETVQRLLPVLCQAHGLTPEQWAIASNIGGKQALETVQRLLPVLCQAHGLTPEQVVA
lASNGGGKQAEETVQRLLPVLCQAHGLTPEQVVAIAS
GLI'PEQVVAIASHDGGRPALESIVAQLSRPDPALAALI^NDHLVALACLGGRPALDAV K GLPEIAPAI.I .R.TNRR.IPERTSHRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE TTLGTGNFKAAKFDTETKDCNE AKKM
LYPERLRRILTMKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERV
RREKISERMKFLQDLVPGCDKITGKAGMLDEir YVQSLQRQIEFLSMKLAIVNPRPDFD
MDDIFAKEVASTPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTS
SDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00484] > I IA-!A!. §.{/;-::. C63)-GS-iNES6-cibl-m †YLN
[00485] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA HiiTEAATGEWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAA QVDLRTLGYSQQQQE JKPKVRSTVAQHBEALVGBGFTBABIV'ALSQHPAALGTVAV
YQDMiAALPEATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLL ]AKRG
G\ AVELAVHAW NALTGAPLNLTPEQVVAL\SNGGG QALETVQRLLPVLCQAHGLTP
EQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPV
Figure imgf000163_0001
ETVQRLLPVLCQAHGLTPEQVVAiAS NGGKQALETVQRLLPVLCQAeGLl EQVVAIA
SNiGGKQALETVQRI PVLCQAFIGL^^
TPEQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAiASNIGGKQALETVQRLL PVLCQAHGLTPEQV^^AIASNGGG QA∑ i QRJJ. VI QAFiGLTPEQVVAIASNiGG .Q Al TVORiJ PVi ( OAHGi 1 PLOV\ A!AS\K-GKQAI J 1 Y Qk 11 ΡΧ .< 'Q Hi > i .T kQY V A iASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAJASNIGG QALETVQRLLPVLCQAH
Figure imgf000163_0002
GLPHAPALI RTNRRIPERTSFJRVAASGGGGSGGGGSNGAIGGDLLLNFPDMSVLERQR AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNFK AAKFDTETKDCNE AKKMTMNRDDLVEEGEEEKSKITEQ NGSTKSIKK
MKHKAKKEE NFSNDSSKVTLYPERLRRILTKELEKTDYIHVRARRGQATDSHSIAERV
RREKISERMKFLQDLVPGCDKITGKAGMLDEIF YVQSLQRQIEFLSMKLAIVNPRPDFD
MDDIFAKEVASTPMTVVPSPEMVLSGYSHEMVHSGYSSEMVNSGYLHVNPMQQVNTS
SDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00486] > I ΙΛ- 1 A !.!.(;;,;;; C63)-NLS-ciblAl
[00487] MYPYDVPDYAS TRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFG
AiH-rrEAATGEWDEVQSG∑,RAADAPPPTM VAVTAARPPRAKPAPRRRAA.QPSDASPA
AQVDLRTLGYSQQQQEKi^KVRS AQHHEALVGHGFTHAHIVALSQHPAALGTVAV
KYQDMIAALPEATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKR
GGVTAVEAVHAWRNALTGAPLNLTPEQV^
TPEQVVAIASNNGG QALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLL
PVLCQAHGL PEQVVAIAS I(Xi QALEl^QRLLPVLCQAi iLlTEQVVAiAS GGG .Q
ALE QRLLP'VLCQAHGLTPEQ'VVAIASNNGG QALEWQRLLP'VLCQAHGLTPEQVV
AIASNIGGKQALETVQRII,PVLCQAi: iLTPEQVV iAS GGGKQALETVQRL∑,PVLCOA
HGLTPEQVVAiAS NGGKQALETVQRLLPVLCQAHGLTPEQVVAiAS iGGKQALEWQ
RLLPVLCQAHGLTPEQVVAIASNGGG QALETVQRLLPVLCQAHGLTPEQVVAIASNIG
GKQALETVQRLLPVLCQAHGLTPEQVVAIAS IGG QALETVQRLLFVLCQAHGLTPEQ
VVAIASNGGG QAL£TVQRLLPVLCQAHGLTPEQVVAIASNiGGKQALETVQRLL.PVLC
QAE iLlTEQVVAiASHDCXiRPALESIVAQLSRPDPALAALTNDiiLVALACLGGRPALDA
VKKGLPHAPALIKRTNRRIPERTSHRVAASSP KKRKVEASNGAIGGDLLLNFPDMSVLE
RQRAHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLS
ISPETTLGTGNFKKRKFDTETKDCNEKKKKMTMNRDDLVEEGEEEKSKITEQ NGSTKS
IKKMKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISER
MKFLQDLVPGCDKITGKAGMLDEIINYVQSLQRGGSVASTPMTVVPSPEMVLSGYSHE
MVHSGYSSEMVNSGYLHVNPMQQVNTSSDPLSCF NGEAPSMWDSHVQNLYGNLGV
[00488] >HA-TALE(ng2, C63i-NLS-ciblA2
[00489] YPYDVPDYASRTRLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDSLPPFGA iiKrELAATGEWiDEVQSGLRAADAPPPTMRVAVTAARPPRA PAJ^RRAAQPSDASPAA QVDLRTLGYSQQQQEKI P VRSTVAQH EALVGHGFT A IVALSQHPAALGTVAVK. YQD liAALPEATHEAiVlVl .QWSGAiL\LEALLTVAGEL GPPLQLDTGQLL IAKRG
G AVF VHAWR AI GAPLNLTPEQVVAIASNGGGK.QALETVQRLL VLCQAHGLTP
Figure imgf000165_0001
LCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPEQWAiAS GGGKQAL ΓΥ ΚΜ r I CQAi SGI TPKQY vAl SYNGGKQ LLTYOki ! ΧΊ ΛΠ(5Κ ΓΡΙ-QX V AL\
SNiGGKQALEWQRLLPVLCQAHGLTPEQVVAJASNGGGKQALEWQRLLPVLCQAHGL
TPF.QVVALASNNGG QALETVQRLLPV∑ QAHG∑,TPF.QVVAiAS ]GGKQALETVQRLL
PVLCQAHGLTPEQVVAiAS GGGKQALETVQRLLPVLCQAeGLTPEQVVAIAS iGGKQ
ALE QRI VI ^QAHGL PEQVVAIASNiGGKQALETVQRI ^PVLCQAHGLTPEQVVA
JASNGGGKQALEWQRLLPVLCQAHGLTPEQVVAIASNiGGKQALETVQRLLPVLCQAe
GLTPEQ AIASHDGGRPALESIVAQLSRPDPALAALT DHLVALACLGGRPALDAV3SX
(}LI5]iAPA!.]KRrNRRIP]:-R:rSeRVAASSP KKR VEASNGAIGGDLLLNFPDMSVLERQR
AHLKYLNPTFDSPLAGFFADSSMITGGEMDSYLSTAGLNLPMMYGETTVEGDSRLSISPE
TTLGTGNFKKRKFDTETKDCNEKKKKMTMNRDDLVEEGEEEKSKITEQ NGSTKSIK
MKHKAKKEE NFSNDSSKVTKELEKTDYIHVRARRGQATDSHSIAERVRREKISERMKF
LQDLVPGCDKITGKAGMLDEIINYVQSLQRQIEFLSMKLAIVNPRPDFDMDDIFAKEVAS
TPMTVVPSPEMVLSGYGGSPLSCF NGEAPSMWDSHVQNLYGNLGV
[00490] > alpha-importin-NLS-CRY2PHR-NLS-VP64_2A_GFP
[00491] MKRPAATKKAGQAKKKK MDK TIVWFRRDLRIEDNPALAAAAHEGSVFP
VFIWCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTG
ATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNS
YWK CLDMSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSP
GWSNADKLLNEFIEKQLIDYAK SK VVGNSTSLLSPYLHFGEISVRHVFQCARMKQII
WARDK SEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKA
WRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLL
DADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIH
HPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTREAQIMIGAAPASPKKKR
KVEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDL
DMLINSRGSGEGRGSLLTCGDVEENPGPVSKGEELFTGVVPILVELDGDVNGHKFSVSG
EGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMP
EGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSH NVYIMADKQK GIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSAL
SKDPNEKRDHMVLLEFVTAAGITLGMDELYKV
[00492] > mutNES-CRY2PHR-NLS-VP64_2A_GFP
[00493] MEQKLISEEDLKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEE
GQF YPGRASRWWMKQ SL AHL S Q SLKAAGSD ATLIKTHNTI S AILD CIRVTG ATKV VFNH
LYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWK CLD
MSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGWSNADK
LLNEFIEKQLIDYAK SK VVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDK SE
GEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYP
LVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILG
WQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTV
LKASGVELGTNYAKPIVDIDTARELLAKAISRTREAQIMIGAAPASPKKKRKVEASGSGR
ADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRGS
GEGRGSLLTCGDVEENPGPVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYG
KLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIF
FKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQ
K GIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRD
HMVLLEFVTAAGITLGMDELYKV
[00494] > CRY2PHR-NL S - VP64-NL S_2 A GFP
[00495] MKMDK TIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRAS
RWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVR
DHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWK CLDMSIESVMLPP
PWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLI
DYAK SK VVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDK SEGEESADLFLR
GIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPLVDAGMREL
WATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISGSIPD
GHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELG
TNYAKPIVDIDTARELLAKAISRTREAQIMIGAAPASPKKKRKVEASGSGRADALDDFDL
DMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSPKKKRKVEASSR
GSGEGRGSLLTCGDVEENPGPVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDAT
YGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQER TIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMAD KQK GIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEK RDHMVLLEFVTAAGITLGMDELYKV
[00496] > Neurog2-TALE(N240,C63)-PYL
[00497] MSRTOLPSPPAPSPAFSADSFSDLLRQFDPSLFNTSLFDS^
EWDEVQSGLRAADAPPPTMRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGY
SQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALP
EATHEAIVGVG QWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVH
Figure imgf000167_0001
GGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPE
QVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHNGGKQALETVQRLLPV
LCQAHGLTPEQVVAIAS IGG QALEWQRLLPVLCQAHGLTPEQVVAIAS GGG QAL
ETVQRLLPVLCQAHGLTPEQVVAIASHNGGKQALETVQRLLPVLCQAHGLTPEQVVAIA
S'NIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGL
TPEQVVAJASNIGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQRLLP
V ί Q A i I G ί . T P Γ. Q V V A I A S \ G G G R P Λ f . ί '. S I V Λ Q ί . S R I > P A I A A. I . T \ Γ) i 11 V Λ f . Λ ( Ί . G G R P Λ
LDAVKKGLPHAPALIK .TNRRIPERTSHRVAASMANSESSSSPVNEEENSQRISTLHHQT
MPSDLTQDEFTQLSQSiAEFHTYQLG GRGSSLLAQRJHAPPETVWSVVRRFDRPQIY H
FIi SCNVSEDFEmVGCTM)VN\ SGLPANTSRERLDLLDDDRRVTGFSITGGEHP R]SIY
KSVTTVHRFEKE,EEEERIWT\^VLESYVVDVPEGNSEEDTRLFADTVIRLNLQKLASITEA
MNRNNNNNNSSQVR
[00498] >ABI- LS-VP64
[00499] MVPLYGFTSJCGRRPE EAAVSTIPRFLQSSSGSMLDGRFDPQSAAHFFGVYD
GHGGSQVANYCRERMHLALAEEIAKEKPMLCDGDTWLEKWKKALFNSFLRVDSEIES
APETVGSTSWAWFPSfflFVANCGDSRAVLCRGKTALPLSVDHKPDREDEAARIEAAG
GKVIQWTSfGARVFGVLAMSRSIGDRYLKPSIIPDPEVTAVKRVKEDDCLILASDGVWDV
IVTOEF-ACEMARKMLLWHKKNAVAGDASLLAD^
GS DNiSVVVVDLKPRRi L S PLNASP K R VEASGSGRADALDDFDLDM LGSDAL DDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLIN
Figure imgf000167_0002
[00501] MOKKYSKAAKH S^
DSGFAAEATEFAEYARRRYTRPANRRAA^
FARFPYFGNATPEVAYFEFF YPTm-IFAEKFA
DENPDNSDVDREEKYEvQTYNQ^
&NGLPGN LJALSLGLTP F ESNF OLA EDA I.QL DITDDDL. LI.AQIGDQYADI.il.. AARNESDAnAADFA VNTEOAAPESASY HF^^
DQSKAFAYFGYJIXKJASQEFEYKF] Pn;J K 3{y] nIJ.A/ j^ REI)IJ...RK.QRll?D (}Sy>I- QIί L()lFi.IL ILJ!R{^EL>FΎPFΊJKD IFf::KIEKILΓF -! YYVGPLARG S FAW TR EETi TPWNFEEYVD GASAQSP] ΒΡ,^1ΊΉ Ί> :!. Ε; : ΐ.ίΡ Ε¾Ι[;ΥΕ ;ΤνΥ ΙΠ ΓΚνΚΥνΊ ϊ G RKPAFLSGEQKKAIVDLLFKTN GTYHDEEKJ FFDRDFEDNEE AEGEAN
RRRRYl VvGRESPjFEIN(AREHFQSGR,F:[LDEFJFSDGFANRARM
QvSGQGDSEPHAEANEAGSPAIKKGEJ^
QEiPqKNSRFAYKRFEEGGFFAGSQI^^^
DIN LSDYDVDAIVPQSFL&DDSTO
EY KFITQERFDYEYKAEEFARAEFSK
YDSLJEEYRVFRFKSKLVSDFEKDPQPYK^^
FAEFVYCIDYKVYDYRKAGARSFGFKRGATARY
NGETGER'A DKGRI>FATVRKV LS PQ
D¾A>PKKYFXAA>8PTVAYSVI vYAKVEKF
Figure imgf000168_0001
EKEAAISPEDNEQRQEFVEQ^^^
EEQ AEG ! ! ΒΕΕΕΕΪΕ EGAPA AFKYEDTFIDP.ER YISYE £V EDAT1J HQSFFGLY ETFJ DLSQ
LGG SAGGGGSGGGGSGGGGSGPKKKRKVAAAGSGRADALDDFDLD LGSDALDDF
DLDMLGSDALDDFDLDMLGSDALDDFDLDMLIN
[00502] >SID4X-NLS-FLAG-i inK r-bSpCas f D ! 0A>H8«0A)- LS
[00503] MGSGMNIQMLLEAADYLERREREAEHGYASMLPGSGMNIQMLLEAADYLE RREREAEHGYASMLPGSGMNIQMLLEAADYLERREREAEHGYASMLPGSGMNIQMLL EAAD YLERREREAEHGYASMLPSRS AGPKKKPv VAAA DY K. D D D D SRLEPGEKP Y C
PECGKSFSQSGALTRHQRTHTRDKEYSKAAEKFFNSVF
DPj-rSPYRAI,R:F4IJAE:AGETAEATRI,KRTARR P. Y TR R K R J C YLO F I ESN E Y4 AR V D DS F F HRLEESPLVEEDKXIlEEHPJFi ^
APPAfiKiAGEGAAE DEYPD^
SEEJ.,ENLJ AQEPCJ E JiNGLPG LL^LSLGLTP F S F DEAEDAKEQESKDTYDDDLEPYE
E QEJDQY PI AY A A NLS DA I L LSDILR V TErrfSAPLSAS ¾ ¾YDEeHQ LTLL AL
Figure imgf000169_0001
LRXQRTFDNGSIPHQH-ΉΑΉ
RFAW TREAEETFn>WNYEEVYDKYE^
Figure imgf000169_0002
YE SGVEDPJE ASLGTYPn^LLKE KDKD A)NEENED]lJE)iVi;F 1P^JRP3E]:;Yi RGAUJCT
YAHEFDDEYRGPQEKRRRYTGWGRESRXL^
fH OSLTPRIA)fOKAQVSGQGDSIJlEHlANI.AG
PEN s VIEYi ARENQTIQEXAYENSE §PR EtE RJ EEGI ELGSQi EKEBPYENTCH..QNPKEY LYY I^QNG lDY YYOQPLDsN lLSDYDVG
V YEiEE!KNYWEQEENA XI JTQR KERRY [PrRAERGGESE[I>KAGPPPRGI.YE1¾QrT1PI-iVA
QILDSR NT XXEN D O E r IlI^KSKIPvSDFRKDFQFYKVIPEIN^ Il^HDAY [PEA
VY(;rPA JKK:YPKPIiSEPVY(R)YlEVYDvRiPRi^
EANGESERjPPLiFTNGETGEFVWDKGRDFAT^
Figure imgf000169_0003
SKYYNELYEASHYEKEKCPEPEDNEQ
VLSAY RDO^EQA iOILFT
S f TGL YETRIDLSQ RGGDKRPAATKKAGQAKKKK
[00504] Epigenetic effector domain sequences
[00505] >hs NCoR
[00506] ASSPKKKRKVEASMNGLMEDPMKVYKDRQFMNVWTDHEKEIFKDKFIQHP
K FGLIASYLERKSVPDCVLYYYLTK NENYKEF
[00507] >pf_Sir2A
[00508] ASSPKKKRKVEASMGNLMISFLKKDTQSITLEELAKIIK CKHVVALTGSGTS AESNIPSFRGSSNSIWSKYDPRIYGTIWGFWKYPEKIWEVIRDISSDYEIEI NGHVALSTL ESLGYLKSVVTQNVDGLHEASGNTKVISLHGNVFEAVCCTCNKIVKLNKIMLQKTSHFM HQLPPECPCGGIFKPNIILFGEVVSSDLLKEAEEEIAKCDLLLVIGTSSTVSTATNLCHFAC
KKKKKIVEINISKTYITNKMSDYHVCAKFSELTKVANILKGSSEK KKIMEF
[00509] >nc_DIM5
[00510] ASSPKKKR VEASMEKAFRPHFFNHGKPDANPKEKK CHWCQIRSFATHAQ
LPISIVNREDDAFLNPNFRFIDHSIIGK VPVADQSFRVGCSCASDEECMYSTCQCLDEMA
PDSDEEADPYTRKKRFAYYSQGAK GLLRDRVLQSQEPIYECHQGCACSKDCPNRVVE
RGRTVPLQIFRTKDRGWGVKCPVNIKRGQFVDRYLGEIITSEEADRRRAESTIARRKDVY
LFALDKFSDPDSLDPLLAGQPLEVDGEYMSGPTRFINHSCDPNMAIFARVGDHADKHIH
DLALFAIKDIPKGTELTFDYVNGLTGLESDAHDPSKISEMTKCLCGTAKCRGYLWEF
[00511] >sc_HST2
[00512] ASSPKKKRKVEASTEMSVRKIAAHMKSNPNAKVIFMVGAGISTSCGIPDFRSP
GTGLYHNLARLKLPYPEAVFDVDFFQSDPLPFYTLAKELYPGNFRPSKFHYLLKLFQDK
DVLKRVYTQNIDTLERQAGVKDDLIIEAHGSFAHCHCIGCGKVYPPQVFKSKLAEHPIKD
FVKCDVCGELVKPAIVFFGEDLPDSFSETWLNDSEWLREKITTSGKHPQQPLVIVVGTSL
AVYPFASLPEEIPRKVKRVLCNLETVGDFKANKRPTDLIVHQYSDEFAEQLVEELGWQE
DFEKILTAQGGMGEF
[00513] >hs_SIRT3
[00514] ASSPKKKRKVEASMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELP
FFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIPASK
LVEAHGTFASATCTVCQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGEPLPQRFL
LHVVDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDVAQL
GDVVHGVESLVELLGWTEEMRDLVQRETGKLDGPDKEF
[00515] >hs_NIPPl
[00516] ASSPKKKRKVEASMAAAANSGSSLPLFDCPTWAGKPPPGLHLDVVKGDKLIE
KLIIDEK YYLFGRNPDLCDFTIDHQSCSRVHAALVYHKHLKRVFLIDLNSTHGTFLGHI
RLEPHKPQQIPIDSTVSFGASTRAYTLREKPQTLPSAVKGDEKMGGEDDELKGLLGLPEE
ETELDNLTEFNTAHNKRISTLTIEEGNLDIQRPKRKRK SRVTFSEDDEIINPEDVDPSVGR
FRNMVQTAVVPVKKKRVEGPGSLGLEESGSRRMQNFAFSGGLYGGLPPTHSEAGSQPH
GIHGTALIGGLPMPYPNLAPDVDLTPVVPSAVNMNPAPNPAVYNPEAVNEEF
[00517] >ct_NUE [00518] ASSPKKKR VEASMTTNSTQDTLYLSLHGGIDSAIPYPVRRVEQLLQFSFLPE
LQFQNAAVKQRIQRLCYREEKRLAVSSLAKWLGQLHKQRLRAPK PPVAICWINSYVG
YGVFARESIPAWSYIGEYTGILRRRQALWLDENDYCFRYPVPRYSFRYFTIDSGMQGNV
TRFINHSDNPNLEAIGAFENGIFHIIIRAIKDILPGEELCYHYGPLYWKHRKKREEFVPQEE
EF
[00519] >hs_MBD2b
[00520] ASSPKKKRKVEASARYLGNTVDLSSFDFRTGKMMPSKLQKNKQRLRNDPLN
QNKGKPDLNTTLPIRQTASIFKQPVTKVTNHPSNKVKSDPQRMNEQPRQLFWEKRLQGL
SASDVTEQIIKTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEK PAV
WLNTSQPLCKAFIVTDEDIRKQEERVQQVRKILEDALMADILSRAADTEEMDIEMDSGD
EAEF
[00521] >ca_HST2
[00522] ASSPKKKRKVEASMPSLDDILKPVAEAVK GK VTFFNGAGISTGAGIPDFRS
PDTGLYANLAKLNLPFAEAVFDIDFFKEDPKPFYTLAEELYPGNFAPTKFHHFIKLLQDQ
GSLKRVYTQNIDTLERLAGVEDKYIVEAHGSFASNHCVDCHKEMTTETLKTYMKDKKI
PSCQHCEGYVKPDIVFFGEGLPVKFFDLWEDDCEDVEVAIVAGTSLTVFPFASLPGEVNK
KCLRVLVNKEKVGTFKHEPRKSDIIALHDCDIVAERLCTLLGLDDKLNEVYEKEKIKYSK
AETKEIKMHEIEDKLKEEAHLKEDKHTTKVDKKEKQNDANDKELEQLIDKAKAEF
[00523] >hs_PHF19
[00524] ASSPKKKRKVEASMENRALDPGTRDSYGATSHLPNKGALAKVKNNFKDLMS
KLTEGQYVLCRWTDGLYYLGKIKRVSSSKQSCLVTFEDNSKYWVLWKDIQHAGVPGEE
PKCNICLGKTSGPLNEILICGKCGLGYHQQCHIPIAGSADQPLLTPWFCRRCIFALAVRKG
GALK GAIARTLQAVKMVLSYQPEELEWDSPHRTNQQQCYCYCGGPGEWYLRMLQCY
RCRQWFHEACTQCLNEPMMFGDRFYLFFCSVCNQGPGGSGSDSSAEGASVPERPDEGID
SHTFESISEDDSSLSHLKSSITNYFGAAGRLACGEKYQVLARRVTPEGKVQYLVEWEGTT
PYEF
[00525] >hs_HDACl l
[00526] ASSPKKKRKVEASMLHTTQLYQHVPETRWPIVYSPRYNITFMGLEKLHPFDA GKWGKVINFLKEEKLLSDSMLVEAREASEEDLLVVHTRRYLNELKWSFAVATITEIPPVI FLPNFLVQRKVLRPLRTQTGGTIMAGKLAVERGWAINVGGGFHHCSSDRGGGFCAYAD ITLAIKFLFERVEGISRATIIDLDAHQGNGHERDFMDDKRVYIMDVYNRHIYPGDRFAKQ AIRR VELEWGTEDDEYLDKVER IK SLQEHLPDVVVYNAGTDILEGDRLGGLSISPA GIVKRDELVFRMVRGRRVPILMVTSGGYQKRTARIIADSILNLFGLGLIGPESPSVSAQNS DTPLLPPAVPEF
[00527] >ml_MesoLo4
[00528] ASSPKKKRKVEASMPLQIVHHPDYDAGFATNHRFPMSKYPLLMEALRARGL
ASPDALNTTEPAPASWLKLAHAADYVDQVISCSVPEKIEREIGFPVGPRVSLRAQLATGG
TILAARLALRHGIACNTAGGSHHARRAQGAGFCTFNDVAVASLVLLDEGAAQNILVVD
LDVHQGDGTADILSDEPGVFTFSMHGERNYPVRKIASDLDIALPDGTGDAAYLRRLATIL
PELSARARWDIVFYNAGVDVHAEDRLGRLALSNGGLRARDEMVIGHFRALGIPVCGVI
GGGYSTDVPALASRHAILFEVASTYAEF
[00529] >pbcvl_vSET
[00530] ASSPKKKRKVEASMFNDRVIVK SPLGGYGVFARKSFEKGELVEECLCIVRH NDDWGTALEDYLFSRK MSAMALGFGAIFNHSKDPNARHELTAGLKRMRIFTIKPIAIG EEITISYGDDYWLSRPRLTQNEF
[00531] >at_KYP
[00532] ASSPKKKRKVEASDISGGLEFKGIPATNRVDDSPVSPTSGFTYIKSLIIEPNVIIP
KSSTGCNCRGSCTDSK CACAKLNGGNFPYVDLNDGRLIESRDVVFECGPHCGCGPKC
VNRTSQKRLRFNLEVFRSAK GWAVRSWEYIPAGSPVCEYIGVVRRTADVDTISDNEYI
FEIDCQQTMQGLGGRQRRLRDVAVPMNNGVSQSSEDENAPEFCIDAGSTGNFARFINHS
CEPNLFVQCVLSSHQDIRLARVVLFAADNISPMQELTYDYGYALDSVHEF
[00533] >tg_TgSET8
[00534] ASSPKKKRKVEASASRRTGEFLRDAQAPSRWLKRSKTGQDDGAFCLETWLA
GAGDDAAGGERGRDREGAADKAKQREERRQKELEERFEEMKVEFEEKAQRMIARRAA
LTGEIYSDGKGSKKPRVPSLPENDDDALIEIIIDPEQGILKWPLSVMSIRQRTVIYQECLRR
DLTACIHLTKVPGKGRAVFAADTILKDDFVVEYKGELCSEREAREREQRYNRSKVPMGS
FMFYFK GSRMMAIDATDEKQDFGPARLINHSRRNPNMTPRAITLGDFNSEPRLIFVARR
NIEKGEELLVDYGERDPDVIKEHPWLNSEF
[00535] >hs_SIRT6
[00536] ASSPKKKRKVEASMSVNYAAGLSPYADKGKCGLPEIFDPPEELERKVWELAR L V WQ S S S V VFHTG AGI ST AS GIPDFRGPHG V WTMEERGL APKFDTTFE S ARPTQTHM AL VQLERVGLLRFLVSQNVDGLHVRSGFPRDKLAELHGNMFVEECAKCKTQYVRDTVVG TMGLKATGRLCTVAKARGLPvACRGELPvDTILDWEDSLPDRDLALADEASRNADLSITL GTSLQIRPSGNLPLATKRRGGRLVIVNLQPTKHDRHADLRIHGYVDEVMTRLMKHLGLE IPAWDGPRVLERALPPLEF
[00537] >ce_Setl
[00538] ASSPKKKRKVEASMKVAAKKLATSRMRKDRAAAASPSSDIENSENPSSLASH
SSSSGRMTPSK TRSRKGVSVKDVSNHKITEFFQVRRSNRKTSKQISDEAKHALRDTVL
KGTNERLLEVYKDVVKGRGIRTKVNFEKGDFVVEYRGVMMEYSEAKVIEEQYSNDEEI
GSYMYFFEHNNK WCIDATKESPWKGRLINHSVLRPNLKTKVVEIDGSHHLILVARRQI
AQGEELLYDYGDRSAETIAK PWLVNTEF
[00539] >mm_G9a
[00540] ASSPKKKRKVEASVRTEKIICRDVARGYENVPIPCVNGVDGEPCPEDYKYISE
NCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQLSIRCWYDKDGRLLQEFNKIEPPLIFE
CNQACSCWRSCK RVVQSGIKVRLQLYRTAKMGWGVRALQTIPQGTFICEYVGELISD
AEADVREDDSYLFDLDNKDGEVYCIDARYYGNISRFINHLCDPNIIPVRVFMLHQDLRFP
RIAFFSSRDIRTGEELGFDYGDRFWDIKSKYFTCQCGSEKCKHSAEAIALEQSRLARLDP
HPELLPDLSSLPPINTEF
[00541] >hs_SIRT5
[00542] AS SPKKKR VE AS S S SMADFR FF AKAKHI VIISGAGVS AESGVPTFRGAGG Y
WRKWQAQDLATPLAFAHNPSRVWEFYHYRREVMGSKEPNAGHRAIAECETRLGKQGR
RVVVITQNIDELHRKAGTK LLEIHGSLFKTRCTSCGVVAENYKSPICPALSGKGAPEPG
TQDASIPVEKLPRCEEAGCGGLLRPHVVWFGENLDPAILEEVDRELAHCDLCLVVGTSS
VVYPAAMFAPQVAARGVPVAEFNTETTPATNRFRFHFQGPCGTTLPEALACHENETVSE
F
[00543] >xl_HDAC8
[00544] ASSPKKKRKVEASMSRVVKPKVASMEEMAAFHTDAYLQHLHKVSEEGDND
DPETLEYGLGYDCPITEGIYDYAAAVGGATLTAAEQLIEGKTRIAVNWPGGWHHAKKD
EASGFCYLNDAVLGILKLREKFDRVLYVDMDLHHGDGVEDAFSFTSKVMTVSLHKFSP
GFFPGTGDVSDIGLGKGRYYSINVPLQDGIQDDKYYQICEGVLKEVFTTFNPEAVVLQLG
ADTIAGDPMCSFNMTPEGIGKCLKYVLQWQLPTLILGGGGYHLPNTARCWTYLTALIVG
RTLSSEIPDHEFFTEYGPDYVLEITPSCRPDRNDTQKVQEILQSIKGNLKRVVEF
[00545] >mm_HPla [00546] ASSPKKKRKVEASMKEGENNKPREKSEGNKRKSSFSNSADDIKSKKKREQSN DIARGFERGLEPEKIIGATDSCGDLMFLMKWKDTDEADLVLAKEANVKCPQIVIAFYEE RLTWHAYPEDAENKEKESAKSEF
[00547] >at_HDTl
[00548] ASSPKKKRKVEASMEFWGIEVKSGKPVTVTPEEGILIHVSQASLGECK K G EFVPLHVKVGNQNLVLGTLSTENIPQLFCDLVFDKEFELSHTWGKGSVYFVGYKTPNIEP QGYSEEEEEEEEEVPAGNAAKAVAKPKAKPAEVKPAVDDEEDESDSDGMDEDDSDGE DSEEEEPTPK PASSKKRANETTPKAPVSAKKAKVAVTPQKTDEKK GGKAANQSEF
[00549] >mm_SAll
[00550] ASSPKKKRKVEASMSRRKQAKPQHFQSDPEVASLPRRDGDTEKGQPSRPTKS KDAHVCGRCCAEFFELSDLLLHK SCTKNQLVLIVNESPASPAKTFPPGPSLNDEF
[00551] >hs_SETD8
[00552] ASSPKKKRKVEASSCDSTNAAIAKQALKKPIKGKQAPRKKAQGKTQQNRKL
TDFYPVRRSSRKSKAELQSEERKRIDELIESGKEEGMKIDLIDGKGRGVIATKQFSRGDFV
VEYHGDLIEITDAKKREALYAQDPSTGCYMYYFQYLSKTYCVDATRETNRLGRLINHSK
CGNCQTKLHDIDGVPHLILIASRDIAAGEELLYDYGDRSKASIEAFPWLKHEF
[00553] >sc RPD3
[00554] ASSPKKKRKVEASRRVAYFYDADVGNYAYGAGHPMKPHRIRMAHSLIMNY
GLYKKMEIYRAKPATKQEMCQFHTDEYIDFLSRVTPDNLEMFKRESVKFNVGDDCPVF
DGLYEYCSISGGGSMEGAARLNRGKCDVAVNYAGGLHHAK SEASGFCYLNDIVLGIIE
LLRYHPRVLYIDIDVHHGDGVEEAFYTTDRVMTCSFHKYGEFFPGTGELRDIGVGAGK
YAVNVPLRDGIDDATYRSVFEPVIKKIMEWYQPSAVVLQCGGDSLSGDRLGCFNLSME
GHANCVNYVKSFGIPMMVVGGGGYTMRNVARTWCFETGLL NVVLDKDLPYEF
[00555] >ec_CobB
[00556] ASSPKKKRKVEASMEKPRVLVLTGAGISAESGIRTFRAADGLWEEHRVEDVA
TPEGFDRDPELVQAFYNARRRQLQQPEIQPNAAHLALAKLQDALGDRFLLVTQNIDNLH
ERAGNTNVIHMHGELLKVRCSQSGQVLDWTGDVTPEDKCHCCQFPAPLRPHVVWFGE
MPLGMDEIYMALSMADIFIAIGTSGHVYPAAGFVHEAKLHGAHTVELNLEPSQVGNEFA
EKYYGPASQVVPEFVEKLLKGLKAGSIAEF
[00557] >hs_SUV39Hl [00558] ASSPK KR VEASNLKCVRILKQFHKDLERELLRRHHRSKTPRHLDPSLANY
LVQKAKQRRALRRWEQELNAKRSHLGRITVENEVDLDGPPRAFVYINEYRVGEGITLNQ
VAVGCECQDCLWAPTGGCCPGASLHKFAYNDQGQVRLRAGLPIYECNSRCRCGYDCP
NRVVQKGIRYDLCIFRTDDGRGWGVRTLEKIRK SFVMEYVGEIITSEEAERRGQIYDRQ
GATYLFDLDYVEDVYTVDAAYYGNISHFVNHSCDPNLQVYNVFIDNLDERLPRIAFFAT
RTIRAGEELTFDYNMQVDPVDMESTRMDSNFGLAGLPGSPKKRVRIECKCGTESCRKYL
FEF
[00559] >hs RCOR1
[00560] AS SPKKKR VE ASSNS WEEGS SGS S SDEEHGGGGMRVGPQ YQ AVVPDFDP A
KLARRSQERDNLGMLVWSPNQNLSEAKLDEYIAIAKEKHGYNMEQALGMLFWHKHNI
EKSLADLPNFTPFPDEWTVEDKVLFEQAFSFHGKTFHRIQQMLPDKSIASLVKFYYSWK
KTRTKTSVMDRHARKQKREREESEDELEEANG NPIDIEVDQNKESKKEVPPTETVPQV
KKEKHSTEF
[00561] >hs_sin3a
[00562] AS SPKXKRXVE AS YKE!S VHLET YPKERATEGI AMEID Y ASCKRLGS S YRALP
KSYQQPKCTGRTPLCKEVLNDTWVSFPSWSEDSTFVSSKKTQYEEHIYRCEDERFELDV
VLETNLATIRVLEAIQKKLSRLSAEEQAKFRLDNTLGGTSEVIHRKALQRIYADKAADIID
GLRK PSIAVPIVLKRLKMKEEEWREAQRGFNKVWREQNEKYYLKSLDHQGINFKQND
TKVLRSKSLLNEIESIYDERQEQATEENAGVPVGPHLSLAYEDKQILEDAAALIIHHVKR
QTGIQKEDKYKIKQIMHHFIPDLLFAQRGDLSDVEEEEEEEMDVDEATGAVEF
[00563] >at_SUVR4
[00564] ASSPKKKRKVEASQSAYLHVSLARISDEDCCANCKGNCLSADFPCTCARETS
GEYAYTKEGLLKEKFLDTCLKMK EPDSFPKVYCKDCPLERDHDKGTYGKCDGHLIRK
FIKECWRKCGCDMQCGNRVVQRGIRCQLQVYFTQEGKGWGLRTLQDLPKGTFICEYIG
EILTNTEL YDRNVRS S SERHT YP VTLD AD WGSEKDLKDEE ALCLD ATICGNVARFINHR
CEDANMIDIPIEIETPDRHYYHIAFFTLRDVKAMDELTWDYMIDFNDKSHPVKAFRCCC
GSESCRDRKIKGSQGKSIERRKIVSAK QQGSKEVSKKRKEF
[00565] >rn_MeCP2_NLS
[00566] ASSPKKKRKVEASVQVKRVLEKSPGKLLVKMPFQASPGGKGEGGGATTSAQ VMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPI KKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPK KEHHHHHHHAESPKAPMPLLPPPPPPEPQSSEDPISPPEPQDLSSSICKEEKMPRAGSLESD
GCPKEPAKTQPMVAAAATTTTTTTTTVAEKYKHRGEGEPvKDIVSSSMPRPNREEPVDSR
TPVTERVSEF
[00567] >mm_SET-TAF 1 B
[00568] ASSPKKKRKVEASMAPKRQSAILPQPKKPRPAAAPKLEDKSASPGLPKGEKE
QQEAIEHIDEVQNEIDRLNEQASEEILKVEQKYNKLRQPFFQKRSELIAKIPNFWVTTFVN
HPQVSALLGEEDEEALHYLTRVEVTEFEDIKSGYRIDFYFDENPYFENKVLSKEFHLNES
GDPSSKSTEIKWKSGKDLTKRSSQTQNKASRKRQHEEPESFFTWFTDHSDAGADELGEV
IKDDIWPNPLQYYLVPDMDDEEGEAEDDDDDDEEEEGLEDIDEEGDEDEGEEDDDEDE
GEEGEEDEGEDDEF
[00569] >ce_Set4
[00570] ASSPK KRKVEASMQLHEQIANISVTFNDIPRSDHSMTPTELCYFDDFATTLV
VDSVLNFTTHKMSKKRRYLYQDEYRTARTVMKTFREQRDWTNAIYGLLTLRSVSHFLS
KLPPNKLFEFRDHIVRFLNMFILDSGYTIQECKRYSQEGHQGAKLVSTGVWSRGDKIERL
SGVVCLLSSEDEDSILAQEGSDFSVMYSTRKRCSTLWLGPGAYINHDCRPTCEFVSHGST
AHIRVLRDMVPGDEITCFYGSEFFGP NIDCECCTCEK MNGAFSYLRGNENAEPIISEK
KTKYELRSRSEF
[00571] Photostimulation Hardware Control Scripts
[00572] The following Arduino script was used to enable the individual control of each 4-well column of a light-stimulated 24-well plate
[00573] //Basic control code for LITE LED array using Arduino UNO
[00574] //LED column address initial ization to PWM-ready Arduino outputs
[00575] int I ed1_p i n = 3;
[00576] int Ied2_pin = 5;
[00577] int Ied3_pin = 6;
[00578] int Ied4_pin = 9;
[00579] int Ied5_pin = 10;
[00580] i nt I ed6_p in = 11;
[00581] //Maximum setting for Arduino PWM
[00582] int uniform_brightness = 255;
[00583] //PWM settings for individual LED columns
[00584] int I ed1_br i ghtness = uniform_brightness/2;
[00585] int I ed2_bri ghtness = uniform_brightness/2;
[00586] int I ed3_bri ghtness = uniform_brightness/2;
[00587] int I ed4_bri ghtness = uniform_brightness/2; [00588] int 1 ed5_br i g ;htness = uniform_brightness/2;
[00589] int 1 ed6_br i g ;htness = uniform_brightness/2;
[00590] //'on' time i in msec
[00591] unsi gned I oni ; uniform_stim_time = 1000; /
[00592] //individual 'on' time settings for LED columns
[00593] unsi gned I oni ; I ed1_st im_t ime = uniform_stim_time
[00594] unsi gned I oni ; Ied2_stim_time = uniform_stim_time
[00595] unsi gned I oni ; Ied3_stim_time = uniform_stim_time
[00596] unsi gned I oni ; Ied4_stim_time = uniform_stim_time
[00597] unsi gned I oni ; Ied5_stim_time = uniform_stim_time
[00598] unsi gned I oni ; Ied6_stim_time = uniform_stim_time
[00599] //'off time in msec
[00600] unsi gned I oni ; uniform_off_time = 14000;
[00601] //individual 'off time settings for LED columns
[00602] unsi gned I oni ; I ed1_of f_t ime = uniform_off_time;
[00603] unsi gned I oni ; led2_off_time = uniform_off_time;
[00604] unsi gned I oni ; led3_off_time = uniform_off_time;
[00605] unsi gned I oni ; led4_off_time = uniform_off_time;
[00606] unsi gned I oni ; led5_off_time = uniform_off_time;
[00607] unsi gned I oni ; led6_off_time = uniform_off_time;
[00608] unsi gned I oni ; currentMi 11 is = 0;
[00609] //initial ize timing and state variables
[00610] unsi gned I oni ; Ied1_last_change = 0;
[00611] unsi gned I oni ; Ied2_last_change = 0;
[00612] unsi gned I oni ; Ied3_last_change = 0;
[00613] unsi gned I oni ; Ied4_last_change = 0;
[00614] unsi gned I oni ; Ied5_last_change = 0;
[00615] unsi gned I oni ; Ied6_last_change = 0;
[00616] int Ied1_ .state = HIGH;
[00617] int Ied2_ .state = HIGH;
[00618] int Ied3_ .state = HIGH;
[00619] int Ied4_ .state = HIGH;
[00620] int Ied5_ .state = HIGH;
[00621] int Ied6_ .state = HIGH;
[00622] unsi gned I oni ; I ed1_t i mer = 0;
[00623] unsi gned I oni ; Ied2_timer = 0;
[00624] unsi gned I oni ; Ied3_timer = 0;
[00625] unsi gned I oni ; Ied4_timer = 0;
[00626] unsi gned I oni ; Ied5_timer = 0;
[00627] unsi gned I oni ; Ied6_timer = 0;
[00628] void setup 0 [ [00629] // setup PWM pins for output
[00630] pinMode(led1_pin, OUTPUT) ;
[00631] pinMode(led2_pin, OUTPUT) ;
[00632] pinMode(led3_pin, OUTPUT) ;
[00633] pinMode(led4_pin, OUTPUT) ;
[00634] pinMode(led5_pin, OUTPUT) ;
[00635] pinMode(led6_pin, OUTPUT) ;
[00636] //LED starting state
[00637] ana I ogWr i te (I ed1_p i n, I ed 1 _b r ightness) ;
[00638] analogWrite(led2_pin, I ed2_br ightness) ;
[00639] analogWrite(led3_pin, I ed3_br ightness) ;
[00640] analogWrite(led4_pin, I ed4_br ightness) ;
[00641] analogWrite(led5_pin, I ed5_br ightness) ;
[00642] analogWrite(led6_pin, I ed6_br ightness) ;
[00643] }
[00644] void loopO [
[00645] currentMi 11 is = mi 11 is () ;
[00646] //identical timing loops for the 6 PWM output pins
[00647] Ied1_timer = currentMi 11 is - Ied1_last_change;
[00648] if (Ied1_state == HIGH) [ //led state is on
[00649] if (Ied1_timer >= Ied1_stim_time) [ //TRUE if stim time is complete
[00650] analogWrite(led1_pin, 0) ; //turn LED off
[00651] Ied1_state = LOW; //change LED state variable
[00652] Ied1_last_change = currentMi 11 is; //mark time of most recent change
[00653] }
[00654] }
[00655] else[ // I ed1 state is off
[00656] if (I ed1_timer >= led1_off_time) [ //TRUE if off time is complete
[00657] analogWrite(led1_pin, I ed1_br i ghtness) ; //turn LED on
[00658] Ied1_state = HIGH; //change LED state variable
[00659] Ied1_last_change = currentMi 11 is; //mark time of most recent change
[00660] }
[00661] }
[00662] I ed2_t imer = currentMi 11 is - Ied2_last_change;
[00663] if (Ied2_state == HIGH) [
[00664] if (Ied2_timer >= Ied2_stim_time) [
[00665] ana I ogWr i te ( I ed2_p in, 0) ;
[00666] Ied2_state = LOW;
[00667] Ied2_last_change = currentMi 11 is;
[00668] }
[00669] } [00670] else[ // I ed2 state is off
[00671] if (Ied2_timer >= led2_off_time) [
[00672] ana I ogWr i te ( I ed2_p i n, I ed2_br i ghtness) ;
[00673] Ied2_state = HIGH;
[00674] Ied2_last_change = currentMi 11 is;
[00675] }
[00676] }
[00677] I ed3_t imer = currentMi 11 is - Ied3_last_change;
[00678] if (Ied3_state == HIGH) [
[00679] if (Ied3_timer >= Ied3_stim_time) [
[00680] ana I ogWr i te ( I ed3_p in, 0) ;
[00681] Ied3_state = LOW;
[00682] Ied3_last_change = currentMi 11 is;
[00683] }
[00684] }
[00685] else[ // I ed3 state is off
[00686] if (Ied3_timer >= led3_off_time) [
[00687] ana I ogWr i te ( I ed3_p i n, I ed3_br i ghtness) ;
[00688] Ied3_state = HIGH;
[00689] Ied3_last_change = currentMi 11 is;
[00690] }
[00691] }
[00692] I ed4_t imer = currentMi 11 is - Ied4_last_change;
[00693] if (Ied4_state == HIGH) [
[00694] if (Ied4_timer >= Ied4_stim_time) [
[00695] ana I ogWr i te ( I ed4_p in, 0) ;
[00696] Ied4_state = LOW;
[00697] Ied4_last_change = currentMi 11 is;
[00698] }
[00699] }
[00700] else[ // I ed4 state is off
[00701] if (Ied4_timer >= led4_off_time) [
[00702] ana I ogWr i te ( I ed4_p i n, I ed4_br i ghtness) ;
[00703] Ied4_state = HIGH;
[00704] Ied4_last_change = currentMi 11 is;
[00705] }
[00706] }
[00707] I ed5_t imer = currentMi 11 is - Ied5_last_change;
[00708] if (Ied5_state == HIGH) [
[00709] if (Ied5_timer >= Ied5_stim_time) [
[00710] analogWrite(led5_pin, 0) ; [00711] Ied5_state = LOW;
[00712] Ied5_last_change = currentMi 11 is;
[00713] }
[00714] }
[00715] else[ // I ed5 state is off
[00716] if (Ied5_timer >= led5_off_time) [
[00717] ana I ogWr i te ( I ed5_p i n, I ed5_br i ghtness) ;
[00718] Ied5_state = HIGH;
[00719] Ied5_last_change = currentMi 11 is;
[00720] }
[00721] }
[00722] I ed6_t imer = currentMi 11 is - Ied6_last_change;
[00723] if (Ied6_state == HIGH) [
[00724] if (Ied6_timer >= Ied6_stim_time) [
[00725] ana I ogWr i te ( I ed6_p in, 0) ;
[00726] Ied6_state = LOW;
[00727] Ied6_last_change = currentMi 11 is;
[00728] }
[00729] }
[00730] else[ // I ed6 state is off
[00731] if (Ied6_timer >= led6_off_time) [
[00732] ana I ogWr i te ( I ed6_p i n, I ed6_br i ghtness) ;
[00733] Ied6_state = HIGH;
[00734] Ied6_last_change = currentMi 11 is;
[00735] }
[00736] }
[00737] }
Example 12
Optical Control of Endogenous Mammalian Transcription
[00738] To test the efficacy of AAV-mediated TALE delivery for modulating transcription in primary mouse cortical neurons, Applicants constructed six TALE-DNA binding domains targeting the genetic loci of three mouse neurotransmitter receptors: Grm5, Grin2a, and Grm2, which encode mGluR5, NMDA subunit 2 A and mGluR2, respectively (FIG.58). To increase the likelihood of a target site accessibility, Applicants used mouse cortex DNase I sensitivity data from the UCSC genome browser to identify putative open chromatin regions. DNase I sensitive regions in the promoter of each target gene provided a guide for the selection of TALE binding sequences (FIG.46). For each TALE, Applicants employed VP64 as a transcriptional activator or a quadruple tandem repeat of the mSin3 interaction domain (SID) (Beerli, R.R., Segal, D.J., Dreier, B. & Barbas, C.F., 3rd Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A 95, 14628-14633 (1998) and Ayer, D.E., Laherty, CD., Lawrence, Q.A., Armstrong, A.P. & Eisenman, R.N. Mad proteins contain a dominant transcription repression domain. Molecular and Cellular Biology 16, 5772-5781 (1996)) as a repressor. Applicants have previously shown that a single SID fused to TALE downregulated a target gene effectively in 293FT cells (Cong, L., Zhou, R., Kuo, Y.-c, Cunniff, M. & Zhang, F. Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun 3, 968 (2012)). Hoping to further improve this TALE repressor, Applicants reasoned that four repeats of SID - analogous to the successful quadruple VP 16 repeat architecture of VP64 (Beerli, R.R., Segal, D.J., Dreier, B. & Barbas, C.F., 3rd Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A 95, 14628-14633 (1998) - might augment its repressive activity. This was indeed the TALE-SID4X constructs enhanced repression ~2-fold over TALE-SID in 293FT cells (FIG. 54).
[00739] Applicants found that four out of six TALE-VP64 constructs (Tl, T2, T5 and T6) efficiently activated their target genes Grm5 and Grm2 in AAV-transduced primary neurons by up to 3- and 8-fold, respectively (FIG. 58). Similarly, four out of six TALE-SID4X repressors (T9, T10, T11, T12) reduced the expression of their endogenous targets Grin2a and Grm2 by up to 2- and 8-fold, respectively (FIG. 58). Together, these results indicate that constitutive TALEs can positively or negatively modulate endogenous target gene expression in neurons. Notably, efficient activation or repression by a given TALE did not predict its efficiency at transcriptional modulation in the opposite direction. Therefore, multiple TALEs may need to be screened to identify the most effective TALE for a particular locus.
[00740] For a neuronal application of LITEs, Applicants selected the Grm2 TALE (T6), which exhibited the strongest level of target upregulation in primary neurons, based on Applicants' comparison of 6 constitutive TALE activators (FIG. 58). Applicants investigated its function using 2 light pulsing frequencies with the same duty cycle of 0.8%. Both stimulation conditions achieved a ~7-fold light-dependent increase in Grm2 mRNA levels (FIG. 38C). Further study confirmed that, significant target gene expression increases could be attained quickly (4-fold upregulation within 4 h; FIG. 38D). In addition, Applicants observed significant upregulation of mGluR2 protein after stimulation, demonstrating that changes effected by LITEs at the m NA level are translated to the protein domain (FIG. 38E). Taken together, these results confirm that LITEs enable temporally precise optical control of endogenous gene expression in neurons.
[00741] As a compliment to Applicants' previously implemented LITE activators, Applicants next engineered a LITE repressor based on the TALE-SID4X constructs. Constitutive Grm2 TALEs (Ti l and T12, FIG. 59A) mediated the highest level of transcription repression, and were chosen as LITE repressors (FIG. 59 A, B). Both light-induced repressors mediated significant downregulation of Grm2 expression, with 1.95-fold and 1.75-fold reductions for Ti l and T12, respectively, demonstrating the feasibility of optically controlled repression in neurons (FIG. 38G).
[00742] In order to deliver LITEs into neurons using AAV, Applicants had to ensure that the total viral genome size, with the LITE transgenes included, did not exceed 4.8 kb (Wu, Z., Yang, H. & Colosi, P. Effect of Genome Size on AAV Vector Packaging. Mo I Ther 18, 80-86 (2009) and Dong JY, F.P., Frizzell RA Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Human Gene Therapy 7, 2101-2112 (1996)). To that end, Applicants shortened the TALE N- and C-termini (keeping 136 aa in the N-terminus and 63 aa in the C- terminus) and exchanged the CRY2PHR and CIB1 domains (TALE-CIB 1 and CRY2PHR-VP64; FIG. 38A). This switch allowed each component of LITE to fit into AAV vectors and did not reduce the efficacy of light-mediated transcription modulation (FIG. 60). These LITEs can be efficiently delivered into primary cortical neurons via co-transduction by a combination of two AAV vectors (FIG. 38B; delivery efficiencies of 83-92% for individual components with >80% co-transduction efficiency).
Example 13
Inducible lentiviral Cas9
[00743] Lentivirus preparation. After cloning pCasESlO (which contains a lentiviral transfer plasmid backbone), HEK293FT at low passage (p=5) were seeded in a T-75 flask to 50% confluence the day before transfection in DMEM with 10% fetal bovine serum and without antibiotics. After 20 hours, media was changed to OptiMEM (serum-free) media and transfection was done 4 hours later. Cells were transfected with lOug of lentiviral transfer plasmid (pCasESlO) and the following packaging plasmids: 5ug of pMD2.G (VSV-g pseudotype), and 7.5ug of psPAX2 (gag/pol/rev/tat). Transfection was done in 4mL OptiMEM with a cationic lipid delivery agent (50uL Lipofectamine 2000 and lOOul Plus reagent). After 6 hours, the media was changed to antibiotic-free DMEM with 10% fetal bovine serum.
[00744] Lentivirus purification. Viral supernatants were harvested after 48 hours. Supernatants were first cleared of debris and filtered through a 0.45um low protein binding (PVDF) filter. They were then spun in a ultracentrifuge for 2 hours at 24,000 rpm. Viral pellets were resuspended in 50ul of DMEM overnight at 4C. They were then aliquotted and immediately frozen at -80C.
[00745] Clonal isolation using FACS. For clonal isolation of HEK293FT and HUES64 human embryonic stem cells, cells were infected in suspension with either lul or 5ul of purified virus. Twenty-four hours post infection, luM doxycycline was added to the cell culture media. After 24 or 48 hours more, cells underwent fluorescence-assisted cell sorting (FACS ) on a BD FACSAria IIu instrument to isolate single cells that robustly expressed EGFP (and hence Cas9) after doxycycline treatment. Cell were plated either in bulk or into individual wells to allow selection of clonal populations with an integrated inducible Cas9 for further use. Sort efficiency was always >95% and cells were visualized immediately after plating to verify EGFP fluorescence.
[00746] FIG. 61 depicts Tet Cas9 vector designs
[00747] FIG. 62 depicts a vector and EGFP expression in 293FT cells.
[00748] Sequence of pCasES020 inducible Cas9:
[00749] caactttgtatagaaaagttggctccgaattcgcccttcaggtccgaggttctagacgagtttactccctatcagtgatagaga acgatgtcgagtttactccctatcagtgatagagaacgtatgtcgagtttactccctatcagtgatagagaacgtatgtcgagtttactccctatc agtgatagagaacgtatgtcgagtttatccctatcagtgatagagaacgtatgtcgagtttactccctatcagtgatagagaacgtatgtcgag gtaggcgtgtacggtgggaggcctatataagcagagctcgtttagtgaaccgtcagatcgcaaagggcgaattcgacccaagtttgtacag ccaccATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAA
AGACGATGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGA
GTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGT
GGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGC
TGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTC
GACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGAT
ACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATG
GCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGA GGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCT
ACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACC
GACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGG
GGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCT
GTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACG
CCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGG
CTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGCAA
CCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGC
CGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACC
TGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGT
CCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCC
CCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCT
GCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGA
CCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAG
TTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCT
CGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCA
GCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAA
GATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTC
CGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGAT
GACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGAC
AAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCT
GCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGT
ATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTC
CTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAA
AGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACT
CCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCAC
GATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGA
CATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGA
GGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGA
AGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATC
CGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGC CAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACA
TCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAAT
CTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGA
CGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGG
CCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAA
GCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCC
GTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGG
GCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATG
TGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGC
TGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGT
CGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC
AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGAT
AAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGT
GGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGA
TCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAG
GATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCC
TACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAG
CGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGA
GCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATG
AACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCT
GATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTG
CCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAG
GTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAA
GCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCC
CCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAG
AAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTT
CGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGG
ACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAG
AGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTC
CAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCC
CGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACG AGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAAT
CTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCA
GGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTT
CAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGC
TGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGAC
CTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGG
CAAAAAAGAAAAAGgaattctctagaGGCAGTGGAGAGGGCAGAGGAAGTCTGCTAACAT
GCGGTGACGTCGAGGAGAATCCTGGCCCAGTGAGCAAGGGCGAGGAGCTGTTCACC
GGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAG
CGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCA
TCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCA
AGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC
GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCG
CATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGC
TGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC
GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCT
CGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCG
ACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGC
GATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGCTCGAGGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGC
TGGCGACGTGGAGGAGAACCCTGGACCTatgtctaggctggacaagagcaaagtcataaacggagctctggaa ttactcaatggtgtcggtatcgaaggcctgacgacaaggaaactcgctcaaaagctgggagttgagcagcctaccctgtactggcacgtga agaacaagcgggccctgctcgatgccctgccaatcgagatgctggacaggcatcatacccacttctgccccctggaaggcgagtcatggc aagactttctgcggaacaacgccaagtcataccgctgtgctctcctctcacatcgcgacggggctaaagtgcatctcggcacccgcccaac agagaaacagtacgaaaccctggaaaatcagctcgcgttcctgtgtcagcaaggcttctccctggagaacgcactgtacgctctgtccgcc gtgggccactttacactgggctgcgtattggaggaacaggagcatcaagtagcaaaagaggaaagagagacacctaccaccgattctatg cccccacttctgagacaagcaattgagctgttcgaccggcagggagccgaacctgccttccttttcggcctggaactaatcatatgtggcctg gagaaacagctaaagtgcgaaagcggcgggccgaccgacgcccttgacgattttgacttagacatgctcccagccgatgcccttgacgatt ttgaccttgacatgctccccgggtaatgtacaaagtggtgaattccggcaattcgatatcaagcttatcgataatcaacctctggattacaaaatt tgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatgg ctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttg ctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaac tcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttc cttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccg cggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcatcgata ccgtcgacctcgagacctagaaaaacatggagcaatcacaagtagcaatacagcagctaccaatgctgattgtgcctggctagaagcaca agaggaggaggaggtgggttttccagtcacacctcaggtacctttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaa agaaaaggggggactggaagggctaattcactcccaacgaagacaagatatccttgatctgtggatctaccacacacaaggctacttccct gattggcagaactacacaccagggccagggatcagatatccactgacctttggatggtgctacaagctagtaccagttgagcaagagaag gtagaagaagccaatgaaggagagaacacccgcttgttacaccctgtgagcctgcatgggatggatgacccggagagagaagtattaga gtggaggtttgacagccgcctagcatttcatcacatggcccgagagctgcatccggactgtactgggtctctctggttagaccagatctgagc ctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtg actctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcgactgtgc cttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgagg aaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaagacaatag caggcatgctggggatgcggtgggctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgcgccctgta gcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttc ccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgac cccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaat agtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaa aaatgagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggc agaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatg catctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggc tgactaattttttttatttatgcagaggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggctttt gcaaaaagctcccgggagcttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcatagtatatcggcatagtataat acgacaaggtgaggaactaaaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttc tggaccgaccggctcgggttctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcg gtccaggaccaggtggtgccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcg tgtccacgaacttccgggacgcctccgggccggccatgaccgagatcggcgagcagccgtgggggcgggagttcgccctgcgcgacc cggccggcaactgcgtgcacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattccaccgccgccttctatgaaaggtt gggcttcggaatcgttttccgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttatt gcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcat caatgtatcttatcatgtctgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctca caattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctca ctgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgct cttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatcca cagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtt tttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagatacca ggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtg gcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagccc gaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggat tagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcg ctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaa gcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgtt aagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaa acttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgt agataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagc aataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagcta gagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattca gctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaa gtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtga gtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagca gaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccact cgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaat aagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttg aatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtcgacggatcgggagatctcccgatc ccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctgcttgtgtgttggaggtcgctgagtagtgc gcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgcttagggttaggcgttttgcgctgcttcgcgat gtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttcc gcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagta acgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagta cgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatcta cgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcc accccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgg gcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtctctctggttagaccagatctgagcctgggagctc tctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaa ctagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccagag gagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgaggggcggcgactggtgagtacgccaaaaattttgac tagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggggagaattagatcgcgatgggaaaaaattcggttaa ggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcagggagctagaacgattcgcagttaatcctggcctgttaga aacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacaggatcagaagaacttagatcattatataatacagtag caaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttagacaagatagaggaagagcaaaacaaaagtaaga ccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaatataaagta gtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagcttt gttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacgctgacggtacaggccagacaattattgtctggtatag tgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggcaa gaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttggggttgctctggaaaactcatttgcaccactgctgtgcctt ggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctggatggagtgggacagagaaattaacaattacacaagc ttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaattattggaattagataaatgggcaagtttgtggaatt ggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggaggcttggtaggtttaagaatagtttttgctgtactttctatag tgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaaccccgaggggacccgacaggcccgaaggaatagaag aagaaggtggagagagagacagagacagatccattcgattagtgaacggatcggcactgcgtgcgccaattctgcagacaaatggcagt attcatccacaattttaaaagaaaaggggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaact aaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacagggacagcagagatccagtttggttaattaa
1. An inducible method of altering expression of a genomic locus of interest in a cell comprising:
(a) contacting the genomic locus with a non-naturally occurring or engineered composition comprising a deoxyribonucleic acid (DNA) binding polypeptide comprising:
(i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or (ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source;
(b) applying the energy source; and
(c) determining that the expression of the genomic locus is altered.
2. The method according to paragraph 1, wherein the at least one or more effector domains is selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-protein recruiting domain, cellular uptake activity associated domain, nucleic acid binding domain and antibody presentation domain.
3. The method according to paragraph 2, wherein the at least one or more effector domains is a nuclease domain or a recombinase domain.
4. The method according to paragraph 3, wherein the nuclease domain is a non-specific Fokl endonuclease catalytic domain.
5. The method according to any one of paragraphs 1-4, wherein the energy sensitive protein is Cryptochrome-2 (CRY2).
6. The method according to any one of paragraphs 1-5, wherein the interacting partner is Cryptochrome -interacting basic helix-loop-helix (CIB1).
7. The method according to any of paragraphs 1-6, wherein the energy source is selected from the group consisting of: electromagnetic radiation, sound energy or thermal energy.
8. The method according to paragraph 7, wherein the electromagnetic radiation is a component of visible light. 9. The method according to paragraph 8, wherein the component of visible light has a wavelength in the range of 450nm-500nm.
10. The method according to paragraph 8, wherein the component of visible light is blue light.
11. The method according to paragraph 1, wherein the applying the energy source comprises stimulation with blue light at an intensity of at least 6.2mW/cm2.
12. The method according to any one of paragraphs 1-11, wherein the DNA binding domain comprises (X1-u-X12X13-X14-33 OT 34 or 35)z,
wherein Xi_n is a chain of 11 contiguous amino acids,
wherein X12X13 is a repeat variable diresidue (RVD),
wherein X14-33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids,
wherein z is at least 5 to 40, and
wherein at least one RVD is selected from the group consisting of NI, HD, NG, NN, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, HI, KI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA, and NC, wherein (*) means that the amino acid at Xi3 is absent.
13. The method according to paragraph 12, wherein z is at least 10 to 26.
14. The method according to paragraph 12, wherein
at least one of Xi_n is a sequence of 12 contiguous amino acids set forth as amino acids 1-11 in a sequence (Xi_n-Xi4-34 or Xi_n-Xi4_35) of FIG. 9 or
at least one of X 14-34 or X14-35 is a sequence of 21 or 22 contiguous amino acids set forth as amino acids 12-32 or 12-33 in a sequence (Xi_n-Xi4-34 or Xi_n-Xi4_35) of FIG. 9 .
15. The method according to paragraph 12, wherein the at least one RVD is selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS for recognition of guanine (G); (b) SI for recognition of adenine (A); (c) HG, KG, RG for recognition of thymine (T); (d) RD, SD for recognition of cytosine (C); (e) NV for recognition of A or G; and (f) H*, HA, KA, N*, NA, NC, NS, RA, S* for recognition of A or T or G or C, wherein (*) means that the amino acid at Xi3 is absent.
16. The method according to paragraph 15, wherein
the RVD for the recognition of G is RN, NH, RH or KH; or
the RVD for the recognition of A is SI; or the RVD for the recognition of T is KG or RG; and
the RVD for the recognition of C is SD or RD.
17. The method according to paragraph 12, wherein at least one of the following is present
[LTLD] or [LTLA] or [LTQV] at Xi_4, or
[EQHG] or [RDHG] at positions X30-33 or X3i_34 or X32-35.
18. The method according to any one of paragraphs 1-17, wherein
the N-terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the
C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region.
19. The method according to any one of paragraphs 1-18, wherein the genomic locus of interest is associated with a gene that encodes for a differentiation factor, a transcription factor, a neurotransmitter transporter, a neurotransmitter synthase, a synaptic protein, a plasticity protein, a presynaptic active zone protein, a post synaptic density protein, a neurotransmitter receptor, an epigenetic modifier, a neural fate specification factor, an axon guidance molecule, an ion channel, a CpG binding protein, a ubiquitination protein, a hormone, a homeobox protein, a growth factor, an oncogenes or a proto-oncogene.
20. An inducible method of repressing expression of a genomic locus of interest in a cell comprising:
(a) contacting the genomic locus with a non-naturally occurring or engineered composition comprising a DNA binding polypeptide comprising:
(i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or (ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source;
(b) applying the energy source; and
(c) determining that the expression of the genomic locus is repressed.
21. The method according to paragraph 20, wherein the polypeptide includes at least one SID repressor domain.
22. The method according to paragraph 21, wherein the polypeptide includes at least four SID repressor domains.
23. The method according to paragraph 21, wherein the polypeptide includes a SID4X repressor domain.
24. The method according to paragraph 20, wherein the polypeptide includes a KRAB repressor domain.
25. The method according to any one of paragraphs 20-24, wherein the energy sensitive protein is Cryptochrome-2 (CRY2).
26. The method according to any one of paragraphs 20-25, wherein the interacting partner is Cryptochrome-interacting basic helix-loop-helix (CIB1).
27. The method according to any one of paragraphs 20-26, wherein the energy source is selected from the group consisting of: electromagnetic radiation, sound energy or thermal energy.
28. The method according to paragraph 20, wherein the electromagnetic radiation is a component of visible light.
29. The method according to paragraph 28, wherein the component of visible light has a wavelength in the range of 450nm-500nm.
30. The method according to paragraph 28, wherein the component of visible light is blue light. 31. The method according to paragraph 20, wherein the applying the energy source comprises stimulation with blue light at an intensity of at least 6.2mW/cm2.
32. The method according to paragraph 20-31, wherein the DNA binding domain comprises (X1-n-X12X13-X14-33 or 34 or 3s)z,
wherein Xi_n is a chain of 11 contiguous amino acids,
wherein X12X13 is a repeat variable diresidue (RVD),
wherein X14-33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids,
wherein z is at least 5 to 40, and
wherein at least one RVD is selected from the group consisting of NI, HD, NG, NN, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, HI, KI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA, and NC, wherein (*) means that the amino acid at Xi3 is absent.
33. The method according to paragraph 32, wherein z is at least 10 to 26.
34. The method according to paragraph 32, wherein
at least one of Xi_n is a sequence of 11 contiguous amino acids set forth as amino acids 1-11 in a sequence (Xi_n-Xi4-34 or Xi_n-Xi4_35) of FIG. 9 or
at least one of X 14-34 or X14-35 is a sequence of 21 or 22 contiguous amino acids set forth as amino acids 12-32 or 12-33 in a sequence (Xi_n-Xi4_34 or Χι_ιι-Χι4_35) of FIG. 9.
35. The method according to any one of paragraphs 20-34, wherein
the N-terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the
C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region.
36. The method according to any one of paragraphs 20-35, wherein the genomic locus of interest is the genomic locus associated with a gene that encodes for a differentiation factor or a component of an ion channel. 37. The method according to paragraph 36, wherein the differentiation factor is SRY- box-2 (SOX2) and is encoded by the gene SOX2.
38. The method according to paragraph 36, wherein the differentiation factor is pl l and is encoded by the gene pll.
39. The method according to paragraph 36, wherein the component of the ion channel is CACNA1C and is encoded by the gene CACNA1C.
40. An inducible method of activating expression of a genomic locus of interest in a cell comprising:
(a) contacting the genomic locus with a non-naturally occurring or engineered composition comprising a DNA binding polypeptide comprising:
(i) a DNA binding domain comprising at least five or more TALE monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or at least one or more activator domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or
at least one or more activator domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source;
(b) applying the energy source; and
(c) determining that the expression of the genomic locus is activated.
41. The method according to paragraph 40, wherein the polypeptide includes at least one VP 16 or VP64 activator domain.
42. The method according to paragraph 40, wherein the polypeptide includes at least one p65 activator domain.
43. The method according to any one of paragraphs 40-42, wherein the energy sensitive protein is CRY2.
44. The method according to any one of paragraph 40-43, wherein the interacting partner is CIB1. 45. The method according to paragraph 40, wherein the energy source is selected from the group consisting of: electromagnetic radiation, sound energy or thermal energy.
46. The method according to paragraph 45, wherein the electromagnetic radiation is a component of visible light.
47. The method according to paragraph 46, wherein the component of visible light has a wavelength in the range of 450nm-500nm.
48. The method according to paragraph 46, wherein the component of visible light is blue light.
49. The method according to paragraph 40, wherein the applying the energy source comprises stimulation with blue light at an intensity of at least 6.2mW/cm2.
50. The method according to any one of paragraphs 40-49, wherein the DNA binding domain comprises p 1-u-X12X13-X14-33 OT 34 or 35)z,
wherein Xi_n is a chain of 11 contiguous amino acids,
wherein X12X13 is a repeat variable diresidue (RVD),
wherein X14-33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids,
wherein z is at least 5 to 40, and
wherein at least one RVD is selected from the group consisting of NI, HD, NG, NN, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, HI, KI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA, and NC, wherein (*) means that the amino acid at Xi3 is absent.
51. The method according to paragraph 50, wherein z is at least 10 to 26.
52. The method according to paragraph 50, wherein
at least one of Xi_n is a sequence of 11 contiguous amino acids set forth as amino acids 1-11 in a sequence (Xi_n-Xi4-34 or Xi_n-Xi4_35) of FIG. 9 or
at least one of X 14-34 or X14-35 is a sequence of 21 or 22 contiguous amino acids set forth as amino acids 12-32 or 12-33 in a sequence (Xi_n-Xi4-34 or Xi_n-Xi4_35) of FIG. 9.
53. The method according to any one of paragraphs 40-52, wherein
the N-terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the
C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region.
54. The method according to any one of paragraphs 40-53, wherein the genomic locus of interest is the genomic locus associated with a gene that encodes for a differentiation factor, an epigenetic modulator or a component of an ion channel.
55. The method according to paragraph 54, wherein the differentiation factor is Neurogenin-2 and is encoded by the gene NEUROG2.
56. The method according to paragraph 54, wherein the differentiation factor is Kreuppel- like factor 4 and is encoded by the gene KLF-4.
57. The method according to paragraph 54, wherein the epigenetic modulator is Tet methylcytosine dioxygenase 1 and is encoded by the gene tet-1.
58. The method according to paragraph 54, wherein the component of the ion channel is CACNA1C and is encoded by the gene CACNA1C.
59. A non-naturally occurring or engineered composition for inducibly altering expression of a genomic locus in a cell wherein the composition comprises a DNA binding polypeptide comprising:
(i) a DNA binding domain comprising at least one or more TALE monomers or half-monomers or
at least one or more effector domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source;
wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to DNA of the genomic locus, and wherein the polypeptide alters the expression of the genomic locus upon application of the energy source.
60. The composition according to paragraph 59, wherein the at least one or more effector domains is selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-protein recruiting domain, cellular uptake activity associated domain, nucleic acid binding domain and antibody presentation domain.
61. The composition according to paragraph 59, wherein the at least one or more effector domains is a nuclease domain or a recombinase domain.
62. The composition according to paragraph 61, wherein the nuclease domain is a nonspecific Fokl endonuclease catalytic domain.
63. The method according to any one of paragraphs 59-62, wherein the energy sensitive protein is Cryptochrome-2 (CRY2).
64. The composition according to any one of paragraphs 59-63, wherein the interacting partner is Cryptochrome-interacting basic helix-loop-helix (CIB1).
65. The composition according to any one of paragraphs 59-64, wherein the energy source is selected from the group consisting of: electromagnetic radiation, sound energy or thermal energy.
66. The composition according to paragraph 65, wherein the electromagnetic radiation is a component of visible light.
67. The composition according to paragraph 66, wherein the component of visible light has a wavelength in the range of 450nm-500nm.
68. The composition according to paragraph 66, wherein the component of visible light is blue light.
69. The composition according to paragraph 59, wherein the applying the energy source comprises stimulation with blue light at an intensity of at least 6.2mW/cm2.
70. The composition according to any one of paragraphs 59-69, wherein the DNA binding domain comprises (X1-n-X12X13-X14-33 OT 34 or 35)z,
wherein Xi_n is a chain of 11 contiguous amino acids, wherein X12X13 is a repeat variable diresidue (RVD),
wherein Xi4_33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids,
wherein z is at least 5 to 40, and
wherein at least one RVD is selected from the group consisting of NI, HD, NG, NN, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, HI, KI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA, and NC, wherein (*) means that the amino acid at Xi3 is absent.
71. The composition according to paragraph 70, wherein z is at least 10 to 26.
72. The composition according to paragraph 70, wherein
at least one of Xi_n is a sequence of 12 contiguous amino acids set forth as amino acids 1-1 1 in a sequence (Xi_n-Xi4_34 or Xi_n-Xi4_35) of FIG. 9 or
at least one of X i4_34 or Xi4_35 is a sequence of 21 or 22 contiguous amino acids set forth as amino acids 12-32 or 12-33 in a sequence (Xi_n-Xi4_34 or Xi_n-Xi4_35) of FIG. 9.
73. The composition according to paragraph 70, wherein the at least one RVD is selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS for recognition of guanine (G); (b) SI for recognition of adenine (A); (c) HG, KG, RG for recognition of thymine (T); (d) RD, SD for recognition of cytosine (C); (e) NV for recognition of A or G; and (f) H*, HA, KA, N*, NA, NC, NS, RA, S* for recognition of A or T or G or C, wherein (*) means that the amino acid at Xi3 is absent.
74. The composition according to paragraph 73, wherein
the RVD for the recognition of G is RN, NH, RH or KH; or
the RVD for the recognition of A is SI; or
the RVD for the recognition of T is KG or RG; and
the RVD for the recognition of C is SD or RD.
75. The composition according to paragraph 70, wherein at least one of the following is present
[LTLD] or [LTLA] or [LTQV] at XM, or
[EQHG] or [RDHG] at positions X30 _33 or X31-34 or X32-35.
76. The composition according to any one of paragraphs 59-75, wherein
the N-terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the
C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region.
77. The composition according to any one of paragraphs 59-76, wherein the genomic locus of interest is associated with a gene that encodes for a differentiation factor, a transcription factor, a neurotransmitter transporter, a neurotransmitter synthase, a synaptic protein, a plasticity protein, a presynaptic active zone protein, a post synaptic density protein, a neurotransmitter receptor, an epigenetic modifier, a neural fate specification factor, an axon guidance molecule, an ion channel, a CpG binding protein, a ubiquitination protein, a hormone, a homeobox protein, a growth factor, an oncogenes or a proto-oncogene.
78. A non-naturally occurring or engineered composition for inducibly repressing expression of a genomic locus in a cell wherein the composition comprises a DNA binding polypeptide comprising:
(i) a DNA binding domain comprising at least one or more TALE monomers or half-monomers or
at least one or more repressor domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers or
at least one or more repressor domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source;
wherein the polypeptide is encoded by and expressed from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to DNA of the genomic locus, and wherein the polypeptide represses the expression of the genomic locus upon application of the energy source. 79. The composition according to paragraph 78, wherein the polypeptide includes at least one SID repressor domain.
80. The composition according to paragraph 79, wherein the polypeptide includes at least four SID repressor domains.
81. The composition according to paragraph 78, wherein the polypeptide includes a SID4X repressor domain.
82. The composition according to paragraph 78, wherein the polypeptide includes a KRAB repressor domain.
83. The composition according to any one of paragraphs 78-82, wherein the energy sensitive protein is Cryptochrome-2 (CRY2).
84. The composition according to any one of paragraphs 78-83, wherein the interacting partner is Cryptochrome-interacting basic helix-loop-helix (CIB 1).
85. The composition according to any one of paragraphs 78-84, wherein the energy source is selected from the group consisting of: electromagnetic radiation, sound energy or thermal energy.
86. The composition according to paragraph 78, wherein the electromagnetic radiation is a component of visible light.
87. The composition according to paragraph 86, wherein the component of visible light has a wavelength in the range of 450nm-500nm.
88. The composition according to paragraph 86, wherein the component of visible light is blue light.
89. The composition according to paragraph 78, wherein the applying the energy source comprises stimulation with blue light at an intensity of at least 6.2mW/cm2.
90. The composition according to any one of paragraphs 78-89, wherein the DNA binding domain comprises (X1-n-X12X13-X14-33 OT 34 or 35)z,
wherein Xi_n is a chain of 1 1 contiguous amino acids,
wherein X12X13 is a repeat variable diresidue (RVD),
wherein X14-33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids,
wherein z is at least 5 to 40, and
wherein at least one RVD is selected from the group consisting of NI, HD, NG, NN, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, HI, KI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA, and NC, wherein (*) means that the amino acid at Xi3 is absent.
91. The composition according to paragraph 90, wherein z is at least 10 to 26.
92. The composition according to paragraph 90, wherein
at least one of Xi_n is a sequence of 11 contiguous amino acids set forth as amino acids 1-11 in a sequence (Xi_n-Xi4_34 or Xi_n-Xi4_35) of FIG. 9 or
at least one of X i4_34 or Xi4_35 is a sequence of 21 or 22 contiguous amino acids set forth as amino acids 12-32 or 12-33 in a sequence (Xi_n-Xi4_34 or Xi_n-Xi _35) of FIG. 9 .
93. The composition according to any one of paragraphs 78-92, wherein
the N-terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the
C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region.
94. The composition according to any of paragraphs 78-93, wherein the genomic locus of interest is the genomic locus associated with a gene that encodes for a differentiation factor or a component of an ion channel.
95. The composition according to paragraph 94, wherein the differentiation factor is SRY-box-2 (SOX2) and is encoded by the gene SOX2.
96. The composition according to paragraph 94, wherein the differentiation factor is pl l and is encoded by the gene pll.
97. The composition according to paragraph 95, wherein the component of the ion channel is CACNA1C and is encoded by the gene CACNA1C.
98. A non-naturally occurring or engineered composition for inducibly activating expression of a genomic locus of interest in a cell wherein the composition comprises a DNA binding polypeptide comprising: (i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source;
wherein the polypeptide is encoded by and expressed from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to DNA of the genomic locus, and wherein the polypeptide activates the expression of the genomic locus upon application of the energy source.
99. The composition according to paragraph 98, wherein the polypeptide includes at least one VP 16 or VP64 activator domain.
100. The composition according to paragraph 98, wherein the polypeptide includes at least one p65 activator domain.
101. The composition according to any one of paragraphs 98-100, wherein the energy sensitive protein is CRY2.
102. The composition according to any one of paragraphs 98-101, wherein the interacting partner is CIB1.
103. The composition according to paragraph 98, wherein the energy source is selected from the group consisting of: electromagnetic radiation, sound energy or thermal energy.
104. The composition according to paragraph 103, wherein the electromagnetic radiation is a component of visible light.
105. The method according to paragraph 104, wherein the component of visible light has a wavelength in the range of 450nm-500nm. 106. The method according to paragraph 104, wherein the component of visible light is blue light.
107. The method according to paragraph 98, wherein the applying the energy source comprises stimulation with blue light at an intensity of at least 6.2mW/cm2.
108. The composition according to any one of paragraphs 98-107, wherein the DNA binding domain comprises (X1-n-X12X13-X14-33 OT 34 or 35)z,
wherein Xi_n is a chain of 11 contiguous amino acids,
wherein X12X13 is a repeat variable diresidue (RVD),
wherein X14-33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids,
wherein z is at least 5 to 40, and
wherein at least one RVD is selected from the group consisting of NI, HD, NG, NN, KN, RN, NH, NQ, SS, SN, NK, KH, RH, HH, HI, KI, RI, SI, KG, HG, RG, SD, ND, KD, RD, YG, HN, NV, NS, HA, S*, N*, KA, H*, RA, NA, and NC, wherein (*) means that the amino acid at Xi3 is absent.
109. The composition according to paragraph 108, wherein z is at least 10 to 26.
110. The composition according to paragraph 108, wherein
at least one of Xi_n is a sequence of 11 contiguous amino acids set forth as amino acids 1-11 in a sequence (Xi_n-Xi4_34 or Xi_n-Xi4_35) of FIG. 9 or
at least one of X i _3 or Xi4_35 is a sequence of 21 or 22 contiguous amino acids set forth as amino acids 12-32 or 12-33 in a sequence (Xi_n-Xi4_34 or Xi_n-Xi _35) of FIG. 9 .
111. The composition according to any one of paragraphs 98-110, wherein
the N-terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the
C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region. 112. The composition according to any one of paragraphs 98-111, wherein the genomic locus of interest is the genomic locus associated with a gene that encodes for a differentiation factor, an epigenetic modulator, a component of an ion channel or a receptor.
113. The composition according to paragraph 112, wherein the differentiation factor is Neurogenin-2 and is encoded by the gene NEUROG2.
114. The composition according to paragraph 112, wherein the differentiation factor is Kreuppel-like factor 4 and is encoded by the gene KLF-4.
115. The composition according to paragraph 112, wherein the epigenetic modulator is Tet methylcytosine dioxygenase 1 and is encoded by the gene tet-1.
116. The composition according to paragraph 112, wherein the component of the ion channel is CACNA1C and is encoded by the gene CACNA1C.
111. The composition according to paragraph 112, wherein the receptor is metabotropic glutamate receptor and is encoded by the gene niGlur2.
118. The composition according to any one of paragraphs 98-117, wherein the expression is chemically inducible.
119. The composition according to paragraph 118, wherein the chemically inducible expression system is an estrogen based (ER) system inducible by 4-hydroxytamoxifen (40HT).
120. The composition according to paragraph 119 wherein the composition further comprises a nuclear exporting signal (NES).
121. The composition of paragraph 120, wherein the NES has the sequence of LDLASLIL.
122. A nucleic acid encoding the composition according to any one of paragraphs 98-
121.
123. The nucleic acid of paragraph 122 wherein the nucleic acid comprises a promoter.
124. The nucleic acid according to paragraph 123, wherein the promoter is a human Synapsin I promoter (hSyn).
125. The nucleic acid according to any one of paragraphs 122-124, wherein the nucleic acid is packaged into an adeno associated viral vector (AAV).
126. An inducible method of altering expression of a genomic locus of interest comprising: (a) contacting the genomic locus with a non-naturally occurring or engineered composition comprising a DNA binding polypeptide comprising:
(i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source;
(b) applying the energy source; and
(c) determining that the expression of the genomic locus is altered.
127. A non-naturally occurring or engineered composition for inducibly altering expression of a genomic locus wherein the composition comprises a DNA binding polypeptide comprising:
(i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the genomic locus of interest or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source; wherein the polypeptide preferentially binds to DNA of the genomic locus, and wherein the polypeptide alters the expression of the genomic locus upon application of the energy source.
128. An inducible method for perturbing expression of a genomic locus of interest in a cell comprising:
(a) contacting the genomic locus with a non-naturally occurring or engineered composition comprising a deoxyribonucleic acid (DNA) binding polypeptide;
(b) applying an inducer source; and
(c) determining that perturbing expression of the genomic locus has occurred.
129. The method of paragraph 128, wherein perturbing expression is altering expression (up or down), altering the expression result (such as with nuclease) or eliminating expression shifting, for example, altering expression to dependent option.
130. The method of paragraph 128 or 129, wherein the inducer source is an energy source (such as wave or heat) or a small molecule.
131. The method of any one of paragraphs 126-130, wherein the DNA binding polypeptide comprises:
(i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half- monomers specifically ordered to target the genomic locus of interest or at least one or more effector domains linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the energy source.
132. An inducible method for perturbing expression of a genomic locus of interest in a cell comprising:
(a) contacting the genomic locus with a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR/Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
II. a second regulatory inducible element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3 Orientation,
wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and
wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the enzyme coding sequence encoding the CRISPR enzyme further encodes a heterologous functional domain.;
(b) applying an inducer source; and
(c) determining that perturbing expression of the genomic locus has occurred.
133. The method of paragraph 132, wherein perturbing expression is altering expression (up or down), altering the expression result (such as with nuclease) or eliminating expression shifting, for example, altering expression to dependent option.
134. The method of paragraph 132 or 133, wherein the inducer source is a chemical.
135. The method of any one of paragraphs 132 to 134, wherein the vector is a lentivirus.
136. The method of any one of paragraphs 132 to 135, wherein the second regulatory inducible element comprises a tetracycline-dependent regulatory system.
137. The method of any one of paragraphs 132 to 135, wherein the second regulatory inducible element comprises a cumate gene switch system.
138. The composition, nucleic acid or method of any one of paragraphs 1-137, wherein the cell is an a prokaryotic cell or a eukaryotic cell. 139. The composition, nucleic acid or method of paragraph 138, wherein the eukaryotic cell is an animal cell.
140. The composition, nucleic acid or method of paragraph 139, wherein the animal cell is a mammalian cell.
* * *
[00750] Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.

Claims

WHAT IS CLAIMED IS:
1. A non-naturally occurring or engineered TALE or CRISPR-Cas system, comprising at least one switch wherein the activity of said TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch.
2. The system according to claim 1 wherein the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system is activated, enhanced, terminated or repressed.
3. The system according to any of the preceding claims wherein contact with the at least one inducer energy source results in a first effect and a second effect.
4. The system according to claim 3 wherein the first effect is one or more of nuclear import, nuclear export, recruitment of a secondary component (such as an effector molecule), conformational change (of protein, DNA or RNA), cleavage, release of cargo (such as a caged molecule or a co-factor), association or dissociation.
5. The system according to claim 3 wherein the second effect is one or more of activation, enhancement, termination or repression of the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system.
6. The system according to any of claims 3-5 wherein the first effect and the second effect occur in a cascade.
7. The system according to any of the preceding claims wherein said TALE or CRISPR-Cas system further comprises at least one nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation.
8. The system according to claim 7 wherein one or more of the NLS, the NES or the functional domain is conditionally activated or inactivated.
9. The system according to claim 7 wherein the mutation is one or more of a mutation in a transcription factor homology region, a mutation in a DNA binding domain (such as mutating basic residues of a basic helix loop helix), a mutation in an endogenous NLS or a mutation in an endogenous NES.
10. The system according to any of the preceding claims wherein the inducer energy source is heat, ultrasound, electromagnetic energy or chemical.
11. The system according to any of the preceding claims wherein the inducer energy source is an antibiotic, a small molecule, a hormone, a hormone derivative, a steroid or a steroid derivative.
12. The system according to any of the preceding claims wherein the inducer energy source is abscisic acid (ABA), doxycycline (DOX), cumate, rapamycin, 4-hydroxytamoxifen (40HT), estrogen or ecdysone.
13. The system according to any one of the preceding claims wherein the at least one switch is selected from the group consisting of antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems.
14. The system according to any one of the preceding claims wherein the at least one switch is selected from the group consisting of tetracycline (Tet)/DOX inducible systems, light inducible systems, ABA inducible systems, cumate repressor/operator systems, 40HT/estrogen inducible systems, ecdysone-based inducible systems and FKBP12/FRAP (FKBP12-rapamycin complex) inducible systems.
15. The system according to claim 10 wherein the inducer energy source is electromagnetic energy.
16. The system according to claim 15 wherein the electromagnetic energy is a component of visible light.
17. The system according to claim 16 wherein the component of visible light has a wavelength in the range of 450nm-700nm.
18. The system according to claim 17 wherein the component of visible light has a wavelength in the range of 450nm-500nm.
19. The system according to claim 18 wherein the component of visible light is blue light.
20. The system according to claim 19 wherein the blue light has an intensity of at least
0.2mW/cm2.
21. The system according to claim 19 wherein the blue light has an intensity of at least
4mW/cm2.
22. The system according to claim 17 wherein the component of visible light has a wavelength in the range of 620-700nm.
23. The system according to claim 22 wherein the component of visible light is red light.
24. The system according to claim 7 wherein the at least one functional domain is selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA
hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, histone deribosylase, histone ubiquitinase, histone deubiquitinase, histone biotinase and histone tail protease.
25. Use of the system in any of the preceding claims for perturbing a genomic or epigenomic locus of interest.
26. Use of the system in any of claims 1-24 for the preparation of a pharmaceutical compound.
27. A method of controlling a non-naturally occurring or engineered TALE or CRISPR-Cas system, comprising providing said TALE or CRISPR-Cas system comprising at least one switch wherein the activity of said TALE or CRISPR-Cas system is controlled by contact with at least one inducer energy source as to the switch.
28. The method according to claim 27 wherein the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system is activated, enhanced, terminated or repressed.
29. The method according to claims 27 or 28 wherein contact with the at least one inducer energy source results in a first effect and a second effect.
30. The method according to claim 29 wherein the first effect is one or more of nuclear import, nuclear export, recruitment of a secondary component (such as an effector molecule), conformational change (of protein, DNA or RNA), cleavage, release of cargo (such as a caged molecule or a co-factor), association or dissociation.
31. The method according to claim 29 wherein the second effect is one or more of activation, enhancement, termination or repression of the control as to the at least one switch or the activity of said TALE or CRISPR-Cas system.
32. The method according to any of claims 29-31 wherein the first effect and the second effect occur in a cascade.
33. The method according to any of claims 27-32 wherein said TALE or CRISPR-Cas system further comprises at least one nuclear localization signal (NLS), nuclear export signal (NES), functional domain, flexible linker, mutation, deletion, alteration or truncation.
34. The method according to claim 33 wherein one or more of the NLS, the NES or the functional domain is conditionally activated or inactivated.
35. The method according to claim 33 wherein the mutation is one or more of a mutation in a transcription factor homology region, a mutation is a DNA binding domain (such as mutating basic residues of a basic helix loop helix), a mutation in an endogenous NLS or a mutation in an endogenous NES.
36. The method according to any of claims 27-35 wherein the inducer energy source is heat, ultrasound, electromagnetic energy or chemical.
37. The method according to any of claims 27-36 wherein the inducer energy source is an antibiotic, a small molecule, a hormone, a hormone derivative, a steroid or a steroid derivative.
38. The method according to any of claims 27-37 wherein the inducer energy source is abscisic acid (ABA), doxycycline (DOX), cumate, rapamycin, 4-hydroxytamoxifen (40HT), estrogen or ecdysone.
39. The method according to any of claims 27-38 wherein the at least one switch is selected from the group consisting of antibiotic based inducible systems, electromagnetic energy based inducible systems, small molecule based inducible systems, nuclear receptor based inducible systems and hormone based inducible systems.
40. The method according to any of claims 27-39 wherein the at least one switch is selected from the group consisting of tetracycline (Tet)/DOX inducible systems, light inducible systems, ABA inducible systems, cumate repressor/operator systems, 40HT/estrogen inducible systems, ecdysone-based inducible systems and FKBP12/FRAP (FKBP12-rapamycin complex) inducible systems.
41. The method according to claim 36 wherein the inducer energy source is electromagnetic energy.
42. The method according to claim 41 wherein the electromagnetic energy is a component of visible light.
43. The method according to claim 42 wherein the component of visible light has a wavelength in the range of 450nm-700nm.
44. The method according to claim 43 wherein the component of visible light has a wavelength in the range of 450nm-500nm.
45. The method according to claim 44 wherein the component of visible light is blue light.
46. The method according to claim 45 wherein the blue light has an intensity of at least
0.2mW/cm2.
47. The method according to claim 45 wherein the blue light has an intensity of at least 4mW/cm2.
48. The method according to claim 43 wherein the component of visible light has a wavelength in the range of 620-700nm.
49. The method according to claim 48 wherein the component of visible light is red light.
50. The method according to claim 33 wherein the at least one functional domain is selected from the group consisting of: transposase domain, integrase domain, recombinase domain, resolvase domain, invertase domain, protease domain, DNA methyltransferase domain, DNA hydroxylmethylase domain, DNA demethylase domain, histone acetylase domain, histone deacetylases domain, nuclease domain, repressor domain, activator domain, nuclear-localization signal domains, transcription-regulatory protein (or transcription complex recruiting) domain, cellular uptake activity associated domain, nucleic acid binding domain, antibody presentation domain, histone modifying enzymes, recruiter of histone modifying enzymes; inhibitor of histone modifying enzymes, histone methyltransferase, histone demethylase, histone kinase, histone phosphatase, histone ribosylase, histone deribosylase, histone ubiquitinase, histone deubiquitinase, histone biotinase and histone tail protease.
51. The system or method according to any of the preceding claims wherein the TALE system comprises a DNA binding polypeptide comprising:
(i) a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target a locus of interest or
at least one or more effector domains
linked to an energy sensitive protein or fragment thereof, wherein the energy sensitive protein or fragment thereof undergoes a conformational change upon induction by an inducer energy source allowing it to bind an interacting partner, and/or
(ii) a DNA binding domain comprising at least one or more TALE monomers or half-monomers specifically ordered to target the locus of interest or
at least one or more effector domains
linked to the interacting partner, wherein the energy sensitive protein or fragment thereof binds to the interacting partner upon induction by the inducer energy source.
52. The system or method of claim 51 wherein the DNA binding polypeptide comprises
(a) a N-terminal capping region
(b) a DNA binding domain comprising at least 5 to 40 Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the locus of interest, and (c) a C-terminal capping region
wherein (a), (b) and (c) are arranged in a predetermined N-terminus to C -terminus orientation,
wherein the genomic locus comprises a target DNA sequence 5'-T0N]N2....Nz Nz+i -3', where T0 and N = A, G, T or C,
wherein the target DNA sequence binds to the DNA binding domain, and the DNA binding domain comprises (X1-n-X12X13-X14-33 OT 34 or 35)z,
wherein Xi_n is a chain of 11 contiguous amino acids,
wherein X12X13 is a repeat variable diresidue (RVD),
wherein Xi4_33 or 34 or 35 is a chain of 21 , 22 or 23 contiguous amino acids,
wherein z is at least 5 to 40,
wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to DNA of the locus of interest.
53. The system or method of claim 52 wherein
the N-terminal capping region or fragment thereof comprises 147 contiguous amino acids of a wild type N-terminal capping region, or
the C-terminal capping region or fragment thereof comprises 68 contiguous amino acids of a wild type C-terminal capping region, or
the N-terminal capping region or fragment thereof comprises 136 contiguous amino acids of a wild type N-terminal capping region and the C-terminal capping region or fragment thereof comprises 183 contiguous amino acids of a wild type C-terminal capping region.
54. The system or method of claim 52 wherein at least one RVD is selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS, NN, SN, KN for recognition of guanine (G); (b) NI, KI, RI, HI, SI for recognition of adenine (A); (c) NG, HG, KG, RG for recognition of thymine (T); (d) RD, SD, HD, ND, KD, YG for recognition of cytosine (C); (e) NV, HN for recognition of A or G; and (f) H*, HA, KA, N*, NA, NC, NS, RA, S*for recognition of A or T or G or C, wherein (*) means that the amino acid at X13 is absent.
55. The system or method of claim 54 wherein at least one RVD is selected from the group consisting of (a) HH, KH, NH, NK, NQ, RH, RN, SS for recognition of guanine (G); (b) SI for recognition of adenine (A); (c) HG, KG, RG for recognition of thymine (T); (d) RD, SD for recognition of cytosine (C); (e) NV, HN for recognition of A or G and (f) H*, HA, KA, N*, NA, NC, NS, RA, S*for recognition of A or T or G or C, wherein (*) means that the amino acid at X13 is absent.
56. The system or method of claim 55 wherein
the RVD for the recognition of G is RN, NH, RH or KH; or
the RVD for the recognition of A is SI; or
the RVD for the recognition of T is KG or RG; and
the RVD for the recognition of C is SD or RD.
57. The system or method of claim 52 wherein at least one of the following is present
[LTLD] or [LTLA] or [LTQV] at X , or
[EQHG] or [RDHG] at positions X30 _33 or X3 i-34 or X32_35.
58. The system or method according to any of claims 51-57 wherein the TALE system is packaged into a AAV or a lentivirus vector.
59. The system or method according to any of claims 1-50 wherein the CRISPR system comprises a vector system comprising:
a) a first regulatory element operably linked to a CRISPR-Cas system guide RNA that targets a locus of interest,
b) a second regulatory inducible element operably linked to a Cas protein,
wherein components (a) and (b) are located on same or different vectors of the system, wherein the guide RNA targets DNA of the locus of interest, wherein the Cas protein and the guide RNA do not naturally occur together.
60. The system or method according to claim 59 wherein the Cas protein is a Cas9 enzyme.
1. The system or method according to claims 59 or 60 wherein the vector is AAV or lentivirus.
PCT/US2013/051418 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof WO2014018423A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EP18200462.2A EP3494997B1 (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof
JP2015524358A JP2015527889A (en) 2012-07-25 2013-07-21 Inducible DNA binding protein and genomic disruption tools and their applications
CN201380049665.5A CN105188767A (en) 2012-07-25 2013-07-21 Inducible DNA binding proteins and genome perturbation tools and applications thereof
AU2013293270A AU2013293270B2 (en) 2012-07-25 2013-07-21 Inducible DNA binding proteins and genome perturbation tools and applications thereof
EP20195578.8A EP3808844A1 (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof
CN202310274470.6A CN116622704A (en) 2012-07-25 2013-07-21 Inducible DNA binding proteins and genomic disruption tools and uses thereof
KR1020157004939A KR102530118B1 (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof
PL18200462T PL3494997T3 (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof
KR1020237014846A KR20230065381A (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof
CA2879997A CA2879997A1 (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof
EP13744916.1A EP2877213B1 (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof
US14/604,641 US20150291966A1 (en) 2012-07-25 2015-01-23 Inducible dna binding proteins and genome perturbation tools and applications thereof
HK15111902.7A HK1210965A1 (en) 2012-07-25 2015-12-03 Inducible dna binding proteins and genome perturbation tools and applications thereof dna
US15/388,248 US20170166903A1 (en) 2012-07-25 2016-12-22 Inducible dna binding proteins and genome perturbation tools and applications thereof
AU2018211340A AU2018211340A1 (en) 2012-07-25 2018-08-03 Inducible dna binding proteins and genome perturbation tools and applications thereof
AU2018247306A AU2018247306B2 (en) 2012-07-25 2018-10-12 Inducible dna binding proteins and genome perturbation tools and applications thereof
US16/297,560 US20190203212A1 (en) 2012-07-25 2019-03-08 Inducible dna binding proteins and genome perturbation tools and applications thereof
US16/535,042 US20190390204A1 (en) 2012-07-25 2019-08-07 Inducible dna binding proteins and genome perturbation tools and applications thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261675778P 2012-07-25 2012-07-25
US61/675,778 2012-07-25
US201261721283P 2012-11-01 2012-11-01
US61/721,283 2012-11-01
US201261736465P 2012-12-12 2012-12-12
US61/736,465 2012-12-12
US201361794458P 2013-03-15 2013-03-15
US61/794,458 2013-03-15
US201361835973P 2013-06-17 2013-06-17
US61/835,973 2013-06-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/604,641 Continuation-In-Part US20150291966A1 (en) 2012-07-25 2015-01-23 Inducible dna binding proteins and genome perturbation tools and applications thereof

Publications (3)

Publication Number Publication Date
WO2014018423A2 true WO2014018423A2 (en) 2014-01-30
WO2014018423A3 WO2014018423A3 (en) 2014-04-03
WO2014018423A8 WO2014018423A8 (en) 2014-06-19

Family

ID=48914461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/051418 WO2014018423A2 (en) 2012-07-25 2013-07-21 Inducible dna binding proteins and genome perturbation tools and applications thereof

Country Status (13)

Country Link
US (4) US20150291966A1 (en)
EP (3) EP3494997B1 (en)
JP (2) JP2015527889A (en)
KR (2) KR102530118B1 (en)
CN (2) CN105188767A (en)
AU (3) AU2013293270B2 (en)
CA (1) CA2879997A1 (en)
DK (1) DK3494997T3 (en)
ES (1) ES2757623T3 (en)
HK (1) HK1210965A1 (en)
PL (1) PL3494997T3 (en)
PT (1) PT3494997T (en)
WO (1) WO2014018423A2 (en)

Cited By (349)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150624A1 (en) * 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
CN104630267A (en) * 2014-07-17 2015-05-20 清华大学 Kit for constructing synthetic gene circuits by utilizing modularization of TALE transcriptional suppressors in mammal animals
KR20150056539A (en) * 2012-07-25 2015-05-26 더 브로드 인스티튜트, 인코퍼레이티드 Inducible dna binding proteins and genome perturbation tools and applications thereof
WO2015089354A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2015089465A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
WO2015113063A1 (en) 2014-01-27 2015-07-30 Georgia Tech Research Corporation Methods and systems for identifying crispr/cas off-target sites
WO2015153940A1 (en) * 2014-04-03 2015-10-08 Massachusetts Institute Of Technology Methods and compositions for the production of guide rna
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015188056A1 (en) * 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
CN105177038A (en) * 2015-09-29 2015-12-23 中国科学院遗传与发育生物学研究所 CRISPR/Cas9 system for efficiently editing plant gene groups in fixed-point mode
US9228208B2 (en) 2013-12-11 2016-01-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
WO2016003814A1 (en) 2014-06-30 2016-01-07 Illumina, Inc. Methods and compositions using one-sided transposition
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016011080A3 (en) * 2014-07-14 2016-03-03 The Regents Of The University Of California Crispr/cas transcriptional modulation
WO2016049531A1 (en) 2014-09-26 2016-03-31 Purecircle Usa Inc. Single nucleotide polymorphism (snp) markers for stevia
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
WO2016069591A2 (en) 2014-10-27 2016-05-06 The Broad Institute Inc. Compositions, methods and use of synthetic lethal screening
WO2016083811A1 (en) 2014-11-27 2016-06-02 Imperial Innovations Limited Genome editing methods
WO2016086227A2 (en) 2014-11-26 2016-06-02 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
WO2016086197A1 (en) 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016138488A2 (en) 2015-02-26 2016-09-01 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
WO2016138574A1 (en) 2015-03-02 2016-09-09 Sinai Health System Homologous recombination factors
WO2016167300A1 (en) * 2015-04-13 2016-10-20 国立大学法人東京大学 Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
WO2016098078A3 (en) * 2014-12-19 2016-10-27 Novartis Ag Dimerization switches and uses thereof
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
WO2016191684A1 (en) * 2015-05-28 2016-12-01 Finer Mitchell H Genome editing vectors
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2016205764A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2017027910A1 (en) 2015-08-14 2017-02-23 The University Of Sydney Connexin 45 inhibition for therapy
US9580701B2 (en) 2015-01-28 2017-02-28 Pioneer Hi-Bred International, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
WO2017035416A2 (en) 2015-08-25 2017-03-02 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
WO2017048316A1 (en) * 2015-09-18 2017-03-23 President And Fellows Of Harvard College Small molecule biosensors
WO2017058926A1 (en) * 2015-10-01 2017-04-06 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
WO2017070605A1 (en) 2015-10-22 2017-04-27 The Broad Institute Inc. Type vi-b crispr enzymes and systems
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075294A1 (en) 2015-10-28 2017-05-04 The Board Institute Inc. Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017078631A1 (en) * 2015-11-05 2017-05-11 Agency For Science, Technology And Research Chemical-inducible genome engineering technology
WO2017064566A3 (en) * 2015-10-16 2017-05-26 Astrazeneca Ab Inducible modification of a cell genome
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017053431A3 (en) * 2015-09-21 2017-06-01 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
KR101748823B1 (en) 2014-04-23 2017-06-19 윤희준 Transcription Activation Like Effector Nuclease for Targeting Myostatin Gene and Methods for Making Myostatin Gene Knock out Animal Using Thereof
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
US9701964B2 (en) 2015-05-06 2017-07-11 Snipr Technologies Limited Altering microbial populations and modifying microbiota
WO2017123559A3 (en) * 2016-01-11 2017-08-24 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
WO2017143042A2 (en) 2016-02-16 2017-08-24 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
WO2017147196A1 (en) 2016-02-22 2017-08-31 Massachusetts Institute Of Technology Methods for identifying and modulating immune phenotypes
WO2017161325A1 (en) 2016-03-17 2017-09-21 Massachusetts Institute Of Technology Methods for identifying and modulating co-occurant cellular phenotypes
WO2016103233A3 (en) * 2014-12-24 2017-09-21 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
WO2017165167A1 (en) 2016-03-23 2017-09-28 The Regents Of The University Of California Methods of treating mitochondrial disorders
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
WO2017180711A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Grna fusion molecules, gene editing systems, and methods of use thereof
WO2017184768A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017184786A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity
WO2017189870A1 (en) 2016-04-27 2017-11-02 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
WO2017189308A1 (en) 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017193139A1 (en) 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US9834786B2 (en) 2012-04-25 2017-12-05 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9833513B2 (en) 2013-09-11 2017-12-05 Eagle Biologics, Inc. Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof
WO2017219027A1 (en) 2016-06-17 2017-12-21 The Broad Institute Inc. Type vi crispr orthologs and systems
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018044920A1 (en) 2016-08-29 2018-03-08 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
JP2018508221A (en) * 2015-03-16 2018-03-29 中国科学院遺▲伝▼与▲発▼育生物学研究所Ｉｎｓｔｉｔｕｔｅ ｏｆ Ｇｅｎｅｔｉｃｓ ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔａｌ Ｂｉｏｌｏｇｙ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ ｏｆ Ｓｃｉｅｎｃｅｓ How to apply non-genetic material to perform site-specific modification of plant genomes
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
US10000772B2 (en) 2012-05-25 2018-06-19 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
WO2018170333A1 (en) 2017-03-15 2018-09-20 The Broad Institute, Inc. Novel cas13b orthologues crispr enzymes and systems
WO2018170515A1 (en) 2017-03-17 2018-09-20 The Broad Institute, Inc. Methods for identifying and modulating co-occurant cellular phenotypes
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
WO2018191520A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
WO2018191388A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US20180340939A1 (en) * 2015-10-28 2018-11-29 The Broad Institute, Inc. Multiplex analysis of single cell constituents
US10150985B2 (en) 2014-02-13 2018-12-11 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2019003193A1 (en) 2017-06-30 2019-01-03 Novartis Ag Methods for the treatment of disease with gene editing systems
WO2019005884A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
US10195273B2 (en) 2016-06-05 2019-02-05 Snipr Technologies Limited Selectively altering microbiota for immune modulation
WO2019027728A1 (en) * 2017-07-31 2019-02-07 Sigma-Aldrich Co. Llc Synthetic guide rna for crispr/cas activator systems
US10227576B1 (en) 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
WO2019052577A1 (en) 2017-09-18 2019-03-21 博雅辑因（北京）生物科技有限公司 Gene editing t cell and use thereof
WO2019060746A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
CN109557315A (en) * 2018-09-28 2019-04-02 山东大学 A kind of light-operated micro-pipe tracer and its application
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2019080917A1 (en) 2017-10-27 2019-05-02 博雅辑因（北京）生物科技有限公司 Method for improving fetal hemoglobin expression
WO2019087113A1 (en) 2017-11-01 2019-05-09 Novartis Ag Synthetic rnas and methods of use
US10287590B2 (en) 2014-02-12 2019-05-14 Dna2.0, Inc. Methods for generating libraries with co-varying regions of polynuleotides for genome modification
WO2019094928A1 (en) 2017-11-10 2019-05-16 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
WO2019099943A1 (en) 2017-11-16 2019-05-23 Astrazeneca Ab Compositions and methods for improving the efficacy of cas9-based knock-in strategies
WO2019100053A1 (en) 2017-11-20 2019-05-23 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2α to improve muscle generation and repair
US10314297B2 (en) 2014-08-14 2019-06-11 Biocytogen Boston Corp DNA knock-in system
US10328182B2 (en) 2013-05-14 2019-06-25 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
EP3502253A1 (en) 2015-06-18 2019-06-26 The Broad Institute Inc. Novel crispr enzymes and systems
US10336807B2 (en) 2016-01-11 2019-07-02 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
EP3514246A1 (en) 2014-02-27 2019-07-24 The Broad Institute Inc. T cell balance gene expression and methods of use thereof
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US10385359B2 (en) 2013-04-16 2019-08-20 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
US10428319B2 (en) 2017-06-09 2019-10-01 Editas Medicine, Inc. Engineered Cas9 nucleases
US10443087B2 (en) 2014-06-13 2019-10-15 Illumina Cambridge Limited Methods and compositions for preparing sequencing libraries
US10450576B2 (en) 2015-03-27 2019-10-22 E I Du Pont De Nemours And Company Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
WO2019204585A1 (en) 2018-04-19 2019-10-24 Massachusetts Institute Of Technology Single-stranded break detection in double-stranded dna
EP3560330A1 (en) 2018-04-24 2019-10-30 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
WO2019210268A2 (en) 2018-04-27 2019-10-31 The Broad Institute, Inc. Sequencing-based proteomics
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US10501738B2 (en) 2018-04-24 2019-12-10 Inscripta, Inc. Automated instrumentation for production of peptide libraries
US10508288B1 (en) 2017-09-30 2019-12-17 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems comprising flow-through electroporation devices
US10519457B2 (en) 2013-08-22 2019-12-31 E I Du Pont De Nemours And Company Soybean U6 polymerase III promoter and methods of use
US10519437B1 (en) 2017-06-30 2019-12-31 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
WO2020006049A1 (en) 2018-06-26 2020-01-02 The Broad Institute, Inc. Crispr/cas and transposase based amplification compositions, systems and methods
WO2020006036A1 (en) 2018-06-26 2020-01-02 Massachusetts Institute Of Technology Crispr effector system based amplification methods, systems, and diagnostics
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
WO2020028555A2 (en) 2018-07-31 2020-02-06 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2020033601A1 (en) 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US10576474B2 (en) 2018-04-13 2020-03-03 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
WO2020047353A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
WO2020049158A1 (en) 2018-09-07 2020-03-12 Astrazeneca Ab Compositions and methods for improved nucleases
US10590375B2 (en) 2018-03-29 2020-03-17 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
US10604746B1 (en) 2018-10-22 2020-03-31 Inscripta, Inc. Engineered enzymes
WO2020077236A1 (en) 2018-10-12 2020-04-16 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US10633626B2 (en) 2018-08-14 2020-04-28 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020097363A2 (en) 2018-11-08 2020-05-14 Triton Algae Innovations, Inc. Compositions and methods for incorporating heme from algae in edible products
EP3653229A1 (en) 2013-12-12 2020-05-20 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
US10676754B2 (en) 2014-07-11 2020-06-09 E I Du Pont De Nemours And Company Compositions and methods for producing plants resistant to glyphosate herbicide
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
US20200214273A1 (en) * 2017-09-19 2020-07-09 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Genome-edited birds
EP3686279A1 (en) 2014-08-17 2020-07-29 The Broad Institute, Inc. Genome editing using cas9 nickases
CN111471675A (en) * 2014-03-05 2020-07-31 国立大学法人神户大学 Method for modifying genome sequence of nucleic acid base for specifically converting target DNA sequence, and molecular complex used therefor
US10731181B2 (en) 2012-12-06 2020-08-04 Sigma, Aldrich Co. LLC CRISPR-based genome modification and regulation
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
WO2020178822A1 (en) 2019-03-05 2020-09-10 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Genome-edited birds
WO2020178759A1 (en) 2019-03-04 2020-09-10 King Abdullah University Of Science And Technology Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
US10787683B1 (en) 2017-08-28 2020-09-29 Inscripta, Inc. Electroporation cuvettes for automation
WO2020206036A1 (en) 2019-04-01 2020-10-08 The Broad Institute, Inc. Novel nucleic acid modifier
US10815467B2 (en) 2019-03-25 2020-10-27 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020221291A1 (en) 2019-04-30 2020-11-05 博雅辑因（北京）生物科技有限公司 Method for predicting effectiveness of treatment of hemoglobinopathy
US10837021B1 (en) 2019-06-06 2020-11-17 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
WO2020229533A1 (en) 2019-05-13 2020-11-19 KWS SAAT SE & Co. KGaA Drought tolerance in corn
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
US20200377910A1 (en) * 2016-04-21 2020-12-03 National University Corporation Kobe University Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor
WO2020243661A1 (en) 2019-05-31 2020-12-03 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
WO2020239680A2 (en) 2019-05-25 2020-12-03 KWS SAAT SE & Co. KGaA Haploid induction enhancer
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10883095B1 (en) 2019-12-10 2021-01-05 Inscripta, Inc. Mad nucleases
WO2021003432A1 (en) 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
US10912797B2 (en) 2016-10-18 2021-02-09 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
EP3772542A1 (en) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
US20210040460A1 (en) 2012-04-27 2021-02-11 Duke University Genetic correction of mutated genes
US10920189B2 (en) 2019-06-21 2021-02-16 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
US20210047648A1 (en) * 2012-10-23 2021-02-18 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US10934536B2 (en) 2018-12-14 2021-03-02 Pioneer Hi-Bred International, Inc. CRISPR-CAS systems for genome editing
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2021043278A1 (en) 2019-09-04 2021-03-11 博雅辑因（北京）生物科技有限公司 Method for evaluating gene editing therapy based on off-target assessment
WO2021050974A1 (en) 2019-09-12 2021-03-18 The Broad Institute, Inc. Engineered adeno-associated virus capsids
WO2021055874A1 (en) 2019-09-20 2021-03-25 The Broad Institute, Inc. Novel type vi crispr enzymes and systems
WO2021074367A1 (en) 2019-10-17 2021-04-22 KWS SAAT SE & Co. KGaA Enhanced disease resistance of crops by downregulation of repressor genes
US11001829B2 (en) 2014-09-25 2021-05-11 The Broad Institute, Inc. Functional screening with optimized functional CRISPR-Cas systems
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11008557B1 (en) 2019-12-18 2021-05-18 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
WO2021111466A1 (en) * 2019-12-02 2021-06-10 Council Of Scientific & Industrial Research Method and kit for detection of polynucleotide
WO2021136176A1 (en) 2019-12-30 2021-07-08 博雅辑因（北京）生物科技有限公司 Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof
WO2021136415A1 (en) 2019-12-30 2021-07-08 博雅辑因（北京）生物科技有限公司 Method for purifying ucart cell and use thereof
US11098325B2 (en) 2017-06-30 2021-08-24 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy
EP3872190A1 (en) 2020-02-26 2021-09-01 Antibodies-Online GmbH A method of using cut&run or cut&tag to validate crispr-cas targeting
US11124796B2 (en) 2014-09-24 2021-09-21 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling competition of multiple cancer mutations in vivo
US11130970B2 (en) 2017-06-23 2021-09-28 Inscripta, Inc. Nucleic acid-guided nucleases
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11147837B2 (en) 2015-07-31 2021-10-19 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11180793B2 (en) 2015-04-24 2021-11-23 Editas Medicine, Inc. Evaluation of Cas9 molecule/guide RNA molecule complexes
US11186843B2 (en) 2014-02-27 2021-11-30 Monsanto Technology Llc Compositions and methods for site directed genomic modification
WO2021239986A1 (en) 2020-05-29 2021-12-02 KWS SAAT SE & Co. KGaA Plant haploid induction
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
US11214800B2 (en) 2015-08-18 2022-01-04 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2022007803A1 (en) 2020-07-06 2022-01-13 博雅辑因（北京）生物科技有限公司 Improved rna editing method
US11225674B2 (en) 2020-01-27 2022-01-18 Inscripta, Inc. Electroporation modules and instrumentation
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
WO2022036180A1 (en) 2020-08-13 2022-02-17 Yale University Compositions and methods for engineering and selection of car t cells with desired phenotypes
WO2022047424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11268088B2 (en) 2020-04-24 2022-03-08 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery
US11268086B2 (en) 2014-03-10 2022-03-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US11299731B1 (en) 2020-09-15 2022-04-12 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11306298B1 (en) 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11332736B2 (en) 2017-12-07 2022-05-17 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
US11332742B1 (en) 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP4001429A1 (en) 2020-11-16 2022-05-25 Antibodies-Online GmbH Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
WO2022155265A2 (en) 2021-01-12 2022-07-21 Mitolab Inc. Context-dependent, double-stranded dna-specific deaminases and uses thereof
US11408012B2 (en) 2017-06-23 2022-08-09 Inscripta, Inc. Nucleic acid-guided nucleases
US11414657B2 (en) 2015-06-29 2022-08-16 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447527B2 (en) 2018-09-18 2022-09-20 Vnv Newco Inc. Endogenous Gag-based capsids and uses thereof
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2022226291A1 (en) 2021-04-22 2022-10-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
US11492630B2 (en) 2015-05-19 2022-11-08 KWS SAAT SE & Co. KGaA Methods and hybrids for targeted nucleic acid editing in plants using CRISPR/Cas systems
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US11512311B2 (en) 2016-03-25 2022-11-29 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
US11514331B2 (en) 2016-04-27 2022-11-29 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
US11530253B2 (en) 2016-02-25 2022-12-20 The Children's Medical Center Corporation Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
US11560568B2 (en) 2014-09-12 2023-01-24 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11566263B2 (en) 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
WO2023006933A1 (en) 2021-07-30 2023-02-02 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
US11578118B2 (en) 2017-10-20 2023-02-14 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
US11578333B2 (en) 2018-10-14 2023-02-14 Snipr Biome Aps Single-vector type I vectors
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
US11597947B2 (en) 2016-12-29 2023-03-07 Asc Therapeutics Inc. Gene editing method using virus
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11603544B2 (en) 2017-06-05 2023-03-14 Fred Hutchinson Cancer Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
WO2023044100A1 (en) 2021-09-20 2023-03-23 Revivicor, Inc. Multitran scenic pigs comprising ten genetic modifications for xenotransplantation
WO2023052508A2 (en) 2021-09-30 2023-04-06 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
US11624077B2 (en) 2017-08-08 2023-04-11 Peking University Gene knockout method
WO2023064732A1 (en) 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
WO2023070043A1 (en) 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2023093862A1 (en) 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
US11667911B2 (en) 2015-09-24 2023-06-06 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/CAS-mediated genome editing
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US11766400B2 (en) 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
WO2023192872A1 (en) 2022-03-28 2023-10-05 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
EP4268831A2 (en) 2018-09-12 2023-11-01 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
CN117257958A (en) * 2023-11-21 2023-12-22 四川大学华西医院 New use of TRPS1 inhibitor and medicine for treating and/or preventing androgenetic alopecia
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11866697B2 (en) 2017-05-18 2024-01-09 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2024020597A1 (en) 2022-07-22 2024-01-25 The Johns Hopkins University Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11897920B2 (en) 2017-08-04 2024-02-13 Peking University Tale RVD specifically recognizing DNA base modified by methylation and application thereof
US11896686B2 (en) 2014-05-09 2024-02-13 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US11905532B2 (en) 2019-06-25 2024-02-20 Massachusetts Institute Of Technology Compositions and methods for molecular memory storage and retrieval
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024042199A1 (en) 2022-08-26 2024-02-29 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
WO2024047587A1 (en) 2022-08-31 2024-03-07 Regel Therapeutics, Inc. Cas-phi compositions and methods of use
US11939593B2 (en) 2018-08-01 2024-03-26 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
US11965154B2 (en) 2018-08-30 2024-04-23 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11963982B2 (en) 2017-05-10 2024-04-23 Editas Medicine, Inc. CRISPR/RNA-guided nuclease systems and methods
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2024119101A1 (en) 2022-12-01 2024-06-06 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
WO2024123789A1 (en) 2022-12-07 2024-06-13 Sanofi Predicting indel frequencies
US12031132B2 (en) 2018-03-14 2024-07-09 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
WO2024168265A1 (en) 2023-02-10 2024-08-15 Possible Medicines Llc Aav delivery of rna guided recombination system
WO2024168253A1 (en) 2023-02-10 2024-08-15 Possible Medicines Llc Delivery of an rna guided recombination system
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections
US12084676B2 (en) 2018-02-23 2024-09-10 Pioneer Hi-Bred International, Inc. Cas9 orthologs
US12098399B2 (en) 2022-06-24 2024-09-24 Tune Therapeutics, Inc. Compositions, systems, and methods for epigenetic regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression
US12105089B2 (en) 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
WO2024201368A1 (en) 2023-03-29 2024-10-03 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
US12110545B2 (en) 2017-01-06 2024-10-08 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US12121524B2 (en) 2019-01-16 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158945A2 (en) * 2011-05-19 2012-11-22 The Scripps Research Institute Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
JP6214530B2 (en) 2011-07-15 2017-10-18 ザ ジェネラル ホスピタル コーポレイション Method for assembling a transcription activator-like effector
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
WO2014124284A1 (en) * 2013-02-07 2014-08-14 The General Hospital Corporation Tale transcriptional activators
KR102210322B1 (en) 2013-03-15 2021-02-01 더 제너럴 하스피탈 코포레이션 Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN105793425B (en) * 2013-06-17 2021-10-26 布罗德研究所有限公司 Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
WO2015126884A1 (en) * 2014-02-18 2015-08-27 Stc.Unm Compositions and methods for controlling cellular function
EP3129485B2 (en) * 2014-04-09 2022-12-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
CA2959070C (en) 2014-08-27 2020-11-10 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
KR102531016B1 (en) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
CN116059378A (en) 2014-12-10 2023-05-05 明尼苏达大学董事会 Genetically modified cells, tissues and organs for the treatment of diseases
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
EP3800255A3 (en) * 2015-06-18 2021-06-23 Robert D. Bowles Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
JP2019507610A (en) 2016-03-04 2019-03-22 インドア バイオテクノロジーズ インコーポレイテッド Fel d1 knockout and related compositions and methods based on CRISPR-Cas genome editing
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
KR20190039703A (en) * 2016-07-05 2019-04-15 더 존스 홉킨스 유니버시티 CRISPR / CAS9-based compositions and methods for treating retinal degeneration
AU2017292169B2 (en) 2016-07-06 2021-12-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
CA3029141A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
WO2018020323A2 (en) * 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
US20190169253A1 (en) * 2016-08-01 2019-06-06 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
SG11201901718VA (en) * 2016-09-08 2019-03-28 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Gene therapy for patients with fanconi anemia
US11261428B2 (en) 2018-03-15 2022-03-01 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20190359661A1 (en) * 2016-11-25 2019-11-28 Nanoscope Technologies, LLC Method and device for pain modulation by optical activation of neurons and other cells
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CN110709060A (en) 2017-03-17 2020-01-17 援救听觉股份有限公司 Gene therapy constructs and methods for treating hearing loss
WO2018208960A1 (en) * 2017-05-09 2018-11-15 Dimension Therapeutics, Inc. Scalable method for producing transfection reagents
CA3065326A1 (en) * 2017-06-14 2018-12-20 Wisconsin Alumni Research Foundation Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
CN109207518B (en) * 2017-07-07 2020-12-01 中国科学院动物研究所 Drug-inducible CRISPR/Cas9 system for gene transcription activation
CN109206520A (en) * 2017-07-07 2019-01-15 中国科学院动物研究所 For the drug induced fusion protein and its encoding gene of genome editor and application
CN109207516B (en) * 2017-07-07 2020-12-01 中国科学院动物研究所 Drug-induced gene transcription activation method
CN109207517B (en) * 2017-07-07 2020-12-01 中国科学院动物研究所 Drug-inducible CRISPR/Cas9 system for genome editing and transcriptional regulation
KR20240046316A (en) * 2017-07-11 2024-04-08 시그마-알드리치 컴퍼니., 엘엘씨 Using nucleosome interacting protein domains to enhance targeted genome modification
WO2019028507A1 (en) * 2017-08-08 2019-02-14 Queensland University Of Technology Methods for diagnosis of early stage heart failure
US20210095251A1 (en) * 2017-08-10 2021-04-01 University Of Massachusetts Human adipose tissue progenitors for autologous cell therapy for lipodystrophy
CN109495227B (en) * 2017-09-11 2020-10-20 维沃移动通信有限公司 Configuration method for controlling resource set, network equipment and terminal
AU2018345841A1 (en) 2017-10-06 2020-05-21 The Research Foundation For The State University For The State Of New York Selective optical aqueous and non-aqueous detection of free sulfites
KR101870694B1 (en) * 2017-10-18 2018-06-25 주식회사 무진메디 Nanoliposome-microbubble assemblies encapsulating complex of Cas9 protein, guide RNA for repressing gene expression or SRD5A2 gene and cationic polymer, and composition comprising the same for improving or treating hair loss
US20210214724A1 (en) * 2017-10-23 2021-07-15 The Broad Institute, Inc. Novel nucleic acid modifiers
CN107858430B (en) * 2017-11-20 2019-01-04 武汉迈特维尔生物科技有限公司 A kind of gene diagnosis kit shifted for diagnosing indication Her-2 overexpression type Bone of Breast Cancer
MA50942A (en) * 2017-12-01 2020-10-07 Encoded Therapeutics Inc MODIFIED DNA BINDING PROTEINS
KR102439221B1 (en) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. Acoustic transducer actuators and controllers
WO2019126643A1 (en) * 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
KR20200108427A (en) * 2018-01-12 2020-09-18 셀진 코포레이션 How to screen for cerebloon modified compounds
CN109507429A (en) * 2018-02-14 2019-03-22 复旦大学 Method based on CRISPR/cas9 and peroxidase APEX2 system identification analysis specific position interaction protein
CN108410909B (en) * 2018-04-12 2021-08-03 吉林大学 Method for regulating cell pathway by using phytohormone ABA and small molecule substance PYR
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
CN112424339A (en) * 2018-07-13 2021-02-26 隆萨有限公司 Methods for improving production of biological products by reducing endogenous protein levels
US20210317412A1 (en) * 2018-07-16 2021-10-14 Agency For Science, Technology And Research Method For Isolating A Cardiomyocyte Population
CN110857440B (en) * 2018-08-23 2021-02-19 武汉纽福斯生物科技有限公司 Recombinant human II type mitochondrial dynamic protein sample GTP enzyme gene sequence and application thereof
US20210340548A1 (en) * 2018-08-31 2021-11-04 Japan Science And Technology Agency Photoactivatable tet expression control system
CN109408766B (en) * 2018-09-26 2023-05-16 国网山西省电力公司电力科学研究院 Ladder diagram frequency calculation method
CN109406469B (en) * 2018-10-24 2021-04-09 中国医科大学 Method for detecting tryptophan based on protein binding induced DNA double-strand allosteric
US20220333089A1 (en) * 2018-11-01 2022-10-20 The University Of Tokyo Split CPF1 Protein
US11739320B2 (en) 2018-11-05 2023-08-29 Wisconsin Alumni Research Foundation Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
WO2020097411A1 (en) * 2018-11-08 2020-05-14 Massachusetts Institute Of Technology Encryption and steganography of synthetic gene circuits
EP3911369A4 (en) * 2019-01-18 2022-11-16 Orthobio Therapeutics, Inc. Gene editing to improve joint function
CN111778277B (en) * 2019-04-04 2023-02-28 中国科学院动物研究所 Ke's syndrome animal model and application thereof
US20220307057A1 (en) * 2019-04-15 2022-09-29 Emendobio Inc. Crispr compositions and methods for promoting gene editing of gata2
MX2021012515A (en) * 2019-04-18 2021-12-10 Meter Health Inc Methods and compositions for treating respiratory arrhythmias.
CN110244048A (en) * 2019-06-19 2019-09-17 中国人民解放军总医院第八医学中心 Application of the SERPING1 albumen as marker in exploitation diagnostic activities reagent lungy
CN110373459B (en) * 2019-06-27 2023-06-27 郑湘榕 Reagent and kit for detecting childhood asthma based on site rs2236647 of STIP1 gene and application
KR102183208B1 (en) * 2019-07-25 2020-11-25 한국과학기술연구원 Methods for reprogramming astrocytes into neurons in spinal cord injury(SCI) animal model using Ngn2
CN110551755A (en) * 2019-07-26 2019-12-10 天津大学 light-controlled protein degradation system, construction method and light-controlled protein degradation method
CN110563822B (en) * 2019-08-27 2021-09-24 上海交通大学 Ganoderma lucidum immunomodulatory protein mutant and application thereof
JP2022169813A (en) * 2019-09-30 2022-11-10 国立研究開発法人産業技術総合研究所 Method of controlling dna-cleaving activity of cas-9 nuclease
WO2021081135A2 (en) * 2019-10-21 2021-04-29 The Regents Of The University Of California Compositions and methods for editing of the cdkl5 gene
WO2021138560A2 (en) 2020-01-02 2021-07-08 The Trustees Of Columbia University In The City Of New York Programmable and portable crispr-cas transcriptional activation in bacteria
CN111376422B (en) * 2020-04-18 2021-08-27 山东宇能环境工程有限公司 Automatic molding production line of heat preservation felt
CN111534590A (en) * 2020-04-30 2020-08-14 福建西陇生物技术有限公司 Colorectal cancer polygene methylation combined detection kit and application thereof
CN111850043A (en) * 2020-06-28 2020-10-30 武汉纽福斯生物科技有限公司 ECEL1 recombinant adeno-associated virus vector and application
CN111778333B (en) * 2020-07-03 2022-11-18 东莞市滨海湾中心医院 Application of reagent for determining EDAR expression level and kit
CN111849991B (en) * 2020-08-05 2022-04-08 武汉纽福斯生物科技有限公司 Oligonucleotide and application thereof
IL300263A (en) 2020-08-07 2023-03-01 Spacecraft Seven Llc Plakophilin-2 (pkp2) gene therapy using aav vector
CN112138146B (en) * 2020-09-25 2022-08-09 安徽医科大学 Application of MANF protein
WO2022076812A2 (en) 2020-10-09 2022-04-14 University Of Massachusetts Targeting nrip1 to alleviate metabolic disease
WO2022109421A1 (en) * 2020-11-20 2022-05-27 Senti Biosciences, Inc. Inducible cell death systems
CN112618963A (en) * 2020-12-12 2021-04-09 安徽省旌一农业旅游发展有限公司 Newborn protection device for phototherapy box
US11777863B2 (en) * 2020-12-21 2023-10-03 Landis+ Gyr Innovations Optimized route for time-critical traffic in mesh network
CN112516288B (en) * 2020-12-22 2023-04-18 西藏阿那达生物医药科技有限责任公司 Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein
CN113444730A (en) * 2021-03-17 2021-09-28 昆明市延安医院 Screening and constructing method of primary hepatocyte klotho gene transduction stem cells
CN113181218A (en) * 2021-03-22 2021-07-30 中国福利会国际和平妇幼保健院 Application of human amniotic epithelial cells in preparation of preparation for repairing uterine scar cells
EP4323534A1 (en) * 2021-04-12 2024-02-21 The Regents of the University of California Gene therapy for arrhythmogenic right ventricular cardiomyopathy
CN113124052B (en) * 2021-04-16 2022-08-23 中国航空发动机研究院 Method for controlling unbalance vibration of electromagnetic bearing-rotor system and electronic equipment
CN113178263A (en) * 2021-04-30 2021-07-27 上海市公共卫生临床中心 Pulmonary tuberculosis lesion activity marker, kit, method and model construction method
CN113416713A (en) * 2021-05-11 2021-09-21 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Construction and application of recombinant adenovirus
CN113519460B (en) * 2021-06-30 2023-02-17 华南农业大学 Construction and application of induced uterine epithelium specific gene engineering mouse
WO2023018674A1 (en) * 2021-08-09 2023-02-16 Amicus Therapeutics, Inc. Determination of gene transduction potency in neuron-like cells
JP7125727B1 (en) 2021-09-07 2022-08-25 国立大学法人千葉大学 Compositions for modifying nucleic acid sequences and methods for modifying target sites in nucleic acid sequences
CN114632156B (en) * 2022-05-17 2022-08-16 中国人民解放军军事科学院军事医学研究院 Use of Tim-3 for the prevention, treatment or alleviation of pain
CN115060901A (en) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 Application of malic enzyme 2 in preparation of diagnostic reagent or therapeutic drug for diseases related to silicosis or pulmonary fibrosis
CN115350176B (en) * 2022-07-14 2023-10-13 深圳大学 Gastric cancer tumor cell and gastric cancer tumor stem cell therapeutic drug and application thereof
CN114990110B (en) * 2022-07-19 2023-07-14 江西农业大学 Nondestructive sampling method for field butterfly monitoring
WO2024023034A1 (en) * 2022-07-25 2024-02-01 Institut National de la Santé et de la Recherche Médicale Use of apelin for the treatment of lymphedema
CN115177730B (en) * 2022-08-05 2024-02-27 华中科技大学同济医学院附属协和医院 PTPN22 and novel application of expression inhibitor thereof
CN115487301B (en) * 2022-11-08 2023-07-07 四川大学华西医院 Use of IL-13 inhibitors for the preparation of a medicament for the delay or treatment of retinitis pigmentosa
WO2024136952A1 (en) * 2022-12-20 2024-06-27 Florida Atlantic University Board Of Trustees Phosphagen system modulators and uses thereof
WO2024192124A1 (en) * 2023-03-13 2024-09-19 Biogen Ma Inc. Engineered cells and cell lines for aav production and methods of making and using the same
CN116519950B (en) * 2023-05-10 2023-11-07 首都医科大学附属北京天坛医院 Biomarker for predicting poststroke depression and application thereof
CN117797249A (en) * 2023-11-14 2024-04-02 苏州祥沁医疗科技有限公司 mRNA-based anti-aging and anti-senile dementia preventive and therapeutic vaccine

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232302A (en) 1990-01-10 1993-08-03 Mayreder Consult Of The United States Inc. Fixing means for connecting components
WO1996039154A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
WO1997003211A1 (en) 1995-07-13 1997-01-30 Isis Pharmaceuticals, Inc. Antisense inhibition of hepatitis b virus replication
WO1997049450A1 (en) 1996-06-24 1997-12-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
WO1998052609A1 (en) 1997-05-19 1998-11-26 Nycomed Imaging As Sonodynamic therapy using an ultrasound sensitizer compound
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
WO1999008713A1 (en) 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
WO1999060164A1 (en) 1998-05-15 1999-11-25 Quark Biotech, Inc. Mechanical stress induced genes, expression products therefrom, and uses thereof
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030049799A1 (en) 2000-10-23 2003-03-13 Schwartz John Jacob Engineered stimulus-responsive switches
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US7745592B2 (en) 2001-05-01 2010-06-29 National Research Council Of Canada Cumate-inducible expression system for eukaryotic cells
US9816739B2 (en) 2011-09-02 2017-11-14 Carrier Corporation Refrigeration system and refrigeration method providing heat recovery
US11696302B2 (en) 2018-09-10 2023-07-04 Ntt Docomo, Inc. User terminal

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9100084A (en) 1991-01-17 1992-08-17 Verstraeten Funderingstech Bv SAFETY BASIN.
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20050220796A1 (en) 2004-03-31 2005-10-06 Dynan William S Compositions and methods for modulating DNA repair
JP2010540534A (en) * 2007-09-28 2010-12-24 イントレキソン コーポレーション Therapeutic gene switch constructs and bioreactors for the expression of biotherapeutic molecules and uses thereof
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
NZ619886A (en) * 2009-08-11 2015-03-27 Sangamo Biosciences Inc Organisms homozygous for targeted modification
PL2816112T3 (en) * 2009-12-10 2019-03-29 Regents Of The University Of Minnesota Tal effector-mediated DNA modification
CA2788850C (en) * 2010-02-09 2019-06-25 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG185481A1 (en) 2010-05-10 2012-12-28 Univ California Endoribonuclease compositions and methods of use thereof
CA2798988C (en) * 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
WO2012167192A2 (en) * 2011-06-01 2012-12-06 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
US9243234B2 (en) * 2011-08-04 2016-01-26 Rutgers, The State University Of New Jersey Sequence-specific MRNA interferase and uses thereof
US20130137173A1 (en) 2011-11-30 2013-05-30 Feng Zhang Nucleotide-specific recognition sequences for designer tal effectors
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
DE202013012241U1 (en) 2012-05-25 2016-01-18 Emmanuelle Charpentier Compositions for RNA-directed modification of a target DNA and for RNA-driven modulation of transcription
ES2757623T3 (en) 2012-07-25 2020-04-29 Broad Inst Inc Inducible DNA binding proteins and genomic disruption tools and applications thereof
ES2926021T3 (en) * 2012-10-23 2022-10-21 Toolgen Inc Composition for cleaving a target DNA comprising a target DNA-specific guide RNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
PL2928496T3 (en) * 2012-12-06 2020-04-30 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
US8993233B2 (en) * 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
WO2014093694A1 (en) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PL2898075T3 (en) * 2012-12-12 2016-09-30 Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
EP2825654B1 (en) * 2012-12-12 2017-04-26 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
MX2015007549A (en) * 2012-12-12 2017-01-20 Broad Inst Inc Engineering of systems, methods and optimized guide compositions for sequence manipulation.
EP3011029B1 (en) * 2013-06-17 2019-12-11 The Broad Institute, Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
AU2014361834B2 (en) * 2013-12-12 2020-10-22 Massachusetts Institute Of Technology CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
CA2932472A1 (en) * 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
EP3985115A1 (en) * 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
MX2017016289A (en) * 2015-06-18 2018-08-15 Broad Inst Inc Crispr enzyme mutations reducing off-target effects.
US11696305B2 (en) 2020-06-18 2023-07-04 Qualcomm Incorporated Scheduling uplink transmissions using relay devices

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232302A (en) 1990-01-10 1993-08-03 Mayreder Consult Of The United States Inc. Fixing means for connecting components
WO1996039154A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
WO1997003211A1 (en) 1995-07-13 1997-01-30 Isis Pharmaceuticals, Inc. Antisense inhibition of hepatitis b virus replication
WO1997049450A1 (en) 1996-06-24 1997-12-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
WO1998052609A1 (en) 1997-05-19 1998-11-26 Nycomed Imaging As Sonodynamic therapy using an ultrasound sensitizer compound
WO1999008713A1 (en) 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
WO1999060164A1 (en) 1998-05-15 1999-11-25 Quark Biotech, Inc. Mechanical stress induced genes, expression products therefrom, and uses thereof
US20030049799A1 (en) 2000-10-23 2003-03-13 Schwartz John Jacob Engineered stimulus-responsive switches
US7745592B2 (en) 2001-05-01 2010-06-29 National Research Council Of Canada Cumate-inducible expression system for eukaryotic cells
US9816739B2 (en) 2011-09-02 2017-11-14 Carrier Corporation Refrigeration system and refrigeration method providing heat recovery
US11696302B2 (en) 2018-09-10 2023-07-04 Ntt Docomo, Inc. User terminal

Non-Patent Citations (144)

* Cited by examiner, † Cited by third party
Title
A. H. MAGADAN ET AL., PLOS ONE, vol. 7, 2012, pages E40913
A. H. MAGADAN; M. E. DUPUIS; M. VILLION; S. MOINEAU: "Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-Cas system", PLOS ONE, vol. 7, 2012, pages E40913
A. J. WOOD ET AL.: "Targeted genome editing across species using ZFNs and TALENs", SCIENCE, vol. 333, 15 July 2011 (2011-07-15), pages 307, XP055102329, DOI: doi:10.1126/science.1207773
AIRAN, R. D.; THOMPSON, K. R.; FENNO, L. E.; BERNSTEIN, H.; DEISSEROTH, K.: "Temporally precise in vivo control of intracellular signalling", NATURE, vol. 458, 2009, pages 1025 - 1029, XP002631861, DOI: doi:10.1038/nature07926
AYER, D.E.; LAHERTY, C.D.; LAWRENCE, Q.A.; ARMSTRONG, A.P.; EISENMAN, R.N.: "Mad proteins contain a dominant transcription repression domain", MOL. CELL. BIOL., vol. 16, 1996, pages 5772 - 5781
AYER, D.E.; LAHERTY, C.D.; LAWRENCE, Q.A.; ARMSTRONG, A.P.; EISENMAN, R.N.: "Mad proteins contain a dominant transcription repression domain", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, 1996, pages 5772 - 5781
B. L. STODDARD: "Homing endonuclease structure and function", QUARTERLY REVIEWS OF BIOPHYSICS, vol. 38, February 2005 (2005-02-01), pages 49, XP008065807, DOI: doi:10.1017/S0033583505004063
BANERJEE, R. ET AL.: "The signaling state of Arabidopsis cryptochrome 2 contains flavin semiquinone", J BIOL CHEM, vol. 282, 2007, pages 14916 - 14922
BANERJEE, R. ET AL.: "The Signaling State of Arabidopsis Cryptochrome 2 Contains Flavin Semiquinone", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, 2007, pages 14916 - 14922
BANERJEE, R. ET AL.: "The signaling state of Arabidopsis cryptochrome 2 contains flavin semiquinone", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, 2007, pages 14916 - 14922
BATCHELDER, C. ET AL.: "Transcriptional repression by the Caenorhabditis elegans germ-line protein PIE-1", GENES DEV., vol. 13, 1999, pages 202 - 212, XP000882525
BEERLI, R. R.; SEGAL, D. J.; DREIER, B.; BARBAS, C. F.: "3rd. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, 1998, pages 14628 - 14633, XP002924795, DOI: doi:10.1073/pnas.95.25.14628
BEERLI, R.R.; SEGAL, D.J.; DREIER, B.; BARBAS, C.F.: "3rd Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks", PROC NATL ACAD SCI U S A, vol. 95, 1998, pages 14628 - 14633, XP002924795, DOI: doi:10.1073/pnas.95.25.14628
BEERLI, R.R.; SEGAL, D.J.; DREIER, B.; BARBAS, C.F.: "3rd Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks", PROC NATL ACAD SCI U SA, vol. 95, 1998, pages 14628 - 14633, XP002924795, DOI: doi:10.1073/pnas.95.25.14628
BLECHER-GONEN, R. ET AL.: "High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states", NATURE PROTOCOLS, vol. 8, 2013, pages 539 - 554, XP055200053, DOI: doi:10.1038/nprot.2013.023
BOCH ET AL., SCIENCE, vol. 326, 2009, pages 1509 - 1512
BOCH, J ET AL., SCIENCE, 2009
BOCH, J. ET AL.: "Breaking the code of DNA binding specificity of TAL-type III effectors", SCIENCE, vol. 326, 2009, pages 1509 - 1512, XP055250971, DOI: doi:10.1126/science.1178811
BOCH, J.; BONAS, U.: "Xanthomonas AvrBs3 family-type III effectors: discovery and function", ANNU. REV. PHYTOPATHOL., vol. 48, 2010, pages 419 - 436, XP055070452, DOI: doi:10.1146/annurev-phyto-080508-081936
BOGDANOVE, A.J.; SCHORNACK, S.; LAHAYE, T.: "TAL effectors: finding plant genes for disease and defense", CURR. OPIN. PLANT BIOL., vol. 13, 2010, pages 394 - 401, XP027173294
BRADLEY ET AL., NATURE, vol. 309, 1984, pages 255 - 258
BRINSTER RL ET AL., NATURE (LONDON, vol. 296, 1982, pages 39 - 42
BUGAJ, L. J.; CHOKSI, A. T.; MESUDA, C. K.; KANE, R. S.; SCHAFFER, D. V.: "Optogenetic protein clustering and signaling activation in mammalian cells", NATURE METHODS, 2013
C. D. MALONE; G. J. HANNON: "Small RNAs as guardians of the genome", CELL, vol. 136, 20 February 2009 (2009-02-20), pages 656
CERMAK, T. ET AL.: "Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting", NUCLEIC ACIDS RES., vol. 39, 2011, pages E82
CONG, L. ET AL.: "Multiplex genome engineering using CRISPR/Cas systems", SCIENCE, vol. 339, 2013, pages 819 - 823, XP055469277, DOI: doi:10.1126/science.1231143
CONG, L.; ZHOU, R.; KUO, Y.-C.; CUNNIFF, M.; ZHANG, F.: "Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains", NAT COMMUN, vol. 3, 2012, pages 968, XP002700145, DOI: doi:10.1038/ncomms1962
CONG, L.; ZHOU, R.; KUO, Y.-C.; CUNNIFF, M.; ZHANG, F.: "Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains", NAT COMMUN, vol. 3, 2012, pages 968, XP002700145, Retrieved from the Internet <URL:http://www.natore.com/ncomms/journal/v3/n7/suppinfo/ncomms1962 S1.html> DOI: doi:10.1038/ncomms1962
CONG, L.; ZHOU, R.; KUO, Y.-C.; CUNNIFF, M.; ZHANG, F.: "Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains", NAT COMMUN, vol. 3, pages 968, XP002700145, DOI: doi:10.1038/ncomms1962
D. BHAYA; M. DAVISON; R. BARRANGOU: "CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation", ANNU REV GENET, vol. 45, 2011, pages 273, XP055118832, DOI: doi:10.1146/annurev-genet-110410-132430
D. REYON ET AL.: "FLASH assembly of TALENs for high- throughput genome editing", NAT BIOTECHNOL, vol. 30, May 2012 (2012-05-01), pages 460
D. Y. GUSCHIN ET AL., METHODS MOL BIOL, vol. 649, 2010, pages 247
DE GROOTE, M. L.; VERSCHURE, P. J.; ROTS, M. G.: "Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes", NUCLEIC ACIDS RESEARCH, vol. 40, 2012, pages 10596 - 10613, XP002744895, DOI: doi:10.1093/nar/gks863
DEISSEROTH, K.: "Optogenetics", NATURE METHODS, vol. 8, 2011, pages 26 - 29
DONG JY, F.P.; FRIZZELL RA: "Quantitative analysis of the packaging capacity of recombinant adeno-associated virus", HUMAN GENE THERAPY, vol. 7, 1996, pages 2101 - 2112, XP000985472
E. DELTCHEVA ET AL., NATURE, vol. 471, 31 March 2011 (2011-03-31), pages 602
E. DELTCHEVA ET AL.: "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III", NATURE, vol. 471, 31 March 2011 (2011-03-31), pages 602, XP055308803, DOI: doi:10.1038/nature09886
ENGLER, C.; GRUETZNER, R.; KANDZIA, R.; MARILLONNET, S.: "Golden gate shuffling: a one-pot DNA shuffling method based on type Ils restriction enzymes", PLOS ONE, vol. 4, 2009, pages E5553
ENGLER, C.; KANDZIA, R.; MARILLONNET, S.: "A one pot, one step, precision cloning method with high throughput capability", PLOS ONE, vol. 3, 2008, pages E3647, XP002613221, DOI: doi:10.1371/journal.pone.0003647
EVANS ET AL., NATURE, vol. 292, 1981, pages 154 - 156
F. J. MOJICA; C. DIEZ-VILLASENOR; J. GARCIA- MARTINEZ; C. ALMENDROS: "Short motif sequences determine the targets of the prokaryotic CRISPR defence system", MICROBIOLOGY, vol. 155, March 2009 (2009-03-01), pages 733, XP055118633, DOI: doi:10.1099/mic.0.023960-0
F. J. MOJICA; C. DIEZ-VILLASENOR; J. GARCIA-MARTINEZ; C. ALMENDROS: "Short motif sequences determine the targets of the prokaryotic CRISPR defence system", MICROBIOLOGY, vol. 155, March 2009 (2009-03-01), pages 733, XP055118633, DOI: doi:10.1099/mic.0.023960-0
F. ZHANG ET AL.: "Efficient construction of sequence- specific TAL effectors for modulating mammalian transcription", NAT BIOTECHNOL, vol. 29, February 2011 (2011-02-01), pages 149, XP055005146, DOI: doi:10.1038/nbt.1775
FUSSENEGGER M, BIOTECHNOL PROG, vol. 17, 2001, pages 1 - 51
G. GASIUNAS; R. BARRANGOU; P. HORVATH; V. SIKSNYS: "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", PROC NATL ACAD SCI U S A, vol. 109, 25 September 2012 (2012-09-25), pages E2579, XP055068588, DOI: doi:10.1073/pnas.1208507109
G. GASIUNAS; R. BARRANGOU; P. HORVATH; V. SIKSNYS: "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", PROC NATL ACAD SCI USA, vol. 109, 25 September 2012 (2012-09-25), pages E2579, XP055068588, DOI: doi:10.1073/pnas.1208507109
G. MEISTER; T. TUSCHL: "Mechanisms of gene silencing by double-stranded RNA", NATURE, vol. 431, 16 September 2004 (2004-09-16), pages 343, XP055153799, DOI: doi:10.1038/nature02873
GASIUNAS, R. ET AL., PROC NATL ACAD SCI U S A, vol. 109, 25 September 2012 (2012-09-25), pages E2579
GOSSLER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 9065 - 9069
GRIEGER, J. C.; CHOI, V. W.; SAMULSKI, R. J.: "Production and characterization of adeno-associated viral vectors", NAT PROTOC, vol. 1, 2006, pages 1412 - 1428, XP001525224
H. DEVEAU ET AL.: "Phage response to CRISPR-encoded resistance in Streptococcus thermophilus", J BACTERIOL, vol. 190, February 2008 (2008-02-01), pages 1390, XP002679468, DOI: doi:10.1128/JB.01412-07
H. DEVEAU ET AL.: "Phage response to CRISPR-encoded resistance in Streptococcus thermophilus", JBACTERIOL, vol. 190, February 2008 (2008-02-01), pages 1390, XP002679468, DOI: doi:10.1128/JB.01412-07
H. DEVEAU; J. E. GARNEAU; S. MOINEAU: "CRISPR/Cas system and its role in phage- bacteria interactions", ANNUAL REVIEW OF MICROBIOLOGY, vol. 64, 2010, pages 475, XP055067789, DOI: doi:10.1146/annurev.micro.112408.134123
HOCKEMEYER, D. ET AL.: "Genetic engineering of human pluripotent cells using TALE nucleases", NAT. BIOTECHNOL., vol. 29, 2011, pages 731 - 734, XP055018244, DOI: doi:10.1038/nbt.1927
HOLKERS, M. ET AL.: "Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells", NUCLEIC ACIDS RESEARCH, 2013
HSU, P. D.; ZHANG, F.: "Dissecting neural function using targeted genome engineering technologies", ACS CHEMICAL NEUROSCIENCE, vol. 3, 2012, pages 603 - 610
HUERTAS, P.: "DNA resection in eukaryotes: deciding how to fix the break", NAT. STRUCT. MOL. BIOL., vol. 17, 2010, pages 11 - 16
HYNES NE ET AL., PROC NATL ACAD SCI USA, vol. 78, 1981, pages 2038 - 2042
J. BOCH ET AL.: "Breaking the code of DNA binding specificity of TAL-type III effectors", SCIENCE, vol. 326, 11 December 2009 (2009-12-11), pages 1509, XP055250971, DOI: doi:10.1126/science.1178811
J. C. MILLER ET AL.: "A TALE nuclease architecture for efficient genome editing", NAT BIOTECHNOL, vol. 29, February 2011 (2011-02-01), pages 143
J. C. MILLER ET AL.: "An improved zinc-fmger nuclease architecture for highly specific genome editing", NAT BIOTECHNOL, vol. 25, July 2007 (2007-07-01), pages 778, XP002465119, DOI: doi:10.1038/nbt1319
J. D. SANDER ET AL.: "Selection- free zinc-finger-nuclease engineering by context-dependent assembly (CoDA", NAT METHODS, vol. 8, January 2011 (2011-01-01), pages 67
J. E. GAMEAU ET AL.: "The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA", NATURE, vol. 468, 4 November 2010 (2010-11-04), pages 67, XP055181397, DOI: doi:10.1038/nature09523
J. E. GARNEAU ET AL., NATURE, vol. 468, 4 November 2010 (2010-11-04), pages 67
JAENISCH, SCIENCE, vol. 240, 1988, pages 1468 - 1474
K. S. MAKAROVA ET AL.: "Evolution and classification of the CRISPR-Cas systems", NAT REV MICROBIOL, vol. 9, June 2011 (2011-06-01), pages 467, XP009155547, DOI: doi:10.1038/nrmicro2577
KAY, S.; HAHN, S.; MAROIS, E.; HAUSE, G.; BONAS, U.: "A bacterial effector acts as a plant transcription factor and induces a cell size regulator", SCIENCE, vol. 318, 2007, pages 648 - 651, XP009125817
KAY, S.; HAHN, S.; MAROIS, E; WIEDUWILD, R.; BONAS, U.: "Detailed analysis of the DNA recognition motifs of the Xanthomonas type III effectors AvrBs3 and AvrBs3Deltarepl6", PLANT J., vol. 59, 2009, pages 859 - 871
KENNEDY M ET AL., NATURE METHODS, 2010
KENNEDY, M. J. ET AL.: "Rapid blue-light- mediated induction of protein interactions in living cells", NATURE METHODS, vol. 7, 2010, pages 973 - 975, XP055039821, DOI: doi:10.1038/nmeth.1524
KENNEDY, M. J. ET AL.: "Rapid blue-light-mediated induction of protein interactions in living cells", NATURE METHODS, vol. 7, 2010, pages 973 - 975, XP055039821, DOI: doi:10.1038/nmeth.1524
KLOCK G ET AL., NATURE, vol. 329, 1987, pages 734 - 736
LATCHMAN AND DS, INT. J. BIOCHEM. CELL BIOL., vol. 29, no. 12, 1997, pages 1305 - 12
LEE F ET AL., NATURE (LONDON, vol. 294, 1981, pages 228 - 232
LEE TI; YOUNG RA, ANNU. REV. GENET., vol. 34, 2000, pages 77 - 137
LEVSKAYA, A.; WEINER, O. D.; LIM, W. A.; VOIGT, C. A.: "Spatiotemporal control of cell signalling using a light-switchable protein interaction", NATURE, vol. 461, 2009, pages 997 - 1001, XP055060672, DOI: doi:10.1038/nature08446
LIANG, F.-S.; HO, W. Q.; CRABTREE, G. R.: "Engineering the ABA Plant Stress Pathway for Regulation of Induced Proximity", SCI. SIGNAL., vol. 4, 2011, pages RS2
LIU, H ET AL., SCIENCE, 2008
LIU, H. ET AL.: "Photoexcited CRY2 interacts with CIB1 to regulate transcription and floral initiation in Arabidopsis", SCIENCE, vol. 322, 2008, pages 1535 - 1539, XP055087542, DOI: doi:10.1126/science.1163927
LOCK M, A. M.; VANDENBERGHE LH; SAMANTA A; TOELEN J; DEBYSER Z; WILSON JM.: "Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale", HUMAN GENE THERAPY, vol. 21, 2010, pages 1259 - 1271
LOCK M, A. M.; VANDENBERGHE LH; SAMANTA A; TOELEN J; DEBYSER Z; WILSON JM: "Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale", HUMAN GENE THERAPY, vol. 21, 2010, pages 1259 - 1271
M. CHRISTIAN ET AL.: "Targeting DNA double-strand breaks with TAL effector nucleases", GENETICS, vol. 186, October 2010 (2010-10-01), pages 757, XP002632806, DOI: doi:10.1534/GENETICS.110.120717
M. H. PORTEUS; D. BALTIMORE: "Chimeric nucleases stimulate gene targeting in human cells", SCIENCE, vol. 300, 2 May 2003 (2003-05-02), pages 763, XP002974231, DOI: doi:10.1126/science.1078395
M. J. MOSCOU; A. J. BOGDANOVE: "A simple cipher governs DNA recognition by TAL effectors", SCIENCE, vol. 326, 11 December 2009 (2009-12-11), pages 1501, XP002599998
M. JINEK ET AL., SCIENCE, vol. 337, 17 August 2012 (2012-08-17), pages 816
M. JINEK ET AL.: "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", SCIENCE, vol. 337, 17 August 2012 (2012-08-17), pages 816, XP055299674, DOI: doi:10.1126/science.1225829
M. JINEK; J. A. DOUDNA: "A three-dimensional view of the molecular machinery of RNA interference", NATURE, vol. 457, 22 January 2009 (2009-01-22), pages 405
M. T. CERTO ET AL.: "Tracking genome engineering outcome at individual DNA breakpoints", NAT METHODS, vol. 8, August 2011 (2011-08-01), pages 671, XP002770350, DOI: doi:10.1038/nmeth.1648
MARGOLIN, J.F. ET AL.: "Kruppel-associated boxes are potent transcriptional repression domains", PROC. NATL. ACAD. SCI. US A, vol. 91, 1994, pages 4509 - 4513, XP002136979, DOI: doi:10.1073/pnas.91.10.4509
MARGOLIN, J.F. ET AL.: "Kruppel-associated boxes are potent transcriptional repression domains", PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 4509 - 4513, XP002136979, DOI: doi:10.1073/pnas.91.10.4509
MARKUSIC ET AL., NUCLEIC ACIDS RESEARCH, vol. 33, no. 6, 2005, pages E63
MAYO KE ET AL., CELL, vol. 29, 1982, pages 99 - 108
MCCLURE, C.; COLE, K. L.; WULFF, P.; KLUGMANN, M.; MURRAY, A. J.: "Production and titering of recombinant adeno-associated viral vectors", J VIS EXP, 2011, pages E3348
MILLER, J. C. ET AL.: "A TALE nuclease architecture for efficient genome editing", NATURE BIOTECHNOLOGY, vol. 29, 2011, pages 143 - 148, XP055458374, DOI: doi:10.1038/nbt.1755
MILLER, J.C. ET AL.: "A TALE nuclease architecture for efficient genome editing", NAT. BIOTECHNOL., vol. 29, 2011, pages 143 - 148, XP055458374, DOI: doi:10.1038/nbt.1755
MITCHELL PJ; TJIAN R, SCIENCE, vol. 245, no. 4916, 1989, pages 371 - 8
MOORE, M. J.; PROUDFOOT, N. J.: "Pre-mRNA processing reaches back to transcription and ahead to translation", CELL, vol. 136, 2009, pages 688 - 700
MOROCZ ET AL., JOURNAL OF MAGNETIC RESONANCE IMAGING, vol. 8, no. 1, 1998, pages 136 - 142
MOSCOU ET AL., SCIENCE, vol. 326, 2009, pages 1501
MOSCOU, M ET AL., SCIENCE, 2009
MOSCOU, M. J.; BOGDANOVE, A. J.: "A simple cipher governs DNA recognition by TAL effectors", SCIENCE, vol. 326, 2009, pages 1501, XP002599998
MOSCOU, M.J.; BOGDANOVE, A.J.: "A simple cipher governs DNA recognition by TAL effectors", SCIENCE, vol. 326, 2009, pages 1501, XP002599998
MOUSSATOV ET AL., ULTRASONICS, vol. 36, no. 8, 1998, pages 893 - 900
MULLICK A; MASSIE B: "Encyclopedia of Cell Technology", 2000, WILEY, article "Transcription, translation and the control of gene expression", pages: 1140 - 1164
MULLICK ET AL., BMC BIOTECHNOLOGY, vol. 6, 2006, pages 43
NAKAMURA, Y. ET AL.: "Codon usage tabulated from the international DNA sequence databases: status for the year 2000", NUCL. ACIDS RES., vol. 28, 2000, pages 292, XP002941557, DOI: doi:10.1093/nar/28.1.292
NE SANJANA; L CONG; Y ZHOU; M M CUNNIFF; G FENG; F ZHANG: "A transcription activator-like effector toolbox for genome engineering", NATURE PROTOCOLS, vol. 7, 2012, pages 171 - 192, XP009170390, DOI: doi:10.1038/nprot.2011.431
NO D ET AL., PROC NATL ACAD SCI USA, vol. 93, 1996, pages 3346 - 3351
NOUER L: "Heat Shock Response", 1991, CRC
P. A. CARR; G. M. CHURCH: "Genome engineering", NAT BIOTECHNOL, vol. 27, December 2009 (2009-12-01), pages 1151, XP055284957, DOI: doi:10.1038/nbt.1590
P. HORVATH; R. BARRANGOU: "CRISPR/Cas, the immune system of bacteria and archaea", SCIENCE, vol. 327, 8 January 2010 (2010-01-08), pages 167, XP055016971, DOI: doi:10.1126/science.1179555
POLSTEIN, L. R.; GERSBACH, C. A.: "Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors", JAM CHEM SOC, vol. 134, 2012, pages 16480 - 16483, XP055493231, DOI: doi:10.1021/ja3065667
POLSTEIN, L. R.; GERSBACH, C. A.: "Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, 2012, pages 16480 - 16483, XP055493231, DOI: doi:10.1021/ja3065667
PROUDFOOT, N. J.; FURGER, A.; DYE, M. J.: "Integrating mRNA processing with transcription", CELL, vol. 108, 2002, pages 501 - 512
R. SAPRANAUSKAS ET AL., NUCLEIC ACIDS RES, vol. 39, November 2011 (2011-11-01), pages 9275
R. SAPRANAUSKAS ET AL.: "The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli", NUCLEIC ACIDS RES, November 2011 (2011-11-01)
R. SAPRANAUSKAS ET AL.: "The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli", NUCLEIC ACIDS RES, vol. 39, November 2011 (2011-11-01), pages 9275, XP055265024, DOI: doi:10.1093/nar/gkr606
RIVERA VM ET AL., NAT MED, vol. 2, 1996, pages 1028 - 1032
ROBERTSON ET AL., NATURE, vol. 322, 1986, pages 445 - 448
ROMER, P. ET AL.: "Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene", SCIENCE, vol. 318, 2007, pages 645 - 648
ROMER, P. ET AL.: "Recognition of AvrBs3-like proteins is mediated by specific binding to promoters of matching pepper Bs3 alleles", PLANT PHYSIOL., vol. 150, 2009, pages 1697 - 1712, XP002570747, DOI: doi:10.1104/PP.109.139931
SAEZ E ET AL., PROC NATL ACAD SCI USA, vol. 97, 2000, pages 14512 - 14517
SEARLE PF ET AL., MOL CELL BIOL, vol. 5, 1985, pages 1480 - 1489
SHIMIZU-SATO, S.; HUQ, E.; TEPPERMAN, J. M.; QUAIL, P. H.: "A light-switchable gene promoter system", NAT BIOTECHNOL, vol. 20, 2002, pages 1041 - 1044, XP002302655, DOI: doi:10.1038/nbt734
SHIMIZU-SATO, S.; HUQ, E.; TEPPERMAN, J. M.; QUAIL, P. H.: "A light-switchable gene promoter system", NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 1041 - 1044, XP002302655, DOI: doi:10.1038/nbt734
STRICKLAND, D. ET AL.: "TULIPs: tunable, light-controlled interacting protein tags for cell biology", NATURE METHODS, vol. 9, 2012, pages 379 - 384, XP055450693, DOI: doi:10.1038/nmeth.1904
STRICKLAND, D. ET AL.: "ULIPs: tunable, light-controlled interacting protein tags for cell biology", NATURE METHODS, vol. 9, 2012, pages 379 - 384, XP055450693, DOI: doi:10.1038/nmeth.1904
TOUR, E.; HITTINGER, C.T.; MCGINNIS, W.: "Evolutionarily conserved domains required for activation and repression functions of the Drosophila Hox protein Ultrabithorax", DEVELOPMENT, vol. 132, 2005, pages 5271 - 5281
TRANHUUHUE ET AL., ACUSTICA, vol. 83, no. 6, 1997, pages 1103 - 1106
WANG, X.; CHEN, X.; YANG, Y.: "Spatiotemporal control of gene expression by a light-switchable transgene system", NATURE METHODS, vol. 9, 2012, pages 266 - 269, XP055087617, DOI: doi:10.1038/nmeth.1892
WEBER, E.; ENGLER, C.; GRUETZNER, R.; WERNER, S.; MARILLONNET, S.: "A modular cloning system for standardized assembly ofmultigene constructs", PLOS ONE, vol. 6, 2011, pages EL6765
WITTEN, ILANA B. ET AL.: "Recombinase-Driver Rat Lines: Tools, Techniques, and Optogenetic Application to Dopamine-Mediated Reinforcement", NEURON, vol. 72, 2011, pages 721 - 733, XP028391748, DOI: doi:10.1016/j.neuron.2011.10.028
WU, Z.; YANG, H.; COLOSI, P.: "Effect of Genome Size on AAV Vector Packaging", MOL THER, vol. 18, 2009, pages 80 - 86, XP055235504, DOI: doi:10.1038/mt.2009.255
YAZAWA, M.; SADAGHIANI, A. M.; HSUEH, B.; DOLMETSCH, R. E.: "Induction of protein-protein interactions in live cells using light", NAT BIOTECHNOL, vol. 27, 2009, pages 941 - 945, XP055051950, DOI: doi:10.1038/nbt.1569
YAZAWA, M.; SADAGHIANI, A. M.; HSUEH, B.; DOLMETSCH, R. E.: "Induction of protein-protein interactions in live cells using light", NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 941 - 945, XP055051950, DOI: doi:10.1038/nbt.1569
YE, H.; DAOUD-EL BABA, M.; PENG, R. W.; FUSSENEGGER, M.: "A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice", SCIENCE, vol. 332, 2011, pages 1565 - 1568, XP002699843, DOI: doi:10.1126/science.1203535
YIZHAR, 0.; FENNO, L. E.; DAVIDSON, T. J.; MOGRI, M.; DEISSEROTH, K.: "Optogenetics in neural systems", NEURON, vol. 71, 2011, pages 9 - 34, XP028379910, DOI: doi:10.1016/j.neuron.2011.06.004
ZHANG ET AL., NATURE BIOTECHNOLOGY, vol. 29, 2011, pages 149 - 153
ZHANG, F ET AL., NATURE BIOTECHNOLOGY, 2011
ZHANG, F. ET AL.: "Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription", NAT. BIOTECHNOL., vol. 29, 2011, pages 149 - 153, XP055005146, DOI: doi:10.1038/nbt.1775
ZHANG, F. ET AL.: "Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription", NATBIOTECHNOL, vol. 29, 2011, pages 149 - 153, XP055005146, DOI: doi:10.1038/nbt.1775
ZHANG, F. ET AL.: "Multimodal fast optical interrogation of neural circuitry", NATURE, vol. 446, 2007, pages 633 - 639, XP002487911, DOI: doi:10.1038/nature05744
ZHANG, F. ET AL.: "Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures", NAT PROTOC, vol. 5, 2010, pages 439 - 456, XP009172355, DOI: doi:10.1038/nprot.2009.226
ZHANG, F. ET AL.: "The microbial opsin family of optogenetic tools", CELL, vol. 147, 2011, pages 1446 - 1457, XP028348924, DOI: doi:10.1016/j.cell.2011.12.004

Cited By (732)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US12006520B2 (en) 2011-07-22 2024-06-11 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US10711257B2 (en) 2011-12-30 2020-07-14 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10435678B2 (en) 2011-12-30 2019-10-08 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US11939604B2 (en) 2011-12-30 2024-03-26 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10954498B2 (en) 2011-12-30 2021-03-23 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US9834786B2 (en) 2012-04-25 2017-12-05 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
US10301646B2 (en) 2012-04-25 2019-05-28 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
US20210040460A1 (en) 2012-04-27 2021-02-11 Duke University Genetic correction of mutated genes
US11976307B2 (en) 2012-04-27 2024-05-07 Duke University Genetic correction of mutated genes
US10626419B2 (en) 2012-05-25 2020-04-21 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10676759B2 (en) 2012-05-25 2020-06-09 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10266850B2 (en) 2012-05-25 2019-04-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10443076B2 (en) 2012-05-25 2019-10-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10227611B2 (en) 2012-05-25 2019-03-12 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10421980B2 (en) 2012-05-25 2019-09-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10415061B2 (en) 2012-05-25 2019-09-17 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10487341B2 (en) 2012-05-25 2019-11-26 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10513712B2 (en) 2012-05-25 2019-12-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10407697B2 (en) 2012-05-25 2019-09-10 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11970711B2 (en) 2012-05-25 2024-04-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10400253B2 (en) 2012-05-25 2019-09-03 The Regents Of The University Of California Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10519467B2 (en) 2012-05-25 2019-12-31 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10526619B2 (en) 2012-05-25 2020-01-07 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10533190B2 (en) 2012-05-25 2020-01-14 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10113167B2 (en) 2012-05-25 2018-10-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10550407B2 (en) 2012-05-25 2020-02-04 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10301651B2 (en) 2012-05-25 2019-05-28 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10563227B2 (en) 2012-05-25 2020-02-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10570419B2 (en) 2012-05-25 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10577631B2 (en) 2012-05-25 2020-03-03 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10597680B2 (en) 2012-05-25 2020-03-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10612045B2 (en) 2012-05-25 2020-04-07 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10308961B2 (en) 2012-05-25 2019-06-04 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10640791B2 (en) 2012-05-25 2020-05-05 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11814645B2 (en) 2012-05-25 2023-11-14 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10000772B2 (en) 2012-05-25 2018-06-19 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10669560B2 (en) 2012-05-25 2020-06-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11674159B2 (en) 2012-05-25 2023-06-13 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10428352B2 (en) 2012-05-25 2019-10-01 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10385360B2 (en) 2012-05-25 2019-08-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10358658B2 (en) 2012-05-25 2019-07-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11186849B2 (en) 2012-05-25 2021-11-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11008590B2 (en) 2012-05-25 2021-05-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11008589B2 (en) 2012-05-25 2021-05-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11634730B2 (en) 2012-05-25 2023-04-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10752920B2 (en) 2012-05-25 2020-08-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11549127B2 (en) 2012-05-25 2023-01-10 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10774344B1 (en) 2012-05-25 2020-09-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11479794B2 (en) 2012-05-25 2022-10-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11473108B2 (en) 2012-05-25 2022-10-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10793878B1 (en) 2012-05-25 2020-10-06 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11401532B2 (en) 2012-05-25 2022-08-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10358659B2 (en) 2012-05-25 2019-07-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10900054B2 (en) 2012-05-25 2021-01-26 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10351878B2 (en) 2012-05-25 2019-07-16 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10337029B2 (en) 2012-05-25 2019-07-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11332761B2 (en) 2012-05-25 2022-05-17 The Regenis of Wie University of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11028412B2 (en) 2012-05-25 2021-06-08 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10982230B2 (en) 2012-05-25 2021-04-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10982231B2 (en) 2012-05-25 2021-04-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11293034B2 (en) 2012-05-25 2022-04-05 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11274318B2 (en) 2012-05-25 2022-03-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10988782B2 (en) 2012-05-25 2021-04-27 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10988780B2 (en) 2012-05-25 2021-04-27 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11242543B2 (en) 2012-05-25 2022-02-08 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11001863B2 (en) 2012-05-25 2021-05-11 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
KR102530118B1 (en) 2012-07-25 2023-05-08 더 브로드 인스티튜트, 인코퍼레이티드 Inducible dna binding proteins and genome perturbation tools and applications thereof
EP3494997B1 (en) 2012-07-25 2019-09-18 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
KR20150056539A (en) * 2012-07-25 2015-05-26 더 브로드 인스티튜트, 인코퍼레이티드 Inducible dna binding proteins and genome perturbation tools and applications thereof
US20210047648A1 (en) * 2012-10-23 2021-02-18 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
US10731181B2 (en) 2012-12-06 2020-08-04 Sigma, Aldrich Co. LLC CRISPR-based genome modification and regulation
US10745716B2 (en) 2012-12-06 2020-08-18 Sigma-Aldrich Co. Llc CRISPR-based genome modification and regulation
US9725714B2 (en) 2013-03-14 2017-08-08 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10125361B2 (en) 2013-03-14 2018-11-13 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9410198B2 (en) 2013-03-14 2016-08-09 Caribou Biosciences, Inc. Compostions and methods of nucleic acid-targeting nucleic acids
US9909122B2 (en) 2013-03-14 2018-03-06 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
GB2527450A (en) * 2013-03-14 2015-12-23 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
US11312953B2 (en) 2013-03-14 2022-04-26 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
WO2014150624A1 (en) * 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9809814B1 (en) 2013-03-14 2017-11-07 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9803194B2 (en) 2013-03-14 2017-10-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US12037596B2 (en) 2013-04-16 2024-07-16 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US10975390B2 (en) 2013-04-16 2021-04-13 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US10385359B2 (en) 2013-04-16 2019-08-20 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US10328182B2 (en) 2013-05-14 2019-06-25 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
US11246965B2 (en) 2013-05-14 2022-02-15 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
US10577644B2 (en) 2013-05-29 2020-03-03 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10519457B2 (en) 2013-08-22 2019-12-31 E I Du Pont De Nemours And Company Soybean U6 polymerase III promoter and methods of use
US11773400B2 (en) 2013-08-22 2023-10-03 E.I. Du Pont De Nemours And Company Methods for producing genetic modifications in a plant genome without incorporating a selectable transgene marker, and compositions thereof
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US10849977B2 (en) 2013-09-11 2020-12-01 Eagle Biologics, Inc. Liquid Protein Formulations Containing Thiamine
US10179172B2 (en) 2013-09-11 2019-01-15 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof
US11986526B2 (en) 2013-09-11 2024-05-21 Eagle Biologics, Inc. Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC)
US9913905B2 (en) 2013-09-11 2018-03-13 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof
US9833513B2 (en) 2013-09-11 2017-12-05 Eagle Biologics, Inc. Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof
US9925263B2 (en) 2013-09-11 2018-03-27 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising procaine and uses thereof
US11819550B2 (en) 2013-09-11 2023-11-21 Eagle Biologics, Inc. Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP)
US10646571B2 (en) 2013-09-11 2020-05-12 Eagle Biologics, Inc. Liquid protein formulations containing cimetidine
US10821183B2 (en) 2013-09-11 2020-11-03 Eagle Biologics, Inc. Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)
US10821184B2 (en) 2013-09-11 2020-11-03 Eagle Biologics, Inc. Liquid protein formulations containing thiamine pyrophosphate (TPP)
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
US11149267B2 (en) 2013-10-28 2021-10-19 The Broad Institute, Inc. Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof
US10190137B2 (en) 2013-11-07 2019-01-29 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US11390887B2 (en) 2013-11-07 2022-07-19 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10640788B2 (en) 2013-11-07 2020-05-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAs
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10208317B2 (en) 2013-12-11 2019-02-19 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
US9228208B2 (en) 2013-12-11 2016-01-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
US10711280B2 (en) 2013-12-11 2020-07-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse ES cell genome
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
US11820997B2 (en) 2013-12-11 2023-11-21 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
WO2015089351A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
WO2015089465A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
EP3653229A1 (en) 2013-12-12 2020-05-20 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
EP3540051A1 (en) 2013-12-12 2019-09-18 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
EP4183876A1 (en) 2013-12-12 2023-05-24 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
EP3653704A1 (en) 2013-12-12 2020-05-20 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2015089354A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
EP3653703A1 (en) 2013-12-12 2020-05-20 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015113063A1 (en) 2014-01-27 2015-07-30 Georgia Tech Research Corporation Methods and systems for identifying crispr/cas off-target sites
US10287590B2 (en) 2014-02-12 2019-05-14 Dna2.0, Inc. Methods for generating libraries with co-varying regions of polynuleotides for genome modification
US10988796B2 (en) 2014-02-13 2021-04-27 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US10150985B2 (en) 2014-02-13 2018-12-11 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US11884963B2 (en) 2014-02-13 2024-01-30 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US11952578B2 (en) 2014-02-27 2024-04-09 Monsanto Technology Llc Compositions and methods for site directed genomic modification
US11186843B2 (en) 2014-02-27 2021-11-30 Monsanto Technology Llc Compositions and methods for site directed genomic modification
US11209440B2 (en) 2014-02-27 2021-12-28 The Broad Institute, Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US11566254B2 (en) 2014-02-27 2023-01-31 Monsanto Technology Llc Compositions and methods for site directed genomic modification
EP3514246A1 (en) 2014-02-27 2019-07-24 The Broad Institute Inc. T cell balance gene expression and methods of use thereof
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
CN111471675A (en) * 2014-03-05 2020-07-31 国立大学法人神户大学 Method for modifying genome sequence of nucleic acid base for specifically converting target DNA sequence, and molecular complex used therefor
CN111500569A (en) * 2014-03-05 2020-08-07 国立大学法人神户大学 Method for modifying genome sequence of nucleic acid base for specifically converting target DNA sequence, and molecular complex used therefor
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11268086B2 (en) 2014-03-10 2022-03-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
WO2015153940A1 (en) * 2014-04-03 2015-10-08 Massachusetts Institute Of Technology Methods and compositions for the production of guide rna
KR101748823B1 (en) 2014-04-23 2017-06-19 윤희준 Transcription Activation Like Effector Nuclease for Targeting Myostatin Gene and Methods for Making Myostatin Gene Knock out Animal Using Thereof
US11896686B2 (en) 2014-05-09 2024-02-13 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
WO2015188056A1 (en) * 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
US10443087B2 (en) 2014-06-13 2019-10-15 Illumina Cambridge Limited Methods and compositions for preparing sequencing libraries
US11299765B2 (en) 2014-06-13 2022-04-12 Illumina Cambridge Limited Methods and compositions for preparing sequencing libraries
US11965158B2 (en) 2014-06-30 2024-04-23 Illumina, Inc. Methods and compositions using one-sided transposition
US10577603B2 (en) 2014-06-30 2020-03-03 Illumina, Inc. Methods and compositions using one-sided transposition
US10968448B2 (en) 2014-06-30 2021-04-06 Illumina, Inc. Methods and compositions using one-sided transposition
WO2016003814A1 (en) 2014-06-30 2016-01-07 Illumina, Inc. Methods and compositions using one-sided transposition
US10676754B2 (en) 2014-07-11 2020-06-09 E I Du Pont De Nemours And Company Compositions and methods for producing plants resistant to glyphosate herbicide
WO2016011080A3 (en) * 2014-07-14 2016-03-03 The Regents Of The University Of California Crispr/cas transcriptional modulation
CN104630267A (en) * 2014-07-17 2015-05-20 清华大学 Kit for constructing synthetic gene circuits by utilizing modularization of TALE transcriptional suppressors in mammal animals
EP4079847A1 (en) * 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US20230279443A1 (en) * 2014-07-30 2023-09-07 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016022363A3 (en) * 2014-07-30 2016-05-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP3177718A4 (en) * 2014-07-30 2018-04-04 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
US10314297B2 (en) 2014-08-14 2019-06-11 Biocytogen Boston Corp DNA knock-in system
US11071289B2 (en) 2014-08-14 2021-07-27 Biocytogen Boston Corp DNA knock-in system
EP3686279A1 (en) 2014-08-17 2020-07-29 The Broad Institute, Inc. Genome editing using cas9 nickases
US11560568B2 (en) 2014-09-12 2023-01-24 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
US11459557B2 (en) 2014-09-24 2022-10-04 The Broad Institute, Inc. Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
US11197467B2 (en) 2014-09-24 2021-12-14 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes
US11124796B2 (en) 2014-09-24 2021-09-21 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
US11001829B2 (en) 2014-09-25 2021-05-11 The Broad Institute, Inc. Functional screening with optimized functional CRISPR-Cas systems
WO2016049531A1 (en) 2014-09-26 2016-03-31 Purecircle Usa Inc. Single nucleotide polymorphism (snp) markers for stevia
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2016069591A2 (en) 2014-10-27 2016-05-06 The Broad Institute Inc. Compositions, methods and use of synthetic lethal screening
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
EP3626832A2 (en) 2014-11-25 2020-03-25 The Brigham and Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
WO2016086197A1 (en) 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
WO2016086227A2 (en) 2014-11-26 2016-06-02 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
WO2016083811A1 (en) 2014-11-27 2016-06-02 Imperial Innovations Limited Genome editing methods
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
US10954514B2 (en) 2014-12-12 2021-03-23 The Broad Institute, Inc. Escorted and functionalized guides for CRISPR-Cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016098078A3 (en) * 2014-12-19 2016-10-27 Novartis Ag Dimerization switches and uses thereof
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
EP3702456A1 (en) 2014-12-24 2020-09-02 The Broad Institute, Inc. Crispr having or associated with destabilization domains
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
WO2016103233A3 (en) * 2014-12-24 2017-09-21 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
US12116619B2 (en) 2014-12-30 2024-10-15 The Broad Institute, Inc. CRISPR mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
US9868962B2 (en) 2015-01-28 2018-01-16 Pioneer Hi-Bred International, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US9771601B2 (en) 2015-01-28 2017-09-26 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US11236364B2 (en) 2015-01-28 2022-02-01 Caribou Biosciences, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US10519468B2 (en) 2015-01-28 2019-12-31 Pioneer Hi-Bred International, Inc. Cells containing CRISPR hybrid DNA/RNA polynucleotides
US10988781B2 (en) 2015-01-28 2021-04-27 Caribou Biosciences, Inc. Method of target cleaving using CRISPR hybrid DNA/RNA polynucleotides
US11459588B2 (en) 2015-01-28 2022-10-04 Caribou Biosciences, Inc. Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotides
US9688972B2 (en) 2015-01-28 2017-06-27 Pioneer Hi-Bred International, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US9580701B2 (en) 2015-01-28 2017-02-28 Pioneer Hi-Bred International, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US9650617B2 (en) 2015-01-28 2017-05-16 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
WO2016138488A2 (en) 2015-02-26 2016-09-01 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US11427869B2 (en) 2015-02-26 2022-08-30 The Broad Institute, Inc. T cell balance gene expression, compositions of matters and methods of use thereof
WO2016138574A1 (en) 2015-03-02 2016-09-09 Sinai Health System Homologous recombination factors
US12043835B2 (en) 2015-03-16 2024-07-23 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Method for making site-directed modification to plant genomes by using non-inheritable materials
JP2018508221A (en) * 2015-03-16 2018-03-29 中国科学院遺▲伝▼与▲発▼育生物学研究所Ｉｎｓｔｉｔｕｔｅ ｏｆ Ｇｅｎｅｔｉｃｓ ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔａｌ Ｂｉｏｌｏｇｙ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ ｏｆ Ｓｃｉｅｎｃｅｓ How to apply non-genetic material to perform site-specific modification of plant genomes
US10450576B2 (en) 2015-03-27 2019-10-22 E I Du Pont De Nemours And Company Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
JPWO2016167300A1 (en) * 2015-04-13 2017-07-13 国立大学法人 東京大学 A set of polypeptides that exhibit nuclease activity or nickase activity in a light-dependent or drug presence, or that suppress or activate target gene expression
US11390860B2 (en) 2015-04-13 2022-07-19 The University Of Tokyo Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
WO2016167300A1 (en) * 2015-04-13 2016-10-20 国立大学法人東京大学 Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
US11180793B2 (en) 2015-04-24 2021-11-23 Editas Medicine, Inc. Evaluation of Cas9 molecule/guide RNA molecule complexes
US10463049B2 (en) 2015-05-06 2019-11-05 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US9701964B2 (en) 2015-05-06 2017-07-11 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10561148B2 (en) 2015-05-06 2020-02-18 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11844760B2 (en) 2015-05-06 2023-12-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11400110B2 (en) 2015-05-06 2022-08-02 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11612617B2 (en) 2015-05-06 2023-03-28 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11147830B2 (en) 2015-05-06 2021-10-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10506812B2 (en) 2015-05-06 2019-12-17 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11642363B2 (en) 2015-05-06 2023-05-09 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11517582B2 (en) 2015-05-06 2022-12-06 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11547716B2 (en) 2015-05-06 2023-01-10 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10624349B2 (en) 2015-05-06 2020-04-21 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10582712B2 (en) 2015-05-06 2020-03-10 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US10524477B2 (en) 2015-05-06 2020-01-07 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11685917B2 (en) 2015-05-08 2023-06-27 The Broad Institute, Inc. Functional genomics using CRISPR-Cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
US11492630B2 (en) 2015-05-19 2022-11-08 KWS SAAT SE & Co. KGaA Methods and hybrids for targeted nucleic acid editing in plants using CRISPR/Cas systems
WO2016191684A1 (en) * 2015-05-28 2016-12-01 Finer Mitchell H Genome editing vectors
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
US11643669B2 (en) 2015-06-17 2023-05-09 Massachusetts Institute Of Technology CRISPR mediated recording of cellular events
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
EP4159856A1 (en) 2015-06-18 2023-04-05 The Broad Institute, Inc. Novel crispr enzymes and systems
US11773412B2 (en) 2015-06-18 2023-10-03 The Broad Institute, Inc. Crispr enzymes and systems
US11060115B2 (en) 2015-06-18 2021-07-13 The Broad Institute, Inc. CRISPR enzymes and systems
EP3502253A1 (en) 2015-06-18 2019-06-26 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
US11421250B2 (en) 2015-06-18 2022-08-23 The Broad Institute, Inc. CRISPR enzymes and systems
WO2016205764A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
EP3666895A1 (en) 2015-06-18 2020-06-17 The Broad Institute, Inc. Novel crispr enzymes and systems
EP4403638A2 (en) 2015-06-18 2024-07-24 The Broad Institute Inc. Novel crispr enzymes and systems
US20180127745A1 (en) * 2015-06-18 2018-05-10 The Broad Institute Inc. Cell sorting
US11236327B2 (en) 2015-06-18 2022-02-01 The Broad Institute, Inc. Cell sorting
US11414657B2 (en) 2015-06-29 2022-08-16 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
US11147837B2 (en) 2015-07-31 2021-10-19 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11266692B2 (en) 2015-07-31 2022-03-08 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11642374B2 (en) 2015-07-31 2023-05-09 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US11642375B2 (en) 2015-07-31 2023-05-09 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US11903966B2 (en) 2015-07-31 2024-02-20 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11583556B2 (en) 2015-07-31 2023-02-21 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11925664B2 (en) 2015-07-31 2024-03-12 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
EP4043074A1 (en) 2015-08-14 2022-08-17 The University of Sydney Connexin 45 inhibition for therapy
WO2017027910A1 (en) 2015-08-14 2017-02-23 The University Of Sydney Connexin 45 inhibition for therapy
US11214800B2 (en) 2015-08-18 2022-01-04 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
JP2018525016A (en) * 2015-08-25 2018-09-06 デューク ユニバーシティ Compositions and methods for improving specificity in genomic engineering using RNA-guided endonucleases
US11427817B2 (en) 2015-08-25 2022-08-30 Duke University Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases
EP4177346A3 (en) * 2015-08-25 2023-07-26 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
EP3341727A4 (en) * 2015-08-25 2019-06-26 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
JP2021166523A (en) * 2015-08-25 2021-10-21 デューク ユニバーシティ Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
EP4345454A3 (en) * 2015-08-25 2024-07-17 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
WO2017035416A2 (en) 2015-08-25 2017-03-02 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
WO2017048316A1 (en) * 2015-09-18 2017-03-23 President And Fellows Of Harvard College Small molecule biosensors
US11693017B2 (en) 2015-09-18 2023-07-04 President And Fellows Of Harvard College Small molecule biosensors
WO2017053431A3 (en) * 2015-09-21 2017-06-01 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
US10369232B2 (en) 2015-09-21 2019-08-06 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
US11667911B2 (en) 2015-09-24 2023-06-06 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/CAS-mediated genome editing
CN105177038A (en) * 2015-09-29 2015-12-23 中国科学院遗传与发育生物学研究所 CRISPR/Cas9 system for efficiently editing plant gene groups in fixed-point mode
CN105177038B (en) * 2015-09-29 2018-08-24 中国科学院遗传与发育生物学研究所 A kind of CRISPR/Cas9 systems of efficient fixed point editor Plant Genome
WO2017058926A1 (en) * 2015-10-01 2017-04-06 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
US11407812B2 (en) 2015-10-01 2022-08-09 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
CN108431225A (en) * 2015-10-16 2018-08-21 阿斯特拉捷利康股份公司 The induction type of cellular genome is modified
US10947559B2 (en) 2015-10-16 2021-03-16 Astrazeneca Ab Inducible modification of a cell genome
AU2016337408B2 (en) * 2015-10-16 2022-11-03 Astrazeneca Ab Inducible modification of a cell genome
WO2017064566A3 (en) * 2015-10-16 2017-05-26 Astrazeneca Ab Inducible modification of a cell genome
WO2017070605A1 (en) 2015-10-22 2017-04-27 The Broad Institute Inc. Type vi-b crispr enzymes and systems
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
US11180730B2 (en) 2015-10-28 2021-11-23 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3
US11186825B2 (en) 2015-10-28 2021-11-30 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1
US20180340939A1 (en) * 2015-10-28 2018-11-29 The Broad Institute, Inc. Multiplex analysis of single cell constituents
WO2017075294A1 (en) 2015-10-28 2017-05-04 The Board Institute Inc. Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US11092607B2 (en) 2015-10-28 2021-08-17 The Board Institute, Inc. Multiplex analysis of single cell constituents
WO2017078631A1 (en) * 2015-11-05 2017-05-11 Agency For Science, Technology And Research Chemical-inducible genome engineering technology
US11261435B2 (en) 2015-11-05 2022-03-01 Agency For Science, Technology And Research Chemical-inducible genome engineering technology
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US11884717B2 (en) 2015-11-19 2024-01-30 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
EP4219689A2 (en) 2015-12-30 2023-08-02 Novartis AG Immune effector cell therapies with enhanced efficacy
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
US11111287B2 (en) 2016-01-11 2021-09-07 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
US11773411B2 (en) 2016-01-11 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
IL260532B1 (en) * 2016-01-11 2023-08-01 Univ Leland Stanford Junior Chimeric proteins- containing systems and uses thereof in regulating gene expression
CN109312335B (en) * 2016-01-11 2023-10-24 斯坦福大学托管董事会 Chimeric proteins and methods of modulating gene expression
US10457961B2 (en) 2016-01-11 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
US9856497B2 (en) 2016-01-11 2018-01-02 The Board Of Trustee Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
WO2017123559A3 (en) * 2016-01-11 2017-08-24 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
US10336807B2 (en) 2016-01-11 2019-07-02 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
CN109312335A (en) * 2016-01-11 2019-02-05 斯坦福大学托管董事会 Chimeric protein and the method for adjusting gene expression
IL260532B2 (en) * 2016-01-11 2023-12-01 Univ Leland Stanford Junior Chimeric proteins- containing systems and uses thereof in regulating gene expression
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
WO2017143042A2 (en) 2016-02-16 2017-08-24 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017147196A1 (en) 2016-02-22 2017-08-31 Massachusetts Institute Of Technology Methods for identifying and modulating immune phenotypes
US11530253B2 (en) 2016-02-25 2022-12-20 The Children's Medical Center Corporation Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
US11427861B2 (en) 2016-03-17 2022-08-30 Massachusetts Institute Of Technology Methods for identifying and modulating co-occurant cellular phenotypes
WO2017161325A1 (en) 2016-03-17 2017-09-21 Massachusetts Institute Of Technology Methods for identifying and modulating co-occurant cellular phenotypes
WO2017165167A1 (en) 2016-03-23 2017-09-28 The Regents Of The University Of California Methods of treating mitochondrial disorders
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11512311B2 (en) 2016-03-25 2022-11-29 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
WO2017180711A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Grna fusion molecules, gene editing systems, and methods of use thereof
US12049651B2 (en) 2016-04-13 2024-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
EP4047092A1 (en) 2016-04-13 2022-08-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
WO2017184768A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017189308A1 (en) 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017184786A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity
US20200377910A1 (en) * 2016-04-21 2020-12-03 National University Corporation Kobe University Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor
US11410746B2 (en) 2016-04-27 2022-08-09 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
US11961008B2 (en) 2016-04-27 2024-04-16 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
WO2017189870A1 (en) 2016-04-27 2017-11-02 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
US11514331B2 (en) 2016-04-27 2022-11-29 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
WO2017193139A1 (en) 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
EP3978022A1 (en) 2016-05-06 2022-04-06 The Brigham and Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US10596255B2 (en) 2016-06-05 2020-03-24 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11471531B2 (en) 2016-06-05 2022-10-18 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10363308B2 (en) 2016-06-05 2019-07-30 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11351252B2 (en) 2016-06-05 2022-06-07 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10603379B2 (en) 2016-06-05 2020-03-31 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11471530B2 (en) 2016-06-05 2022-10-18 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10195273B2 (en) 2016-06-05 2019-02-05 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10953090B2 (en) 2016-06-05 2021-03-23 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11291723B2 (en) 2016-06-05 2022-04-05 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11141481B2 (en) 2016-06-05 2021-10-12 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10300138B2 (en) 2016-06-05 2019-05-28 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10765740B2 (en) 2016-06-05 2020-09-08 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10300139B2 (en) 2016-06-05 2019-05-28 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11788083B2 (en) 2016-06-17 2023-10-17 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
WO2017219027A1 (en) 2016-06-17 2017-12-21 The Broad Institute Inc. Type vi crispr orthologs and systems
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US12031150B2 (en) 2016-07-13 2024-07-09 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
EP4219462A1 (en) 2016-07-13 2023-08-02 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US11566263B2 (en) 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11999947B2 (en) 2016-08-03 2024-06-04 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
US12084663B2 (en) 2016-08-24 2024-09-10 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018044920A1 (en) 2016-08-29 2018-03-08 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11896615B2 (en) 2016-10-13 2024-02-13 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
EP4190335A1 (en) 2016-10-13 2023-06-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11154574B2 (en) 2016-10-18 2021-10-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US10912797B2 (en) 2016-10-18 2021-02-09 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
US11766400B2 (en) 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
US11832598B2 (en) 2016-11-04 2023-12-05 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US11597947B2 (en) 2016-12-29 2023-03-07 Asc Therapeutics Inc. Gene editing method using virus
US12110545B2 (en) 2017-01-06 2024-10-08 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11739308B2 (en) 2017-03-15 2023-08-29 The Broad Institute, Inc. Cas13b orthologues CRISPR enzymes and systems
WO2018170333A1 (en) 2017-03-15 2018-09-20 The Broad Institute, Inc. Novel cas13b orthologues crispr enzymes and systems
EP4361261A2 (en) 2017-03-15 2024-05-01 The Broad Institute Inc. Novel cas13b orthologues crispr enzymes and systems
WO2018170515A1 (en) 2017-03-17 2018-09-20 The Broad Institute, Inc. Methods for identifying and modulating co-occurant cellular phenotypes
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
WO2018191388A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
WO2018191520A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US11840711B2 (en) 2017-04-12 2023-12-12 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
US11963982B2 (en) 2017-05-10 2024-04-23 Editas Medicine, Inc. CRISPR/RNA-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11866697B2 (en) 2017-05-18 2024-01-09 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11603544B2 (en) 2017-06-05 2023-03-14 Fred Hutchinson Cancer Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
US11098297B2 (en) 2017-06-09 2021-08-24 Editas Medicine, Inc. Engineered Cas9 nucleases
US10428319B2 (en) 2017-06-09 2019-10-01 Editas Medicine, Inc. Engineered Cas9 nucleases
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US11220697B2 (en) 2017-06-23 2022-01-11 Inscripta, Inc. Nucleic acid-guided nucleases
US11306327B1 (en) 2017-06-23 2022-04-19 Inscripta, Inc. Nucleic acid-guided nucleases
US11408012B2 (en) 2017-06-23 2022-08-09 Inscripta, Inc. Nucleic acid-guided nucleases
US11697826B2 (en) 2017-06-23 2023-07-11 Inscripta, Inc. Nucleic acid-guided nucleases
US11130970B2 (en) 2017-06-23 2021-09-28 Inscripta, Inc. Nucleic acid-guided nucleases
WO2019005884A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
US10584334B1 (en) 2017-06-30 2020-03-10 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10689645B1 (en) 2017-06-30 2020-06-23 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US11597921B2 (en) 2017-06-30 2023-03-07 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10738301B1 (en) 2017-06-30 2020-08-11 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10954512B1 (en) 2017-06-30 2021-03-23 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10894958B1 (en) 2017-06-30 2021-01-19 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US11203751B2 (en) 2017-06-30 2021-12-21 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10787663B1 (en) 2017-06-30 2020-09-29 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US11034953B1 (en) 2017-06-30 2021-06-15 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10647982B1 (en) 2017-06-30 2020-05-12 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10519437B1 (en) 2017-06-30 2019-12-31 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10584333B1 (en) 2017-06-30 2020-03-10 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
WO2019003193A1 (en) 2017-06-30 2019-01-03 Novartis Ag Methods for the treatment of disease with gene editing systems
US11098325B2 (en) 2017-06-30 2021-08-24 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US12105089B2 (en) 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019027728A1 (en) * 2017-07-31 2019-02-07 Sigma-Aldrich Co. Llc Synthetic guide rna for crispr/cas activator systems
US11897920B2 (en) 2017-08-04 2024-02-13 Peking University Tale RVD specifically recognizing DNA base modified by methylation and application thereof
US11624077B2 (en) 2017-08-08 2023-04-11 Peking University Gene knockout method
US10787683B1 (en) 2017-08-28 2020-09-29 Inscripta, Inc. Electroporation cuvettes for automation
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019052577A1 (en) 2017-09-18 2019-03-21 博雅辑因（北京）生物科技有限公司 Gene editing t cell and use thereof
US20200214273A1 (en) * 2017-09-19 2020-07-09 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Genome-edited birds
WO2019060746A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US10508288B1 (en) 2017-09-30 2019-12-17 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems comprising flow-through electroporation devices
US10822621B2 (en) 2017-09-30 2020-11-03 Inscripta, Inc. Automated nucleic acid assembly and introduction of nucleic acids into cells
US10557150B1 (en) 2017-09-30 2020-02-11 Inscripta, Inc. Automated nucleic acid assembly and introduction of nucleic acids into cells
US10851389B2 (en) 2017-09-30 2020-12-01 Inscripta, Inc. Modification of cells by introduction of exogenous material
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11578118B2 (en) 2017-10-20 2023-02-14 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
WO2019080920A1 (en) 2017-10-27 2019-05-02 博雅辑因（北京）生物科技有限公司 Method for increasing fetal hemoglobin expression level
WO2019080917A1 (en) 2017-10-27 2019-05-02 博雅辑因（北京）生物科技有限公司 Method for improving fetal hemoglobin expression
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
WO2019087113A1 (en) 2017-11-01 2019-05-09 Novartis Ag Synthetic rnas and methods of use
US10940171B2 (en) 2017-11-10 2021-03-09 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
WO2019094928A1 (en) 2017-11-10 2019-05-16 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
WO2019099943A1 (en) 2017-11-16 2019-05-23 Astrazeneca Ab Compositions and methods for improving the efficacy of cas9-based knock-in strategies
US10953036B2 (en) 2017-11-20 2021-03-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
WO2019100053A1 (en) 2017-11-20 2019-05-23 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2α to improve muscle generation and repair
US12042507B2 (en) 2017-11-20 2024-07-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
US11332736B2 (en) 2017-12-07 2022-05-17 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US12005127B2 (en) 2018-01-17 2024-06-11 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US12084676B2 (en) 2018-02-23 2024-09-10 Pioneer Hi-Bred International, Inc. Cas9 orthologs
US12031132B2 (en) 2018-03-14 2024-07-09 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US10590375B2 (en) 2018-03-29 2020-03-17 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
US10717959B2 (en) 2018-03-29 2020-07-21 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
US10883077B2 (en) 2018-03-29 2021-01-05 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
US10799868B1 (en) 2018-04-13 2020-10-13 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10737271B1 (en) 2018-04-13 2020-08-11 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10639637B1 (en) 2018-04-13 2020-05-05 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10576474B2 (en) 2018-04-13 2020-03-03 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
WO2019204585A1 (en) 2018-04-19 2019-10-24 Massachusetts Institute Of Technology Single-stranded break detection in double-stranded dna
US11332850B2 (en) 2018-04-24 2022-05-17 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10501738B2 (en) 2018-04-24 2019-12-10 Inscripta, Inc. Automated instrumentation for production of peptide libraries
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US11396718B2 (en) 2018-04-24 2022-07-26 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
WO2019206927A1 (en) 2018-04-24 2019-10-31 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
US11473214B2 (en) 2018-04-24 2022-10-18 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
EP3560330A1 (en) 2018-04-24 2019-10-30 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
US11542633B2 (en) 2018-04-24 2023-01-03 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US11555184B2 (en) 2018-04-24 2023-01-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10774324B2 (en) 2018-04-24 2020-09-15 Inscripta, Inc. Automated instrumentation for production of peptide libraries
US11236441B2 (en) 2018-04-24 2022-02-01 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10995424B2 (en) 2018-04-24 2021-05-04 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10774446B1 (en) 2018-04-24 2020-09-15 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10711374B1 (en) 2018-04-24 2020-07-14 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US11085131B1 (en) 2018-04-24 2021-08-10 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10676842B2 (en) 2018-04-24 2020-06-09 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US11293117B2 (en) 2018-04-24 2022-04-05 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210268A2 (en) 2018-04-27 2019-10-31 The Broad Institute, Inc. Sequencing-based proteomics
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US10920222B2 (en) 2018-04-30 2021-02-16 Snipr Biome Aps Treating and preventing microbial infections
US11643653B2 (en) 2018-04-30 2023-05-09 Snipr Biome Aps Treating and preventing microbial infections
US11788085B2 (en) 2018-04-30 2023-10-17 Snipr Biome Aps Treating and preventing microbial infections
US11421227B2 (en) 2018-04-30 2022-08-23 Snipr Biome Aps Treating and preventing microbial infections
US11485973B2 (en) 2018-04-30 2022-11-01 Snipr Biome Aps Treating and preventing microbial infections
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US10329547B1 (en) 2018-06-13 2019-06-25 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US10597648B2 (en) 2018-06-13 2020-03-24 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US10781432B1 (en) 2018-06-13 2020-09-22 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US10457922B1 (en) 2018-06-13 2019-10-29 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US11555181B2 (en) 2018-06-13 2023-01-17 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US10227576B1 (en) 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020006049A1 (en) 2018-06-26 2020-01-02 The Broad Institute, Inc. Crispr/cas and transposase based amplification compositions, systems and methods
WO2020006036A1 (en) 2018-06-26 2020-01-02 Massachusetts Institute Of Technology Crispr effector system based amplification methods, systems, and diagnostics
WO2020028555A2 (en) 2018-07-31 2020-02-06 The Broad Institute, Inc. Novel crispr enzymes and systems
US11939593B2 (en) 2018-08-01 2024-03-26 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
WO2020033601A1 (en) 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10760043B2 (en) 2018-08-14 2020-09-01 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10723995B1 (en) 2018-08-14 2020-07-28 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11046928B2 (en) 2018-08-14 2021-06-29 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10801008B1 (en) 2018-08-14 2020-10-13 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11072774B2 (en) 2018-08-14 2021-07-27 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11268061B2 (en) 2018-08-14 2022-03-08 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10744463B2 (en) 2018-08-14 2020-08-18 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10844344B2 (en) 2018-08-14 2020-11-24 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11365383B1 (en) 2018-08-14 2022-06-21 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11685889B2 (en) 2018-08-14 2023-06-27 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10835869B1 (en) 2018-08-14 2020-11-17 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10647958B2 (en) 2018-08-14 2020-05-12 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10954485B1 (en) 2018-08-14 2021-03-23 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11739290B2 (en) 2018-08-14 2023-08-29 Inscripta, Inc Instruments, modules, and methods for improved detection of edited sequences in live cells
US10633627B2 (en) 2018-08-14 2020-04-28 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10633626B2 (en) 2018-08-14 2020-04-28 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10625212B2 (en) 2018-08-14 2020-04-21 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
US11965154B2 (en) 2018-08-30 2024-04-23 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
WO2020047353A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
WO2020049158A1 (en) 2018-09-07 2020-03-12 Astrazeneca Ab Compositions and methods for improved nucleases
EP4268831A2 (en) 2018-09-12 2023-11-01 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
US11447527B2 (en) 2018-09-18 2022-09-20 Vnv Newco Inc. Endogenous Gag-based capsids and uses thereof
US11505578B2 (en) 2018-09-18 2022-11-22 Vnv Newco Inc. Endogenous Gag-based capsids and uses thereof
CN109557315A (en) * 2018-09-28 2019-04-02 山东大学 A kind of light-operated micro-pipe tracer and its application
WO2020077236A1 (en) 2018-10-12 2020-04-16 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
US11629350B2 (en) 2018-10-14 2023-04-18 Snipr Biome Aps Single-vector type I vectors
US11578333B2 (en) 2018-10-14 2023-02-14 Snipr Biome Aps Single-vector type I vectors
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US10876102B2 (en) 2018-10-22 2020-12-29 Inscripta, Inc. Engineered enzymes
US10655114B1 (en) 2018-10-22 2020-05-19 Inscripta, Inc. Engineered enzymes
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
US10640754B1 (en) 2018-10-22 2020-05-05 Inscripta, Inc. Engineered enzymes
US11345903B2 (en) 2018-10-22 2022-05-31 Inscripta, Inc. Engineered enzymes
US10604746B1 (en) 2018-10-22 2020-03-31 Inscripta, Inc. Engineered enzymes
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020097363A2 (en) 2018-11-08 2020-05-14 Triton Algae Innovations, Inc. Compositions and methods for incorporating heme from algae in edible products
WO2020097370A2 (en) 2018-11-08 2020-05-14 Triton Algae Innovations, Inc. Methods for overproducing protoporphyrin ix in algae and compositions therefrom
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
US11807878B2 (en) 2018-12-14 2023-11-07 Pioneer Hi-Bred International, Inc. CRISPR-Cas systems for genome editing
US10934536B2 (en) 2018-12-14 2021-03-02 Pioneer Hi-Bred International, Inc. CRISPR-CAS systems for genome editing
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US11384344B2 (en) 2018-12-17 2022-07-12 The Broad Institute, Inc. CRISPR-associated transposase systems and methods of use thereof
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US12121524B2 (en) 2019-01-16 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
WO2020178759A1 (en) 2019-03-04 2020-09-10 King Abdullah University Of Science And Technology Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion
WO2020178822A1 (en) 2019-03-05 2020-09-10 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Genome-edited birds
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11136572B2 (en) 2019-03-25 2021-10-05 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11274296B2 (en) 2019-03-25 2022-03-15 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11149260B2 (en) 2019-03-25 2021-10-19 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11034945B2 (en) 2019-03-25 2021-06-15 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11746347B2 (en) 2019-03-25 2023-09-05 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11306299B2 (en) 2019-03-25 2022-04-19 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US11279919B2 (en) 2019-03-25 2022-03-22 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US10815467B2 (en) 2019-03-25 2020-10-27 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020206036A1 (en) 2019-04-01 2020-10-08 The Broad Institute, Inc. Novel nucleic acid modifier
WO2020221291A1 (en) 2019-04-30 2020-11-05 博雅辑因（北京）生物科技有限公司 Method for predicting effectiveness of treatment of hemoglobinopathy
WO2020229533A1 (en) 2019-05-13 2020-11-19 KWS SAAT SE & Co. KGaA Drought tolerance in corn
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020239680A2 (en) 2019-05-25 2020-12-03 KWS SAAT SE & Co. KGaA Haploid induction enhancer
WO2020243661A1 (en) 2019-05-31 2020-12-03 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
US11053507B2 (en) 2019-06-06 2021-07-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11254942B2 (en) 2019-06-06 2022-02-22 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11634719B2 (en) 2019-06-06 2023-04-25 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US10837021B1 (en) 2019-06-06 2020-11-17 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11015162B1 (en) 2019-06-20 2021-05-25 Inscripta, Inc. Flow through electroporation modules and instrumentation
US11118153B2 (en) 2019-06-20 2021-09-14 Inscripta, Inc. Flow through electroporation modules and instrumentation
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
US11078458B2 (en) 2019-06-21 2021-08-03 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
US10920189B2 (en) 2019-06-21 2021-02-16 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
US11066675B2 (en) 2019-06-25 2021-07-20 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US11905532B2 (en) 2019-06-25 2024-02-20 Massachusetts Institute Of Technology Compositions and methods for molecular memory storage and retrieval
WO2021003432A1 (en) 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
EP3772542A1 (en) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
US11872286B2 (en) 2019-08-30 2024-01-16 Yale University Compositions and methods for delivery of nucleic acids to cells
US11850284B2 (en) 2019-08-30 2023-12-26 Yale University Compositions and methods for delivery of nucleic acids to cells
US12005121B2 (en) 2019-08-30 2024-06-11 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2021043278A1 (en) 2019-09-04 2021-03-11 博雅辑因（北京）生物科技有限公司 Method for evaluating gene editing therapy based on off-target assessment
WO2021050974A1 (en) 2019-09-12 2021-03-18 The Broad Institute, Inc. Engineered adeno-associated virus capsids
WO2021055874A1 (en) 2019-09-20 2021-03-25 The Broad Institute, Inc. Novel type vi crispr enzymes and systems
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
WO2021074367A1 (en) 2019-10-17 2021-04-22 KWS SAAT SE & Co. KGaA Enhanced disease resistance of crops by downregulation of repressor genes
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
US11319542B2 (en) 2019-11-19 2022-05-03 Inscripta, Inc. Methods for increasing observed editing in bacteria
US11891609B2 (en) 2019-11-19 2024-02-06 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021111466A1 (en) * 2019-12-02 2021-06-10 Council Of Scientific & Industrial Research Method and kit for detection of polynucleotide
US11085030B2 (en) 2019-12-10 2021-08-10 Inscripta, Inc. MAD nucleases
US11193115B2 (en) 2019-12-10 2021-12-07 Inscripta, Inc. Mad nucleases
US10883095B1 (en) 2019-12-10 2021-01-05 Inscripta, Inc. Mad nucleases
US11053485B2 (en) 2019-12-10 2021-07-06 Inscripta, Inc. MAD nucleases
US11174471B2 (en) 2019-12-10 2021-11-16 Inscripta, Inc. Mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
US10724021B1 (en) 2019-12-13 2020-07-28 Inscripta, Inc. Nucleic acid-guided nucleases
US10745678B1 (en) 2019-12-13 2020-08-18 Inscripta, Inc. Nucleic acid-guided nucleases
US11104890B1 (en) 2019-12-18 2021-08-31 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US11198857B2 (en) 2019-12-18 2021-12-14 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US11008557B1 (en) 2019-12-18 2021-05-18 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US11359187B1 (en) 2019-12-18 2022-06-14 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US11286471B1 (en) 2019-12-18 2022-03-29 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
WO2021136415A1 (en) 2019-12-30 2021-07-08 博雅辑因（北京）生物科技有限公司 Method for purifying ucart cell and use thereof
WO2021136176A1 (en) 2019-12-30 2021-07-08 博雅辑因（北京）生物科技有限公司 Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
US11225674B2 (en) 2020-01-27 2022-01-18 Inscripta, Inc. Electroporation modules and instrumentation
US11667932B2 (en) 2020-01-27 2023-06-06 Inscripta, Inc. Electroporation modules and instrumentation
EP3872190A1 (en) 2020-02-26 2021-09-01 Antibodies-Online GmbH A method of using cut&run or cut&tag to validate crispr-cas targeting
US11591592B2 (en) 2020-04-24 2023-02-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells using microcarriers
US11268088B2 (en) 2020-04-24 2022-03-08 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery
US11845932B2 (en) 2020-04-24 2023-12-19 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery
US11407994B2 (en) 2020-04-24 2022-08-09 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery
US12031126B2 (en) 2020-05-08 2024-07-09 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
WO2021239986A1 (en) 2020-05-29 2021-12-02 KWS SAAT SE & Co. KGaA Plant haploid induction
WO2022007803A1 (en) 2020-07-06 2022-01-13 博雅辑因（北京）生物科技有限公司 Improved rna editing method
WO2022036180A1 (en) 2020-08-13 2022-02-17 Yale University Compositions and methods for engineering and selection of car t cells with desired phenotypes
WO2022047424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
US11299731B1 (en) 2020-09-15 2022-04-12 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11597923B2 (en) 2020-09-15 2023-03-07 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
EP4001429A1 (en) 2020-11-16 2022-05-25 Antibodies-Online GmbH Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)
US11306298B1 (en) 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
US11965186B2 (en) 2021-01-04 2024-04-23 Inscripta, Inc. Nucleic acid-guided nickases
US11332742B1 (en) 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
WO2022155265A2 (en) 2021-01-12 2022-07-21 Mitolab Inc. Context-dependent, double-stranded dna-specific deaminases and uses thereof
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2022226291A1 (en) 2021-04-22 2022-10-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2023006933A1 (en) 2021-07-30 2023-02-02 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
WO2023044100A1 (en) 2021-09-20 2023-03-23 Revivicor, Inc. Multitran scenic pigs comprising ten genetic modifications for xenotransplantation
US12123015B2 (en) 2021-09-21 2024-10-22 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2023052508A2 (en) 2021-09-30 2023-04-06 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
WO2023064732A1 (en) 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
WO2023070043A1 (en) 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
WO2023093862A1 (en) 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
WO2023192872A1 (en) 2022-03-28 2023-10-05 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
US12098399B2 (en) 2022-06-24 2024-09-24 Tune Therapeutics, Inc. Compositions, systems, and methods for epigenetic regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024020597A1 (en) 2022-07-22 2024-01-25 The Johns Hopkins University Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024042199A1 (en) 2022-08-26 2024-02-29 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding
WO2024047587A1 (en) 2022-08-31 2024-03-07 Regel Therapeutics, Inc. Cas-phi compositions and methods of use
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024119101A1 (en) 2022-12-01 2024-06-06 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
WO2024123789A1 (en) 2022-12-07 2024-06-13 Sanofi Predicting indel frequencies
WO2024168253A1 (en) 2023-02-10 2024-08-15 Possible Medicines Llc Delivery of an rna guided recombination system
WO2024168265A1 (en) 2023-02-10 2024-08-15 Possible Medicines Llc Aav delivery of rna guided recombination system
WO2024201368A1 (en) 2023-03-29 2024-10-03 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
CN117257958B (en) * 2023-11-21 2024-02-09 四川大学华西医院 New use of TRPS1 inhibitor and medicine for treating and/or preventing androgenetic alopecia
CN117257958A (en) * 2023-11-21 2023-12-22 四川大学华西医院 New use of TRPS1 inhibitor and medicine for treating and/or preventing androgenetic alopecia

Also Published As

Publication number Publication date
AU2013293270B2 (en) 2018-08-16
KR102530118B1 (en) 2023-05-08
EP3808844A1 (en) 2021-04-21
EP2877213A2 (en) 2015-06-03
CN116622704A (en) 2023-08-22
DK3494997T3 (en) 2019-12-02
US20150291966A1 (en) 2015-10-15
US20170166903A1 (en) 2017-06-15
KR20150056539A (en) 2015-05-26
US20190390204A1 (en) 2019-12-26
WO2014018423A8 (en) 2014-06-19
EP3494997A1 (en) 2019-06-12
EP2877213B1 (en) 2020-12-02
PT3494997T (en) 2019-12-05
AU2018247306A1 (en) 2018-11-08
US20190203212A1 (en) 2019-07-04
JP2018082709A (en) 2018-05-31
AU2018247306B2 (en) 2021-08-19
CN105188767A (en) 2015-12-23
PL3494997T3 (en) 2020-04-30
WO2014018423A3 (en) 2014-04-03
AU2013293270A1 (en) 2015-02-26
JP2015527889A (en) 2015-09-24
KR20230065381A (en) 2023-05-11
EP3494997B1 (en) 2019-09-18
HK1210965A1 (en) 2016-05-13
CA2879997A1 (en) 2014-01-30
AU2018211340A1 (en) 2018-08-23
ES2757623T3 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
AU2018247306B2 (en) Inducible dna binding proteins and genome perturbation tools and applications thereof
US11332719B2 (en) Recombinant virus and preparations thereof
JP2020185014A (en) Compositions for linking dna-binding domains and cleavage domains
JP2023164823A (en) RNA-guided gene editing and gene regulation
CA3058584A1 (en) Method for inducing exon skipping by genome editing
Kim et al. Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing
US20130273656A1 (en) Method to increase gene targeting frequency
CA3151336A1 (en) Compositions and methods for identifying regulators of cell type fate specification
US11072782B2 (en) Construct for epigenetic modification and its use in the silencing of genes
EP4284935A1 (en) Functional nucleic acid molecule and method
US20210198328A1 (en) Modulated cas-inhibitors
WO2012136476A1 (en) Method of activating a target gene in a cell
CN116490615A (en) Engineered CRISPR-Cas13f systems and uses thereof
US20190024072A1 (en) Construct for epigenetic modification and its use in the silencing of genes
Class et al. Patent application title: RECOMBINANT VIRUS AND PREPARATIONS THEREOF Inventors: Feng Zhang (Cambridge, MA, US) Feng Zhang (Cambridge, MA, US) Mark D. Brigham (Somerville, MA, US) Le Cong (Cambridge, MA, US) Le Cong (Cambridge, MA, US) Silvana Konermann (Zurich, CH)
WO2024023530A1 (en) Functional nucleic acid molecule and method
Activators CRISPR Reagents and Services from GenScript
Wysocka-Kapcinska Nuclear World

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380049665.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13744916

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2879997

Country of ref document: CA

Ref document number: 2015524358

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013744916

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157004939

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013293270

Country of ref document: AU

Date of ref document: 20130721

Kind code of ref document: A